Drug 1 ATC Code	Drug 1 Name	Drug 1 RxCUI	Drug 1 Class Name	Drug 1 Code	Drug 2 ATC Code	Drug 2 Name	Drug 2 RxCUI	Drug 2 Class Name	Drug 2 Code	Clinical Source	Source File	Description	Severity	Comment
L04AA24	ABATACEPT 	614391				ANTI-TNF ALPHA				ANSM	1-ABATACEPT.html	Increase of immunosupression	Not recommended	
L04AA24	ABATACEPT 	614391						ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	1-ABATACEPT.html	Risk of possibly fatal general vaccine disease. 	Not recommended	And, for the three months following the end of the treatment.
S01AA13	FUSIDIC ACID	4608			S01XA18	CICLOSPORIN	3008			ANSM	10-FUSIDIC-ACID.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia 	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function and adjustment of the dosage during the treatment and after it is stopped. 
S01AA13	FUSIDIC ACID	4608						HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	10-FUSIDIC-ACID.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type.	Contraindication	Stop the treatment with the HMG-COA Reductase Inhibitor before starting the treatment with fusidic acid or use another antibiotic.
S01AA13	FUSIDIC ACID	4608						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	10-FUSIDIC-ACID.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	Contraindication	
N02AE01	BUPRENORPHINE	1819						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to the simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N07BC01	BUPRENORPHINE	1819						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to the simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N07BC51	BUPRENORPHINE	1819						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to the simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N02AE01	BUPRENORPHINE	1819			J05AE08	ATAZANAVIR	343047			ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor 	Take into account	
N07BC01	BUPRENORPHINE	1819			J05AE08	ATAZANAVIR	343047			ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor 	Take into account	
N07BC51	BUPRENORPHINE	1819			J05AE08	ATAZANAVIR	343047			ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor 	Take into account	
N02AE01	BUPRENORPHINE	1819						BENZODIAZEPINES AND RELATED	N05-001	ANSM	100-BUPRENORPHINE.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.	Take into account	Evaluate carefully the risk/benefits relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed dosages.
N07BC01	BUPRENORPHINE	1819						BENZODIAZEPINES AND RELATED	N05-001	ANSM	100-BUPRENORPHINE.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.	Take into account	Evaluate carefully the risk/benefits relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed dosages.
N07BC51	BUPRENORPHINE	1819						BENZODIAZEPINES AND RELATED	N05-001	ANSM	100-BUPRENORPHINE.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.	Take into account	Evaluate carefully the risk/benefits relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed dosages.
N02AE01	BUPRENORPHINE	1819						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N07BC01	BUPRENORPHINE	1819						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N07BC51	BUPRENORPHINE	1819						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N02AE01	BUPRENORPHINE	1819			J02AC02	ITRACONAZOLE	28031			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC01	BUPRENORPHINE	1819			J02AC02	ITRACONAZOLE	28031			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC51	BUPRENORPHINE	1819			J02AC02	ITRACONAZOLE	28031			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N02AE01	BUPRENORPHINE	1819			D01AC08	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N02AE01	BUPRENORPHINE	1819			G01AF11	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N02AE01	BUPRENORPHINE	1819			J02AB02	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC01	BUPRENORPHINE	1819			D01AC08	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC01	BUPRENORPHINE	1819			G01AF11	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC01	BUPRENORPHINE	1819			J02AB02	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC51	BUPRENORPHINE	1819			D01AC08	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC51	BUPRENORPHINE	1819			G01AF11	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N07BC51	BUPRENORPHINE	1819			J02AB02	KETOCONAZOLE	6135			ANSM	100-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
N02AE01	BUPRENORPHINE	1819			J05AE04	NELFINAVIR	134527			ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N07BC01	BUPRENORPHINE	1819			J05AE04	NELFINAVIR	134527			ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N07BC51	BUPRENORPHINE	1819			J05AE04	NELFINAVIR	134527			ANSM	100-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
N06AX12	BUPROPION	42347			N06AA04	CLOMIPRAMINE	2597			ANSM	101-BUPROPION.html	Risk of increase of the undesirable effects of the cloripramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion.
N06AX12	BUPROPION	42347			N06AA01	DESIPRAMINE	3247			ANSM	101-BUPROPION.html	Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.
N06AX12	BUPROPION	42347			C01BC04	FLECAINIDE	4441			ANSM	101-BUPROPION.html	Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.
N06AX12	BUPROPION	42347						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	101-BUPROPION.html	Risk of hypertensive crises. From the fact of the length of action of the MAOI, this interaction is still theoretically possible two weeks after it is stopped	Contraindication	
N06AX12	BUPROPION	42347						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	101-BUPROPION.html	Risk of hypertensive crises	Contraindication	
N06AX12	BUPROPION	42347						MAOI-B 	N04BD0-001	ANSM	101-BUPROPION.html	Risk of hypertensive crises	Contraindication	
N06AX12	BUPROPION	42347			R06AD07	MEQUITAZINE	29528			ANSM	101-BUPROPION.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
N06AX12	BUPROPION	42347			C07AB02	METOPROLOL	6918			ANSM	101-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
N06AX12	BUPROPION	42347			C07FB02	METOPROLOL	6918			ANSM	101-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
N06AX12	BUPROPION	42347			C07CB02	METOPROLOL	6918			ANSM	101-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
N06AX12	BUPROPION	42347			C07BB02	METOPROLOL	6918			ANSM	101-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
N06AX12	BUPROPION	42347			C07BB52	METOPROLOL	6918			ANSM	101-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
N06AX12	BUPROPION	42347			C07AB52	METOPROLOL	6918			ANSM	101-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
N06AX12	BUPROPION	42347			N06AA10	NORTRIPTYLINE	7531			ANSM	101-BUPROPION.html	Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.
N06AX12	BUPROPION	42347			C01BC03	PROPAFENONE	8754			ANSM	101-BUPROPION.html	Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.
N06AX12	BUPROPION	42347			L02BA01	TAMOXIFEN	10324			ANSM	101-BUPROPION.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]	Not recommended	
N06AX12	BUPROPION	42347			N02AX02	TRAMADOL	10689			ANSM	101-BUPROPION.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
N06AX12	BUPROPION	42347			N02AX52	TRAMADOL	10689			ANSM	101-BUPROPION.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
N06AX12	BUPROPION	42347			L01XE15	VEMURAFENIB	1147220			ANSM	101-BUPROPION.html	Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity	Take into account	
N05BE01	BUSPIRONE	1827				GRAPEFRUIT JUICE				ANSM	102-BUSPIRONE.html	Risk of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit juice	Take into account	
N05BE01	BUSPIRONE	1827			N05BA01	DIAZEPAM	3322			ANSM	102-BUSPIRONE.html	Risk of increase of the undesirable effects of the buspirone	Take into account	
N05BE01	BUSPIRONE	1827			C08DB01	DILTIAZEM	3443			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
N05BE01	BUSPIRONE	1827			D10AF02	ERYTHROMYCIN	4053			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
N05BE01	BUSPIRONE	1827			D10AF52	ERYTHROMYCIN	4053			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
N05BE01	BUSPIRONE	1827			J01FA01	ERYTHROMYCIN	4053			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
N05BE01	BUSPIRONE	1827			S01AA17	ERYTHROMYCIN	4053			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
N05BE01	BUSPIRONE	1827			J02AC02	ITRACONAZOLE	28031			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
N05BE01	BUSPIRONE	1827			J04AB02	RIFAMPICIN	9384			ANSM	102-BUSPIRONE.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
N05BE01	BUSPIRONE	1827			J04AM02	RIFAMPICIN	9384			ANSM	102-BUSPIRONE.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
N05BE01	BUSPIRONE	1827			J04AM05	RIFAMPICIN	9384			ANSM	102-BUSPIRONE.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
N05BE01	BUSPIRONE	1827			J04AM06	RIFAMPICIN	9384			ANSM	102-BUSPIRONE.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
N05BE01	BUSPIRONE	1827			C08DA01	VERAPAMIL	11170			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
N05BE01	BUSPIRONE	1827			C08DA51	VERAPAMIL	11170			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
N05BE01	BUSPIRONE	1827			C09BB10	VERAPAMIL	11170			ANSM	102-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
L01AB01	BUSULFAN	1828			V03AC03	DEFERASIROX	614373			ANSM	103-BUSULFAN.html	Risk of increase of the toxicity of the busulfan due to decrease of its clearance by the deferasirox	Take into account	
L01AB01	BUSULFAN	1828			J02AC02	ITRACONAZOLE	28031			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole	Not recommended	
L01AB01	BUSULFAN	1828			A02BD08	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			A02BD03	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			A02BD02	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			A01AB17	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			D06BX01	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			G01AF01	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			J01XD01	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			P01AB01	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01AB01	BUSULFAN	1828			A02BD01	METRONIDAZOLE	6922			ANSM	103-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
L01CD04	CABAZITAXEL	996051						ENZYMATIC INDUCERS	N03-J05-001	ANSM	104-CABAZITAXEL.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
L01CD04	CABAZITAXEL	996051						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	104-CABAZITAXEL.html	Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzyme inhibitor.
N06BC01	CAFFEINE 	1886			J01MA02	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
N06BC01	CAFFEINE 	1886			S01AE03	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
N06BC01	CAFFEINE 	1886			S02AA15	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
N06BC01	CAFFEINE 	1886			S03AA07	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
V04CG30	CAFFEINE 	1886			J01MA02	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
V04CG30	CAFFEINE 	1886			S01AE03	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
V04CG30	CAFFEINE 	1886			S02AA15	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
V04CG30	CAFFEINE 	1886			S03AA07	CIPROFLOXACIN	2551			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
N06BC01	CAFFEINE 	1886			B01AC07	DIPYRIDAMOLE	3521			ANSM	105-CAFFEINE.html	With dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine	Precaution for use	Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test.
V04CG30	CAFFEINE 	1886			B01AC07	DIPYRIDAMOLE	3521			ANSM	105-CAFFEINE.html	With dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine	Precaution for use	Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test.
N06BC01	CAFFEINE 	1886			J01MA04	ENOXACIN	3925			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
V04CG30	CAFFEINE 	1886			J01MA04	ENOXACIN	3925			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
N06BC01	CAFFEINE 	1886			D11AX04	LITHIUM	6448			ANSM	105-CAFFEINE.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the lithemia	Take into account	
V04CG30	CAFFEINE 	1886			D11AX04	LITHIUM	6448			ANSM	105-CAFFEINE.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the lithemia	Take into account	
N06BC01	CAFFEINE 	1886			C01BB02	MEXILETINE	6926			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
V04CG30	CAFFEINE 	1886			C01BB02	MEXILETINE	6926			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
N06BC01	CAFFEINE 	1886			J01MA06	NORFLOXACINE	7517			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
N06BC01	CAFFEINE 	1886			S01AE02	NORFLOXACINE	7517			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
V04CG30	CAFFEINE 	1886			J01MA06	NORFLOXACINE	7517			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
V04CG30	CAFFEINE 	1886			S01AE02	NORFLOXACINE	7517			ANSM	105-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
N06BC01	CAFFEINE 	1886			N03AX17	STIRIPENTOL	37119			ANSM	105-CAFFEINE.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of caffeine.
V04CG30	CAFFEINE 	1886			N03AX17	STIRIPENTOL	37119			ANSM	105-CAFFEINE.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of caffeine.
H05BA	CALCITONIN	36118			D11AX04	LITHIUM	6448			ANSM	106-CALCITONIN.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
H05BA03	CALCITONIN	36118			D11AX04	LITHIUM	6448			ANSM	106-CALCITONIN.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
H05BA02	CALCITONIN	36118			D11AX04	LITHIUM	6448			ANSM	106-CALCITONIN.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
H05BA01	CALCITONIN	36118			D11AX04	LITHIUM	6448			ANSM	106-CALCITONIN.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
A12AA	CALCIUM	1428011						BISPHOSPHONATES	M05B-001	ANSM	107-CALCIUM.html	For calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the calcium salts and antacids at a different time from the bisphosphonates 
A12AA	CALCIUM	1428011						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the calcium salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
A12AA	CALCIUM	1428011						DIGITALIS GLYCOSIDES	C01AA0	ANSM	107-CALCIUM.html	Risk of serious arrhythmias, even lethal ones with the calcium salts administered by IV route 	Contraindication	-with calcium salts via IV aside from parenteral supplementation
A12AA	CALCIUM	1428011						THIAZIDE DIURETICS AND RELATED	C03-003	ANSM	107-CALCIUM.html	Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. 	Take into account	
A12AA	CALCIUM	1428011			L01XX11	ESTRAMUSTINE	4089			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the estramustine	Precaution for use	Take the calcium salts at a different time from the estramustine (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			B03A	IRON	1431589			ANSM	107-CALCIUM.html	With the iron salts by oral route: decrease of the digestive absorption of the iron salts	Precaution for use	Take the iron salts at a different time from meals and in the absence of calcium.
A12AA	CALCIUM	1428011						THYROID HORMONES	H03AA	ANSM	107-CALCIUM.html	Decrease of the absorption of the thyroid hormones	Precaution for use	Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			V10BX01	STRONTIUM	81638			ANSM	107-CALCIUM.html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).
A12AA	CALCIUM	1428011			M05BX03	STRONTIUM	81638			ANSM	107-CALCIUM.html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).
A12AA	CALCIUM	1428011			A12CB	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			A12CB01	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			A12CB02	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			A12CB03	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			B05X	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			B05XA	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
A12AA	CALCIUM	1428011			B05XA12	ZINC	1431163			ANSM	107-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
N03AF01	CARBAMAZEPINE	2002				GRAPEFRUIT JUICE				ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit juice	Not recommended	
N03AF01	CARBAMAZEPINE	2002			S01EC01	ACETAZOLAMIDE	167			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose.	Precaution for use	Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage
N03AF01	CARBAMAZEPINE	2002			A02BA01	CIMETIDINE	2541			ANSM	108-CARBAMAZEPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine 	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine 
N03AF01	CARBAMAZEPINE	2002			A02BA51	CIMETIDINE	2541			ANSM	108-CARBAMAZEPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine 	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine 
N03AF01	CARBAMAZEPINE	2002			J01FA09	CLARITHROMYCIN	21212			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			A02BD06	CLARITHROMYCIN	21212			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			A02BD07	CLARITHROMYCIN	21212			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			A02BD05	CLARITHROMYCIN	21212			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			A02BD04	CLARITHROMYCIN	21212			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			N03AE01	CLONAZEPAM	2598			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinincal monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants
N03AF01	CARBAMAZEPINE	2002			N05AH02	CLOZAPINE	2626			ANSM	108-CARBAMAZEPINE.html	Risk of increase of the serious hematological effects 	Not recommended	
N03AF01	CARBAMAZEPINE	2002			G03XA01	DANAZOL	3102			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine, with signs of overdose	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			C01AA05	DIGOXIN 	3407			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia	Precaution for use	Exercise caution in the interpretation of the plasma concentrations.
N03AF01	CARBAMAZEPINE	2002						POTASSIUM LOWERING DIURETICS	C03	ANSM	108-CARBAMAZEPINE.html	Risk of symptomatic hyponatremia	Precaution for use	Clinical monitoring and laboratory tests. If possible, use another class of diuretics.
N03AF01	CARBAMAZEPINE	2002			D10AF02	ERYTHROMYCIN	4053			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
N03AF01	CARBAMAZEPINE	2002			D10AF52	ERYTHROMYCIN	4053			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
N03AF01	CARBAMAZEPINE	2002			J01FA01	ERYTHROMYCIN	4053			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
N03AF01	CARBAMAZEPINE	2002			S01AA17	ERYTHROMYCIN	4053			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
N03AF01	CARBAMAZEPINE	2002			N03AD01	ETHOSUXIMIDE	4135			ANSM	108-CARBAMAZEPINE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
N03AF01	CARBAMAZEPINE	2002			N03AD51	ETHOSUXIMIDE	4135			ANSM	108-CARBAMAZEPINE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
N03AF01	CARBAMAZEPINE	2002			N03AX10	FELBAMATE	24812			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.
N03AF01	CARBAMAZEPINE	2002			D01AC15	FLUCONAZOLE	4450			ANSM	108-CARBAMAZEPINE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.
N03AF01	CARBAMAZEPINE	2002			J02AC01	FLUCONAZOLE	4450			ANSM	108-CARBAMAZEPINE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.
N03AF01	CARBAMAZEPINE	2002			N06AB03	FLUOXETINE	4493			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 
N03AF01	CARBAMAZEPINE	2002			N06CA03	FLUOXETINE	4493			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 
N03AF01	CARBAMAZEPINE	2002			N06AB08	FLUVOXAMINE	42355			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
N03AF01	CARBAMAZEPINE	2002			N05AD01	HALOPERIDOL	5093			ANSM	108-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped. 
N03AF01	CARBAMAZEPINE	2002			J04AM03	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AC01	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AC51	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AM02	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AM05	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AM06	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AM01	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J04AM04	ISONIAZID	6038			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			J01FA07	JOSAMYCIN	6084			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.
N03AF01	CARBAMAZEPINE	2002			N03AX09	LAMOTRIGINE	28439			ANSM	108-CARBAMAZEPINE.html	Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine. 
N03AF01	CARBAMAZEPINE	2002			D11AX04	LITHIUM	6448			ANSM	108-CARBAMAZEPINE.html	Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped.	Not recommended	
N03AF01	CARBAMAZEPINE	2002				ST JOHNS WORT	258326			ANSM	108-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine	Not recommended	
N03AF01	CARBAMAZEPINE	2002			N05AH03	OLANZAPINE	61381			ANSM	108-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine.
N03AF01	CARBAMAZEPINE	2002			N06AB05	PAROXETINE	32937			ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
N03AF01	CARBAMAZEPINE	2002						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	108-CARBAMAZEPINE.html	Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness	Take into account	Use prudence with respect to the interpretation of the plasma concentrations.
N03AF01	CARBAMAZEPINE	2002						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	108-CARBAMAZEPINE.html	Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)	Take into account	Use prudence in the interpretation of the plasma concentrations. 
N03AF01	CARBAMAZEPINE	2002			J04AB02	RIFAMPICIN	9384			ANSM	108-CARBAMAZEPINE.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
N03AF01	CARBAMAZEPINE	2002			J04AM02	RIFAMPICIN	9384			ANSM	108-CARBAMAZEPINE.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
N03AF01	CARBAMAZEPINE	2002			J04AM05	RIFAMPICIN	9384			ANSM	108-CARBAMAZEPINE.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
N03AF01	CARBAMAZEPINE	2002			J04AM06	RIFAMPICIN	9384			ANSM	108-CARBAMAZEPINE.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
N03AF01	CARBAMAZEPINE	2002			N05AX08	RISPERIDONE	35636			ANSM	108-CARBAMAZEPINE.html	Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.
N03AF01	CARBAMAZEPINE	2002			C10AA01	SIMVASTATIN	36567			ANSM	108-CARBAMAZEPINE.html	Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism	Not recommended	
N03AF01	CARBAMAZEPINE	2002			N03AX11	TOPIRAMATE	38404			ANSM	108-CARBAMAZEPINE.html	Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the carbamazepine and after it is stopped. 
N03AF01	CARBAMAZEPINE	2002						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	108-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and adjustment of the dosage of the two anticonvulsants.
L01AD01	CARMUSTINE	2105			A02BA01	CIMETIDINE	2541			ANSM	109-CARMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine) 	Not recommended	
L01AD01	CARMUSTINE	2105			A02BA51	CIMETIDINE	2541			ANSM	109-CARMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine) 	Not recommended	
C04AC01	NICOTINIC ACID	446722				ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect 	Take into account	
C04AC01	NICOTINIC ACID	446722				ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect 	Take into account	
C04AC02	NICOTINIC ACID	446722				ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect 	Take into account	
C04AC02	NICOTINIC ACID	446722				ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect 	Take into account	
C04AC03	NICOTINIC ACID	446722				ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect 	Take into account	
C04AC07	NICOTINIC ACID	446722				ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect 	Take into account	
C07AG02	CARVEDILOL	20352			A02BA01	CIMETIDINE	2541			ANSM	110-CARVEDILOL.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	Contraindication	Use another gastric H2 receptor antagonist.
C07AG02	CARVEDILOL	20352			A02BA51	CIMETIDINE	2541			ANSM	110-CARVEDILOL.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	Contraindication	Use another gastric H2 receptor antagonist.
C07AG02	CARVEDILOL	20352			J04AB02	RIFAMPICIN	9384			ANSM	110-CARVEDILOL.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
C07AG02	CARVEDILOL	20352			J04AM02	RIFAMPICIN	9384			ANSM	110-CARVEDILOL.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
C07AG02	CARVEDILOL	20352			J04AM05	RIFAMPICIN	9384			ANSM	110-CARVEDILOL.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
C07AG02	CARVEDILOL	20352			J04AM06	RIFAMPICIN	9384			ANSM	110-CARVEDILOL.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
V04CG01	CATION EXCHANGE RESINS	2161			A06AD18	SORBITOL	9945			ANSM	111-CATION-EXCHANGE-RESINS.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	Not recommended	
V04CG01	CATION EXCHANGE RESINS	2161			A06AG07	SORBITOL	9945			ANSM	111-CATION-EXCHANGE-RESINS.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	Not recommended	
V04CG01	CATION EXCHANGE RESINS	2161			B05CX02	SORBITOL	9945			ANSM	111-CATION-EXCHANGE-RESINS.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	Not recommended	
V04CG01	CATION EXCHANGE RESINS	2161			V04CC01	SORBITOL	9945			ANSM	111-CATION-EXCHANGE-RESINS.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	Not recommended	
J01DB03	CEFALOTIN	2236						AMINOGLYCOSIDES	J01GB-001	ANSM	112-CEFALOTIN.html	Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion	Precaution for use	Monitoring of renal function.
J01DC03	CEFAMANDOLE	2178						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	113-CEFAMANDOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
J01DD12	CEFOPERAZONE	2184						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	114-CEFOPERAZONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
J01DD62	CEFOPERAZONE	2184						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	114-CEFOPERAZONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
J01DC05	CEFOTETAN	2187						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	115-CEFOTETAN.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
J01DD04	CEFTRIAXONE	2193						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	116-CEFTRIAXONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
J01DD54	CEFTRIAXONE	2193						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	116-CEFTRIAXONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
N05BA02	CHLORDIAZEPOXIDE	2356			A02BA01	CIMETIDINE	2541			ANSM	117-CHLORDIAZEPOXIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn patients of the increase of risk when driving an automobile or using machinery.
N05BA02	CHLORDIAZEPOXIDE	2356			A02BA51	CIMETIDINE	2541			ANSM	117-CHLORDIAZEPOXIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn patients of the increase of risk when driving an automobile or using machinery.
P01BA01	CHLOROQUINE	2393			L04AD01	CICLOSPORIN	3008			ANSM	118-CHLOROQUINE.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. 
P01BA01	CHLOROQUINE	2393			S01XA18	CICLOSPORIN	3008			ANSM	118-CHLOROQUINE.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. 
P01BA01	CHLOROQUINE	2393			A02BA01	CIMETIDINE	2541			ANSM	118-CHLOROQUINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
P01BA01	CHLOROQUINE	2393			A02BA51	CIMETIDINE	2541			ANSM	118-CHLOROQUINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
P01BA01	CHLOROQUINE	2393						THYROID HORMONES	H03AA	ANSM	118-CHLOROQUINE.html	Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.
N05AA01	CHLORPROMAZINE	2403			A10AC01	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AC02	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AC03	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AC04	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AD01	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AD02	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AD03	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AD04	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AD05	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AE01	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AE02	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AE03	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AE04	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AE05	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403			A10AF01	INSULIN	5856			ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
N05AA01	CHLORPROMAZINE	2403						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	119-CHLORPROMAZINE.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the neuroleptic during the treatment and after it is stopped.
			BILE ACIDS	A05AA-001	S01XA18	CICLOSPORIN	3008			ANSM	12-BILE-ACIDS.html	Risk of variation of the blood concentrations of ciclosporin	Take into account	
D01AE14	CICLOPIROX	21090						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	120-CICLOPIROX.html	[no text in document]	[ambiguous]	
G01AX12	CICLOPIROX	21090						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	120-CICLOPIROX.html	[no text in document]	[ambiguous]	
L04AD01	CICLOSPORIN	3008			D06AX01	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
L04AD01	CICLOSPORIN	3008			D09AA02	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
L04AD01	CICLOSPORIN	3008			J01XC01	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
L04AD01	CICLOSPORIN	3008			S01AA13	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
S01XA18	CICLOSPORIN	3008			D06AX01	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
S01XA18	CICLOSPORIN	3008			D09AA02	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
S01XA18	CICLOSPORIN	3008			J01XC01	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
S01XA18	CICLOSPORIN	3008			S01AA13	FUSIDIC ACID	4608			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precautions for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the treatment and after it is stopped. 
L04AD01	CICLOSPORIN	3008						BILE ACIDS	A05AA-001	ANSM	121-CICLOSPORIN.html	Risk of variation of the blood concentrations of ciclosporin 	Take into account	
S01XA18	CICLOSPORIN	3008						BILE ACIDS	A05AA-001	ANSM	121-CICLOSPORIN.html	Risk of variation of the blood concentrations of ciclosporin 	Take into account	
L04AD01	CICLOSPORIN	3008			L01XE13	AFATINIB	1430438			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ciclosporin	Precaution for use	It is recommended that the ciclosporin be administered as far from the afatinib as possible, preferably an interval of 6 to 12 hours away from the administration of the afatinib. 
S01XA18	CICLOSPORIN	3008			L01XE13	AFATINIB	1430438			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ciclosporin	Precaution for use	It is recommended that the ciclosporin be administered as far from the afatinib as possible, preferably an interval of 6 to 12 hours away from the administration of the afatinib. 
L04AD01	CICLOSPORIN	3008			C09XA02	ALISKIREN	325646			ANSM	121-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
L04AD01	CICLOSPORIN	3008			C09XA52	ALISKIREN	325646			ANSM	121-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
L04AD01	CICLOSPORIN	3008			C09DX02	ALISKIREN	325646			ANSM	121-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
S01XA18	CICLOSPORIN	3008			C09XA02	ALISKIREN	325646			ANSM	121-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
S01XA18	CICLOSPORIN	3008			C09XA52	ALISKIREN	325646			ANSM	121-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
S01XA18	CICLOSPORIN	3008			C09DX02	ALISKIREN	325646			ANSM	121-CICLOSPORIN.html	Increase by nearly 5 times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
L04AD01	CICLOSPORIN	3008			C02KX02	AMBRISENTAN	358274			ANSM	121-CICLOSPORIN.html	Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )	Take into account	
S01XA18	CICLOSPORIN	3008			C02KX02	AMBRISENTAN	358274			ANSM	121-CICLOSPORIN.html	Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )	Take into account	
L04AD01	CICLOSPORIN	3008						AMINOGLYCOSIDES	J01GB-001	ANSM	121-CICLOSPORIN.html	Increase of the creatinemia larger than with ciclosporin alone, with increase of the nephrotoxic risk 	Take into account	
S01XA18	CICLOSPORIN	3008						AMINOGLYCOSIDES	J01GB-001	ANSM	121-CICLOSPORIN.html	Increase of the creatinemia larger than with ciclosporin alone, with increase of the nephrotoxic risk 	Take into account	
L04AD01	CICLOSPORIN	3008			C01BD01	AMIODARONE	703			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone
S01XA18	CICLOSPORIN	3008			C01BD01	AMIODARONE	703			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone
L04AD01	CICLOSPORIN	3008			A01AB04	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD01	CICLOSPORIN	3008			A07AA07	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD01	CICLOSPORIN	3008			G01AA03	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD01	CICLOSPORIN	3008			J02AA01	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
S01XA18	CICLOSPORIN	3008			A01AB04	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
S01XA18	CICLOSPORIN	3008			A07AA07	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
S01XA18	CICLOSPORIN	3008			G01AA03	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
S01XA18	CICLOSPORIN	3008			J02AA01	AMPHOTERICIN B 	732			ANSM	121-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD01	CICLOSPORIN	3008						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	121-CICLOSPORIN.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	Increase of the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analog is stopped
S01XA18	CICLOSPORIN	3008						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	121-CICLOSPORIN.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	Increase of the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analog is stopped
L04AD01	CICLOSPORIN	3008						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	121-CICLOSPORIN.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	Monitor renal function at the beginning of the treatment with the NSAI.
S01XA18	CICLOSPORIN	3008						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	121-CICLOSPORIN.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	Monitor renal function at the beginning of the treatment with the NSAI.
L04AD01	CICLOSPORIN	3008			C10AA05	ATORVASTATIN	83367			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)	Precaution for use	Do not exceed the dosage of 10mg/day of atorvastatine. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.
S01XA18	CICLOSPORIN	3008			C10AA05	ATORVASTATIN	83367			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)	Precaution for use	Do not exceed the dosage of 10mg/day of atorvastatine. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.
L04AD01	CICLOSPORIN	3008			J01FA10	AZITHROMYCIN 	18631			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped
S01XA18	CICLOSPORIN	3008			J01FA10	AZITHROMYCIN 	18631			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped
L04AD01	CICLOSPORIN	3008			C02KX01	BOSENTAN	75207			ANSM	121-CICLOSPORIN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	Contraindication	
S01XA18	CICLOSPORIN	3008			C02KX01	BOSENTAN	75207			ANSM	121-CICLOSPORIN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	Contraindication	
L04AD01	CICLOSPORIN	3008			P01BA01	CHLOROQUINE	2393			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. 
S01XA18	CICLOSPORIN	3008			P01BA01	CHLOROQUINE	2393			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. 
L04AD01	CICLOSPORIN	3008			A02BA01	CIMETIDINE	2541			ANSM	121-CICLOSPORIN.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			A02BA51	CIMETIDINE	2541			ANSM	121-CICLOSPORIN.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			A02BA01	CIMETIDINE	2541			ANSM	121-CICLOSPORIN.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			A02BA51	CIMETIDINE	2541			ANSM	121-CICLOSPORIN.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			D10AF01	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
L04AD01	CICLOSPORIN	3008			G01AA10	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
L04AD01	CICLOSPORIN	3008			J01FF01	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
L04AD01	CICLOSPORIN	3008			D10AF51	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
S01XA18	CICLOSPORIN	3008			D10AF01	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
S01XA18	CICLOSPORIN	3008			G01AA10	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
S01XA18	CICLOSPORIN	3008			J01FF01	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
S01XA18	CICLOSPORIN	3008			D10AF51	CLINDAMYCIN	2582			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.
L04AD01	CICLOSPORIN	3008			M04AC01	COLCHICINE	2683			ANSM	121-CICLOSPORIN.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, especially in cases of pre-existing renal insufficiency	Not recommended	
S01XA18	CICLOSPORIN	3008			M04AC01	COLCHICINE	2683			ANSM	121-CICLOSPORIN.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, especially in cases of pre-existing renal insufficiency	Not recommended	
L04AD01	CICLOSPORIN	3008			B01AE07	DABIGATRAN	1037042			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of dabigatran by more than twice, with increase of the risk of bleeding	Contraindication	
S01XA18	CICLOSPORIN	3008			B01AE07	DABIGATRAN	1037042			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of dabigatran by more than twice, with increase of the risk of bleeding	Contraindication	
L04AD01	CICLOSPORIN	3008			G03XA01	DANAZOL	3102			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
S01XA18	CICLOSPORIN	3008			G03XA01	DANAZOL	3102			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
L04AD01	CICLOSPORIN	3008						POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	121-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
S01XA18	CICLOSPORIN	3008						POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	121-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
L04AD01	CICLOSPORIN	3008						POTASSIUM LOWERING DIURETICS	C03	ANSM	121-CICLOSPORIN.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Tale into account	
S01XA18	CICLOSPORIN	3008						POTASSIUM LOWERING DIURETICS	C03	ANSM	121-CICLOSPORIN.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Tale into account	
L04AD01	CICLOSPORIN	3008			L01XX41	ERIBULINE	1045453			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of eribuline by the ciclosporin	Not recommended	
S01XA18	CICLOSPORIN	3008			L01XX41	ERIBULINE	1045453			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of eribuline by the ciclosporin	Not recommended	
L04AD01	CICLOSPORIN	3008			L01XE10	EVEROLIMUS	141704			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together 	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped. 
L04AD01	CICLOSPORIN	3008			L04AA18	EVEROLIMUS	141704			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together 	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped. 
S01XA18	CICLOSPORIN	3008			L01XE10	EVEROLIMUS	141704			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together 	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped. 
S01XA18	CICLOSPORIN	3008			L04AA18	EVEROLIMUS	141704			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together 	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped. 
L04AD01	CICLOSPORIN	3008			C10BA05	EZETIMIBE	341248			ANSM	121-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
L04AD01	CICLOSPORIN	3008			C10AX09	EZETIMIBE	341248			ANSM	121-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
L04AD01	CICLOSPORIN	3008			C10BA02	EZETIMIBE	341248			ANSM	121-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
S01XA18	CICLOSPORIN	3008			C10BA05	EZETIMIBE	341248			ANSM	121-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
S01XA18	CICLOSPORIN	3008			C10AX09	EZETIMIBE	341248			ANSM	121-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
S01XA18	CICLOSPORIN	3008			C10BA02	EZETIMIBE	341248			ANSM	121-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
L04AD01	CICLOSPORIN	3008			C10AB05	FENOFIBRATE	8703			ANSM	121-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function during and after the administration of the two medications together. 
L04AD01	CICLOSPORIN	3008			C10BA03	FENOFIBRATE	8703			ANSM	121-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function during and after the administration of the two medications together. 
L04AD01	CICLOSPORIN	3008			C10BA04	FENOFIBRATE	8703			ANSM	121-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function during and after the administration of the two medications together. 
S01XA18	CICLOSPORIN	3008			C10AB05	FENOFIBRATE	8703			ANSM	121-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function during and after the administration of the two medications together. 
S01XA18	CICLOSPORIN	3008			C10BA03	FENOFIBRATE	8703			ANSM	121-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function during and after the administration of the two medications together. 
S01XA18	CICLOSPORIN	3008			C10BA04	FENOFIBRATE	8703			ANSM	121-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function during and after the administration of the two medications together. 
L04AD01	CICLOSPORIN	3008			A07AA12	FIDAXOMICIN	1111103			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of the fidaxomicin. 	Not recommended	
S01XA18	CICLOSPORIN	3008			A07AA12	FIDAXOMICIN	1111103			ANSM	121-CICLOSPORIN.html	Increase of the plasma concentrations of the fidaxomicin. 	Not recommended	
L04AD01	CICLOSPORIN	3008			J01FA07	JOSAMYCIN	6084			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
S01XA18	CICLOSPORIN	3008			J01FA07	JOSAMYCIN	6084			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
L04AD01	CICLOSPORIN	3008			C09BB02	LERCANIDIPINE	135056			ANSM	121-CICLOSPORIN.html	Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications togetherand after it is stopped.
L04AD01	CICLOSPORIN	3008			C08CA13	LERCANIDIPINE	135056			ANSM	121-CICLOSPORIN.html	Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications togetherand after it is stopped.
S01XA18	CICLOSPORIN	3008			C09BB02	LERCANIDIPINE	135056			ANSM	121-CICLOSPORIN.html	Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications togetherand after it is stopped.
S01XA18	CICLOSPORIN	3008			C08CA13	LERCANIDIPINE	135056			ANSM	121-CICLOSPORIN.html	Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications togetherand after it is stopped.
L04AD01	CICLOSPORIN	3008			L01BA0	METHOTREXATE	6851			ANSM	121-CICLOSPORIN.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
L04AD01	CICLOSPORIN	3008			L04AX03	METHOTREXATE	6851			ANSM	121-CICLOSPORIN.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
S01XA18	CICLOSPORIN	3008			L01BA0	METHOTREXATE	6851			ANSM	121-CICLOSPORIN.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
S01XA18	CICLOSPORIN	3008			L04AX03	METHOTREXATE	6851			ANSM	121-CICLOSPORIN.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
L04AD01	CICLOSPORIN	3008			D07AA01	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			D10AA02	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			H02AB04	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			D07CA02	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			S01CA08	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			H02BX01	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			D07AA01	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			D10AA02	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			H02AB04	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			D07CA02	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			S01CA08	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01XA18	CICLOSPORIN	3008			H02BX01	METHYLPREDNISOLONE	6902			ANSM	121-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
L04AD01	CICLOSPORIN	3008			J01FA05	MIDECAMYCIN	30005			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. 
S01XA18	CICLOSPORIN	3008			J01FA05	MIDECAMYCIN	30005			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. 
L04AD01	CICLOSPORIN	3008			N06BA07	MODAFINIL	30125			ANSM	121-CICLOSPORIN.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
S01XA18	CICLOSPORIN	3008			N06BA07	MODAFINIL	30125			ANSM	121-CICLOSPORIN.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
L04AD01	CICLOSPORIN	3008			C08CA05	NIFEDIPINE	7417			ANSM	121-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
L04AD01	CICLOSPORIN	3008			C08GA01	NIFEDIPINE	7417			ANSM	121-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
L04AD01	CICLOSPORIN	3008			C08CA55	NIFEDIPINE	7417			ANSM	121-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
S01XA18	CICLOSPORIN	3008			C08CA05	NIFEDIPINE	7417			ANSM	121-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
S01XA18	CICLOSPORIN	3008			C08GA01	NIFEDIPINE	7417			ANSM	121-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
S01XA18	CICLOSPORIN	3008			C08CA55	NIFEDIPINE	7417			ANSM	121-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	Use another dihydropyridine.
L04AD01	CICLOSPORIN	3008			A08AB01	ORLISTAT	37925			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	Take the orlistat at a different time form the ciclosporin (at least 3 hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the medications together, and at the time of a possible increase in the dosage of the orlistat.
S01XA18	CICLOSPORIN	3008			A08AB01	ORLISTAT	37925			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	Take the orlistat at a different time form the ciclosporin (at least 3 hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the medications together, and at the time of a possible increase in the dosage of the orlistat.
L04AD01	CICLOSPORIN	3008			C10AA08	PITAVASTATIN	861634			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	Contraindication	
S01XA18	CICLOSPORIN	3008			C10AA08	PITAVASTATIN	861634			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	Contraindication	
L04AD01	CICLOSPORIN	3008			A12BA	POTASSIUM	8588			ANSM	121-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid the administration of these two substances together unless there is a pre-existing hypokalemia.
S01XA18	CICLOSPORIN	3008			A12BA	POTASSIUM	8588			ANSM	121-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid the administration of these two substances together unless there is a pre-existing hypokalemia.
L04AD01	CICLOSPORIN	3008			A07EA01	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			C05AA04	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			D07AA03	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			D07XA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			H02AB06	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			R01AD02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S01BA04	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S01CB02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S02BA03	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S03BA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			D07CA03	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S01CA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S02CA01	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S03CA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			D07BA01	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			S01BB02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			V03AB05	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			A01AC54	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			R01AD52	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			A07EA01	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			C05AA04	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			D07AA03	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			D07XA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			H02AB06	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			R01AD02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S01BA04	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S01CB02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S02BA03	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S03BA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			D07CA03	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S01CA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S02CA01	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S03CA02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			D07BA01	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			S01BB02	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			V03AB05	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			A01AC54	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
S01XA18	CICLOSPORIN	3008			R01AD52	PREDNISOLONE	8638			ANSM	121-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
L04AD01	CICLOSPORIN	3008			A10BX02	REPAGLINIDE	73044			ANSM	121-CICLOSPORIN.html	Increase of more than double of the concentrations of the repaglinide due to increase of its absorption	Not recommended	
S01XA18	CICLOSPORIN	3008			A10BX02	REPAGLINIDE	73044			ANSM	121-CICLOSPORIN.html	Increase of more than double of the concentrations of the repaglinide due to increase of its absorption	Not recommended	
L04AD01	CICLOSPORIN	3008			C10AA07	ROSUVASTATIN	301542			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	Contraindication	
S01XA18	CICLOSPORIN	3008			C10AA07	ROSUVASTATIN	301542			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	Contraindication	
L04AD01	CICLOSPORIN	3008			J01FA06	ROXITHROMYCIN	9478			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. 
S01XA18	CICLOSPORIN	3008			J01FA06	ROXITHROMYCIN	9478			ANSM	121-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. 
L04AD01	CICLOSPORIN	3008			C10AA01	SIMVASTATIN	36567			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolosis type due to decrease of the metabolism of the simvastatin	Precaution for use	Do not exceed the dosage of 10mg/day of simavastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
S01XA18	CICLOSPORIN	3008			C10AA01	SIMVASTATIN	36567			ANSM	121-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolosis type due to decrease of the metabolism of the simvastatin	Precaution for use	Do not exceed the dosage of 10mg/day of simavastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
L04AD01	CICLOSPORIN	3008			L04AA10	SIROLIMUS	35302			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together	Precaution for use	It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped.
S01XA18	CICLOSPORIN	3008			L04AA10	SIROLIMUS	35302			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together	Precaution for use	It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped.
L04AD01	CICLOSPORIN	3008			M04AB02	SULFINPYRAZONE	10205			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped.
S01XA18	CICLOSPORIN	3008			M04AB02	SULFINPYRAZONE	10205			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped.
L04AD01	CICLOSPORIN	3008			D01AE15	TERBINAFINE	37801			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
L04AD01	CICLOSPORIN	3008			D01BA02	TERBINAFINE	37801			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
S01XA18	CICLOSPORIN	3008			D01AE15	TERBINAFINE	37801			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
S01XA18	CICLOSPORIN	3008			D01BA02	TERBINAFINE	37801			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
L04AD01	CICLOSPORIN	3008			B01AC05	TICLOPIDINE	10594			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage when the ticlodipine is stopped. 
S01XA18	CICLOSPORIN	3008			B01AC05	TICLOPIDINE	10594			ANSM	121-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage when the ticlodipine is stopped. 
L04AD01	CICLOSPORIN	3008			J01E	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EA	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE02	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE05	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE07	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE01	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE03	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EE04	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			J01EA01	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01E	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EA	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE02	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE05	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE07	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE01	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE03	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EE04	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
S01XA18	CICLOSPORIN	3008			J01EA01	TRIMETHOPRIM	10829			ANSM	121-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
L04AD01	CICLOSPORIN	3008			C08DA01	VERAPAMIL	11170			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
L04AD01	CICLOSPORIN	3008			C08DA51	VERAPAMIL	11170			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
L04AD01	CICLOSPORIN	3008			C09BB10	VERAPAMIL	11170			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
S01XA18	CICLOSPORIN	3008			C08DA01	VERAPAMIL	11170			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
S01XA18	CICLOSPORIN	3008			C08DA51	VERAPAMIL	11170			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
S01XA18	CICLOSPORIN	3008			C09BB10	VERAPAMIL	11170			ANSM	121-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
A02BA01	CIMETIDINE	2541			N01AH02	ALFENTANIL	480			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the cimetidine.
A02BA51	CIMETIDINE	2541			N01AH02	ALFENTANIL	480			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the cimetidine.
A02BA01	CIMETIDINE	2541						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. 
A02BA51	CIMETIDINE	2541						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. 
A02BA01	CIMETIDINE	2541			N03AF01	CARBAMAZEPINE	2002			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine 	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine
A02BA51	CIMETIDINE	2541			N03AF01	CARBAMAZEPINE	2002			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine 	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine
A02BA01	CIMETIDINE	2541			L01AD01	CARMUSTINE	2105			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)	Not recommended	
A02BA51	CIMETIDINE	2541			L01AD01	CARMUSTINE	2105			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)	Not recommended	
A02BA01	CIMETIDINE	2541			C07AG02	CARVEDILOL	20352			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	Contraindication	Use another H2 receptor antagonist.
A02BA51	CIMETIDINE	2541			C07AG02	CARVEDILOL	20352			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	Contraindication	Use another H2 receptor antagonist.
A02BA01	CIMETIDINE	2541			N05BA02	CHLORDIAZEPOXIDE	2356			ANSM	122-CIMETIDINE.html	With the cemitidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn patients of the increase of risk when driving an automobile or using machinery.
A02BA51	CIMETIDINE	2541			N05BA02	CHLORDIAZEPOXIDE	2356			ANSM	122-CIMETIDINE.html	With the cemitidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn patients of the increase of risk when driving an automobile or using machinery.
A02BA01	CIMETIDINE	2541			P01BA01	CHLOROQUINE	2393			ANSM	122-CIMETIDINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
A02BA51	CIMETIDINE	2541			P01BA01	CHLOROQUINE	2393			ANSM	122-CIMETIDINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
A02BA01	CIMETIDINE	2541			L04AD01	CICLOSPORIN	3008			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
A02BA01	CIMETIDINE	2541			S01XA18	CICLOSPORIN	3008			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
A02BA51	CIMETIDINE	2541			L04AD01	CICLOSPORIN	3008			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
A02BA51	CIMETIDINE	2541			S01XA18	CICLOSPORIN	3008			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
A02BA01	CIMETIDINE	2541			N05BA01	DIAZEPAM	3322			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn the patient of the increase of risk when driving an automobile or using machinery. 
A02BA51	CIMETIDINE	2541			N05BA01	DIAZEPAM	3322			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn the patient of the increase of risk when driving an automobile or using machinery. 
A02BA01	CIMETIDINE	2541			C01BB01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			C05AD01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			D04AB01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			N01BB02	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			R02AD02	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			S01HA07	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			S02DA01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			N01BB52	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			C01BB01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			C05AD01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			D04AB01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			N01BB02	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			R02AD02	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			S01HA07	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			S02DA01	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			N01BB52	LIDOCAINE	6387			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			L01AD02	LOMUSTINE	6466			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
A02BA51	CIMETIDINE	2541			L01AD02	LOMUSTINE	6466			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
A02BA01	CIMETIDINE	2541			N02AC52	METHADONE	6813			ANSM	122-CIMETIDINE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			N07BC02	METHADONE	6813			ANSM	122-CIMETIDINE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			N02AC52	METHADONE	6813			ANSM	122-CIMETIDINE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			N07BC02	METHADONE	6813			ANSM	122-CIMETIDINE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			C07AB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA01	CIMETIDINE	2541			C07FB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA01	CIMETIDINE	2541			C07CB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA01	CIMETIDINE	2541			C07BB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA01	CIMETIDINE	2541			C07BB52	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA01	CIMETIDINE	2541			C07AB52	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA51	CIMETIDINE	2541			C07AB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA51	CIMETIDINE	2541			C07FB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA51	CIMETIDINE	2541			C07CB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA51	CIMETIDINE	2541			C07BB02	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA51	CIMETIDINE	2541			C07BB52	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA51	CIMETIDINE	2541			C07AB52	METOPROLOL	6918			ANSM	122-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2 receptor antagonist
A02BA01	CIMETIDINE	2541			N06AG02	MOCLOBEMIDE	30121			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring with possible adjustment of the dosage of the moclobemide
A02BA51	CIMETIDINE	2541			N06AG02	MOCLOBEMIDE	30121			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring with possible adjustment of the dosage of the moclobemide
A02BA01	CIMETIDINE	2541			C08CA05	NIFEDIPINE	7417			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			C08GA01	NIFEDIPINE	7417			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541			C08CA55	NIFEDIPINE	7417			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			C08CA05	NIFEDIPINE	7417			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			C08GA01	NIFEDIPINE	7417			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541			C08CA55	NIFEDIPINE	7417			ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
A02BA01	CIMETIDINE	2541						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of the phenytoin, and possible adjustment of its dosage during the treatment with cimetidine and after it is stopped.
A02BA51	CIMETIDINE	2541						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of the phenytoin, and possible adjustment of its dosage during the treatment with cimetidine and after it is stopped.
A02BA01	CIMETIDINE	2541						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. 
A02BA51	CIMETIDINE	2541						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	122-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. 
H05BX01	CINACALCET	407990			R05DA09	DEXTROMETHORPHAN	3289			ANSM	123-CINACALCET.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Contraindication	
H05BX01	CINACALCET	407990			N07XX59	DEXTROMETHORPHAN	3289			ANSM	123-CINACALCET.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Contraindication	
H05BX01	CINACALCET	407990			C01BC04	FLECAINIDE	4441			ANSM	123-CINACALCET.html	Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.
H05BX01	CINACALCET	407990			R06AD07	MEQUITAZINE	29528			ANSM	123-CINACALCET.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
H05BX01	CINACALCET	407990			C07AB02	METOPROLOL	6918			ANSM	123-CINACALCET.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with cinacalcet.
H05BX01	CINACALCET	407990			C01BC03	PROPAFENONE	8754			ANSM	123-CINACALCET.html	Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.
J01MA02	CIPROFLOXACIN	2551			N06AX22	AGOMELATINE	306718			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
S01AE03	CIPROFLOXACIN	2551			N06AX22	AGOMELATINE	306718			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
S02AA15	CIPROFLOXACIN	2551			N06AX22	AGOMELATINE	306718			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
S03AA07	CIPROFLOXACIN	2551			N06AX22	AGOMELATINE	306718			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
J01MA02	CIPROFLOXACIN	2551			N06BC01	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
J01MA02	CIPROFLOXACIN	2551			V04CG3	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
S01AE03	CIPROFLOXACIN	2551			N06BC01	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
S01AE03	CIPROFLOXACIN	2551			V04CG3	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
S02AA15	CIPROFLOXACIN	2551			N06BC01	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
S02AA15	CIPROFLOXACIN	2551			V04CG3	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
S03AA07	CIPROFLOXACIN	2551			N06BC01	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
S03AA07	CIPROFLOXACIN	2551			V04CG3	CAFFEINE 	1886			ANSM	124-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
J01MA02	CIPROFLOXACIN	2551			N05AH02	CLOZAPINE	2626			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
S01AE03	CIPROFLOXACIN	2551			N05AH02	CLOZAPINE	2626			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
S02AA15	CIPROFLOXACIN	2551			N05AH02	CLOZAPINE	2626			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
S03AA07	CIPROFLOXACIN	2551			N05AH02	CLOZAPINE	2626			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
J01MA02	CIPROFLOXACIN	2551						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	124-CIPROFLOXACIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
S01AE03	CIPROFLOXACIN	2551						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	124-CIPROFLOXACIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
S02AA15	CIPROFLOXACIN	2551						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	124-CIPROFLOXACIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
S03AA07	CIPROFLOXACIN	2551						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	124-CIPROFLOXACIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
J01MA02	CIPROFLOXACIN	2551			L01BA0	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
J01MA02	CIPROFLOXACIN	2551			L04AX03	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
S01AE03	CIPROFLOXACIN	2551			L01BA0	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
S01AE03	CIPROFLOXACIN	2551			L04AX03	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
S02AA15	CIPROFLOXACIN	2551			L01BA0	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
S02AA15	CIPROFLOXACIN	2551			L04AX03	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
S03AA07	CIPROFLOXACIN	2551			L01BA0	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
S03AA07	CIPROFLOXACIN	2551			L04AX03	METHOTREXATE	6851			ANSM	124-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
J01MA02	CIPROFLOXACIN	2551						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	124-CIPROFLOXACIN.html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
S01AE03	CIPROFLOXACIN	2551						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	124-CIPROFLOXACIN.html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
S02AA15	CIPROFLOXACIN	2551						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	124-CIPROFLOXACIN.html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
S03AA07	CIPROFLOXACIN	2551						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	124-CIPROFLOXACIN.html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
J01MA02	CIPROFLOXACIN	2551			N04BC04	ROPINIROLE	72302			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
S01AE03	CIPROFLOXACIN	2551			N04BC04	ROPINIROLE	72302			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
S02AA15	CIPROFLOXACIN	2551			N04BC04	ROPINIROLE	72302			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
S03AA07	CIPROFLOXACIN	2551			N04BC04	ROPINIROLE	72302			ANSM	124-CIPROFLOXACIN.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
J01MA02	CIPROFLOXACIN	2551						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	124-CIPROFLOXACIN.html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia 
S01AE03	CIPROFLOXACIN	2551						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	124-CIPROFLOXACIN.html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia 
S02AA15	CIPROFLOXACIN	2551						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	124-CIPROFLOXACIN.html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia 
S03AA07	CIPROFLOXACIN	2551						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	124-CIPROFLOXACIN.html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia 
			CITRATES	V09HX				ALUMINUM (SALTS)	A02AD0-001	ANSM	125-CITRATES.html	Risk of facilitation of systemic uptake of the aluminum, especially in case of altered renal function. 	Precaution for use	Take the aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including natural citrates (citrus fruits). 
L01BB04	CLADRIBINE	44157			J05AF05	LAMIVUDINE	68244			ANSM	126-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
L01BB04	CLADRIBINE	44157			J05AR02	LAMIVUDINE	68244			ANSM	126-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
L01BB04	CLADRIBINE	44157			J05AR07	LAMIVUDINE	68244			ANSM	126-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
L01BB04	CLADRIBINE	44157			J05AR01	LAMIVUDINE	68244			ANSM	126-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
L01BB04	CLADRIBINE	44157			J05AR04	LAMIVUDINE	68244			ANSM	126-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
L01BB04	CLADRIBINE	44157			J05AR05	LAMIVUDINE	68244			ANSM	126-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J01FA09	CLARITHROMYCIN	21212						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	127-CLARITHROMYCIN.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
A02BD04	CLARITHROMYCIN	21212						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	127-CLARITHROMYCIN.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
A02BD05	CLARITHROMYCIN	21212						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	127-CLARITHROMYCIN.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
A02BD06	CLARITHROMYCIN	21212						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	127-CLARITHROMYCIN.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
A02BD07	CLARITHROMYCIN	21212						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	127-CLARITHROMYCIN.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
J01FA09	CLARITHROMYCIN	21212			J05AE08	ATAZANAVIR	343047			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these together.
A02BD04	CLARITHROMYCIN	21212			J05AE08	ATAZANAVIR	343047			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these together.
A02BD05	CLARITHROMYCIN	21212			J05AE08	ATAZANAVIR	343047			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these together.
A02BD06	CLARITHROMYCIN	21212			J05AE08	ATAZANAVIR	343047			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these together.
A02BD07	CLARITHROMYCIN	21212			J05AE08	ATAZANAVIR	343047			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these together.
J01FA09	CLARITHROMYCIN	21212			C10AA05	ATORVASTATIN	83367			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Administer weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
A02BD04	CLARITHROMYCIN	21212			C10AA05	ATORVASTATIN	83367			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Administer weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
A02BD05	CLARITHROMYCIN	21212			C10AA05	ATORVASTATIN	83367			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Administer weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
A02BD06	CLARITHROMYCIN	21212			C10AA05	ATORVASTATIN	83367			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Administer weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
A02BD07	CLARITHROMYCIN	21212			C10AA05	ATORVASTATIN	83367			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Administer weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
J01FA09	CLARITHROMYCIN	21212			N03AF01	CARBAMAZEPINE	2002			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
A02BD04	CLARITHROMYCIN	21212			N03AF01	CARBAMAZEPINE	2002			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
A02BD05	CLARITHROMYCIN	21212			N03AF01	CARBAMAZEPINE	2002			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
A02BD06	CLARITHROMYCIN	21212			N03AF01	CARBAMAZEPINE	2002			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
A02BD07	CLARITHROMYCIN	21212			N03AF01	CARBAMAZEPINE	2002			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
J01FA09	CLARITHROMYCIN	21212			G04BD10	DARIFENACIN	136198			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
A02BD04	CLARITHROMYCIN	21212			G04BD10	DARIFENACIN	136198			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
A02BD05	CLARITHROMYCIN	21212			G04BD10	DARIFENACIN	136198			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
A02BD06	CLARITHROMYCIN	21212			G04BD10	DARIFENACIN	136198			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
A02BD07	CLARITHROMYCIN	21212			G04BD10	DARIFENACIN	136198			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J01FA09	CLARITHROMYCIN	21212			A01AC02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			C05AA09	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			D07AB19	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			D07XB05	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			D10AA03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			H02AB02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			R01AD03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S01BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S01CB01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S02BA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S03BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			D07CB04	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S01CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S02CA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			S03CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	CLARITHROMYCIN	21212			R01AD53	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			A01AC02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			C05AA09	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			D07AB19	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			D07XB05	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			D10AA03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			H02AB02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			R01AD03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S01BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S01CB01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S02BA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S03BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			D07CB04	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S01CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S02CA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			S03CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD04	CLARITHROMYCIN	21212			R01AD53	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			A01AC02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			C05AA09	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			D07AB19	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			D07XB05	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			D10AA03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			H02AB02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			R01AD03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S01BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S01CB01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S02BA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S03BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			D07CB04	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S01CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S02CA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			S03CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD05	CLARITHROMYCIN	21212			R01AD53	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			A01AC02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			C05AA09	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			D07AB19	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			D07XB05	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			D10AA03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			H02AB02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			R01AD03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S01BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S01CB01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S02BA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S03BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			D07CB04	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S01CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S02CA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			S03CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD06	CLARITHROMYCIN	21212			R01AD53	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			A01AC02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			C05AA09	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			D07AB19	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			D07XB05	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			D10AA03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			H02AB02	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			R01AD03	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S01BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S01CB01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S02BA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S03BA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			D07CB04	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S01CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S02CA06	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			S03CA01	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A02BD07	CLARITHROMYCIN	21212			R01AD53	DEXAMETHASONE	3264			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J01FA09	 CLARITHROMYCIN	21212			C01AA05	DIGOXIN 	3407			ANSM	127-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
A02BD04	 CLARITHROMYCIN	21212			C01AA05	DIGOXIN 	3407			ANSM	127-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
A02BD05	 CLARITHROMYCIN	21212			C01AA05	DIGOXIN 	3407			ANSM	127-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
A02BD06	 CLARITHROMYCIN	21212			C01AA05	DIGOXIN 	3407			ANSM	127-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
A02BD07	 CLARITHROMYCIN	21212			C01AA05	DIGOXIN 	3407			ANSM	127-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
J01FA09	CLARITHROMYCIN	21212			C01BA03	DISOPYRAMIDE	3541			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
A02BD04	CLARITHROMYCIN	21212			C01BA03	DISOPYRAMIDE	3541			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
A02BD05	CLARITHROMYCIN	21212			C01BA03	DISOPYRAMIDE	3541			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
A02BD06	CLARITHROMYCIN	21212			C01BA03	DISOPYRAMIDE	3541			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
A02BD07	CLARITHROMYCIN	21212			C01BA03	DISOPYRAMIDE	3541			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
J01FA09	CLARITHROMYCIN	21212			R06AX22	EBASTINE	23796			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
A02BD04	CLARITHROMYCIN	21212			R06AX22	EBASTINE	23796			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
A02BD05	CLARITHROMYCIN	21212			R06AX22	EBASTINE	23796			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
A02BD06	CLARITHROMYCIN	21212			R06AX22	EBASTINE	23796			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
A02BD07	CLARITHROMYCIN	21212			R06AX22	EBASTINE	23796			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
J01FA09	CLARITHROMYCIN	21212			L01XX41	ERIBULINE	1045453			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
A02BD04	CLARITHROMYCIN	21212			L01XX41	ERIBULINE	1045453			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
A02BD05	CLARITHROMYCIN	21212			L01XX41	ERIBULINE	1045453			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
A02BD06	CLARITHROMYCIN	21212			L01XX41	ERIBULINE	1045453			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
A02BD07	CLARITHROMYCIN	21212			L01XX41	ERIBULINE	1045453			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
J01FA09	CLARITHROMYCIN	21212			J05AG04	ETRAVIRINE	475969			ANSM	127-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
A02BD04	CLARITHROMYCIN	21212			J05AG04	ETRAVIRINE	475969			ANSM	127-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
A02BD05	CLARITHROMYCIN	21212			J05AG04	ETRAVIRINE	475969			ANSM	127-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
A02BD06	CLARITHROMYCIN	21212			J05AG04	ETRAVIRINE	475969			ANSM	127-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
A02BD07	CLARITHROMYCIN	21212			J05AG04	ETRAVIRINE	475969			ANSM	127-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
J01FA09	CLARITHROMYCIN	21212			G04BD11	FESOTERODINE	797195			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD04	CLARITHROMYCIN	21212			G04BD11	FESOTERODINE	797195			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD05	CLARITHROMYCIN	21212			G04BD11	FESOTERODINE	797195			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD06	CLARITHROMYCIN	21212			G04BD11	FESOTERODINE	797195			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD07	CLARITHROMYCIN	21212			G04BD11	FESOTERODINE	797195			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolisers, with risk of overdose	Not recommended	
J01FA09	CLARITHROMYCIN	21212			A07AA12	FIDAXOMICIN	1111103			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A02BD04	CLARITHROMYCIN	21212			A07AA12	FIDAXOMICIN	1111103			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A02BD05	CLARITHROMYCIN	21212			A07AA12	FIDAXOMICIN	1111103			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A02BD06	CLARITHROMYCIN	21212			A07AA12	FIDAXOMICIN	1111103			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A02BD07	CLARITHROMYCIN	21212			A07AA12	FIDAXOMICIN	1111103			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
J01FA09	CLARITHROMYCIN	21212			A10BB01	GLIBENCLAMIDE	4815			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. 
A02BD04	CLARITHROMYCIN	21212			A10BB01	GLIBENCLAMIDE	4815			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. 
A02BD05	CLARITHROMYCIN	21212			A10BB01	GLIBENCLAMIDE	4815			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. 
A02BD06	CLARITHROMYCIN	21212			A10BB01	GLIBENCLAMIDE	4815			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. 
A02BD07	CLARITHROMYCIN	21212			A10BB01	GLIBENCLAMIDE	4815			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. 
J01FA09	CLARITHROMYCIN	21212			A10BB12	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
J01FA09	CLARITHROMYCIN	21212			A10BD06	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD04	CLARITHROMYCIN	21212			A10BB12	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD04	CLARITHROMYCIN	21212			A10BD06	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD05	CLARITHROMYCIN	21212			A10BB12	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD05	CLARITHROMYCIN	21212			A10BD06	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD06	CLARITHROMYCIN	21212			A10BB12	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD06	CLARITHROMYCIN	21212			A10BD06	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD07	CLARITHROMYCIN	21212			A10BB12	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
A02BD07	CLARITHROMYCIN	21212			A10BD06	GLIMEPIRIDE	25789			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 
J01FA09	CLARITHROMYCIN	21212			P01BX01	HALOFANTRINE	50749			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If it is possible, interrupt the macrolide. If administering the two together cannot be avoided, test of the QT before hand and monitor EKG.
A02BD04	CLARITHROMYCIN	21212			P01BX01	HALOFANTRINE	50749			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If it is possible, interrupt the macrolide. If administering the two together cannot be avoided, test of the QT before hand and monitor EKG.
A02BD05	CLARITHROMYCIN	21212			P01BX01	HALOFANTRINE	50749			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If it is possible, interrupt the macrolide. If administering the two together cannot be avoided, test of the QT before hand and monitor EKG.
A02BD06	CLARITHROMYCIN	21212			P01BX01	HALOFANTRINE	50749			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If it is possible, interrupt the macrolide. If administering the two together cannot be avoided, test of the QT before hand and monitor EKG.
A02BD07	CLARITHROMYCIN	21212			P01BX01	HALOFANTRINE	50749			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If it is possible, interrupt the macrolide. If administering the two together cannot be avoided, test of the QT before hand and monitor EKG.
J01FA09	CLARITHROMYCIN	21212						IMMUNOSUPPRESSANTS	L04A	ANSM	127-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
A02BD04	CLARITHROMYCIN	21212						IMMUNOSUPPRESSANTS	L04A	ANSM	127-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
A02BD05	CLARITHROMYCIN	21212						IMMUNOSUPPRESSANTS	L04A	ANSM	127-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
A02BD06	CLARITHROMYCIN	21212						IMMUNOSUPPRESSANTS	L04A	ANSM	127-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
A02BD07	CLARITHROMYCIN	21212						IMMUNOSUPPRESSANTS	L04A	ANSM	127-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
J01FA09	CLARITHROMYCIN	21212						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	-with the avanafil
A02BD04	CLARITHROMYCIN	21212						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	-with the avanafil
A02BD05	CLARITHROMYCIN	21212						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	-with the avanafil
A02BD06	CLARITHROMYCIN	21212						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	-with the avanafil
A02BD07	CLARITHROMYCIN	21212						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	-with the avanafil
J01FA09	CLARITHROMYCIN	21212						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment. 
A02BD04	CLARITHROMYCIN	21212						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment. 
A02BD05	CLARITHROMYCIN	21212						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment. 
A02BD06	CLARITHROMYCIN	21212						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment. 
A02BD07	CLARITHROMYCIN	21212						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment. 
J01FA09	CLARITHROMYCIN	21212			J01XX08	LINEZOLIDE	190376			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
A02BD04	CLARITHROMYCIN	21212			J01XX08	LINEZOLIDE	190376			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
A02BD05	CLARITHROMYCIN	21212			J01XX08	LINEZOLIDE	190376			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
A02BD06	CLARITHROMYCIN	21212			J01XX08	LINEZOLIDE	190376			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
A02BD07	CLARITHROMYCIN	21212			J01XX08	LINEZOLIDE	190376			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
J01FA09	CLARITHROMYCIN	21212			P01BF01	LUMEFANTRINE	847728			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. 
A02BD04	CLARITHROMYCIN	21212			P01BF01	LUMEFANTRINE	847728			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. 
A02BD05	CLARITHROMYCIN	21212			P01BF01	LUMEFANTRINE	847728			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. 
A02BD06	CLARITHROMYCIN	21212			P01BF01	LUMEFANTRINE	847728			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. 
A02BD07	CLARITHROMYCIN	21212			P01BF01	LUMEFANTRINE	847728			ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. 
J01FA09	CLARITHROMYCIN	21212						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the medications together. 
A02BD04	CLARITHROMYCIN	21212						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the medications together. 
A02BD05	CLARITHROMYCIN	21212						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the medications together. 
A02BD06	CLARITHROMYCIN	21212						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the medications together. 
A02BD07	CLARITHROMYCIN	21212						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	127-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the medications together. 
J01FA09	CLARITHROMYCIN	21212			N05CD08	MIDAZOLAM	6960			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Precaution for use	Clinical monitoring and reduction of the dosage of the midazolam during the treatment with the clarithromycin
A02BD04	CLARITHROMYCIN	21212			N05CD08	MIDAZOLAM	6960			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Precaution for use	Clinical monitoring and reduction of the dosage of the midazolam during the treatment with the clarithromycin
A02BD05	CLARITHROMYCIN	21212			N05CD08	MIDAZOLAM	6960			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Precaution for use	Clinical monitoring and reduction of the dosage of the midazolam during the treatment with the clarithromycin
A02BD06	CLARITHROMYCIN	21212			N05CD08	MIDAZOLAM	6960			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Precaution for use	Clinical monitoring and reduction of the dosage of the midazolam during the treatment with the clarithromycin
A02BD07	CLARITHROMYCIN	21212			N05CD08	MIDAZOLAM	6960			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Precaution for use	Clinical monitoring and reduction of the dosage of the midazolam during the treatment with the clarithromycin
J01FA09	CLARITHROMYCIN	21212			R06AX25	MIZOLASTINE	61455			ANSM	127-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A02BD04	CLARITHROMYCIN	21212			R06AX25	MIZOLASTINE	61455			ANSM	127-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A02BD05	CLARITHROMYCIN	21212			R06AX25	MIZOLASTINE	61455			ANSM	127-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A02BD06	CLARITHROMYCIN	21212			R06AX25	MIZOLASTINE	61455			ANSM	127-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A02BD07	CLARITHROMYCIN	21212			R06AX25	MIZOLASTINE	61455			ANSM	127-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J01FA09	CLARITHROMYCIN	21212			C10AA03	PRAVASTATIN	42463			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
A02BD04	CLARITHROMYCIN	21212			C10AA03	PRAVASTATIN	42463			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
A02BD05	CLARITHROMYCIN	21212			C10AA03	PRAVASTATIN	42463			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
A02BD06	CLARITHROMYCIN	21212			C10AA03	PRAVASTATIN	42463			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
A02BD07	CLARITHROMYCIN	21212			C10AA03	PRAVASTATIN	42463			ANSM	127-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
J01FA09	CLARITHROMYCIN	21212			A10BX02	REPAGLINIDE	73044			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.
A02BD04	CLARITHROMYCIN	21212			A10BX02	REPAGLINIDE	73044			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.
A02BD05	CLARITHROMYCIN	21212			A10BX02	REPAGLINIDE	73044			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.
A02BD06	CLARITHROMYCIN	21212			A10BX02	REPAGLINIDE	73044			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.
A02BD07	CLARITHROMYCIN	21212			A10BX02	REPAGLINIDE	73044			ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.
J01FA09	CLARITHROMYCIN	21212			J04AB04	RIFABUTIN	55672			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the use of the two medications together.
A02BD04	CLARITHROMYCIN	21212			J04AB04	RIFABUTIN	55672			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the use of the two medications together.
A02BD05	CLARITHROMYCIN	21212			J04AB04	RIFABUTIN	55672			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the use of the two medications together.
A02BD06	CLARITHROMYCIN	21212			J04AB04	RIFABUTIN	55672			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the use of the two medications together.
A02BD07	CLARITHROMYCIN	21212			J04AB04	RIFABUTIN	55672			ANSM	127-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the use of the two medications together.
J01FA09	CLARITHROMYCIN	21212			C10AA01	SIMVASTATIN	36567			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Contraindication	
A02BD04	CLARITHROMYCIN	21212			C10AA01	SIMVASTATIN	36567			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Contraindication	
A02BD05	CLARITHROMYCIN	21212			C10AA01	SIMVASTATIN	36567			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Contraindication	
A02BD06	CLARITHROMYCIN	21212			C10AA01	SIMVASTATIN	36567			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Contraindication	
A02BD07	CLARITHROMYCIN	21212			C10AA01	SIMVASTATIN	36567			ANSM	127-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Contraindication	
J01FA09	CLARITHROMYCIN	21212			G04BD08	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J01FA09	CLARITHROMYCIN	21212			G04CA53	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD04	CLARITHROMYCIN	21212			G04BD08	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD04	CLARITHROMYCIN	21212			G04CA53	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD05	CLARITHROMYCIN	21212			G04BD08	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD05	CLARITHROMYCIN	21212			G04CA53	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD06	CLARITHROMYCIN	21212			G04BD08	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD06	CLARITHROMYCIN	21212			G04CA53	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD07	CLARITHROMYCIN	21212			G04BD08	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A02BD07	CLARITHROMYCIN	21212			G04CA53	SOLIFENACIN	322167			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of solefenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J01FA09	CLARITHROMYCIN	21212						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
A02BD04	CLARITHROMYCIN	21212						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
A02BD05	CLARITHROMYCIN	21212						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
A02BD06	CLARITHROMYCIN	21212						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
A02BD07	CLARITHROMYCIN	21212						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	127-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
J01FA09	CLARITHROMYCIN	21212						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
A02BD04	CLARITHROMYCIN	21212						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
A02BD05	CLARITHROMYCIN	21212						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
A02BD06	CLARITHROMYCIN	21212						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
A02BD07	CLARITHROMYCIN	21212						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
J01FA09	CLARITHROMYCIN	21212			G04BD07	TOLTERODINE	119565			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD04	CLARITHROMYCIN	21212			G04BD07	TOLTERODINE	119565			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD05	CLARITHROMYCIN	21212			G04BD07	TOLTERODINE	119565			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD06	CLARITHROMYCIN	21212			G04BD07	TOLTERODINE	119565			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
A02BD07	CLARITHROMYCIN	21212			G04BD07	TOLTERODINE	119565			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
J01FA09	CLARITHROMYCIN	21212			N06AX16	VENLAFAXINE	39786			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
A02BD04	CLARITHROMYCIN	21212			N06AX16	VENLAFAXINE	39786			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
A02BD05	CLARITHROMYCIN	21212			N06AX16	VENLAFAXINE	39786			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
A02BD06	CLARITHROMYCIN	21212			N06AX16	VENLAFAXINE	39786			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
A02BD07	CLARITHROMYCIN	21212			N06AX16	VENLAFAXINE	39786			ANSM	127-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
J01FA09	CLARITHROMYCIN	21212						VINCA ALKALOIDS	L01CA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	Strict clinical monitoring and laboratory testing. Possibly, use another antibiotic. 
A02BD04	CLARITHROMYCIN	21212						VINCA ALKALOIDS	L01CA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	Strict clinical monitoring and laboratory testing. Possibly, use another antibiotic. 
A02BD05	CLARITHROMYCIN	21212						VINCA ALKALOIDS	L01CA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	Strict clinical monitoring and laboratory testing. Possibly, use another antibiotic. 
A02BD06	CLARITHROMYCIN	21212						VINCA ALKALOIDS	L01CA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	Strict clinical monitoring and laboratory testing. Possibly, use another antibiotic. 
A02BD07	CLARITHROMYCIN	21212						VINCA ALKALOIDS	L01CA	ANSM	127-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	Strict clinical monitoring and laboratory testing. Possibly, use another antibiotic. 
J01FA09	CLARITHROMYCIN	21212			N05CF02	ZOLPIDEM	39993			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zolpidem	Take into account	
A02BD04	CLARITHROMYCIN	21212			N05CF02	ZOLPIDEM	39993			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zolpidem	Take into account	
A02BD05	CLARITHROMYCIN	21212			N05CF02	ZOLPIDEM	39993			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zolpidem	Take into account	
A02BD06	CLARITHROMYCIN	21212			N05CF02	ZOLPIDEM	39993			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zolpidem	Take into account	
A02BD07	CLARITHROMYCIN	21212			N05CF02	ZOLPIDEM	39993			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zolpidem	Take into account	
J01FA09	CLARITHROMYCIN	21212			N05CF01	ZOPICLONE	40001			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
A02BD04	CLARITHROMYCIN	21212			N05CF01	ZOPICLONE	40001			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
A02BD05	CLARITHROMYCIN	21212			N05CF01	ZOPICLONE	40001			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
A02BD06	CLARITHROMYCIN	21212			N05CF01	ZOPICLONE	40001			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
A02BD07	CLARITHROMYCIN	21212			N05CF01	ZOPICLONE	40001			ANSM	127-CLARITHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
D10AF01	CLINDAMYCIN	2582						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	128-CLINDAMYCIN.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. 
G01AA10	CLINDAMYCIN	2582						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	128-CLINDAMYCIN.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. 
J01FF01	CLINDAMYCIN	2582						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	128-CLINDAMYCIN.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. 
D10AF51	CLINDAMYCIN	2582						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	128-CLINDAMYCIN.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. 
D10AF01	CLINDAMYCIN	2582			L04AD01	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
D10AF01	CLINDAMYCIN	2582			S01XA18	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
G01AA10	CLINDAMYCIN	2582			L04AD01	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
G01AA10	CLINDAMYCIN	2582			S01XA18	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
J01FF01	CLINDAMYCIN	2582			L04AD01	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
J01FF01	CLINDAMYCIN	2582			S01XA18	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
D10AF51	CLINDAMYCIN	2582			L04AD01	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
D10AF51	CLINDAMYCIN	2582			S01XA18	CICLOSPORIN	3008			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.
D10AF01	CLINDAMYCIN	2582			D11AH01	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
D10AF01	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
D10AF01	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
G01AA10	CLINDAMYCIN	2582			D11AH01	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
G01AA10	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
G01AA10	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
J01FF01	CLINDAMYCIN	2582			D11AH01	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
J01FF01	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
J01FF01	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
D10AF51	CLINDAMYCIN	2582			D11AH01	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
D10AF51	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
D10AF51	CLINDAMYCIN	2582			L04AD02	TACROLIMUS	42316			ANSM	128-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	Reinforced testing of blood dosages of tacrolimus and possible increase of its dosage.
N05BA09	CLOBAZAM	21241			N03AX17	STIRIPENTOL	37119			ANSM	129-CLOBAZAM.html	Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of that anticonvulsant as well.
D05BB02	ACITRETIN	16818				ALCOHOL (DRINK OR INGREDIENT)				ANSM	13-ACITRETIN.html	For women of child bearing age, risk of transformation of the acitretin into etretinate, a powerful agent of birth defects and malformations with a very prolonged half life (120 days), which exposes the woman to a major risk of these birth defects and malformations of the child in case of pregnancy, during the treatment and two months after it ends. 	Contraindication	
D05BB02	ACITRETIN	16818			L01BA0	METHOTREXATE	6851			ANSM	13-ACITRETIN.html	Risk of increase of the hepatoxicity of the methotrexate	Not recommended	If administering these substances together is judged necessary, strengthen liver function testing. 
N06AA04	CLOMIPRAMINE	2597			N06AX12	BUPROPION	42347			ANSM	130-CLOMIPRAMINE.html	Risk of increase of the undesirable effects of the clomipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion. 
N03AE01	CLONAZEPAM	2598			N03AF01	CARBAMAZEPINE	2002			ANSM	131-CLONAZEPAM.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants
C02AC01	CLONIDINE	2599						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	132-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
N02CX02	CLONIDINE	2599						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	132-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
S01EA04	CLONIDINE	2599						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	132-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
C02LC01	CLONIDINE	2599						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	132-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
C02LC51	CLONIDINE	2599						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	132-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
C02AC01	CLONIDINE	2599			C08DB01	DILTIAZEM	3443			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
N02CX02	CLONIDINE	2599			C08DB01	DILTIAZEM	3443			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
S01EA04	CLONIDINE	2599			C08DB01	DILTIAZEM	3443			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C02LC01	CLONIDINE	2599			C08DB01	DILTIAZEM	3443			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C02LC51	CLONIDINE	2599			C08DB01	DILTIAZEM	3443			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C02AC01	CLONIDINE	2599			C08DA01	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02AC01	CLONIDINE	2599			C08DA51	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02AC01	CLONIDINE	2599			C09BB10	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
N02CX02	CLONIDINE	2599			C08DA01	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
N02CX02	CLONIDINE	2599			C08DA51	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
N02CX02	CLONIDINE	2599			C09BB10	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
S01EA04	CLONIDINE	2599			C08DA01	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
S01EA04	CLONIDINE	2599			C08DA51	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
S01EA04	CLONIDINE	2599			C09BB10	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02LC01	CLONIDINE	2599			C08DA01	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02LC01	CLONIDINE	2599			C08DA51	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02LC01	CLONIDINE	2599			C09BB10	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02LC51	CLONIDINE	2599			C08DA01	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02LC51	CLONIDINE	2599			C08DA51	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02LC51	CLONIDINE	2599			C09BB10	VERAPAMIL	11170			ANSM	132-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to the addition of the negative effects on conduction)	Take into account	
C02AC01	CLONIDINE	2599			G04BE04	YOHIMBINE	220982			ANSM	132-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
N02CX02	CLONIDINE	2599			G04BE04	YOHIMBINE	220982			ANSM	132-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
S01EA04	CLONIDINE	2599			G04BE04	YOHIMBINE	220982			ANSM	132-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
C02LC01	CLONIDINE	2599			G04BE04	YOHIMBINE	220982			ANSM	132-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
C02LC51	CLONIDINE	2599			G04BE04	YOHIMBINE	220982			ANSM	132-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
B01AC04	CLOPIDOGREL	32968			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	133-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	-except in validated indications for this combination of drugs in acute coronary syndromes. 
B01AC04	CLOPIDOGREL	32968						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	133-CLOPIDOGREL.html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
N05AH02	CLOZAPINE	2626						BENZODIAZEPINES AND RELATED	N05-001	ANSM	134-CLOZAPINE.html	Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.	Take into account	
N05AH02	CLOZAPINE	2626			N03AF01	CARBAMAZEPINE	2002			ANSM	134-CLOZAPINE.html	Risk of increase of the serious hematological effects 	Not recommended	
N05AH02	CLOZAPINE	2626			J01MA02	CIPROFLOXACIN	2551			ANSM	134-CLOZAPINE.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
N05AH02	CLOZAPINE	2626			S01AE03	CIPROFLOXACIN	2551			ANSM	134-CLOZAPINE.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
N05AH02	CLOZAPINE	2626			S02AA15	CIPROFLOXACIN	2551			ANSM	134-CLOZAPINE.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
N05AH02	CLOZAPINE	2626			S03AA07	CIPROFLOXACIN	2551			ANSM	134-CLOZAPINE.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with ciprofloxacin and after it is stopped. 
N05AH02	CLOZAPINE	2626			N06AB08	FLUVOXAMINE	42355			ANSM	134-CLOZAPINE.html	Increase of the plasma concentrations of clozapine with signs of overdose	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.
N05AH02	CLOZAPINE	2626						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	134-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.
N05AH02	CLOZAPINE	2626			J04AB02	RIFAMPICIN	9384			ANSM	134-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
N05AH02	CLOZAPINE	2626			J04AM02	RIFAMPICIN	9384			ANSM	134-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
N05AH02	CLOZAPINE	2626			J04AM05	RIFAMPICIN	9384			ANSM	134-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
N05AH02	CLOZAPINE	2626			J04AM06	RIFAMPICIN	9384			ANSM	134-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
V03AX03	COBICISTAT	1306284						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	135-COBICISTAT.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
J05AR09	COBICISTAT	1306284						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	135-COBICISTAT.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
V03AX03	COBICISTAT	1306284			C01BD01	AMIODARONE	703			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	Contraindication	
J05AR09	COBICISTAT	1306284			C01BD01	AMIODARONE	703			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	Contraindication	
V03AX03	COBICISTAT	1306284						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to the increase of its metabolism by the inducer	Contraindication	
J05AR09	COBICISTAT	1306284						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to the increase of its metabolism by the inducer	Contraindication	
V03AX03	COBICISTAT	1306284				ST JOHNS WORT	258326			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J05AR09	COBICISTAT	1306284				ST JOHNS WORT	258326			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
V03AX03	COBICISTAT	1306284			C01BA01	QUINIDINE	9068			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
V03AX03	COBICISTAT	1306284			C01BA51	QUINIDINE	9068			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
V03AX03	COBICISTAT	1306284			C01BA71	QUINIDINE	9068			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
J05AR09	COBICISTAT	1306284			C01BA01	QUINIDINE	9068			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
J05AR09	COBICISTAT	1306284			C01BA51	QUINIDINE	9068			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
J05AR09	COBICISTAT	1306284			C01BA71	QUINIDINE	9068			ANSM	135-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
V03AX03	COBICISTAT	1306284			J04AB04	RIFABUTIN	55672			ANSM	135-COBICISTAT.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half).
J05AR09	COBICISTAT	1306284			J04AB04	RIFABUTIN	55672			ANSM	135-COBICISTAT.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half).
V03AX03	COBICISTAT	1306284			J04AB02	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
V03AX03	COBICISTAT	1306284			J04AM02	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
V03AX03	COBICISTAT	1306284			J04AM05	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
V03AX03	COBICISTAT	1306284			J04AM06	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J05AR09	COBICISTAT	1306284			J04AB02	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J05AR09	COBICISTAT	1306284			J04AM02	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J05AR09	COBICISTAT	1306284			J04AM05	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J05AR09	COBICISTAT	1306284			J04AM06	RIFAMPICIN	9384			ANSM	135-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
V03AX03	COBICISTAT	1306284						VINCA ALKALOIDS	L01CA	ANSM	135-COBICISTAT.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	Strict clinincal monitoring and possible adjustment of the dosage of the antimitotic
J05AR09	COBICISTAT	1306284						VINCA ALKALOIDS	L01CA	ANSM	135-COBICISTAT.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	Strict clinincal monitoring and possible adjustment of the dosage of the antimitotic
M04AC01	COLCHICINE	2683						AZOLE ANTIFUNGALS	J02AC-001	ANSM	136-COLCHICINE.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	Not recommended	
M04AC01	COLCHICINE	2683						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	136-COLCHICINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped. 
M04AC01	COLCHICINE	2683			L04AD01	CICLOSPORIN	3008			ANSM	136-COLCHICINE.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, espceially in cases of pre-existing renal insufficiency	Not recommended	
M04AC01	COLCHICINE	2683			S01XA18	CICLOSPORIN	3008			ANSM	136-COLCHICINE.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, espceially in cases of pre-existing renal insufficiency	Not recommended	
M04AC01	COLCHICINE	2683						FIBRATES	C01AB-001	ANSM	136-COLCHICINE.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	Clinical monitoring and laboratory tests, particularly at the beginning of the administration of these substances together. 
M04AC01	COLCHICINE	2683						HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	136-COLCHICINE.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	Clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together.
M04AC01	COLCHICINE	2683						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	136-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not recommended	
M04AC01	COLCHICINE	2683						MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	136-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Contraindication	
M04AC01	COLCHICINE	2683						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	136-COLCHICINE.html	Increase od the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the therapy with ombitasvir + paritaprevir	Contraindication	-with patients having renal and/or hepatic insufficiency
M04AC01	COLCHICINE	2683			J01FG01	PRISTINAMYCIN	66958			ANSM	136-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Contraindication	
M04AC01	COLCHICINE	2683			J05AE11	TELAPREVIR	1102261			ANSM	136-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to decrease of its metabolism	Not recommended	In particular with patients having renal and hepatic insufficiency.
M04AC01	COLCHICINE	2683			C08DA01	VERAPAMIL	11170			ANSM	136-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
M04AC01	COLCHICINE	2683			C08DA51	VERAPAMIL	11170			ANSM	136-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
M04AC01	COLCHICINE	2683			C09BB10	VERAPAMIL	11170			ANSM	136-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
A07AA10	COLISTIN	2709						CURARES	M03A-001	ANSM	137-COLISTIN.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarization at the end of anesthesia.
J01XB01	COLISTIN	2709						CURARES	M03A-001	ANSM	137-COLISTIN.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarization at the end of anesthesia.
L01XE16	CRIZOTINIB	1148495						SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	138-CRIZOTINIB.html	Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib	Not recommended	
			CURARES	M03A-001				AMINOGLYCOSIDES	J01GB-001	ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
			CURARES	M03A-001	A07AA10	COLISTIN	2709			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of the curarization at the end of anesthesia.
			CURARES	M03A-001	J01XB01	COLISTIN	2709			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of the curarization at the end of anesthesia.
			CURARES	M03A-001				LINCOSANIDES	J01FF0	ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
			CURARES	M03A-001	A07AA05	POLYMYXIN B	8536			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is admininstered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
			CURARES	M03A-001	J01XB02	POLYMYXIN B	8536			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is admininstered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
			CURARES	M03A-001	S01AA18	POLYMYXIN B	8536			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is admininstered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
			CURARES	M03A-001	S02AA11	POLYMYXIN B	8536			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is admininstered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
			CURARES	M03A-001	S03AA03	POLYMYXIN B	8536			ANSM	139-CURARES.html	Increase of the effects of the curares when the antibiotic is admininstered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
A01AD01	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.
B02BC09	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.
C01CA24	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.
C01CA03	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.
A01AD01	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
B02BC09	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
C01CA24	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
C01CA03	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
A01AD01	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
B02BC09	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
C01CA24	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
C01CA03	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
A01AD01	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
B02BC09	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
C01CA24	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
C01CA03	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992						MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
			NON-DEPOLARIZING CURARES	M03A-002				GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	140-NON-DEPOLARIZING-CURARES.html	With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).	Take into account	
B03BA01	CYANOCOBALAMIN	11248						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	141-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12	Take into account	
B03BA02	CYANOCOBALAMIN	11248						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	141-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12	Take into account	
B03BA51	CYANOCOBALAMIN	11248						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	141-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12	Take into account	
B03BA01	CYANOCOBALAMIN	11248						PROTON PUMP INHIBITORS	A02BC-001	ANSM	141-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
B03BA02	CYANOCOBALAMIN	11248						PROTON PUMP INHIBITORS	A02BC-001	ANSM	141-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
B03BA51	CYANOCOBALAMIN	11248						PROTON PUMP INHIBITORS	A02BC-001	ANSM	141-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped. 
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A12AA	CALCIUM	1428011			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the calcium salts at a different time from the tetracycline antibiotic (more than two hours apart, if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	B03A	IRON	1431589			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)	Precaution for use	Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart, if possible). 
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA				RETINOIDS	D05-D10	ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Risk of intracranial hypertension	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	V10BX01	STRONTIUM	81638			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the strontium 	Precaution for use	Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	M05BX03	STRONTIUM	81638			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the strontium 	Precaution for use	Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A11C	VITAMIN A	11246			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A11CA	VITAMIN A	11246			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A11CA01	VITAMIN A	11246			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A11CA02	VITAMIN A	11246			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A11CB	VITAMIN A	11246			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	V04CB01	VITAMIN A	11246			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 	Contraindication	
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A12CB	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A12CB01	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A12CB02	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	A12CB03	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	B05X	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	B05XA	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	B05XA12	ZINC	1431163			ANSM	142-TETRACYCLINE ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
L01AA01	CYCLOPHOSPHAMIDE	3002			L01XX08	PENTOSTATIN	8011			ANSM	143-CYCLOPHOSPHAMIDE.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
R06AX02	CYPROHEPTADINE	3013						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	144-CYPROHEPTADINE.html	Risk of decrease of the effectiveness of the antidepressant	Take into account 	
G03HA01	CYPROTERONE	3014				ST JOHNS WORT	258326			ANSM	145-CYPROTERONE.html	Decrease of the effectiveness of the progestin, due to increase of its hepatic metabolism by the St Johns Wort 	Not recommended	
G03HB01	CYPROTERONE	3014				ST JOHNS WORT	258326			ANSM	145-CYPROTERONE.html	Decrease of the effectiveness of the progestin, due to increase of its hepatic metabolism by the St Johns Wort 	Not recommended	
			CYTOTOXICS	L01				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	146-CYTOTOXICS.html	Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy	Precaution for use	More frequent testing of the INR
			CYTOTOXICS	L01				IMMUNOSUPPRESSANTS	L04A	ANSM	146-CYTOTOXICS.html	Excessive immunodepression with risk of lymphoproliferative syndrome	Take into account	
			CYTOTOXICS	L01				PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	146-CYTOTOXICS.html	Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of effectiveness of the cytotoxic due to the increase of its hepatic metabolismby the phenytoin or the fosphenytoin	Not recommended	
			CYTOTOXICS	L01				ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	146-CYTOTOXICS.html	Risk of general vaccine disease, possibly fatal	Contraindication	--and during the 6 months following the end of the chemotherapy
B01AE07	DABIGATRAN	1037042			C01BD01	AMIODARONE	703			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	For post surgical indications:
B01AE07	DABIGATRAN	1037042						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	147-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
B01AE07	DABIGATRAN	1037042			L04AD01	CICLOSPORIN	3008			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			S01XA18	CICLOSPORIN	3008			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			C01BD07	DRONEDARONE	233698			ANSM	147-DABIGATRAN.html	Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			J02AC02	ITRACONAZOLE	28031			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			D01AC08	KETOCONAZOLE	6135			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			G01AF11	KETOCONAZOLE	6135			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			J02AB02	KETOCONAZOLE	6135			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			C01BA01	QUINIDINE	9068			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
B01AE07	DABIGATRAN	1037042			C01BA51	QUINIDINE	9068			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
B01AE07	DABIGATRAN	1037042			C01BA71	QUINIDINE	9068			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
B01AE07	DABIGATRAN	1037042			J04AB02	RIFAMPICIN	9384			ANSM	147-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
B01AE07	DABIGATRAN	1037042			J04AM02	RIFAMPICIN	9384			ANSM	147-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
B01AE07	DABIGATRAN	1037042			J04AM05	RIFAMPICIN	9384			ANSM	147-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
B01AE07	DABIGATRAN	1037042			J04AM06	RIFAMPICIN	9384			ANSM	147-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
B01AE07	DABIGATRAN	1037042			D11AH01	TACROLIMUS	42316			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			L04AD02	TACROLIMUS	42316			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			L04AD02	TACROLIMUS	42316			ANSM	147-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	Contraindication	
B01AE07	DABIGATRAN	1037042			B01AC24	TICAGRELOR	1116632			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Take into account	
B01AE07	DABIGATRAN	1037042			C08DA01	VERAPAMIL	11170			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.
B01AE07	DABIGATRAN	1037042			C08DA51	VERAPAMIL	11170			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.
B01AE07	DABIGATRAN	1037042			C09BB10	VERAPAMIL	11170			ANSM	147-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.
L01AX04	DACARBAZINE	3098			L01AD05	FOTEMUSTINE	25287			ANSM	148-DACARBAZINE.html	With the dacarbazine in large doses: risk of pulmonary toxicity (adult respiratory distress syndrome*).*Translators note: In Englsih ARDS is often called acute respiratory distress syndrome, but it is also called adult respiratory distress syndrome to distinguish it from infant respiratory distress syndrome. "Acute adult respiratory distress syndrome" which would be the literal translation from the French here is not usually used in English.	Precaution for use	Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine. 
J05AX14	DACLATASVIR	1606218			C01BD01	AMIODARONE	703			ANSM	149-DACLATASVIR.html	Only in the combination daclatasvir/sofosbuvir:Possibly abrupt onset of bradycardia, that can have fatal consequences	Not recommended	If the administration of these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the daclatasvir/sofosbuvir combination
J05AX14	DACLATASVIR	1606218			A01AC02	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			C05AA09	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			D07AB19	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			D07XB05	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			D10AA03	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			H02AB02	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			R01AD03	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S01BA01	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S01CB01	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S02BA06	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S03BA01	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			D07CB04	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S01CA01	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S02CA06	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			S03CA01	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218			R01AD53	DEXAMETHASONE	3264			ANSM	149-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	With the exception of the dexamethasone administered in a single dose. 
J05AX14	DACLATASVIR	1606218						ENZYMATIC INDUCERS	N03-J05-001	ANSM	149-DACLATASVIR.html	Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication	
J05AX14	DACLATASVIR	1606218						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	149-DACLATASVIR.html	Increase of the concentrations of daclatasvir by the inhibitor.	Precaution for use	The dose of daclatasvir must be decreased to 30 mg 1 time per day in case of administration with the inhibitor.
J05AX14	DACLATASVIR	1606218				ST JOHNS WORT	258326			ANSM	149-DACLATASVIR.html	Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns Wort	Contraindication	
L01XE13	AFATINIB	1430438			C01BD01	AMIODARONE	703			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.	Precaution for use	It is recommended that the amiodarone be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			S01XA18	CICLOSPORIN	3008			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ciclosporin	Precaution for use	It is recommended that the ciclosporin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			D10AF02	ERYTHROMYCIN	4053			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.	Precaution for use	It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			D10AF52	ERYTHROMYCIN	4053			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.	Precaution for use	It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			J01FA01	ERYTHROMYCIN	4053			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.	Precaution for use	It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			S01AA17	ERYTHROMYCIN	4053			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.	Precaution for use	It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the protease inhibiter.	Precaution for use	It is recommended that the protease inhibitor be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			J02AC02	ITRACONAZOLE	28031			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the itraconazole.	Precaution for use	It is recommended that the itraconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			D01AC08	KETOCONAZOLE	6135			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			G01AF11	KETOCONAZOLE	6135			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			J02AB02	KETOCONAZOLE	6135			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
L01XE13	AFATINIB	1430438			C08DA01	VERAPAMIL	11170			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the verapamil.	Precaution for use	It is recommended that the verapamil be administered as great a distance from the afatanib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
J01FG02	DALFOPRISTIN	229369			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	150-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	DALFOPRISTIN	229369			N02CA02	ERGOTAMINE	4025			ANSM	150-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	DALFOPRISTIN	229369			N02CA51	ERGOTAMINE	4025			ANSM	150-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	DALFOPRISTIN	229369			N02CA52	ERGOTAMINE	4025			ANSM	150-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	DALFOPRISTIN	229369			N02CA72	ERGOTAMINE	4025			ANSM	150-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	DALFOPRISTIN	229369						IMMUNOSUPPRESSANTS	L04A	ANSM	150-DALFOPRISTIN.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
J01FG02	DALFOPRISTIN	229369			N05AG02	PIMOZIDE	8331			ANSM	150-DALFOPRISTIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes.	Not recommended	
G03XA01	DANAZOL	3102						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	151-DANAZOL.html	Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			N03AF01	CARBAMAZEPINE	2002			ANSM	151-DANAZOL.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine.
G03XA01	DANAZOL	3102			L04AD01	CICLOSPORIN	3008			ANSM	151-DANAZOL.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
G03XA01	DANAZOL	3102			S01XA18	CICLOSPORIN	3008			ANSM	151-DANAZOL.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
G03XA01	DANAZOL	3102			A10AC01	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AC02	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AC03	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AC04	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AD01	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AD02	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AD03	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AD04	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AD05	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AE01	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AE02	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AE03	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AE04	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AE05	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			A10AF01	INSULIN	5856			ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			C10AA01	SIMVASTATIN	36567			ANSM	151-DANAZOL.html	Increased risk of onset of rhabdomyolysis.	Not recommended	If administering these medications together is deemed necessary, do not exceed the dose of 10mg of simvastatin.
G03XA01	DANAZOL	3102						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	151-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	If the administration of the substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped. 
G03XA01	DANAZOL	3102			D11AH01	TACROLIMUS	42316			ANSM	151-DANAZOL.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.
G03XA01	DANAZOL	3102			L04AD02	TACROLIMUS	42316			ANSM	151-DANAZOL.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.
G03XA01	DANAZOL	3102			L04AD02	TACROLIMUS	42316			ANSM	151-DANAZOL.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.
M03CA	DANTROLENE	3105						DIHYDROPYRIDINES	C08CA-002	ANSM	152-DANTROLENE.html	With the dantrolene administered via IV: cases of fatal ventricular fibrillations are constantly observed in animals when verapamil and dantrolene are administered via IV. The administration of a calcium channel blocker and dantrolene is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Not recommended	
M03CA01	DANTROLENE	3105						DIHYDROPYRIDINES	C08CA-002	ANSM	152-DANTROLENE.html	With the dantrolene administered via IV: cases of fatal ventricular fibrillations are constantly observed in animals when verapamil and dantrolene are administered via IV. The administration of a calcium channel blocker and dantrolene is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Not recommended	
M03CA	DANTROLENE	3105			C08DB01	DILTIAZEM	3443			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication	
M03CA01	DANTROLENE	3105			C08DB01	DILTIAZEM	3443			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication	
M03CA	DANTROLENE	3105			C08DA01	VERAPAMIL	11170			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication 	
M03CA	DANTROLENE	3105			C08DA51	VERAPAMIL	11170			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication 	
M03CA	DANTROLENE	3105			C09BB10	VERAPAMIL	11170			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication 	
M03CA01	DANTROLENE	3105			C08DA01	VERAPAMIL	11170			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication 	
M03CA01	DANTROLENE	3105			C08DA51	VERAPAMIL	11170			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication 	
M03CA01	DANTROLENE	3105			C09BB10	VERAPAMIL	11170			ANSM	152-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Contraindication 	
G04BX14	DAPOXETINE	69394						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	153-DAPOXETINE.html	Risk of increase of the undesirable effects, especially of the vertigo or syncope type	Contraindication	
G04BX14	DAPOXETINE	69394						MEDICATIONS LEADING TO ORTHOSTATIC HYPOTENSION	N05AA-001	ANSM	153-DAPOXETINE.html	Risk of increase of the undesirable effects, especially of the vertigo and fainting type	Nor recommended	-with the type 5 phosphodiesterase inhibitors 
D10AX05	DAPSONE	3108			J05AF01	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
D10AX05	DAPSONE	3108			J05AR01	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
D10AX05	DAPSONE	3108			J05AR04	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
D10AX05	DAPSONE	3108			J05AR05	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J04BA02	DAPSONE	3108			J05AF01	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J04BA02	DAPSONE	3108			J05AR01	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J04BA02	DAPSONE	3108			J05AR04	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J04BA02	DAPSONE	3108			J05AR05	ZIDOVUDINE 	11413			ANSM	154-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J01XX09	DAPTOMYCIN	22299						HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	155-DAPTOMYCIN.html	Risk of addition of undesirable effects (dose dependent) of the rhabdomyolysis type.	Not recommended	If administering these substances together cannot be avoided, reinforce laboratory testing (CPK levels more than once a week) and strict clinical monitoring. 
G04BD10	DARIFENACIN	136198			J01FA09	CLARITHROMYCIN	21212			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			A02BD04	CLARITHROMYCIN	21212			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			A02BD05	CLARITHROMYCIN	21212			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			A02BD06	CLARITHROMYCIN	21212			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			A02BD07	CLARITHROMYCIN	21212			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			D10AF02	ERYTHROMYCIN	4053			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			D10AF52	ERYTHROMYCIN	4053			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			J01FA01	ERYTHROMYCIN	4053			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			S01AA17	ERYTHROMYCIN	4053			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			C01BC04	FLECAINIDE	4441			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of felcainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			J02AC02	ITRACONAZOLE	28031			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			D01AC08	KETOCONAZOLE	6135			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			G01AF11	KETOCONAZOLE	6135			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			J02AB02	KETOCONAZOLE	6135			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			C07AB02	METOPROLOL	6918			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			C07FB02	METOPROLOL	6918			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			C07CB02	METOPROLOL	6918			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			C07BB02	METOPROLOL	6918			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			C07BB52	METOPROLOL	6918			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			C07AB52	METOPROLOL	6918			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			J05AE04	NELFINAVIR	134527			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			J02AC04	POSACONAZOLE	282446			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			C01BC03	PROPAFENONE	8754			ANSM	156-DARIFENACIN.html	Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use.	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.
G04BD10	DARIFENACIN	136198			J01FA15	TELITHROMYCIN	274786			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G04BD10	DARIFENACIN	136198			J02AC03	VORICONAZOLE	121243			ANSM	156-DARIFENACIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
	DASABUVIR	1597381			G03AA15	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB07	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA09	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB05	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA12	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03CA01	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			L02AA03	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA01	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA10	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB06	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA07	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB03	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA03	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB02	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA08	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA04	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB01	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA13	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AA05	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			G03AB04	ETHINYLESTRADIOL	4124			ANSM	157-DASABUVIR.html	Increase of hepatoxicity	Contraindication	
	DASABUVIR	1597381			C10AB04	GEMFIBROZIL	4719			ANSM	157-DASABUVIR.html	Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil	Contraindication	
	DASABUVIR	1597381						ENZYMATIC INDUCERS	N03-J05-001	ANSM	157-DASABUVIR.html	Risk of reduction of the plasma concentrations of the dasabuvir by the inducer.	Contraindication	
	DASABUVIR	1597381				ST JOHNS WORT	258326			ANSM	157-DASABUVIR.html	Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort	Contraindication	
	DASABUVIR	1597381			L01XX23	MITOTANE	7004			ANSM	157-DASABUVIR.html	Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane	Contraindication	
V03AC03	DEFERASIROX	614373			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	158-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	158-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
V03AC03	DEFERASIROX	614373						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	158-DEFERASIROX.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
V03AC03	DEFERASIROX	614373						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	158-DEFERASIROX.html	Increase of the risk of causing ulcers and digestive hemorrhage 	Take into account	
V03AC03	DEFERASIROX	614373			L01AB01	BUSULFAN	1828			ANSM	158-DEFERASIROX.html	Risk of increase of the toxocity of the bufulfan by decrease of its clearance by the deferasirox.	Take into account	
V03AC03	DEFERASIROX	614373			V03AC02	DEFERIPRONE	11645			ANSM	158-DEFERASIROX.html	Risk of hyperchelation	Contraindication	
V03AC03	DEFERASIROX	614373			V03AC01	DEFEROXAMINE	3131			ANSM	158-DEFERASIROX.html	Risk of hyperchelation	Contraindication	
V03AC03	DEFERASIROX	614373			A10BX02	REPAGLINIDE	73044			ANSM	158-DEFERASIROX.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the deferasirox	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests.
V03AC03	DEFERASIROX	614373			J04AB02	RIFAMPICIN	9384			ANSM	158-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.
V03AC03	DEFERASIROX	614373			J04AM02	RIFAMPICIN	9384			ANSM	158-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.
V03AC03	DEFERASIROX	614373			J04AM05	RIFAMPICIN	9384			ANSM	158-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.
V03AC03	DEFERASIROX	614373			J04AM06	RIFAMPICIN	9384			ANSM	158-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.
V03AC02	DEFERIPRONE	11645			V03AC03	DEFERASIROX	614373			ANSM	159-DEFERIPRONE.html	Risk of hyperchelation	Contraindication	
N06AX22	AGOMELATINE	306718			J01MA02	CIPROFLOXACIN	2551			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
N06AX22	AGOMELATINE	306718			S01AE03	CIPROFLOXACIN	2551			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
N06AX22	AGOMELATINE	306718			S02AA15	CIPROFLOXACIN	2551			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
N06AX22	AGOMELATINE	306718			S03AA07	CIPROFLOXACIN	2551			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 	Contraindication	
N06AX22	AGOMELATINE	306718			N06AB08	FLUVOXAMINE	42355			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	Contraindication	
V03AC01	DEFEROXAMINE	3131			A11GA	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			A11GA01	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			A11GA01	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			A11GB	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			A11GB01	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			G01AD03	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			S01XA15	ASCORBIC ACID	1151			ANSM	160-DEFEROXAMINE.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomolies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
V03AC01	DEFEROXAMINE	3131			V03AC03	DEFERASIROX	614373			ANSM	160-DEFEROXAMINE.html	Risk of hyperchelation	Contraindication	
B01AX01	DEFIBROTIDE	1311089						PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	161-DEFIBROTIDE.html	Increased risk of hemorrhage	Not recommended	
B01AX01	DEFIBROTIDE	1311089						ORAL ANTICOAGULANTS	B01A-001	ANSM	161-DEFIBROTIDE.html	Increased risk of hemorrhage.	Not recommended	
B01AX01	DEFIBROTIDE	1311089						HEPARINS	B01AB	ANSM	161-DEFIBROTIDE.html	Increased risk of hemorrhage.	Not recommended	
B01AX01	DEFIBROTIDE	1311089						THROMBOLYTICS	B01AD	ANSM	161-DEFIBROTIDE.html	Increased risk of hemorrhage.	Contraindication	
J04AK06	DELAMANID							ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	162-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AK06	DELAMANID				J04AB02	RIFAMPICIN	9384			ANSM	162-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AK06	DELAMANID				J04AM02	RIFAMPICIN	9384			ANSM	162-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AK06	DELAMANID				J04AM05	RIFAMPICIN	9384			ANSM	162-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AK06	DELAMANID				J04AM06	RIFAMPICIN	9384			ANSM	162-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
			AMINOSALICYLIC ACID DERIVATIVES (ASA) 	A07EC-001	L04AX01	AZATHIOPRINE	1256			ANSM	163-AMINOSALICYLIC-ACID-DERIVATIVES-(ASA).html	Risk of increase of the myelosuppressor effect of the azathioprine due to inhibition of its hepatic metabolism by the ASA derivative, especially in patients presenting a partial deficit of thiopurine methyltransferase (TPMT) 	Take into account	
			AMINOSALICYLIC ACID DERIVATIVES (ASA) 	A07EC-001	L01BB02	MERCAPTOPURINE	103			ANSM	163-AMINOSALICYLIC-ACID-DERIVATIVES-(ASA).html	Risk of increase of the myelosuppressor effect of the mercatopurine due to inhibition of its hepatic metabolism by the ASA derivative, especially in patients presenting a partial deficit of thiopurine methyltransferase (TPMT)	Take into account	
			NITRATE DERIVATIVES AND RELATED	C01D-001				TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	164-NITRATE-DERIVATIVES-AND-RELATED.html	Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and especially provoking an acute coronary accident	Contraindication	
			NITRATE DERIVATIVES AND RELATED	C01D-001				MEDICATIONS THAT LOWER BLOOD PRESSURE 	MLBP	ANSM	164-NITRATE-DERIVATIVES-AND-RELATED.html	Increase of the risk of hypotension, especially orthostatic.	Take into account	
			NITRATE DERIVATIVES AND RELATED	C01D-001	C02KX05	RIOCIGUAT	1439816			ANSM	164-NITRATE-DERIVATIVES-AND-RELATED.html	Risk of significant hypotension (synergic effect).	Contraindication	
N06AA01	DESIPRAMINE	3247			N06AX12	BUPROPION	42347			ANSM	165-DESIPRAMINE.html	Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.
A01AC02	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
C05AA09	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
D07AB19	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
D07XB05	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
D10AA03	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
H02AB02	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
R01AD03	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S01BA01	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S01CB01	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S02BA06	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S03BA01	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
D07CB04	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S01CA01	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S02CA06	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
S03CA01	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
R01AD53	DEXAMETHASONE	3264			L02BG01	AMINOGLUTETHIMIDE	677			ANSM	166-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
A01AC02	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J01FA09	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			A02BD04	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			A02BD05	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			A02BD06	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			A02BD07	CLARITHROMYCIN	21212			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
C05AA09	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
D07AB19	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
D07XB05	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
D10AA03	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
H02AB02	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
R01AD03	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S01BA01	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S01CB01	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S02BA06	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S03BA01	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
D07CB04	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S01CA01	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S02CA06	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
S03CA01	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
R01AD53	DEXAMETHASONE	3264			J05AX14	DACLATASVIR	1606218			ANSM	166-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	Contraindication	With the exception of dexamethasone administered in a single dose. 
A01AC02	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			D10AF02	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			D10AF52	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J01FA01	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			S01AA17	ERYTHROMYCIN	4053			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J02AC02	ITRACONAZOLE	28031			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			D01AC08	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			G01AF11	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J02AB02	KETOCONAZOLE	6135			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J05AE04	NELFINAVIR	134527			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J02AC0	POSACONAZOLE	282446			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
C05AA09	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
D07AB19	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
D07XB05	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
D10AA03	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
H02AB02	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
R01AD03	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S01BA01	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S01CB01	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S02BA06	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S03BA01	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
D07CB04	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S01CA01	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S02CA06	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
S03CA01	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
R01AD53	DEXAMETHASONE	3264			P02BA01	PRAZIQUANTEL	8628			ANSM	166-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
A01AC02	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
C05AA09	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
D07AB19	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
D07XB05	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
D10AA03	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
H02AB02	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
R01AD03	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S01BA01	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S01CB01	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S02BA06	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S03BA01	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
D07CB04	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S01CA01	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S02CA06	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
S03CA01	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
R01AD53	DEXAMETHASONE	3264			J05AG05	RILPIVIRINE	1102270			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose.
A01AC02	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
C05AA09	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
D07AB19	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
D07XB05	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
D10AA03	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
H02AB02	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
R01AD03	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S01BA01	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S01CB01	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S02BA06	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S03BA01	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
D07CB04	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S01CA01	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S02CA06	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
S03CA01	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
R01AD53	DEXAMETHASONE	3264			J05AE14	SIMEPREVIR	1482790			ANSM	166-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metaolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose.
A01AC02	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J01FA15	TELITHROMYCIN	274786			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
A01AC02	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
C05AA09	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07AB19	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07XB05	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D10AA03	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
H02AB02	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD03	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01BA01	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CB01	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02BA06	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03BA01	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
D07CB04	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S01CA01	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S02CA06	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
S03CA01	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
R01AD53	DEXAMETHASONE	3264			J02AC03	VORICONAZOLE	121243			ANSM	166-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
B05AA05	DEXTRAN 40	42635						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	167-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
B03AC06	DEXTRAN 40	42635						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	167-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
B05AA05	DEXTRAN 40	42635						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	167-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
B03AC06	DEXTRAN 40	42635						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	167-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
R05DA09	DEXTROMETHORPHAN	3289			H05BX01	CINACALCET	407990			ANSM	168-DEXTROMETHORPHAN.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Contraindication	
N07XX59	DEXTROMETHORPHAN	3289			H05BX01	CINACALCET	407990			ANSM	168-DEXTROMETHORPHAN.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Contraindication	
R05DA09	DEXTROMETHORPHAN	3289						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	168-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N07XX59	DEXTROMETHORPHAN	3289						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	168-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
R05DA09	DEXTROMETHORPHAN	3289						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	168-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N07XX59	DEXTROMETHORPHAN	3289						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	168-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N05BA01	DIAZEPAM	3322			N05BE01	BUSPIRONE	1827			ANSM	169-DIAZEPAM.html	Risk of increase of the undesirable effects of the buspirone	Take into account	
N05BA01	DIAZEPAM	3322			A02BA01	CIMETIDINE	2541			ANSM	169-DIAZEPAM.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn the patient of the increase of risk when driving an automobile or using machinery. 
N05BA01	DIAZEPAM	3322			A02BA51	CIMETIDINE	2541			ANSM	169-DIAZEPAM.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	Warn the patient of the increase of risk when driving an automobile or using machinery. 
N05BA01	DIAZEPAM	3322						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	169-DIAZEPAM.html	Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin. 
N05BA01	DIAZEPAM	3322			N03AX17	STIRIPENTOL	37119			ANSM	169-DIAZEPAM.html	Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well.
P02CA03	ALBENDAZOLE	430						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	17-ALBENDAZOL.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of loss of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 
P02CA03	ALBENDAZOLE	430						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	17-ALBENDAZOL.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of loss of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer [sic] and after it is stopped. 
P02CA03	ALBENDAZOLE	430			J04AB02	RIFAMPICIN	9384			ANSM	17-ALBENDAZOL.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of loss of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 
P02CA03	ALBENDAZOLE	430			J04AM02	RIFAMPICIN	9384			ANSM	17-ALBENDAZOL.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of loss of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 
P02CA03	ALBENDAZOLE	430			J04AM05	RIFAMPICIN	9384			ANSM	17-ALBENDAZOL.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of loss of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 
P02CA03	ALBENDAZOLE	430			J04AM06	RIFAMPICIN	9384			ANSM	17-ALBENDAZOL.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of loss of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 
J05AF02	DIDANOSINE	3364			M04AA01	ALLOPURINOL	519			ANSM	170-DIDANOSINE.html	Increase of the plasma concentrations of didanosine and of its undesirable effects	Not recommended	
J05AF02	DIDANOSINE	3364			J05AB06	GANCICLOVIR	4678			ANSM	170-DIDANOSINE.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
J05AF02	DIDANOSINE	3364			S01AD09	GANCICLOVIR	4678			ANSM	170-DIDANOSINE.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
J05AF02	DIDANOSINE	3364			P01CX01	PENTAMIDINE	7994			ANSM	170-DIDANOSINE.html	Increased risk of onset of pancreatitis due to addition of undesirable effects	Precaution for use	Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. 
J05AF02	DIDANOSINE	3364			J05AB04	RIBAVIRIN	9344			ANSM	170-DIDANOSINE.html	Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite	Not recommended	
J05AF02	DIDANOSINE	3364			J05AF07	TENOFOVIR DISOPROXIL	300195			ANSM	170-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
J05AF02	DIDANOSINE	3364			J05AR06	TENOFOVIR DISOPROXIL	300195			ANSM	170-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
J05AF02	DIDANOSINE	3364			J05AR08	TENOFOVIR DISOPROXIL	300195			ANSM	170-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
J05AF02	DIDANOSINE	3364			J05AR09	TENOFOVIR DISOPROXIL	300195			ANSM	170-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
J05AF02	DIDANOSINE	3364			J05AR03	TENOFOVIR DISOPROXIL	300195			ANSM	170-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
J05AF02	DIDANOSINE	3364			L04AX02	THALIDOMIDE	10432			ANSM	170-DIDANOSINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together. 
J05AF02	DIDANOSINE	3364			J05AF03	ZALCITABINE	3363			ANSM	170-DIDANOSINE.html	Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. 
			DIGITALIS GLYCOSIDES	C01AA0	C01BD01	AMIODARONE	703			ANSM	171-DIGITALIS-GLYCOSIDES.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. When digoxin is used, increase of the digoxinemia due to decrease of the renal clearance of the digoxin.	Precaution for use	Clinical monitoring, EKG, and, when there is reason to, test the digoxinemia and adjust the dosage of the digoxin. 
			DIGITALIS GLYCOSIDES	C01AA0				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	171-DIGITALIS-GLYCOSIDES.html	Disorders of autoregulation (bradycardia, sinus arrest) and disorders of sino-atrial and atrioventricular conduction	Take into account	
			DIGITALIS GLYCOSIDES	C01AA0	A12AA	CALCIUM	1428011			ANSM	171-DIGITALIS-GLYCOSIDES.html	Risk of serious arrhythmias, even lethal ones with the calcium salts administered by IV route	Contraindication	-with calcium salts via IV aside from parenteral supplementation
			DIGITALIS GLYCOSIDES	C01AA0				POTASSIUM LOWERING AGENTS	C03-001	ANSM	171-DIGITALIS-GLYCOSIDES.html	Hypokaliemia promoting the toxic effects of the digitalis glycosides	Precaution for use	Correct any pre-existing hypokaliemia and maintain clinical monitoring, monitoring of electrolyte balance, and electrocardographic monitoring 
			DIGITALIS GLYCOSIDES	C01AA0	C01CA17	MIDODRINE	6963			ANSM	171-DIGITALIS-GLYCOSIDES.html	Disorders of autoregulation (increase of the bradycardia inducing effect of the midodrine) and disorders of atrioventricular conduction	Not recommended	If administering theses substances together cannot be avoided, strengthen clinical monitoring and EKG.
C01AA04	DIGITOXIN	3403						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	172-DIGITOXIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin (increase of its hepatic metabolism)	Precaution for use	Clinical monitoring, EKG, and, possibly, monitoring of the digitoxinemia. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after it is stopped, or choose digoxin, less metabolized by the liver. 
C01AA04	DIGITOXIN	3403			J04AB02	RIFAMPICIN	9384			ANSM	172-DIGITOXIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the blood level of digitoxin. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after it is stopped, or choose digoxin, less metabolized by the liver. 
C01AA04	DIGITOXIN	3403			J04AM02	RIFAMPICIN	9384			ANSM	172-DIGITOXIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the blood level of digitoxin. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after it is stopped, or choose digoxin, less metabolized by the liver. 
C01AA04	DIGITOXIN	3403			J04AM05	RIFAMPICIN	9384			ANSM	172-DIGITOXIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the blood level of digitoxin. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after it is stopped, or choose digoxin, less metabolized by the liver. 
C01AA04	DIGITOXIN	3403			J04AM06	RIFAMPICIN	9384			ANSM	172-DIGITOXIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the blood level of digitoxin. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after it is stopped, or choose digoxin, less metabolized by the liver. 
C01AA05	DIGOXIN 	3407			J01FA10	AZITHROMYCIN	18631			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during treatment with the azithromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			N03AF01	CARBAMAZEPINE	2002			ANSM	173-DIGOXIN.html	Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia	Precaution for use	Exercise caution in the interpretation of the plasma concentrations.
C01AA05	DIGOXIN 	3407			J01FA09	CLARITHROMYCIN	21212			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			A02BD04	CLARITHROMYCIN	21212			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			A02BD05	CLARITHROMYCIN	21212			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			A02BD06	CLARITHROMYCIN	21212			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			A02BD07	CLARITHROMYCIN	21212			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			C01BD07	DRONEDARONE	233698			ANSM	173-DIGOXIN.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG. 	Not recommended	Reduce the doses of digoxin by half. 
C01AA05	DIGOXIN 	3407			D10AF02	ERYTHROMYCIN	4053			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			D10AF52	ERYTHROMYCIN	4053			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			J01FA01	ERYTHROMYCIN	4053			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407			S01AA17	ERYTHROMYCIN	4053			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped. 
C01AA05	DIGOXIN 	3407				HYDROQUINIDINE	27220			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).	Precaution for use	Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage. 
C01AA05	DIGOXIN 	3407						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	173-DIGOXIN.html	Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.
C01AA05	DIGOXIN 	3407			J02AC02	ITRACONAZOLE	28031			ANSM	173-DIGOXIN.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG, and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.
C01AA05	DIGOXIN 	3407				ST JOHNS WORT	258326			ANSM	173-DIGOXIN.html	Decrease of the digoxinemia, by reason of the enzyme inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure). 	Contraindication	In the case of the two substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns wort is stopped. 
C01AA05	DIGOXIN 	3407			A02BC01	OMEPRAZOLE	7646			ANSM	173-DIGOXIN.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 
C01AA05	DIGOXIN 	3407			A02BD05	OMEPRAZOLE	7646			ANSM	173-DIGOXIN.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 
C01AA05	DIGOXIN 	3407			A02BD01	OMEPRAZOLE	7646			ANSM	173-DIGOXIN.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 
C01AA05	DIGOXIN 	3407			J02AC04	POSACONAZOLE	282446			ANSM	173-DIGOXIN.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digxoin during the treatment with the posaconazole and after it is stopped.
C01AA05	DIGOXIN 	3407			C01BC03	PROPAFENONE	8754			ANSM	173-DIGOXIN.html	Risk of increase of the digoxinemia, especially with older patients	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.
C01AA05	DIGOXIN 	3407			C01BA01	QUINIDINE	9068			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 
C01AA05	DIGOXIN 	3407			C01BA51	QUINIDINE	9068			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 
C01AA05	DIGOXIN 	3407			C01BA71	QUINIDINE	9068			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 
C01AA05	DIGOXIN 	3407			P01BC01	QUININE	9071			ANSM	173-DIGOXIN.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
C01AA05	DIGOXIN 	3407			M09AA72	QUININE	9071			ANSM	173-DIGOXIN.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
C01AA05	DIGOXIN 	3407			M09AA	QUININE	9071			ANSM	173-DIGOXIN.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
C01AA05	DIGOXIN 	3407			C01EB18	RANOLAZINE	35829			ANSM	173-DIGOXIN.html	Increase of the digoxinemia	Precaution for use	Clinical monitoring, laboratory tests, and possibly EKG. Adjustment of the dosage of the digoxin if needed.
C01AA05	DIGOXIN 	3407			A02BX02	SUCRALFATE	10156			ANSM	173-DIGOXIN.html	Decrease of the digestive absorption of the digoxin	Precaution for use	Take the sucralfate at a different time from the digoxin (more than 2 hours apart, if possible).
C01AA05	DIGOXIN 	3407			A07EC01	SULFASALAZINE	9524			ANSM	173-DIGOXIN.html	Decrease of the digoxinemia that can reach 50%	Precaution for use	Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.
C01AA05	DIGOXIN 	3407			J05AE11	TELAPREVIR	1102261			ANSM	173-DIGOXIN.html	Increase of the digoxinemia	Precaution for use	Clinical monitoring, laboratory tests, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped.
C01AA05	DIGOXIN 	3407			J01FA15	TELITHROMYCIN	274786			ANSM	173-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the telithromycin and after it is stopped
C01AA05	DIGOXIN 	3407			C08DA01	VERAPAMIL	11170			ANSM	173-DIGOXIN.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG, and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.
C01AA05	DIGOXIN 	3407			C08DA51	VERAPAMIL	11170			ANSM	173-DIGOXIN.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG, and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.
C01AA05	DIGOXIN 	3407			C09BB10	VERAPAMIL	11170			ANSM	173-DIGOXIN.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG, and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.
N02CA01	DIHYDROERGOTAMINE	3418			J01FG02	DALFOPRISTIN	229369			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418			C08DB01	DILTIAZEM	3443			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418			J05AG03	EFAVIRENZ	195085			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418			J05AR06	EFAVIRENZ	195085			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418						MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418			J01FG02	QUINUPRISTINE	135098			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418			N03AX17	STIRIPENTOL	37119			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	Contraindication	
N02CA01	DIHYDROERGOTAMINE	3418			P02BX04	TRICLABENDAZOLE	38608			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication 	Wait 24 hours between stopping the triclabendazole and taking the medication derived from ergot of rye, and the reverse.
N02CA01	DIHYDROERGOTAMINE	3418			J02AC03	VORICONAZOLE	121243			ANSM	174-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
			DIHYDROPYRIDINES	C08CA-002				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	175-DIHYDROPYRIDINES.html	Hypotension, heart failure with patients having latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion	Take into account	
			DIHYDROPYRIDINES	C08CA-002				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	175-DIHYDROPYRIDINES.html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative inotropic effect of the dihydropyridines in vitro, more or less marked, and susceptible of adding to the negative inotropic effects of the beta blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion. 	Take into account	
			DIHYDROPYRIDINES	C08CA-002	M03CA	DANTROLENE	3105			ANSM	175-DIHYDROPYRIDINES.html	With the dantrolene administered via IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered via IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Not recommended	
			DIHYDROPYRIDINES	C08CA-002	M03CA01	DANTROLENE	3105			ANSM	175-DIHYDROPYRIDINES.html	With the dantrolene administered via IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered via IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Not recommended	
C08DB01	DILTIAZEM	3443			N01AH02	ALFENTANIL 	480			ANSM	176-DILTIAZEM.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use:	Adjust the dosage of the alfentanil when administered with the diltiazem. 
C08DB01	DILTIAZEM	3443			C01BD01	AMIODARONE	703			ANSM	176-DILTIAZEM.html	For diltiazem by injection: risk of bradycardia and of atrioventricular blockFor deltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.	Not recommended	-with diltiazem administered intravenously
C08DB01	DILTIAZEM	3443			C10AA05	ATORVASTATIN	83367			ANSM	176-DILTIAZEM.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use lower doses of the cholesterol lowering agent or another statin not affected by this type of interaction.
C08DB01	DILTIAZEM	3443						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	176-DILTIAZEM.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	The administration of these medications together should only be done under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment.
C08DB01	DILTIAZEM	3443						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	176-DILTIAZEM.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction	Not recommended	
C08DB01	DILTIAZEM	3443			N05BE01	BUSPIRONE	1827			ANSM	176-DILTIAZEM.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
C08DB01	DILTIAZEM	3443			C02AC01	CLONIDINE	2599			ANSM	176-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DB01	DILTIAZEM	3443			N02CX02	CLONIDINE	2599			ANSM	176-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DB01	DILTIAZEM	3443			S01EA04	CLONIDINE	2599			ANSM	176-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DB01	DILTIAZEM	3443			C02LC01	CLONIDINE	2599			ANSM	176-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DB01	DILTIAZEM	3443			C02LC51	CLONIDINE	2599			ANSM	176-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DB01	DILTIAZEM	3443			M03CA	DANTROLENE	3105			ANSM	176-DILTIAZEM.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantolene together is thus potentially dangerous. However, some patients have received nifedipine and dantolene together without incident	Contraindication	
C08DB01	DILTIAZEM	3443			M03CA01	DANTROLENE	3105			ANSM	176-DILTIAZEM.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantolene together is thus potentially dangerous. However, some patients have received nifedipine and dantolene together without incident	Contraindication	
C08DB01	DILTIAZEM	3443			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	176-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
C08DB01	DILTIAZEM	3443			C01BD07	DRONEDARONE	233698			ANSM	176-DILTIAZEM.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Begin the treatment with the calcium channel blocker at the minimum recommended dosages and adjust the doses according to the EKG.
C08DB01	DILTIAZEM	3443			N02CA02	ERGOTAMINE	4025			ANSM	176-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
C08DB01	DILTIAZEM	3443			N02CA51	ERGOTAMINE	4025			ANSM	176-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
C08DB01	DILTIAZEM	3443			N02CA52	ERGOTAMINE	4025			ANSM	176-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
C08DB01	DILTIAZEM	3443			N02CA72	ERGOTAMINE	4025			ANSM	176-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
C08DB01	DILTIAZEM	3443			C07AB09	ESMOLOL	49737			ANSM	176-DILTIAZEM.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest.	Not recommended	-in case of alteration of left ventricular function
C08DB01	DILTIAZEM	3443			L01XE27	IBRUTINIB	1442981			ANSM	176-DILTIAZEM.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time that these medications are administered together.
C08DB01	DILTIAZEM	3443						IMMUNOSUPPRESSANTS	L04A	ANSM	176-DILTIAZEM.html	Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
C08DB01	DILTIAZEM	3443			C01EB17	IVABRADINE	77417			ANSM	176-DILTIAZEM.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules. 	Contraindication	
C08DB01	DILTIAZEM	3443			N05CD08	MIDAZOLAM	6960			ANSM	176-DILTIAZEM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the diltiazem
C08DB01	DILTIAZEM	3443			C08CA05	NIFEDIPINE	7417			ANSM	176-DILTIAZEM.html	Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08DB01	DILTIAZEM	3443			C08CA05	NIFEDIPINE	7417			ANSM	176-DILTIAZEM.html	Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08DB01	DILTIAZEM	3443			C08GA01	NIFEDIPINE	7417			ANSM	176-DILTIAZEM.html	Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08DB01	DILTIAZEM	3443			C08CA55	NIFEDIPINE	7417			ANSM	176-DILTIAZEM.html	Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08DB01	DILTIAZEM	3443			N05AG02	PIMOZIDE	8331			ANSM	176-DILTIAZEM.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C08DB01	DILTIAZEM	3443			C10AA01	SIMVASTATIN	36567			ANSM	176-DILTIAZEM.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Do not exceed the dosage of 20 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction
C08DB01	DILTIAZEM	3443			G04CA02	TAMSULOSINE	77492			ANSM	176-DILTIAZEM.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if that were the case.
C08DB01	DILTIAZEM	3443			G04CA52	TAMSULOSINE	77492			ANSM	176-DILTIAZEM.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if that were the case.
C08DB01	DILTIAZEM	3443			G04CA53	TAMSULOSINE	77492			ANSM	176-DILTIAZEM.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, if that were the case.
C08DB01	DILTIAZEM	3443			B01AC24	TICAGRELOR	1116632			ANSM	176-DILTIAZEM.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolsim	Take into account	
R03DA01	DIPROPHYLLINE	3714			M04AB01	PROBENECID	8698			ANSM	177-DIPROPHYLLINE.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
R03DB01	DIPROPHYLLINE	3714			M04AB01	PROBENECID	8698			ANSM	177-DIPROPHYLLINE.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
R03DA51	DIPROPHYLLINE	3714			M04AB01	PROBENECID	8698			ANSM	177-DIPROPHYLLINE.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
B01AC07	DIPYRIDAMOLE	3521				THEINE				ANSM	178-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theine	Precaution for use	Avoid the consumption of theine based products during the 24 hours before myocardial perfusion imaging with dipyridamole
B01AC07	DIPYRIDAMOLE	3521						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	178-DIPYRIDAMOLE.html	With the dipyridamole by injection: increase of the antihypertensive effect	Take into account	
B01AC07	DIPYRIDAMOLE	3521			N06BC01	CAFFEINE 	1886			ANSM	178-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine 	Precaution for use	Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test. 
B01AC07	DIPYRIDAMOLE	3521			V04CG30	CAFFEINE 	1886			ANSM	178-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine 	Precaution for use	Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test. 
B01AC07	DIPYRIDAMOLE	3521						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	178-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline	Precaution for use	Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.
C01BA03	DISOPYRAMIDE	3541			J01FA09	CLARITHROMYCIN	21212			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			A02BD04	CLARITHROMYCIN	21212			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			A02BD05	CLARITHROMYCIN	21212			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			A02BD06	CLARITHROMYCIN	21212			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			A02BD07	CLARITHROMYCIN	21212			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			D10AF02	ERYTHROMYCIN	4053			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type.	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			D10AF52	ERYTHROMYCIN	4053			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type.	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			J01FA01	ERYTHROMYCIN	4053			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type.	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			S01AA17	ERYTHROMYCIN	4053			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type.	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
C01BA03	DISOPYRAMIDE	3541			J01FA07	JOSAMYCIN	6084			ANSM	179-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type.	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
			URINARY ALKALIZERS	B05-001		HYDROQUINIDINE	27220			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of renal excretion of the hydroquinidine by alkalinizing of the urine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
			URINARY ALKALIZERS	B05-001	C01BA01	QUINIDINE	9068			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
			URINARY ALKALIZERS	B05-001	C01BA51	QUINIDINE	9068			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
			URINARY ALKALIZERS	B05-001	C01BA71	QUINIDINE	9068			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
N07BB01	DISULFIRAM	3554						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	180-DISULFIRAM.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped
N07BB01	DISULFIRAM	3554			J04AM03	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AC01	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AC51	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AM02	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AM05	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AM06	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AM01	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			J04AM04	ISONIAZID	6038			ANSM	180-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
N07BB01	DISULFIRAM	3554			A02BD08	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			A02BD03	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			A02BD02	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			A01AB17	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			D06BX01	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			G01AF01	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			J01XD01	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			P01AB01	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554			A02BD01	METRONIDAZOLE	6922			ANSM	180-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
N07BB01	DISULFIRAM	3554						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	180-DISULFIRAM.html	Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)	Not recommended	If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped. 
			DIURETICS	C0E-001	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	181-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use:	Hydrate the patient and monitor renal function at the start of treatment.
			DIURETICS	C0E-001				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	181-DIURETICS.html	Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment
			DIURETICS	C0E-001				IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	181-DIURETICS.html	In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used	Precaution for use	Rehydrate before administration of the iodinated product
			LOOP DIURETICS	C03CA-001				AMINOGLYCOSIDES	J01GB-001	ANSM	182-LOOP-DIURETICS.html	Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)	Precaution for use	The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and possibly, of the plasma concentrations of the aminoglycoside
			LOOP DIURETICS	C03CA-001	D11AX04	LITHIUM	6448			ANSM	182-LOOP-DIURETICS.html	Increase of the lithemia with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)		
			LOOP DIURETICS	C03CA-001	A10BA02	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD13	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD11	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD05	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD03	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD10	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD07	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD02	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001	A10BD08	METFORMIN	6809			ANSM	182-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
			LOOP DIURETICS	C03CA-001				PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA	ANSM	182-LOOP-DIURETICS.html	Risk of addition of the ototoxic and/or nephrotoxic effects		
										ANSM	182-LOOP-DIURETICS.html			
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004				POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Contraindication	Contraindication unless there is hypokalemia.
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004				ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Except for the eplerenone and the spironolactone in doses between 12.5mg and 50 mg/day for the treatment of heart failure as well as in cases of hypokalemia: Risk of hyperkalemia (possibly lethal) especially when there is renal insufficiency (addition of the effects of the hyperkalemia inducing substances)	Not recommended	If administering these medications together is justified, strict testing of the kalemia and of the renal function.
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	L04AD01	CICLOSPORIN	3008			ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	S01XA18	CICLOSPORIN	3008			ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004				POTASSIUM LOWERING DIURETICS	C03	ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	The rational choice of these two medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia	Precaution for use	Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment.
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004				ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Except for the eplerenone and the spironolactone in doses between 12.5 mg and 50 mg/day for the treatment of heart failure as well as in cases of hypokalemia: Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	If the administration of the two medications together is justified, strict testing of the kalemia and of the renal function.
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	D11AX04	LITHIUM 	6448			ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Increase of the lithemia with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	A12BA	POTASSIUM	8588			ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially with renal insufficiency (addition of the hyperkalemia producing effects)	Contraindication	-aside from hypokalemia or in case of parenteral use of the potassium salts
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	D11AH01	TACROLIMUS	42316			ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	L04AD02	TACROLIMUS	42316			ANSM	183-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
			POTASSIUM LOWERING DIURETICS	C03				ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	184-POTASSIUM-LOWERING-DIURETICS.html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of treatment or at an increase in the dosage of a treatment with an angiotensin II antagonist where there is pre-existing fluid depletion. 	Precaution for use	With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:
			POTASSIUM LOWERING DIURETICS	C03	N03AF01	CARBAMAZEPINE	2002			ANSM	184-POTASSIUM-LOWERING-DIURETICS.html	Risk of symptomatic hyponatremia	Precaution for use	Clinical monitoring and laboratory tests. If possible, use another class of diuretics.
			POTASSIUM LOWERING DIURETICS	C03	L04AD01	CICLOSPORIN	3008			ANSM	184-POTASSIUM-LOWERING-DIURETICS.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Take into account	
			POTASSIUM LOWERING DIURETICS	C03	S01XA18	CICLOSPORIN	3008			ANSM	184-POTASSIUM-LOWERING-DIURETICS.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Take into account	
			POTASSIUM LOWERING DIURETICS	C03				POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	184-POTASSIUM-LOWERING-DIURETICS.html	The rational choice of these medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia	Precaution for use	Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment. 
			POTASSIUM LOWERING DIURETICS	C03				ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	184-POTASSIUM-LOWERING-DIURETICS.html	Risk of abrupt arterial hypotension and/or renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inihitor in cases of pre-existing fluid depletion	Precaution for use	In arterial hypertension, when there is fluid depletion from previous treatment with a diuretic, it is necessary:
			THIAZIDE DIURETICS AND RELATED	C03-003	A12AA	CALCIUM	1428011			ANSM	185-THIAZIDE-DIURETICS-AND-RELATED.html	Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. 	Take into account	
			THIAZIDE DIURETICS AND RELATED	C03-003	D11AX04	LITHIUM	6448			ANSM	185-THIAZIDE-DIURETICS-AND-RELATED.html	Increase of the lithemia with signs of overdose of lithium, as with a reduced sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, strict monitoring of the lithemia and adjustment of the dosage of the lithium.
L01CD02	DOCETAXEL	72962			C01BD07	DRONEDARONE	233698			ANSM	186-DOCETAXEL.html	Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism 	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.
L01CD02	DOCETAXEL	72962						ENZYMATIC INDUCERS	N03-J05-001	ANSM	186-DOCETAXEL.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
L01CD02	DOCETAXEL	72962						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	186-DOCETAXEL.html	Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.
C01BD04	DOFETILIDE	49247			J05AX12	DOLUTEGRAVIR	1433868			ANSM	187-DOFETILIDE.html	Risk of increase of the plasma concentrations of dofetilide by the dolutegravir (inhibition of the renal elimination of the dofetilide.	Contraindication	
J05AX12	DOLUTEGRAVIR	1433868						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	188-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir by increase of its metabolism by the inducer	Not recommended	
J05AX12	DOLUTEGRAVIR	1433868			C01BD04	DOFETILIDE	49247			ANSM	188-DOLUTEGRAVIR.html	Risk of increase of the plasma concentration of dofetilide by the dolutegravir (inhibition of the renal elimination of the dofetilide).	Contraindication	
J05AX12	DOLUTEGRAVIR	1433868				ST JOHNS WORT	258326			ANSM	188-DOLUTEGRAVIR.html	Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort.	Not recommended	
J05AX12	DOLUTEGRAVIR	1433868			J04AB02	RIFAMPICIN	9384			ANSM	188-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer. 	Not recommended	--in case of resistance to the class of integrase inhibitors.
J05AX12	DOLUTEGRAVIR	1433868			J04AM02	RIFAMPICIN	9384			ANSM	188-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer. 	Not recommended	--in case of resistance to the class of integrase inhibitors.
J05AX12	DOLUTEGRAVIR	1433868			J04AM05	RIFAMPICIN	9384			ANSM	188-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer. 	Not recommended	--in case of resistance to the class of integrase inhibitors.
J05AX12	DOLUTEGRAVIR	1433868			J04AM06	RIFAMPICIN	9384			ANSM	188-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer. 	Not recommended	--in case of resistance to the class of integrase inhibitors.
			DOPAMINERGICS	N04B-002				ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	189-DOPAMINERGICS.html	Reciprocal antagonism between the dopaminergic and the neuropleptic	Contraindication	Use an antiemetic that does not have extrapyramidal effects. 
			DOPAMINERGICS	N04B-002	N07XX06	TETRABENAZINE	10390			ANSM	189-DOPAMINERGICS.html	Reciprocal antagonism between the dopaminergic and the tetrabenazine	Not recommended	
			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001				VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not Recommended	
			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001				ANTIPARKINSONIAN ANTICHOLINERGICS	N04AA-001	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of increase of neuropsychological disorders	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together. 
			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001				MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. 	Not recommended	
			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001				ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
ERGOT	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
CLASS	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
CODE	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
G02CB	DOPAMINERGIC ALKALOIDS OF 							INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
			DOPAMINERGICS, EXCEPT PARKINSON	G02CB-002				ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	190-DOPAMINERGICS,-EXCEPT-PARKINSON.html	Reciprocal antagonism of the dopamine agonist and the neuroleptics	Contraindication	
L01DB01	DOXORUBICIN	3639			C08DA01	VERAPAMIL	11170			ANSM	191-DOXORUBICIN.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
L01DB01	DOXORUBICIN	3639			C08DA51	VERAPAMIL	11170			ANSM	191-DOXORUBICIN.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
L01DB01	DOXORUBICIN	3639			C09BB10	VERAPAMIL	11170			ANSM	191-DOXORUBICIN.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
A01AB22	DOXYCYCLINE	3640						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	192-DOXYCYCLINE.html	Decrease of the plasma concentations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the doxycycline. 
J01AA02	DOXYCYCLINE	3640						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	192-DOXYCYCLINE.html	Decrease of the plasma concentations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the doxycycline. 
C01BD07	DRONEDARONE	233698						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	193-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
C01BD07	DRONEDARONE	233698						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	193-DRONEDARONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. 
C01BD07	DRONEDARONE	233698			B01AE07	DABIGATRAN	1037042			ANSM	193-DRONEDARONE.html	Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
C01BD07	DRONEDARONE	233698			C01AA05	DIGOXIN 	3407			ANSM	193-DRONEDARONE.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG. 	Not recommended	Reduce the doses of digoxin by half. 
C01BD07	DRONEDARONE	233698			C08DB01	DILTIAZEM	3443			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment with the calcium channel blocker with minimum recommended dosages, and adjust the doses according to the EKG.
C01BD07	DRONEDARONE	233698			L01CD02	DOCETAXEL	72962			ANSM	193-DRONEDARONE.html	Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.
C01BD07	DRONEDARONE	233698			A07AA12	FIDAXOMICIN	1111103			ANSM	193-DRONEDARONE.html	Increase of the plasma concentrations of fidaxomicin.	Not recommended	
C01BD07	DRONEDARONE	233698						IMMUNOSUPPRESSANTS	L04A	ANSM	193-DRONEDARONE.html	Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Not recommended	
C01BD07	DRONEDARONE	233698						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	193-DRONEDARONE.html	Large increase of the concentrations of drodedarone due to decrease of its metabolism	Contraindication	
C01BD07	DRONEDARONE	233698				ST JOHNS WORT	258326			ANSM	193-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
C01BD07	DRONEDARONE	233698			C01BA01	QUINIDINE	9068			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at the minimum recommended dosages, and adjust the doses according to the EKG. 
C01BD07	DRONEDARONE	233698			C01BA51	QUINIDINE	9068			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at the minimum recommended dosages, and adjust the doses according to the EKG. 
C01BD07	DRONEDARONE	233698			C01BA71	QUINIDINE	9068			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at the minimum recommended dosages, and adjust the doses according to the EKG. 
C01BD07	DRONEDARONE	233698			J04AB02	RIFAMPICIN	9384			ANSM	193-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
C01BD07	DRONEDARONE	233698			J04AM02	RIFAMPICIN	9384			ANSM	193-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
C01BD07	DRONEDARONE	233698			J04AM05	RIFAMPICIN	9384			ANSM	193-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
C01BD07	DRONEDARONE	233698			J04AM06	RIFAMPICIN	9384			ANSM	193-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
C01BD07	DRONEDARONE	233698			C10AA01	SIMVASTATIN	36567			ANSM	193-DRONEDARONE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Not recommended	
C01BD07	DRONEDARONE	233698			C08DA01	VERAPAMIL	11170			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG. 
C01BD07	DRONEDARONE	233698			C08DA51	VERAPAMIL	11170			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG. 
C01BD07	DRONEDARONE	233698			C09BB10	VERAPAMIL	11170			ANSM	193-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG. 
G03FA17	DROSPIRENONE	840781			J05AE12	BOCEPREVIR	1102129			ANSM	194-DROSPIRENONE.html	Increase of more than double of the concentrations of drosperinone when taken with the boceprevir	Not recommended	Choose a contraceptive with another progestin, especially in cases of hyperkalemia
G03AA12	DROSPIRENONE	840781			J05AE12	BOCEPREVIR	1102129			ANSM	194-DROSPIRENONE.html	Increase of more than double of the concentrations of drosperinone when taken with the boceprevir	Not recommended	Choose a contraceptive with another progestin, especially in cases of hyperkalemia
N06AX21	DULOXETINE	72625			J01MA04	ENOXACIN	3925			ANSM	195-DULOXETINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin	Contraindication	
N06AX21	DULOXETINE	72625			C01BC04	FLECAINIDE	4441			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.
N06AX21	DULOXETINE	72625			N06AB08	FLUVOXAMINE	42355			ANSM	195-DULOXETINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine	Contraindication	
N06AX21	DULOXETINE	72625			R06AD07	MEQUITAZINE	29528			ANSM	195-DULOXETINE.html	Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor 	Not recommended	
N06AX21	DULOXETINE	72625			C07AB02	METOPROLOL	6918			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			C07FB02	METOPROLOL	6918			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			C07CB02	METOPROLOL	6918			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			C07BB02	METOPROLOL	6918			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			C07BB52	METOPROLOL	6918			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			C07AB52	METOPROLOL	6918			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			C01BC03	PROPAFENONE	8754			ANSM	195-DULOXETINE.html	Increase of the plasma concentrations of propafenone with risk of overdose due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. 
N06AX21	DULOXETINE	72625			L02BA01	TAMOXIFEN	10324			ANSM	195-DULOXETINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine	Not recommended	
R06AX22	EBASTINE	23796			J01FA09	CLARITHROMYCIN	21212			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			D10AF02	ERYTHROMYCIN	4053			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			D10AF52	ERYTHROMYCIN	4053			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			J01FA01	ERYTHROMYCIN	4053			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			S01AA17	ERYTHROMYCIN	4053			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			J02AC02	ITRACONAZOLE	28031			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			J01FA07	JOSAMYCIN	6084			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			D01AC08	KETOCONAZOLE	6135			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			G01AF11	KETOCONAZOLE	6135			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
R06AX22	EBASTINE	23796			J02AB02	KETOCONAZOLE	6135			ANSM	196-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
D01AC03	ECONAZOLE	3743						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	197-ECONAZOLE.html	Regardless of the route of administration of the econazole:Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
G01AF05	ECONAZOLE	3743						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	197-ECONAZOLE.html	Regardless of the route of administration of the econazole:Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
J05AG03	EFAVIRENZ	195085						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR06	EFAVIRENZ	195085						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AG03	EFAVIRENZ	195085						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	198-EFAVIRENZ.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
J05AR06	EFAVIRENZ	195085						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	198-EFAVIRENZ.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
J05AG03	EFAVIRENZ	195085			J05AE08	ATAZANAVIR	343047			ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
J05AR06	EFAVIRENZ	195085			J05AE08	ATAZANAVIR	343047			ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
J05AG03	EFAVIRENZ	195085			P01AX06	ATOVAQUONE	60212			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
J05AR06	EFAVIRENZ	195085			P01AX06	ATOVAQUONE	60212			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
J05AG03	EFAVIRENZ	195085			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J05AR06	EFAVIRENZ	195085			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J05AG03	EFAVIRENZ	195085			N02CA02	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AG03	EFAVIRENZ	195085			N02CA51	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AG03	EFAVIRENZ	195085			N02CA52	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AG03	EFAVIRENZ	195085			N02CA72	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AR06	EFAVIRENZ	195085			N02CA02	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AR06	EFAVIRENZ	195085			N02CA51	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AR06	EFAVIRENZ	195085			N02CA52	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AR06	EFAVIRENZ	195085			N02CA72	ERGOTAMINE	4025			ANSM	198-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	Contraindication	
J05AG03	EFAVIRENZ	195085			J05AE02	INDINAVIR	114289			ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together.
J05AR06	EFAVIRENZ	195085			J05AE02	INDINAVIR	114289			ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together.
J05AG03	EFAVIRENZ	195085			N05AG02	PIMOZIDE	8331			ANSM	198-EFAVIRENZ.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J05AR06	EFAVIRENZ	195085			N05AG02	PIMOZIDE	8331			ANSM	198-EFAVIRENZ.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J05AG03	EFAVIRENZ	195085			J04AB04	RIFABUTIN	55672			ANSM	198-EFAVIRENZ.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	Adjustment of the dosage of the rifabutin during the treatment with efavirenz.
J05AR06	EFAVIRENZ	195085			J04AB04	RIFABUTIN	55672			ANSM	198-EFAVIRENZ.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	Adjustment of the dosage of the rifabutin during the treatment with efavirenz.
J05AG03	EFAVIRENZ	195085			J04AB02	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AG03	EFAVIRENZ	195085			J04AM02	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AG03	EFAVIRENZ	195085			J04AM05	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AG03	EFAVIRENZ	195085			J04AM06	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR06	EFAVIRENZ	195085			J04AB02	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR06	EFAVIRENZ	195085			J04AM02	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR06	EFAVIRENZ	195085			J04AM05	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR06	EFAVIRENZ	195085			J04AM06	RIFAMPICIN	9384			ANSM	198-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AG03	EFAVIRENZ	195085			J02AC03	VORICONAZOLE	121243			ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together. 
J05AR06	EFAVIRENZ	195085			J02AC03	VORICONAZOLE	121243			ANSM	198-EFAVIRENZ.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together. 
B02BX05	ELTROMBOPAG	711942						HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	199-ELTROMBOPAG.html	Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the statin.
L02BX03	ABIRATERONE	1100072						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	2-ABIRATERONE.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
L02BX03	ABIRATERONE	1100072			C01BC04	FLECAINIDE	4441			ANSM	2-ABIRATERONE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiratarone.	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			C07AB02	METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			C07CB02	METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			C07BB02	METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			C07BB52	METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			C07AB52	METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			C01BC03	PROPAFENONE	8754			ANSM	2-ABIRATERONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone
L02BX03	ABIRATERONE	1100072			J04AB02	RIFAMPICIN	9384			ANSM	2-ABIRATERONE.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
L02BX03	ABIRATERONE	1100072			J04AM02	RIFAMPICIN	9384			ANSM	2-ABIRATERONE.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
L02BX03	ABIRATERONE	1100072			J04AM05	RIFAMPICIN	9384			ANSM	2-ABIRATERONE.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
L02BX03	ABIRATERONE	1100072			J04AM06	RIFAMPICIN	9384			ANSM	2-ABIRATERONE.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001				DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J05AE12	BOCEPREVIR	1102129			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or of those of the extremities (ergotism) or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J01FA09	CLARITHROMYCIN	21212			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	A02BD04	CLARITHROMYCIN	21212			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	A02BD05	CLARITHROMYCIN	21212			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	A02BD06	CLARITHROMYCIN	21212			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	A02BD07	CLARITHROMYCIN	21212			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	V03AX03	COBICISTAT	1306284			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	D10AF02	ERYTHROMYCIN	4053			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	D10AF52	ERYTHROMYCIN	4053			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J01FA01	ERYTHROMYCIN	4053			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	S01AA17	ERYTHROMYCIN	4053			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J02AC02	ITRACONAZOLE	28031			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	D01AC08	KETOCONAZOLE	6135			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	G01AF11	KETOCONAZOLE	6135			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J02AB02	KETOCONAZOLE	6135			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J05AE04	NELFINAVIR	134527			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001				OMBITASVIR + PARITAPREVIR	OMPA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir combination 	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J02AC04	POSACONAZOLE	282446			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001				ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure.	Not recommended	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001				INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J05AE11	TELAPREVIR	1102261			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye) 	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J01FA15	TELITHROMYCIN	274786			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure.	Contraindication	
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001				TRIPTANS	N02CC-001	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of arterial hypertension, of constriction of coronary arteries	Contraindication 	Wait 6 to 24 hours, depending on the triptan, between taking it and the ergot alkaloid.
			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	J02AC03	VORICONAZOLE	121243			ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure 	Contraindication	
J05AX11	ELVITEGRAVIR	1306286						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	200-ELVITEGRAVIR.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin	Precaution for use	Use an estroprogestin contraceptive with at leaset 30ug of ethinylestradiol. 
J05AR09	ELVITEGRAVIR	1306286						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	200-ELVITEGRAVIR.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin	Precaution for use	Use an estroprogestin contraceptive with at leaset 30ug of ethinylestradiol. 
J05AX11	ELVITEGRAVIR	1306286			J04AB04	RIFABUTIN	55672			ANSM	200-ELVITEGRAVIR.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
J05AR09	ELVITEGRAVIR	1306286			J04AB04	RIFABUTIN	55672			ANSM	200-ELVITEGRAVIR.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
J01MA04	ENOXACIN	3925			N06BC01	CAFFEINE 	1886			ANSM	201-ENOXACIN.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
J01MA04	ENOXACIN	3925			V04CG30	CAFFEINE 	1886			ANSM	201-ENOXACIN.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
J01MA04	ENOXACIN	3925			N06AX21	DULOXETINE	72625			ANSM	201-ENOXACIN.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the exnoxacin	Contraindication	
J01MA04	ENOXACIN	3925			N04BC04	ROPINIROLE	72302			ANSM	201-ENOXACIN.html	Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. 
J01MA04	ENOXACIN	3925						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	201-ENOXACIN.html	Overdose of theophylline due to substantial decrease of its metabolism	Contraindication	
N04BX02	ENTACAPONE	60307			B03A	IRON	1431589			ANSM	202-ENTACAPONE.html	Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone	Precaution for use	Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).
L02BB04	ENZALUTAMIDE	1307298			C10AB04	GEMFIBROZIL	4719			ANSM	203-ENZALUTAMIDE.html	Increase of the active fraction of the enzalutamide	Precaution for use	Reduce the dose of enzalutamide by half when it is administered with the gemfibrozil
C03DA04	EPLERENONE	298869						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	204-EPLERENONE.html	Increase of the risk of hyperkalemia, especially with older patients	Precaution for use	Strict testing of the kalemia and of the renal function during the administration of these substances together. 
C03DA04	EPLERENONE	298869						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	204-EPLERENONE.html	Increase of the risk of hyperkalemia, especially with older patients.	Precaution for use	Strict testing of the kalemia and of renal function during the administration of these substances together. 
C03DA04	EPLERENONE	298869						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	204-EPLERENONE.html	Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia	Contraindication	
N02CA02	ERGOTAMINE	4025			J01FG02	DALFOPRISTIN	229369			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). 	Contraindication	
N02CA51	ERGOTAMINE	4025			J01FG02	DALFOPRISTIN	229369			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). 	Contraindication	
N02CA52	ERGOTAMINE	4025			J01FG02	DALFOPRISTIN	229369			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). 	Contraindication	
N02CA72	ERGOTAMINE	4025			J01FG02	DALFOPRISTIN	229369			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). 	Contraindication	
N02CA02	ERGOTAMINE	4025			C08DB01	DILTIAZEM	3443			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
N02CA51	ERGOTAMINE	4025			C08DB01	DILTIAZEM	3443			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
N02CA52	ERGOTAMINE	4025			C08DB01	DILTIAZEM	3443			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
N02CA72	ERGOTAMINE	4025			C08DB01	DILTIAZEM	3443			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
N02CA02	ERGOTAMINE	4025			J05AG03	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA02	ERGOTAMINE	4025			J05AR06	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA51	ERGOTAMINE	4025			J05AG03	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA51	ERGOTAMINE	4025			J05AR06	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA52	ERGOTAMINE	4025			J05AG03	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA52	ERGOTAMINE	4025			J05AR06	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA72	ERGOTAMINE	4025			J05AG03	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA72	ERGOTAMINE	4025			J05AR06	EFAVIRENZ	195085			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	Contraindication	
N02CA02	ERGOTAMINE	4025						MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
N02CA51	ERGOTAMINE	4025						MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
N02CA52	ERGOTAMINE	4025						MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
N02CA72	ERGOTAMINE	4025						MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
N02CA02	ERGOTAMINE	4025			C07AA02	OXPRENOLOL	7801			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA51	ERGOTAMINE	4025			C07AA02	OXPRENOLOL	7801			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA52	ERGOTAMINE	4025			C07AA02	OXPRENOLOL	7801			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA72	ERGOTAMINE	4025			C07AA02	OXPRENOLOL	7801			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA02	ERGOTAMINE	4025			C07AA05	PROPRANOLOL	8787			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA51	ERGOTAMINE	4025			C07AA05	PROPRANOLOL	8787			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA52	ERGOTAMINE	4025			C07AA05	PROPRANOLOL	8787			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA72	ERGOTAMINE	4025			C07AA05	PROPRANOLOL	8787			ANSM	205-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
N02CA02	ERGOTAMINE	4025			J01FG02	QUINUPRISTINE	135098			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	
N02CA51	ERGOTAMINE	4025			J01FG02	QUINUPRISTINE	135098			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	
N02CA52	ERGOTAMINE	4025			J01FG02	QUINUPRISTINE	135098			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	
N02CA72	ERGOTAMINE	4025			J01FG02	QUINUPRISTINE	135098			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	
N02CA02	ERGOTAMINE	4025			N03AX17	STIRIPENTOL	37119			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).	Contraindication	
N02CA51	ERGOTAMINE	4025			N03AX17	STIRIPENTOL	37119			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).	Contraindication	
N02CA52	ERGOTAMINE	4025			N03AX17	STIRIPENTOL	37119			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).	Contraindication	
N02CA72	ERGOTAMINE	4025			N03AX17	STIRIPENTOL	37119			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).	Contraindication	
N02CA02	ERGOTAMINE	4025			P02BX04	TRICLABENDAZOLE	38608			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse
N02CA51	ERGOTAMINE	4025			P02BX04	TRICLABENDAZOLE	38608			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse
N02CA52	ERGOTAMINE	4025			P02BX04	TRICLABENDAZOLE	38608			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse
N02CA72	ERGOTAMINE	4025			P02BX04	TRICLABENDAZOLE	38608			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	Contraindication	Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse
N02CA02	ERGOTAMINE	4025			J02AC03	VORICONAZOLE	121243			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA51	ERGOTAMINE	4025			J02AC03	VORICONAZOLE	121243			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA52	ERGOTAMINE	4025			J02AC03	VORICONAZOLE	121243			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
N02CA72	ERGOTAMINE	4025			J02AC03	VORICONAZOLE	121243			ANSM	205-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
L01XX41	ERIBULINE	1045453			L04AD01	CICLOSPORIN	3008			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ciclosporin.	Not recommended	
L01XX41	ERIBULINE	1045453			S01XA18	CICLOSPORIN	3008			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ciclosporin.	Not recommended	
L01XX41	ERIBULINE	1045453			J01FA09	CLARITHROMYCIN	21212			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
L01XX41	ERIBULINE	1045453			A02BD04	CLARITHROMYCIN	21212			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
L01XX41	ERIBULINE	1045453			A02BD05	CLARITHROMYCIN	21212			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
L01XX41	ERIBULINE	1045453			A02BD06	CLARITHROMYCIN	21212			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
L01XX41	ERIBULINE	1045453			A02BD07	CLARITHROMYCIN	21212			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
L01XX41	ERIBULINE	1045453						ENZYMATIC INDUCERS	N03-J05-001	ANSM	206-ERIBULINE.html	Risk of decrease of the plasma concentrations of eribuline by the inducer	Not recommended	
L01XX41	ERIBULINE	1045453						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ritonavir.	Not recommended	
L01XX41	ERIBULINE	1045453				ST JOHNS WORT	258326			ANSM	206-ERIBULINE.html	Risk of decrease of the plasma concentrations of eribuline by the St John's wort.	Not recommended	
L01XX41	ERIBULINE	1045453			C08DA01	VERAPAMIL	11170			ANSM	206-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the verapamil. 	Not recommended	
D10AF02	ERYTHROMYCIN	4053			L01XE13	AFATINIB	1430438			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin	Precaution for use	It is recommendedthat the erythromycin be administered as distant as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.
D10AF52	ERYTHROMYCIN	4053			L01XE13	AFATINIB	1430438			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin	Precaution for use	It is recommendedthat the erythromycin be administered as distant as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.
J01FA01	ERYTHROMYCIN	4053			L01XE13	AFATINIB	1430438			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin	Precaution for use	It is recommendedthat the erythromycin be administered as distant as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.
S01AA17	ERYTHROMYCIN	4053			L01XE13	AFATINIB	1430438			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin	Precaution for use	It is recommendedthat the erythromycin be administered as distant as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.
D10AF02	ERYTHROMYCIN	4053						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	207-ERYTHROMYCIN.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
D10AF52	ERYTHROMYCIN	4053						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	207-ERYTHROMYCIN.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J01FA01	ERYTHROMYCIN	4053						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	207-ERYTHROMYCIN.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
S01AA17	ERYTHROMYCIN	4053						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	207-ERYTHROMYCIN.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
D10AF02	ERYTHROMYCIN	4053			N01AH02	ALFENTANIL	480			ANSM	207-ERYTHROMYCIN.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin
D10AF52	ERYTHROMYCIN	4053			N01AH02	ALFENTANIL	480			ANSM	207-ERYTHROMYCIN.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin
J01FA01	ERYTHROMYCIN	4053			N01AH02	ALFENTANIL	480			ANSM	207-ERYTHROMYCIN.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin
S01AA17	ERYTHROMYCIN	4053			N01AH02	ALFENTANIL	480			ANSM	207-ERYTHROMYCIN.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin
D10AF02	ERYTHROMYCIN	4053			C10AA05	ATORVASTATIN	83367			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction.
D10AF52	ERYTHROMYCIN	4053			C10AA05	ATORVASTATIN	83367			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction.
J01FA01	ERYTHROMYCIN	4053			C10AA05	ATORVASTATIN	83367			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction.
S01AA17	ERYTHROMYCIN	4053			C10AA05	ATORVASTATIN	83367			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction.
D10AF02	ERYTHROMYCIN	4053			N05BE01	BUSPIRONE	1827			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
D10AF52	ERYTHROMYCIN	4053			N05BE01	BUSPIRONE	1827			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
J01FA01	ERYTHROMYCIN	4053			N05BE01	BUSPIRONE	1827			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
S01AA17	ERYTHROMYCIN	4053			N05BE01	BUSPIRONE	1827			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
D10AF02	ERYTHROMYCIN	4053			N03AF01	CARBAMAZEPINE	2002			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycine) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
D10AF52	ERYTHROMYCIN	4053			N03AF01	CARBAMAZEPINE	2002			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycine) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
J01FA01	ERYTHROMYCIN	4053			N03AF01	CARBAMAZEPINE	2002			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycine) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
S01AA17	ERYTHROMYCIN	4053			N03AF01	CARBAMAZEPINE	2002			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	It is possible to use other macrolides (except spiramycine) whose interference on the clinical level is currently considered minimal or nonexistent. However, in cases of Legionnaires' disease, erythromycin is still the antibiotic of choice; clinical monitoring with testing of plasma concentrations of carbamazepine is thus preferable in this specialized environment. 
D10AF02	ERYTHROMYCIN	4053			G04BD10	DARIFENACIN	136198			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
D10AF52	ERYTHROMYCIN	4053			G04BD10	DARIFENACIN	136198			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J01FA01	ERYTHROMYCIN	4053			G04BD10	DARIFENACIN	136198			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
S01AA17	ERYTHROMYCIN	4053			G04BD10	DARIFENACIN	136198			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
D10AF02	ERYTHROMYCIN	4053			A01AC02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			C05AA09	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			D07AB19	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			D07XB05	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			D10AA03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			H02AB02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			R01AD03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S01BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S01CB01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S02BA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S03BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			D07CB04	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S01CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S02CA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			S03CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			R01AD53	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			A01AC02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			C05AA09	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			D07AB19	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			D07XB05	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			D10AA03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			H02AB02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			R01AD03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S01BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S01CB01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S02BA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S03BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			D07CB04	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S01CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S02CA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			S03CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF52	ERYTHROMYCIN	4053			R01AD53	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			A01AC02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			C05AA09	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			D07AB19	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			D07XB05	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			D10AA03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			H02AB02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			R01AD03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S01BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S01CB01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S02BA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S03BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			D07CB04	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S01CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S02CA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			S03CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
J01FA01	ERYTHROMYCIN	4053			R01AD53	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			A01AC02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			C05AA09	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			D07AB19	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			D07XB05	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			D10AA03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			H02AB02	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			R01AD03	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S01BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S01CB01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S02BA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S03BA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			D07CB04	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S01CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S02CA06	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			S03CA01	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
S01AA17	ERYTHROMYCIN	4053			R01AD53	DEXAMETHASONE	3264			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account 	
D10AF02	ERYTHROMYCIN	4053			C01AA05	DIGOXIN 	3407			ANSM	207-ERYTHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption 	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. 
D10AF52	ERYTHROMYCIN	4053			C01AA05	DIGOXIN 	3407			ANSM	207-ERYTHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption 	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. 
J01FA01	ERYTHROMYCIN	4053			C01AA05	DIGOXIN 	3407			ANSM	207-ERYTHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption 	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. 
S01AA17	ERYTHROMYCIN	4053			C01AA05	DIGOXIN 	3407			ANSM	207-ERYTHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption 	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. 
D10AF02	ERYTHROMYCIN	4053			C01BA03	DISOPYRAMIDE	3541			ANSM	207-ERYTHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
D10AF52	ERYTHROMYCIN	4053			C01BA03	DISOPYRAMIDE	3541			ANSM	207-ERYTHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
J01FA01	ERYTHROMYCIN	4053			C01BA03	DISOPYRAMIDE	3541			ANSM	207-ERYTHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
S01AA17	ERYTHROMYCIN	4053			C01BA03	DISOPYRAMIDE	3541			ANSM	207-ERYTHROMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
D10AF02	ERYTHROMYCIN	4053			R06AX22	EBASTINE	23796			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
D10AF52	ERYTHROMYCIN	4053			R06AX22	EBASTINE	23796			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
J01FA01	ERYTHROMYCIN	4053			R06AX22	EBASTINE	23796			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
S01AA17	ERYTHROMYCIN	4053			R06AX22	EBASTINE	23796			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
D10AF02	ERYTHROMYCIN	4053			G04BD11	FESOTERODINE	797195			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
D10AF52	ERYTHROMYCIN	4053			G04BD11	FESOTERODINE	797195			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
J01FA01	ERYTHROMYCIN	4053			G04BD11	FESOTERODINE	797195			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
S01AA17	ERYTHROMYCIN	4053			G04BD11	FESOTERODINE	797195			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
D10AF02	ERYTHROMYCIN	4053			A07AA12	FIDAXOMICIN	1111103			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
D10AF52	ERYTHROMYCIN	4053			A07AA12	FIDAXOMICIN	1111103			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
J01FA01	ERYTHROMYCIN	4053			A07AA12	FIDAXOMICIN	1111103			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
S01AA17	ERYTHROMYCIN	4053			A07AA12	FIDAXOMICIN	1111103			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
D10AF02	ERYTHROMYCIN	4053			A10BB01	GLIBENCLAMIDE	4815			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
D10AF52	ERYTHROMYCIN	4053			A10BB01	GLIBENCLAMIDE	4815			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
J01FA01	ERYTHROMYCIN	4053			A10BB01	GLIBENCLAMIDE	4815			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
S01AA17	ERYTHROMYCIN	4053			A10BB01	GLIBENCLAMIDE	4815			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
D10AF02	ERYTHROMYCIN	4053			A10BB12	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
D10AF02	ERYTHROMYCIN	4053			A10BD06	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
D10AF52	ERYTHROMYCIN	4053			A10BB12	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
D10AF52	ERYTHROMYCIN	4053			A10BD06	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
J01FA01	ERYTHROMYCIN	4053			A10BB12	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
J01FA01	ERYTHROMYCIN	4053			A10BD06	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
S01AA17	ERYTHROMYCIN	4053			A10BB12	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
S01AA17	ERYTHROMYCIN	4053			A10BD06	GLIMEPIRIDE	25789			ANSM	207-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
D10AF02	ERYTHROMYCIN	4053			P01BX01	HALOFANTRINE	50749			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
D10AF52	ERYTHROMYCIN	4053			P01BX01	HALOFANTRINE	50749			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
J01FA01	ERYTHROMYCIN	4053			P01BX01	HALOFANTRINE	50749			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
S01AA17	ERYTHROMYCIN	4053			P01BX01	HALOFANTRINE	50749			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
D10AF02	ERYTHROMYCIN	4053						IMMUNOSUPPRESSANTS	L04A	ANSM	207-ERYTHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
D10AF52	ERYTHROMYCIN	4053						IMMUNOSUPPRESSANTS	L04A	ANSM	207-ERYTHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
J01FA01	ERYTHROMYCIN	4053						IMMUNOSUPPRESSANTS	L04A	ANSM	207-ERYTHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
S01AA17	ERYTHROMYCIN	4053						IMMUNOSUPPRESSANTS	L04A	ANSM	207-ERYTHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
D10AF02	ERYTHROMYCIN	4053						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
D10AF52	ERYTHROMYCIN	4053						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
J01FA01	ERYTHROMYCIN	4053						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
S01AA17	ERYTHROMYCIN	4053						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
D10AF02	ERYTHROMYCIN	4053			P01BF01	LUMEFANTRINE	847728			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
D10AF52	ERYTHROMYCIN	4053			P01BF01	LUMEFANTRINE	847728			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
J01FA01	ERYTHROMYCIN	4053			P01BF01	LUMEFANTRINE	847728			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
S01AA17	ERYTHROMYCIN	4053			P01BF01	LUMEFANTRINE	847728			ANSM	207-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
D10AF02	ERYTHROMYCIN	4053			N05CD0	MIDAZOLAM	6960			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
D10AF52	ERYTHROMYCIN	4053			N05CD0	MIDAZOLAM	6960			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
J01FA01	ERYTHROMYCIN	4053			N05CD0	MIDAZOLAM	6960			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
S01AA17	ERYTHROMYCIN	4053			N05CD0	MIDAZOLAM	6960			ANSM	207-ERYTHROMYCIN.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
D10AF02	ERYTHROMYCIN	4053			R06AX25	MIZOLASTINE	61455			ANSM	207-ERYTHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
D10AF52	ERYTHROMYCIN	4053			R06AX25	MIZOLASTINE	61455			ANSM	207-ERYTHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J01FA01	ERYTHROMYCIN	4053			R06AX25	MIZOLASTINE	61455			ANSM	207-ERYTHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
S01AA17	ERYTHROMYCIN	4053			R06AX25	MIZOLASTINE	61455			ANSM	207-ERYTHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
D10AF02	ERYTHROMYCIN	4053			C10AA03	PRAVASTATIN	42463			ANSM	207-ERYTHROMYCIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
D10AF52	ERYTHROMYCIN	4053			C10AA03	PRAVASTATIN	42463			ANSM	207-ERYTHROMYCIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
J01FA01	ERYTHROMYCIN	4053			C10AA03	PRAVASTATIN	42463			ANSM	207-ERYTHROMYCIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
S01AA17	ERYTHROMYCIN	4053			C10AA03	PRAVASTATIN	42463			ANSM	207-ERYTHROMYCIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
D10AF02	ERYTHROMYCIN	4053			C10AA01	SIMVASTATIN	36567			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Contraindication	
D10AF52	ERYTHROMYCIN	4053			C10AA01	SIMVASTATIN	36567			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Contraindication	
J01FA01	ERYTHROMYCIN	4053			C10AA01	SIMVASTATIN	36567			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Contraindication	
S01AA17	ERYTHROMYCIN	4053			C10AA01	SIMVASTATIN	36567			ANSM	207-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Contraindication	
D10AF02	ERYTHROMYCIN	4053			G04BD08	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
D10AF02	ERYTHROMYCIN	4053			G04CA53	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
D10AF52	ERYTHROMYCIN	4053			G04BD08	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
D10AF52	ERYTHROMYCIN	4053			G04CA53	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J01FA01	ERYTHROMYCIN	4053			G04BD08	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J01FA01	ERYTHROMYCIN	4053			G04CA53	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
S01AA17	ERYTHROMYCIN	4053			G04BD08	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
S01AA17	ERYTHROMYCIN	4053			G04CA53	SOLIFENACIN	322167			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
D10AF02	ERYTHROMYCIN	4053						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	207-ERYTHROMYCIN.html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference at the clinical level is currently considered minimum or nonexistent. However, in the case of legionnaire's disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
D10AF52	ERYTHROMYCIN	4053						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	207-ERYTHROMYCIN.html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference at the clinical level is currently considered minimum or nonexistent. However, in the case of legionnaire's disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
J01FA01	ERYTHROMYCIN	4053						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	207-ERYTHROMYCIN.html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference at the clinical level is currently considered minimum or nonexistent. However, in the case of legionnaire's disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
S01AA17	ERYTHROMYCIN	4053						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	207-ERYTHROMYCIN.html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiramycin) whose interference at the clinical level is currently considered minimum or nonexistent. However, in the case of legionnaire's disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
D10AF02	ERYTHROMYCIN	4053			G04BD07	TOLTERODINE	119565			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
D10AF52	ERYTHROMYCIN	4053			G04BD07	TOLTERODINE	119565			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
J01FA01	ERYTHROMYCIN	4053			G04BD07	TOLTERODINE	119565			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
S01AA17	ERYTHROMYCIN	4053			G04BD07	TOLTERODINE	119565			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
D10AF02	ERYTHROMYCIN	4053			N06AX16	VENLAFAXINE	39786			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
D10AF52	ERYTHROMYCIN	4053			N06AX16	VENLAFAXINE	39786			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
J01FA01	ERYTHROMYCIN	4053			N06AX16	VENLAFAXINE	39786			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
S01AA17	ERYTHROMYCIN	4053			N06AX16	VENLAFAXINE	39786			ANSM	207-ERYTHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
D10AF02	ERYTHROMYCIN	4053			C08DA01	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
D10AF02	ERYTHROMYCIN	4053			C08DA51	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
D10AF02	ERYTHROMYCIN	4053			C09BB10	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
D10AF52	ERYTHROMYCIN	4053			C08DA01	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
D10AF52	ERYTHROMYCIN	4053			C08DA51	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
D10AF52	ERYTHROMYCIN	4053			C09BB10	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
J01FA01	ERYTHROMYCIN	4053			C08DA01	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
J01FA01	ERYTHROMYCIN	4053			C08DA51	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
J01FA01	ERYTHROMYCIN	4053			C09BB10	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
S01AA17	ERYTHROMYCIN	4053			C08DA01	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
S01AA17	ERYTHROMYCIN	4053			C08DA51	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
S01AA17	ERYTHROMYCIN	4053			C09BB10	VERAPAMIL	11170			ANSM	207-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.
D10AF02	ERYTHROMYCIN	4053						VINCA ALKALOIDS	L01CA	ANSM	207-ERYTHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly use another antibiotic.
D10AF52	ERYTHROMYCIN	4053						VINCA ALKALOIDS	L01CA	ANSM	207-ERYTHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly use another antibiotic.
J01FA01	ERYTHROMYCIN	4053						VINCA ALKALOIDS	L01CA	ANSM	207-ERYTHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly use another antibiotic.
S01AA17	ERYTHROMYCIN	4053						VINCA ALKALOIDS	L01CA	ANSM	207-ERYTHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly use another antibiotic.
D10AF02	ERYTHROMYCIN	4053			N05CF02	ZOLPIDEM	39993			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zolpidem 	Take into account	
D10AF52	ERYTHROMYCIN	4053			N05CF02	ZOLPIDEM	39993			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zolpidem 	Take into account	
J01FA01	ERYTHROMYCIN	4053			N05CF02	ZOLPIDEM	39993			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zolpidem 	Take into account	
S01AA17	ERYTHROMYCIN	4053			N05CF02	ZOLPIDEM	39993			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zolpidem 	Take into account	
D10AF02	ERYTHROMYCIN	4053			N05CF01	ZOPICLONE	40001			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
D10AF52	ERYTHROMYCIN	4053			N05CF01	ZOPICLONE	40001			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
J01FA01	ERYTHROMYCIN	4053			N05CF01	ZOPICLONE	40001			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
S01AA17	ERYTHROMYCIN	4053			N05CF01	ZOPICLONE	40001			ANSM	207-ERYTHROMYCIN.html	Slight increase of the sedative effects of the zopiclone	Take into account	
C07AB09	ESMOLOL	49737			C01BD01	AMIODARONE	703			ANSM	208-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
C07AB09	ESMOLOL	49737						CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	208-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
C07AB09	ESMOLOL	49737			C08DB01	DILTIAZEM	3443			ANSM	208-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest	Not recommended	-in case of alteration of left ventricular function
C07AB09	ESMOLOL	49737			C01BC03	PROPAFENONE	8754			ANSM	208-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
C07AB09	ESMOLOL	49737			C08DA01	VERAPAMIL	11170			ANSM	208-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of left ventricular function
C07AB09	ESMOLOL	49737			C08DA51	VERAPAMIL	11170			ANSM	208-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of left ventricular function
C07AB09	ESMOLOL	49737			C09BB10	VERAPAMIL	11170			ANSM	208-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of left ventricular function
L01XX11	ESTRAMUSTINE	4089			M05BA02	CLODRONIC ACID	3350			ANSM	209-ESTRAMUSTINE.html	Risk of increase of the plasma concentrations of estramustine by the clodronate	Precaution for use	Clinical monitoring during the administration of these substances together. 
L01XX11	ESTRAMUSTINE	4089			A12AA	CALCIUM	1428011			ANSM	209-ESTRAMUSTINE.html	Decrease of the digestive absorption of the estramustine	Precaution for use	Take the calcium salts at a different time from the estramustine (more than 2 hours apart if possible).
L01XX11	ESTRAMUSTINE	4089						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	209-ESTRAMUSTINE.html	Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)	Not recommended	
L03AC01	ALDESLEUKIN	70223						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	21-ALDESLEUKIN.html	Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: skin rash or more rarely low blood pressure, oliguria, or even renal failure	Take into account	
			NON-CONTRACEPTIVE ESTROGENS	G03C-001				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	210-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen .	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. 
			NON-CONTRACEPTIVE ESTROGENS	G03C-001	J05AE12	BOCEPREVIR	1102129			ANSM	210-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the boceprevir.
			NON-CONTRACEPTIVE ESTROGENS	G03C-001				THYROID HORMONES	H03AA	ANSM	210-NON-CONTRACEPTIVE-ESTROGENS.html	Risk of clinical hypothyroidism in cases of estrogen replacement therapy.	Precaution for use	Clinical monitoring and laboratory tests; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.
			NON-CONTRACEPTIVE ESTROGENS	G03C-001	N03AF02	OXCARBAZEPINE	32624			ANSM	210-NON-CONTRACEPTIVE-ESTROGENS.html	Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with oxcarbazepin and after it is stopped.
			NON-CONTRACEPTIVE ESTROGENS	G03C-001	J05AE11	TELAPREVIR	1102261			ANSM	210-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen.	Precaution for use	Clinical monitoringand possible adjustment of the dose of the hormonal treatment during the administration of the telaprevir and after it is stopped.
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	A04AD12	APREPITANT	358255			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the concentrations of the estrogen-progestin or of the progestatif, with risk of lower contraceptive effectiveness.	Precaution for use	Another method of contraception, in particular a barrier method, should be used during the treatment with the aprepitant and a cycle after. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	J05AE12	BOCEPREVIR	1102129			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Except for the combination with ethinylestradiol (0.035 mg)/norethisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir.	Precaution for use	Use an additional or alternative reliable contraceptive method during the length of the administration of boceprevir.
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	C02KX01	BOSENTAN	75207			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the length of time that the two substances are administered together and for a cycle after. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	J05AX11	ELVITEGRAVIR	1306286			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. In addition, increase of the concentrations of the progestin	Precaution for use	Use a combined estrogen-progestin contraceptive with at least 30ug of ethinylestradiol
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	J05AR09	ELVITEGRAVIR	1306286			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. In addition, increase of the concentrations of the progestin	Precaution for use	Use a combined estrogen-progestin contraceptive with at least 30ug of ethinylestradiol
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	D01AA08	GRISEOFULVIN	5021			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism 	Precaution for use	Another method of contraception, in particular a barrier method or IUD, should be used during the time the two substances are administered together and a cycle after. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	D01BA01	GRISEOFULVIN	5021			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism 	Precaution for use	Another method of contraception, in particular a barrier method or IUD, should be used during the time the two substances are administered together and a cycle after. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001				ENZYMATIC INDUCERS	N03-J05-001	ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used during the time the substances are administered together and a cycle after. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive because of the increase of its hepatic metabolism by the ritonavir.	Not recommended	Another method of contraception, in particular a barrier method (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	N03AX09	LAMOTRIGINE	28439			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism	Not recommended	-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001		ST JOHNS WORT	258326			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can have possibly serious consequences (pregnancy).	Contraindication	
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	N06BA07	MODAFINIL	30125			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential	Not recommended	Use oral contraceptives containing estrogens and progestins which have 50 micrograms of estrogen or another method of contraception. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	J05AE04	NELFINAVIR	134527			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive	Not recommended	Another method of contraception, in particular a barrier method (condom or IUD), should be used during the length of the treatment with these substances together and a cycle after. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	N03AF03	RUFINAMIDE	69036			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Moderate decrease of the concentrations of ethinylestradiol	Precaution for use	Another contraceptive method, in particular a barrier type or IUD, should be used. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	J05AE11	TELAPREVIR	1102261			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness by increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the time these are administered together and two cycles following. 
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	38404	TOPIRAMATE	38404			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	For doses of topiramate >=200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen 	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used.
			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	L01XE15	VEMURAFENIB	1147220			ANSM	211-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness 	Not recommended	
L04AB01	ETANERCEPT	214555			L04AC03	ANAKINRA	72435			ANSM	212-ETANERCEPT.html	Increased risk of serious infections and neutropenia	Not recommended	
G03AA15	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB07	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA09	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB05	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA12	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03CA01	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
L02AA03	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA01	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA10	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB06	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA07	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB03	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA03	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB02	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA08	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA04	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB01	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA13	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA05	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AB04	ETHINYLESTRADIOL	4124				DASABUVIR	1597381			ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	Contraindication	
G03AA15	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB07	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA09	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB05	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA12	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03CA01	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
L02AA03	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA01	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA10	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB06	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA07	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB03	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA03	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB02	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA08	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA04	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB01	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA13	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA05	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AB04	ETHINYLESTRADIOL	4124			M01AH05	ETORICOXIB	307296			ANSM	213-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
G03AA15	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB07	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA09	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB05	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA12	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03CA01	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
L02AA03	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA01	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA10	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB06	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA07	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB03	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA03	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB02	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA08	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA04	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB01	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA13	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AA05	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
G03AB04	ETHINYLESTRADIOL	4124						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	213-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	Contraindication	
N03AD01	ETHOSUXIMIDE	4135			N03AF01	CARBAMAZEPINE	2002			ANSM	214-ETHOSUXIMIDE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
N03AD51	ETHOSUXIMIDE	4135			N03AF01	CARBAMAZEPINE	2002			ANSM	214-ETHOSUXIMIDE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
M01AH05	ETORICOXIB	307296			G03AA15	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB07	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA09	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB05	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA12	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03CA01	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			L02AA03	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA01	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA10	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB06	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA07	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB03	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA03	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB02	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA08	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA04	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB01	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA13	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AA05	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
M01AH05	ETORICOXIB	307296			G03AB04	ETHINYLESTRADIOL	4124			ANSM	215-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
J05AG04	ETRAVIRINE	475969			J01FA09	CLARITHROMYCIN	21212			ANSM	216-ETRAVIRINE.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
L01XE10	EVEROLIMUS	141704			L04AD01	CICLOSPORIN	3008			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped  
L01XE10	EVEROLIMUS	141704			S01XA18	CICLOSPORIN	3008			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped  
L04AA18	EVEROLIMUS	141704			L04AD01	CICLOSPORIN	3008			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped  
L04AA18	EVEROLIMUS	141704			S01XA18	CICLOSPORIN	3008			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped  
L01XE10	EVEROLIMUS	141704			C08DA01	VERAPAMIL	11170			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
L01XE10	EVEROLIMUS	141704			C08DA51	VERAPAMIL	11170			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
L01XE10	EVEROLIMUS	141704			C09BB10	VERAPAMIL	11170			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
L04AA18	EVEROLIMUS	141704			C08DA01	VERAPAMIL	11170			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
L04AA18	EVEROLIMUS	141704			C08DA51	VERAPAMIL	11170			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
L04AA18	EVEROLIMUS	141704			C09BB10	VERAPAMIL	11170			ANSM	217-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
L02BG06	EXEMESTANE	258494			J04AB02	RIFAMPICIN	9384			ANSM	218-EXEMESTANE.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
L02BG06	EXEMESTANE	258494			J04AM02	RIFAMPICIN	9384			ANSM	218-EXEMESTANE.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
L02BG06	EXEMESTANE	258494			J04AM05	RIFAMPICIN	9384			ANSM	218-EXEMESTANE.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
L02BG06	EXEMESTANE	258494			J04AM06	RIFAMPICIN	9384			ANSM	218-EXEMESTANE.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
C10BA05	EZETIMIBE	341248			L04AD01	CICLOSPORIN	3008			ANSM	219-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
C10BA05	EZETIMIBE	341248			S01XA18	CICLOSPORIN	3008			ANSM	219-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
C10AX09	EZETIMIBE	341248			L04AD01	CICLOSPORIN	3008			ANSM	219-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
C10AX09	EZETIMIBE	341248			S01XA18	CICLOSPORIN	3008			ANSM	219-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
C10BA02	EZETIMIBE	341248			L04AD01	CICLOSPORIN	3008			ANSM	219-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
C10BA02	EZETIMIBE	341248			S01XA18	CICLOSPORIN	3008			ANSM	219-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
C10BA05	EZETIMIBE	341248			C10AB05	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA05	EZETIMIBE	341248			C10BA03	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA05	EZETIMIBE	341248			C10BA04	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10AX09	EZETIMIBE	341248			C10AB05	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10AX09	EZETIMIBE	341248			C10BA03	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10AX09	EZETIMIBE	341248			C10BA04	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA02	EZETIMIBE	341248			C10AB05	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA02	EZETIMIBE	341248			C10BA03	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA02	EZETIMIBE	341248			C10BA04	FENOFIBRATE	8703			ANSM	219-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
N01AH02	ALFENTANIL	480			A02BA01	CIMETIDINE	2541			ANSM	22-ALFENTANIL.html	With cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the cimetidine.
N01AH02	ALFENTANIL	480			A02BA51	CIMETIDINE	2541			ANSM	22-ALFENTANIL.html	With cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the cimetidine.
N01AH02	ALFENTANIL	480			C08DB01	DILTIAZEM	3443			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use:	Adjust the dosage of the alfentanil when administered with the diltiazem. 
N01AH02	ALFENTANIL	480			D10AF02	ERYTHROMYCIN	4053			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin.
N01AH02	ALFENTANIL	480			D10AF52	ERYTHROMYCIN	4053			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin.
N01AH02	ALFENTANIL	480			J01FA01	ERYTHROMYCIN	4053			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin.
N01AH02	ALFENTANIL	480			S01AA17	ERYTHROMYCIN	4053			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the erythromycin.
N01AH02	ALFENTANIL	480			D01AC15	FLUCONAZOLE	4450			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the fluconazole
N01AH02	ALFENTANIL	480			J02AC01	FLUCONAZOLE	4450			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the fluconazole
N01AH02	ALFENTANIL	480						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism.	Precaution for use 	Clinical monitoring and adjustment of the dosage of the opioid analgesic when administered with a strong inhibitor of CYP3A4.
N03AX10	FELBAMATE	24812			N03AF01	CARBAMAZEPINE	2002			ANSM	220-FELBAMATE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.
N03AX10	FELBAMATE	24812						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	220-FELBAMATE.html	Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed. 
N03AX10	FELBAMATE 	24812						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	220-FELBAMATE.html	Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed adjustment of the dosage during the treatment with the felbamate.
N03AX10	FELBAMATE	24812						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	220-FELBAMATE.html	Increase of the plasma concentrations of the valproic acid, with risk of overdose	Precaution for use	Clinical monitoring, laboratory tests, and possible adjustment of the dosage of the valproate or of the valpromide during the treatment with the felbamate and after it is stopped. 
C10AB05	FENOFIBRATE	8703			L04AD01	CICLOSPORIN	3008			ANSM	221-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function, during and after the administration of the two medications together. 
C10AB05	FENOFIBRATE	8703			S01XA18	CICLOSPORIN	3008			ANSM	221-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function, during and after the administration of the two medications together. 
C10BA03	FENOFIBRATE	8703			L04AD01	CICLOSPORIN	3008			ANSM	221-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function, during and after the administration of the two medications together. 
C10BA03	FENOFIBRATE	8703			S01XA18	CICLOSPORIN	3008			ANSM	221-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function, during and after the administration of the two medications together. 
C10BA04	FENOFIBRATE	8703			L04AD01	CICLOSPORIN	3008			ANSM	221-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function, during and after the administration of the two medications together. 
C10BA04	FENOFIBRATE	8703			S01XA18	CICLOSPORIN	3008			ANSM	221-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	Clinical monitoring and laboratory tests of renal function, during and after the administration of the two medications together. 
C10AB05	FENOFIBRATE	8703			C10BA05	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10AB05	FENOFIBRATE	8703			C10AX09	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10AB05	FENOFIBRATE	8703			C10BA02	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA03	FENOFIBRATE	8703			C10BA05	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA03	FENOFIBRATE	8703			C10AX09	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA03	FENOFIBRATE	8703			C10BA02	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA04	FENOFIBRATE	8703			C10BA05	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA04	FENOFIBRATE	8703			C10AX09	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
C10BA04	FENOFIBRATE	8703			C10BA02	EZETIMIBE	341248			ANSM	221-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
N01AH01	FENTANYL	4337						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
N01AH51	FENTANYL	4337						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
N02AB03	FENTANYL	4337						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
N01AH01	FENTANYL	4337						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	222-FENTANYL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
N01AH51	FENTANYL	4337						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	222-FENTANYL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
N02AB03	FENTANYL	4337						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	222-FENTANYL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
N01AH01	FENTANYL	4337			J04AB02	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH01	FENTANYL	4337			J04AM02	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH01	FENTANYL	4337			J04AM05	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH01	FENTANYL	4337			J04AM06	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH51	FENTANYL	4337			J04AB02	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH51	FENTANYL	4337			J04AM02	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH51	FENTANYL	4337			J04AM05	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N01AH51	FENTANYL	4337			J04AM06	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N02AB03	FENTANYL	4337			J04AB02	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N02AB03	FENTANYL	4337			J04AM02	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N02AB03	FENTANYL	4337			J04AM05	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
N02AB03	FENTANYL	4337			J04AM06	RIFAMPICIN	9384			ANSM	222-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	Choose another opioid.
B03A	IRON	1431589			B03AC	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			B03AC01	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			B03AC02	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			B03AC03	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			B03AC05	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			B03AC06	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			B03AC07	INJECTABLR IRON SALTS	1431591			ANSM	223-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
B03A	IRON	1431589			G04BX03	ACETOHYDROXAMIC ACID	16728			ANSM	223-IRON.html	Decrease of the digestive absorption of these two medications due to chelation of the iron	Take into account	
B03A	IRON	1431589						BISPHOSPHONATES	M05B-001	ANSM	223-IRON.html	For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
B03A	IRON	1431589			A12AA	CALCIUM	1428011			ANSM	223-IRON.html	With the iron salts by oral route: decrease of the digestive absorption of the iron salts	Precaution for use	Take the iron salts at a different time from meals and in the absence of calcium. 
B03A	IRON	1431589						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	223-IRON.html	With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)	Precaution for use	Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart if possible). 
B03A	IRON	1431589			N04BX02	ENTACAPONE	60307			ANSM	223-IRON.html	Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone	Precaution for use	Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).
B03A	IRON	1431589						FLUOROQUINOLONES	J01MA-001	ANSM	223-IRON.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).
B03A	IRON	1431589						THYROID HORMONES	H03AA	ANSM	223-IRON.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible). 
B03A	IRON	1431589			N04BA01	LEVODOPA	6375			ANSM	223-IRON.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
B03A	IRON	1431589			N04BA02	LEVODOPA	6375			ANSM	223-IRON.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
B03A	IRON	1431589			N04BA03	LEVODOPA	6375			ANSM	223-IRON.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
B03A	IRON	1431589			C02AB	METHYLDOPA	6876			ANSM	223-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).
B03A	IRON	1431589			C02LB	METHYLDOPA	6876			ANSM	223-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).
B03A	IRON	1431589			C02AB01	METHYLDOPA	6876			ANSM	223-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).
B03A	IRON	1431589			C02LB01	METHYLDOPA	6876			ANSM	223-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).
B03A	IRON	1431589			C02AB02	METHYLDOPA	6876			ANSM	223-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).
B03A	IRON	1431589			M01CC01	PENICILLAMINE	7975			ANSM	223-IRON.html	Decrease of the digestive absorption of the penicillamine	Precaution for use	Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).
B03A	IRON	1431589			V10BX01	STRONTIUM	81638			ANSM	223-IRON.html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the iron salts (more than two hours apart if possible).
B03A	IRON	1431589			M05BX03	STRONTIUM	81638			ANSM	223-IRON.html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the iron salts (more than two hours apart if possible).
B03A	IRON	1431589			A12CB	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B03A	IRON	1431589			A12CB01	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B03A	IRON	1431589			A12CB02	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B03A	IRON	1431589			A12CB03	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B03A	IRON	1431589			B05X	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B03A	IRON	1431589			B05XA	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B03A	IRON	1431589			B05XA12	ZINC	1431163			ANSM	223-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
G04BD11	FESOTERODINE	797195			J01FA09	CLARITHROMYCIN	21212			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
G04BD11	FESOTERODINE	797195			D10AF02	ERYTHROMYCIN	4053			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
G04BD11	FESOTERODINE	797195			D10AF52	ERYTHROMYCIN	4053			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
G04BD11	FESOTERODINE	797195			J01FA01	ERYTHROMYCIN	4053			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
G04BD11	FESOTERODINE	797195			S01AA17	ERYTHROMYCIN	4053			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose.	Not recommended	
G04BD11	FESOTERODINE	797195						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
G04BD11	FESOTERODINE	797195			J02AC02	ITRACONAZOLE	28031			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
G04BD11	FESOTERODINE	797195			D01AC08	KETOCONAZOLE	6135			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
G04BD11	FESOTERODINE	797195			G01AF11	KETOCONAZOLE	6135			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
G04BD11	FESOTERODINE	797195			J02AB02	KETOCONAZOLE	6135			ANSM	224-FESOTERODINE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
			FIBRATES	C01AB-001				FIBRATES	C01AB-001	ANSM	225-FIBRATES.html	Increased risk of undesirable effects of the rhabdomyolosis type and of pharmacodynamic antagonism between the two molecules	Contraindication	
			FIBRATES	C01AB-001				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	225-FIBRATES.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. 
			FIBRATES	C01AB-001	M04AC01	COLCHICINE	2683			ANSM	225-FIBRATES.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolosis	Precaution for use	Clinical monitoring and laboratory tests, particularly at the beginning of the administration of these substances together. 
			FIBRATES	C01AB-001				HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	225-FIBRATES.html	Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. In addition, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin	Contraindication	--for doses of 40mg of rosuvastatin
A07AA12	FIDAXOMICIN	1111103			C01BD01	AMIODARONE	703			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of fidaxomycin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			L04AD01	CICLOSPORIN	3008			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			S01XA18	CICLOSPORIN	3008			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			J01FA09	CLARITHROMYCIN	21212			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			A02BD04	CLARITHROMYCIN	21212			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			A02BD05	CLARITHROMYCIN	21212			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			A02BD06	CLARITHROMYCIN	21212			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			A02BD07	CLARITHROMYCIN	21212			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			C01BD07	DRONEDARONE	233698			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			D10AF02	ERYTHROMYCIN	4053			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			D10AF52	ERYTHROMYCIN	4053			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			J01FA01	ERYTHROMYCIN	4053			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			S01AA17	ERYTHROMYCIN	4053			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			D01AC08	KETOCONAZOLE	6135			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			G01AF11	KETOCONAZOLE	6135			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			J02AB02	KETOCONAZOLE	6135			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
A07AA12	FIDAXOMICIN	1111103			C08DA01	VERAPAMIL	11170			ANSM	226-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
L04AA27	FINGOLIMOD	1012892						BRADYCARIA INDUCING DRUGS	C0N0S0	ANSM	227-FINGOLIMOD.html	Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms	Not recommended	Clinical monitoring and continuous EKG during the 24 hours following the first dose.
C01BC04	FLECAINIDE	4441			L02BX03	ABIRATERONE	1100072			ANSM	228-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone
C01BC04	FLECAINIDE	4441			N06AX12	BUPROPION	42347			ANSM	228-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.
C01BC04	FLECAINIDE	4441			H05BX01	CINACALCET	407990			ANSM	228-FLECAINIDE.html	Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.
C01BC04	FLECAINIDE	4441			G04BD10	DARIFENACIN	136198			ANSM	228-FLECAINIDE.html	Increase of the plasma concentrations of flecainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.
C01BC04	FLECAINIDE	4441			N06AX21	DULOXETINE	72625			ANSM	228-FLECAINIDE.html	Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.
C01BC04	FLECAINIDE	4441			D01AE15	TERBINAFINE	37801			ANSM	228-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the terbinafine. 
C01BC04	FLECAINIDE	4441			D01BA02	TERBINAFINE	37801			ANSM	228-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the terbinafine. 
D01AC15	FLUCONAZOLE	4450			N01AH02	ALFENTANIL	480			ANSM	229-FLUCONAZOLE.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the fluconazole
J02AC01	FLUCONAZOLE	4450			N01AH02	ALFENTANIL	480			ANSM	229-FLUCONAZOLE.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Adjust the dosage of the alfentanil when administered with the fluconazole
D01AC15	FLUCONAZOLE	4450						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	229-FLUCONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped. 
J02AC01	FLUCONAZOLE	4450						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	229-FLUCONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped. 
D01AC15	FLUCONAZOLE	4450			N03AF01	CARBAMAZEPINE	2002			ANSM	229-FLUCONAZOLE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.
J02AC01	FLUCONAZOLE	4450			N03AF01	CARBAMAZEPINE	2002			ANSM	229-FLUCONAZOLE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.
D01AC15	FLUCONAZOLE	4450						IMMUNOSUPPRESSANTS	L04A	ANSM	229-FLUCONAZOLE.html	Risk of increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism and of the creatinemia	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the immunosuppressant's dosage during the administration of the substances together and after it is stopped. 
J02AC01	FLUCONAZOLE	4450						IMMUNOSUPPRESSANTS	L04A	ANSM	229-FLUCONAZOLE.html	Risk of increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism and of the creatinemia	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the immunosuppressant's dosage during the administration of the substances together and after it is stopped. 
D01AC15	FLUCONAZOLE	4450			R07AX02	IVACAFTOR	1243041			ANSM	229-FLUCONAZOLE.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by half, that is 150 mg/day.
J02AC01	FLUCONAZOLE	4450			R07AX02	IVACAFTOR	1243041			ANSM	229-FLUCONAZOLE.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by half, that is 150 mg/day.
D01AC15	FLUCONAZOLE	4450			C09CA01	LOSARTAN	52175			ANSM	229-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
D01AC15	FLUCONAZOLE	4450			C09DB06	LOSARTAN	52175			ANSM	229-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
D01AC15	FLUCONAZOLE	4450			C09DA01	LOSARTAN	52175			ANSM	229-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
J02AC01	FLUCONAZOLE	4450			C09CA01	LOSARTAN	52175			ANSM	229-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
J02AC01	FLUCONAZOLE	4450			C09DB06	LOSARTAN	52175			ANSM	229-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
J02AC01	FLUCONAZOLE	4450			C09DA01	LOSARTAN	52175			ANSM	229-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
D01AC15	FLUCONAZOLE	4450			J05AG01	NEVIRAPINE	53654			ANSM	229-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
D01AC15	FLUCONAZOLE	4450			J05AR07	NEVIRAPINE	53654			ANSM	229-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
D01AC15	FLUCONAZOLE	4450			J05AR05	NEVIRAPINE	53654			ANSM	229-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J02AC01	FLUCONAZOLE	4450			J05AG01	NEVIRAPINE	53654			ANSM	229-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J02AC01	FLUCONAZOLE	4450			J05AR07	NEVIRAPINE	53654			ANSM	229-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J02AC01	FLUCONAZOLE	4450			J05AR05	NEVIRAPINE	53654			ANSM	229-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
D01AC15	FLUCONAZOLE	4450						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	229-FLUCONAZOLE.html	Increase of the plasma oncentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	Strict clinical monitoring and laboratory tests.
J02AC01	FLUCONAZOLE	4450						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	229-FLUCONAZOLE.html	Increase of the plasma oncentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	Strict clinical monitoring and laboratory tests.
D01AC15	FLUCONAZOLE	4450			N05AG02	PIMOZIDE	8331			ANSM	229-FLUCONAZOLE.html	Increased risk of disorders of ventricular rhythm, especially of torsades de pointes.	Contraindication	
J02AC01	FLUCONAZOLE	4450			N05AG02	PIMOZIDE	8331			ANSM	229-FLUCONAZOLE.html	Increased risk of disorders of ventricular rhythm, especially of torsades de pointes.	Contraindication	
D01AC15	FLUCONAZOLE	4450			J04AB04	RIFABUTIN	55672			ANSM	229-FLUCONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the treatment with the two medications together. 
J02AC01	FLUCONAZOLE	4450			J04AB04	RIFABUTIN	55672			ANSM	229-FLUCONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the treatment with the two medications together. 
D01AC15	FLUCONAZOLE	4450			J04AB02	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC15	FLUCONAZOLE	4450			J04AM02	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC15	FLUCONAZOLE	4450			J04AM05	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC15	FLUCONAZOLE	4450			J04AM06	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC01	FLUCONAZOLE	4450			J04AB02	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC01	FLUCONAZOLE	4450			J04AM02	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC01	FLUCONAZOLE	4450			J04AM05	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC01	FLUCONAZOLE	4450			J04AM06	RIFAMPICIN	9384			ANSM	229-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC15	FLUCONAZOLE	4450						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	229-FLUCONAZOLE.html	Increase of the half life of the sulfonamide with possible onset of hypoglycemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole.
J02AC01	FLUCONAZOLE	4450						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	229-FLUCONAZOLE.html	Increase of the half life of the sulfonamide with possible onset of hypoglycemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole.
D01AC15	FLUCONAZOLE	4450						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	229-FLUCONAZOLE.html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped.
J02AC01	FLUCONAZOLE	4450						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	229-FLUCONAZOLE.html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped.
G04CA01	ALFUZOSIN	17300						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	23-ALFUZOSIN.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. .	Contraindication 	
G04CA51	ALFUZOSIN	17300						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	23-ALFUZOSIN.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. .	Contraindication 	
G04CA01	ALFUZOSIN	17300						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	23-ALFUZOSIN.html	Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the therapy with the two medications.	Contraindication	
G04CA51	ALFUZOSIN	17300						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	23-ALFUZOSIN.html	Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the therapy with the two medications.	Contraindication	
D01AE21	FLUCYTOSINE	4451			J05AF01	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
D01AE21	FLUCYTOSINE	4451			J05AR01	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
D01AE21	FLUCYTOSINE	4451			J05AR04	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
D01AE21	FLUCYTOSINE	4451			J05AR05	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J02AX01	FLUCYTOSINE	4451			J05AF01	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J02AX01	FLUCYTOSINE	4451			J05AR01	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J02AX01	FLUCYTOSINE	4451			J05AR04	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J02AX01	FLUCYTOSINE	4451			J05AR05	ZIDOVUDINE (AZT)	11413			ANSM	230-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
L01BB05	FLUDARABINE	24698			L01XX08	PENTOSTATIN	8011			ANSM	231-FLUDARABINE.html	Increase of the risk of pulmonary toxicity that could be fatal. 	Not recommended	
			FLUOROQUINOLONES	J01MA-001				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	232-FLUOROQUINOLONES.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped.
			FLUOROQUINOLONES	J01MA-001	B03A	IRON	1431589			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001				GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	232-FLUOROQUINOLONES.html	Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving prolonged corticotherapy 	Take into account	
			FLUOROQUINOLONES	J01MA-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	OLATE	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	MOFETIL	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	7145	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	L04AA06	MYCOPHENOLATE MOFETIL				ANSM	232-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 	Take into account	
			FLUOROQUINOLONES	J01MA-001	V10BX01	STRONTIUM	81638			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the fluoroquinolones (more than two hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	M05BX03	STRONTIUM	81638			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the fluoroquinolones (more than two hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	A02BX02	SUCRALFATE	10156			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the sucralfate at a different time from the fluoroquinolone (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	A12CB	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	A12CB01	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	A12CB02	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	A12CB03	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	B05X	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	B05XA	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROQUINOLONES	J01MA-001	B05XA12	ZINC	1431163			ANSM	232-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001		FOLINIC ACID	6313			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. 	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If taking these medications together cannot be avoided, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped. 
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	L03AB01	INTERFERON ALFA	1431112			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	A02BD08	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	A02BD03	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	A02BD02	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	A01AB17	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	D06BX01	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	G01AF01	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	J01XD01	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	P01AB01	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	A02BD01	METRONIDAZOLE	6922			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	G01AF06	ORNIDAZOLE	7701			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	J01XD03	ORNIDAZOLE	7701			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
			FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	P01AB03	ORNIDAZOLE	7701			ANSM	233-FLUOROURACIL-(AND-BY-EXTRAPOLATION,-TEGAFUR-AND-CAPECITABINE).html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
N06AB03	FLUOXETINE	4493			N06BA09	ATOMOXETINE	38400			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism	Not recommended	If administering the two together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped. 
N06CA03	FLUOXETINE	4493			N06BA09	ATOMOXETINE	38400			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism	Not recommended	If administering the two together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped. 
N06AB03	FLUOXETINE	4493			N03AF01	CARBAMAZEPINE	2002			ANSM	234-FLUOXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 
N06CA03	FLUOXETINE	4493			N03AF01	CARBAMAZEPINE	2002			ANSM	234-FLUOXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 
N06AB03	FLUOXETINE	4493			R06AD07	MEQUITAZINE	29528			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor 	Not recommended	
N06CA03	FLUOXETINE	4493			R06AD07	MEQUITAZINE	29528			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor 	Not recommended	
N06AB03	FLUOXETINE	4493			C07AB02	METOPROLOL	6918			ANSM	234-FLUOXETINE.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication 	
N06CA03	FLUOXETINE	4493			C07AB02	METOPROLOL	6918			ANSM	234-FLUOXETINE.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication 	
N06AB03	FLUOXETINE	4493			C07AB12	NEBIVOLOL	31555			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
N06AB03	FLUOXETINE	4493			C07BB12	NEBIVOLOL	31555			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
N06CA03	FLUOXETINE	4493			C07AB12	NEBIVOLOL	31555			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
N06CA03	FLUOXETINE	4493			C07BB12	NEBIVOLOL	31555			ANSM	234-FLUOXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
N06AB03	FLUOXETINE	4493						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	234-FLUOXETINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with fluoxetine and after it is stopped. 
N06CA03	FLUOXETINE	4493						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	234-FLUOXETINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with fluoxetine and after it is stopped. 
N06AB03	FLUOXETINE	4493			N05AX08	RISPERIDONE	35636			ANSM	234-FLUOXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. 
N06CA03	FLUOXETINE	4493			N05AX08	RISPERIDONE	35636			ANSM	234-FLUOXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. 
N06AB03	FLUOXETINE	4493			L02BA01	TAMOXIFEN	10324			ANSM	234-FLUOXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine. 	Not recommended	
N06CA03	FLUOXETINE	4493			L02BA01	TAMOXIFEN	10324			ANSM	234-FLUOXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine. 	Not recommended	
N06AB08	FLUVOXAMINE	42355			N06AX22	AGOMELATINE	306718			ANSM	235-FLUVOXAMINE.html	Increase of the concentrations of agomelatine, with risk of increase of the undesirable effects.	Contraindication	
N06AB08	FLUVOXAMINE	42355			N03AF01	CARBAMAZEPINE	2002			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.
N06AB08	FLUVOXAMINE	42355			N05AH02	CLOZAPINE	2626			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of clozapine with signs of overdose	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.
N06AB08	FLUVOXAMINE	42355			N06AX21	DULOXETINE	72625			ANSM	235-FLUVOXAMINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine	Contraindication	
N06AB08	FLUVOXAMINE	42355			C01BB01	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			C05AD01	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			D04AB01	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			N01BB02	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			R02AD02	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			S01HA07	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			S02DA01	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			N01BB52	LIDOCAINE	6387			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N06AB08	FLUVOXAMINE	42355			N02AC52	METHADONE	6813			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.
N06AB08	FLUVOXAMINE	42355			N07BC02	METHADONE	6813			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.
N06AB08	FLUVOXAMINE	42355			C01BB02	MEXILETINE	6926			ANSM	235-FLUVOXAMINE.html	Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.
N06AB08	FLUVOXAMINE	42355			N05AH03	OLANZAPINE	61381			ANSM	235-FLUVOXAMINE.html	Increase of the concentrations of the olanzapine, with risk of increase of the undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.
N06AB08	FLUVOXAMINE	42355						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped. 
N06AB08	FLUVOXAMINE	42355			L04AX05	PIRFENIDONE	88221			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of pirfenidone with signs of overdose	Contraindication 	
N06AB08	FLUVOXAMINE	42355			C07AA05	PROPRANOLOL	8787			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia	Precaution for use	Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped. 
N06AB08	FLUVOXAMINE	42355			N04BC04	ROPINIROLE	72302			ANSM	235-FLUVOXAMINE.html	Increase of the plasma concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. 
N06AB08	FLUVOXAMINE	42355						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	235-FLUVOXAMINE.html	Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline) 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with fluvoxamine and after it is stopped.
			FOLATES	V03-				PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	236-FOLATES.html	Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.
			FOLATES	V03-				PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	236-FOLATES.html	Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. 
J05AE07	FOSAMPRENAVIR	358262			J05AX09	MARAVIROC	620216			ANSM	237-FOSAMPRENAVIR.html	Significant decrease of the concentrations of amprenavir that can lead to a loss of viralogical response	Not recommended	
J05AD01	FOSCARNET	33562			P01CX01	PENTAMIDINE	7994			ANSM	238-FOSCARNET.html	Risk of severe hypocalcemia	Precaution for use	Monitoring of the calcemia and supplementation if necessary.
L01AD05	FOTEMUSTINE 	25287			L01AX04	DACARBAZINE	3098			ANSM	239-FOTEMUSTINE.html	With the dacarbazine in large doses: risk of pulmonary toxicity (adult acute respiratory distress syndrome ).	Precaution for use	Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine. 
C09DX02	ALISKIREN	325646				GRAPEFRUIT JUICE				ANSM	24-ALISKIREN.html	Risk of loss of effectiveness of the aliskiren when grapefruit juice is consumed	Not recommended	
C09DX02	ALISKIREN	325646						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	24-ALISKIREN.html	Risk of hyperkalemia, renal insufficiency, increase of cardiovascular mortality 	Contraindication	-for patients with diabetes or renal insufficiency
C09DX02	ALISKIREN	325646			L04AD01	CICLOSPORIN	3008			ANSM	24-ALISKIREN.html	Increase by nearly five times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
C09DX02	ALISKIREN	325646			S01XA18	CICLOSPORIN	3008			ANSM	24-ALISKIREN.html	Increase by nearly five times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 	Contraindication	
C09DX02	ALISKIREN	325646						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	24-ALISKIREN.html	Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality 	Contraindication 	-for patients with diabetes or renal insufficiency
C09DX02	ALISKIREN	325646			J02AC02	ITRACONAZOLE	28031			ANSM	24-ALISKIREN.html	Increase by nearly six times the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Contraindication	
C09DX02	ALISKIREN	325646			C01BA71	QUINIDINE	9068			ANSM	24-ALISKIREN.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C09DX02	ALISKIREN	325646			C09BB10	VERAPAMIL	11170			ANSM	24-ALISKIREN.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Precaution for use	Clinical monitoring
C03CA01	FUROSEMIDE	460						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	240-FUROSEMIDE.html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide. 
C03CA01	FUROSEMIDE	460						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	240-FUROSEMIDE.html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide. 
C03CB01	FUROSEMIDE	460						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	240-FUROSEMIDE.html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide. 
C03EB01	FUROSEMIDE	460						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	240-FUROSEMIDE.html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide. 
J05AB06	GANCICLOVIR	4678			J05AF02	DIDANOSINE	3364			ANSM	241-GANCICLOVIR.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
S01AD09	GANCICLOVIR	4678			J05AF02	DIDANOSINE	3364			ANSM	241-GANCICLOVIR.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
J05AB06	GANCICLOVIR	4678			J05AF03	ZALCITABINE	3363			ANSM	241-GANCICLOVIR.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together. 
S01AD09	GANCICLOVIR	4678			J05AF03	ZALCITABINE	3363			ANSM	241-GANCICLOVIR.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together. 
J05AB06	GANCICLOVIR	4678			J05AF01	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
J05AB06	GANCICLOVIR	4678			J05AR01	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
J05AB06	GANCICLOVIR	4678			J05AR04	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
J05AB06	GANCICLOVIR	4678			J05AR05	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
S01AD09	GANCICLOVIR	4678			J05AF01	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
S01AD09	GANCICLOVIR	4678			J05AR01	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
S01AD09	GANCICLOVIR	4678			J05AR04	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
S01AD09	GANCICLOVIR	4678			J05AR05	ZIDOVUDINE 	11413			ANSM	241-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
C10AB04	GEMFIBROZIL	4719						GLITAZONE ANTIDIABETICS	A10BG0	ANSM	242-GEMFIBROZIL.html	Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
C10AB04	GEMFIBROZIL	4719				DASABUVIR	1597381			ANSM	242-GEMFIBROZIL.html	Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil	Contraindication	
C10AB04	GEMFIBROZIL	4719			L02BB04	ENZALUTAMIDE	130729			ANSM	242-GEMFIBROZIL.html	Increase of the active fraction of the enzalutamide	Precaution for use	Reduce the dose of enzalutamide by half when administered with the gemfibrozil.
C10AB04	GEMFIBROZIL	4719			A10BX02	REPAGLINIDE	73044			ANSM	242-GEMFIBROZIL.html	Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfiborzil	Contraindication	
A10BB01	GLIBENCLAMIDE	4815			C02KX01	BOSENTAN	75207			ANSM	243-GLIBENCLAMIDE.html	Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepatoxicity have been reported with these substances administered together. 	Precaution for use	Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants 
A10BB01	GLIBENCLAMIDE	4815			J01FA09	CLARITHROMYCIN	21212			ANSM	243-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide as needed during the treatment with the clarithromycin 
A10BB01	GLIBENCLAMIDE	4815			D10AF02	ERYTHROMYCIN	4053			ANSM	243-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB01	GLIBENCLAMIDE	4815			D10AF52	ERYTHROMYCIN	4053			ANSM	243-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB01	GLIBENCLAMIDE	4815			J01FA01	ERYTHROMYCIN	4053			ANSM	243-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB01	GLIBENCLAMIDE	4815			S01AA17	ERYTHROMYCIN	4053			ANSM	243-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 	Precaution for use	Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB12	GLIMEPIRIDE	25789			J01FA09	CLARITHROMYCIN	21212			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin
A10BD06	GLIMEPIRIDE	25789			J01FA09	CLARITHROMYCIN	21212			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin
A10BB12	GLIMEPIRIDE	25789			D10AF02	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB12	GLIMEPIRIDE	25789			D10AF52	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB12	GLIMEPIRIDE	25789			J01FA01	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BB12	GLIMEPIRIDE	25789			S01AA17	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BD06	GLIMEPIRIDE	25789			D10AF02	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BD06	GLIMEPIRIDE	25789			D10AF52	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BD06	GLIMEPIRIDE	25789			J01FA01	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
A10BD06	GLIMEPIRIDE	25789			S01AA17	ERYTHROMYCIN	4053			ANSM	244-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
			GLINIDES	A10BX-001				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	245-GLINIDES.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
			GLINIDES	A10BX-001				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	245-GLINIDES.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient, and reinforce, especially at the beginning of treatment, self-monitoring of blood glucose.
A10BB07	GLIPIZIDE	4821			J02AC03	VORICONAZOLE	121243			ANSM	246-GLIPIZIDE.html	Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia. 	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.
			GLIPTINS	A10B-001				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	247-GLIPTINS.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
			GLIPTINS	A10B-001				ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	247-GLIPTINS.html	Increase of the risk of the onset of angioedema, due to the reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the ACE inhibitor	Take into account	
			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001				IMMUNOSUPPRESSANTS	L04A	ANSM	248-ANTI-LYMPHOCYTE-GLOBULINS.html	Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)	Take into account	
			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001				ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	248-ANTI-LYMPHOCYTE-GLOBULINS.html	Risk of possibly fatal general illness. This risk is increased in older patients already immunodepressed by the underlying disease.	Take into account	In particular, use an inactive vaccine when one exists (poliomyelitis)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001				ORAL ANTICOAGULANTS	B01A-001	ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the Vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) in large doses or in treatment prolonged beyond 10 days. 	Precaution for use	When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, laboratory tests on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addison's disease treated with hydrocortisone and in cases of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Increase of the risk of ulceration and of gastrointestinal hemorrhage	Take into account	
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001				NON-DEPOLARIZING CURARES	M03A-002	ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).	Take into account	
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001				FLUOROQUINOLONES	J01MA-001	ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving corticotherapy for a prolonged period	Take into account	
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM03	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AC01	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AC51	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM02	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM05	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM06	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM01	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM04	ISONIAZID	6038			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AB02	RIFAMPICIN	9384			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with rifampicin and after it is stopped. 
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM02	RIFAMPICIN	9384			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with rifampicin and after it is stopped. 
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM05	RIFAMPICIN	9384			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with rifampicin and after it is stopped. 
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	J04AM06	RIFAMPICIN	9384			ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with rifampicin and after it is stopped. 
			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001				ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	249-GLUCOCORTICOIDS-(EXCEPT-FOR-HYDROCORTISONE).html	With the exception of inhaled and local routes, and for doses greater than 10mg/day of prednisone-equivalent (or > 2mg/kg/day for a child or > 20mg/day for a child of more than 10 kg) during more than two weeks and for the "bolus" of corticoids: risk of possibly fatal general vaccine disease.	Contraindication 	And during the 3 months following the end of the therapy with the corticoid.
M04AA01	ALLOPURINOL	519						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	25-ALLOPURINOL.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. 
M04AA01	ALLOPURINOL	519			J05AF02	DIDANOSINE	3364			ANSM	25-ALLOPURINOL.html	Increase of the plasma concentrations of didanosine and of its undesirable effects	Not recommended	
M04AA01	ALLOPURINOL	519						AMINOPENICILLINS	J01CA	ANSM	25-ALLOPURINOL.html	Increased risk of cutaneous reactions	Take into account	
M04AA01	ALLOPURINOL	519			J05AB03	VIDARABINE	11194			ANSM	25-ALLOPURINOL.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
M04AA01	ALLOPURINOL	519			S01AD06	VIDARABINE	11194			ANSM	25-ALLOPURINOL.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
A06AG04	GLYCEROL	4910			D11AX04	LITHIUM	6448			ANSM	250-GLYCEROL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
A06AX01	GLYCEROL	4910			D11AX04	LITHIUM	6448			ANSM	250-GLYCEROL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
A16AX09	GLYCEROL	4910			D11AX04	LITHIUM	6448			ANSM	250-GLYCEROL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
D01AA08	GRISEOFULVIN	5021						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	251-GRISEOFULVIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with griseofulvin and a week after it is stopped 
D01BA01	GRISEOFULVIN	5021						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	251-GRISEOFULVIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with griseofulvin and a week after it is stopped 
D01AA08	GRISEOFULVIN	5021						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	251-GRISEOFULVIN.html	Risk of decrease of the contraceptive effectiveness due to the increase of its hepatic metabolism	Precaution for use	Another method of contraception, in particular a barrier method or IUD, should be used during the time the two substances are administered together and a cycle after. 
D01BA01	GRISEOFULVIN	5021						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	251-GRISEOFULVIN.html	Risk of decrease of the contraceptive effectiveness due to the increase of its hepatic metabolism	Precaution for use	Another method of contraception, in particular a barrier method or IUD, should be used during the time the two substances are administered together and a cycle after. 
D01AA08	GRISEOFULVIN	5021						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	251-GRISEOFULVIN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Another contraceptive method, in particular a barrier method or IUD, should be used during the administration of the two substances together and one cycle following. 
D01BA01	GRISEOFULVIN	5021						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	251-GRISEOFULVIN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Another contraceptive method, in particular a barrier method or IUD, should be used during the administration of the two substances together and one cycle following. 
C02CC02	GUANETHIDINE	5036						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	252-GUANETHIDINE.html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	Contraindication	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
S01EX01	GUANETHIDINE	5036						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	252-GUANETHIDINE.html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	Contraindication	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
C02LF01	GUANETHIDINE	5036						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	252-GUANETHIDINE.html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	Contraindication	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
P01BX01	HALOFANTRINE	50749				GRAPEFRUIT JUICE				ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
P01BX01	HALOFANTRINE	50749						AZOLE ANTIFUNGALS	J02AC-001	ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering the substances together cannot be avoided, testing of the QT before the beginning of the treatment and EKG monitoring
P01BX01	HALOFANTRINE	50749			J01FA09	CLARITHROMYCIN	21212			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, test the QT before hand and monitor EKG.
P01BX01	HALOFANTRINE	50749			D10AF02	ERYTHROMYCIN	4053			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and monitor EKG.
P01BX01	HALOFANTRINE	50749			D10AF52	ERYTHROMYCIN	4053			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and monitor EKG.
P01BX01	HALOFANTRINE	50749			J01FA01	ERYTHROMYCIN	4053			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and monitor EKG.
P01BX01	HALOFANTRINE	50749			S01AA17	ERYTHROMYCIN	4053			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT beforehand and monitor EKG.
P01BX01	HALOFANTRINE	50749						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
P01BX01	HALOFANTRINE	50749			J01FA07	JOSAMYCIN	6084			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			A01AB09	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			A07AC01	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			D01AC02	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			G01AF04	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			J02AB01	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			S02AA13	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			D01AC52	MICONAZOLE	6932			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
P01BX01	HALOFANTRINE	50749			N03AX17	STIRIPENTOL	37119			ANSM	253-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
N05AD01	HALOPERIDOL	5093			N03AF01	CARBAMAZEPINE	2002			ANSM	254-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped. 
N05AD01	HALOPERIDOL	5093			J04AB02	RIFAMPICIN	9384			ANSM	254-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
N05AD01	HALOPERIDOL	5093			J04AM02	RIFAMPICIN	9384			ANSM	254-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
N05AD01	HALOPERIDOL	5093			J04AM05	RIFAMPICIN	9384			ANSM	254-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
N05AD01	HALOPERIDOL	5093			J04AM06	RIFAMPICIN	9384			ANSM	254-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
N01AB01	HALOTHANE	5095						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	255-HALOTHANE.html	In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity	Not recommended	Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane
N01AB01	HALOTHANE	5095						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	255-HALOTHANE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
			HEPARINS	B01AB				PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	256-HEPARINS.html	Increased risk of hemorrhage 	Take into account	
			HEPARINS	B01AB	B01AX01	DEFIBROTIDE	1311089			ANSM	256-HEPARINS.html	Increased risk of hemorrhage	Not recommended	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001				ORAL ANTICOAGULANTS	B01A-001	ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage	Precaution for use	Strengthen clinical monitoring and, if the situation requires, laboratory tests. 
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	B05AA05	DEXTRAN 40	42635			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	B03AC06	DEXTRAN 40	42635			ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001				THROMBOLYTICS	B01AD	ANSM	257-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests.	Take into account	
			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	258-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	Increase of the risk of hemorrhage 	Take into account	
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage	Precaution for use	When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring.
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	B05AA05	DEXTRAN 40	42635			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40) 	Not recommended	
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	B03AC06	DEXTRAN 40	42635			ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40) 	Not recommended	
			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003				THROMBOLYTICS	B01AD	ANSM	259-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage	Take into account	
			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001				ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Increase of the hypotensive effect. Risk of severe orthostatic hypotension. .	Not recommended	
			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001				ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Increase of the hypotensive effect. Increased risk of orthostatic hypotension 	Take into account	
			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001				TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Risk of orthostatic hypotension, especially in older patients	Not recommended	-with doxazosin
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly laboratory tests 	Take into account	
			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	260-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	Increase of the risk of hemorrhage	Take into account	
			THYROID HORMONES	H03AA				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid in patients with hypothyroidism due to increase of the metabolism of the T3 and of the T4	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped. 
			THYROID HORMONES	H03AA	A12AA	CALCIUM	1428011			ANSM	261-THYROID HORMONES.html	Decrease of absorption of the thyroid hormones	Precaution for use	Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).
			THYROID HORMONES	H03AA	P01BA01	CHLOROQUINE	2393			ANSM	261-THYROID HORMONES.html	Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment of the dosage of the thyroid hormone if needed during the treatment with the antimalarial and after it is stopped.
			THYROID HORMONES	H03AA				NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	261-THYROID HORMONES.html	Risk of clinical hypothyroidism in cases of estrogen substitution therapy	Precaution for use	Clinical monitoring and laboratory tests; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.
			THYROID HORMONES	H03AA	B03A	IRON	1431589			ANSM	261-THYROID HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).
			THYROID HORMONES	H03AA	L01XE01	IMATINIB	282388			ANSM	261-THYROID HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
			THYROID HORMONES	H03AA				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	261-THYROID HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones due to the increase of their hepatic metabolism by the ritonavir	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the thyroid hormones.
			THYROID HORMONES	H03AA	A08AB01	ORLISTAT	37925			ANSM	261-THYROID HORMONES.html	Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat	Take into account	
			THYROID HORMONES	H03AA	P01BB01	PROGUANIL	2382			ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. 
			THYROID HORMONES	H03AA	P01BB51	PROGUANIL	2382			ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. 
			THYROID HORMONES	H03AA				CHELATING RESINS	C10-V0	ANSM	261-THYROID HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).
			THYROID HORMONES	H03AA	J04AB04	RIFABUTIN	55672			ANSM	261-THYROID HORMONES.html	Described for phenytoin, rifampicin, and carbamazepine. [sic]Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.
			THYROID HORMONES	H03AA	J04AB02	RIFAMPICIN	9384			ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped. 
			THYROID HORMONES	H03AA	J04AM02	RIFAMPICIN	9384			ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped. 
			THYROID HORMONES	H03AA	J04AM05	RIFAMPICIN	9384			ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped. 
			THYROID HORMONES	H03AA	J04AM06	RIFAMPICIN	9384			ANSM	261-THYROID HORMONES.html	Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped. 
			THYROID HORMONES	H03AA	A02BX02	SUCRALFATE	10156			ANSM	261-THYROID HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	Take the thyroid hormones at a different time from the sulcralfate (more than 2 hours apart if possible).
			THYROID HORMONES	H03AA	L01XE04	SUNITINIB	357977			ANSM	261-THYROID HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
			MINERAL OILS	A06AA-		LATEX CONDOMS				ANSM	262-MINERAL-OILS.html	Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)	Contraindication	Use hydrosoluble lubricants (glycerin, polyacrylamide...).
A01AC03	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
A07EA02	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07XA01	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
H02AB09	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S01BA02	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S01CB03	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S02BA01	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07AC16	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07CA01	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S01CA03	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S02CA03	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S03CA04	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07BA04	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
S01BB01	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07AB11	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07AB02	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
D07BB04	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
R01AD60	HYDROCORTISONE	5492						ENZYMATIC INDUCERS	N03-J05-001	ANSM	263-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
	HYDROQUINIDINE	27220						URINARY ALKALIZERS	B05-001	ANSM	264-HYDROQUINIDINE.html	Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine due to alkalinizing of the urine )	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped. 
	HYDROQUINIDINE	27220			C01AA05	DIGOXIN 	3407			ANSM	264-HYDROQUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).	Precaution for use	Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage.
	HYDROQUINIDINE	27220			J02AC02	ITRACONAZOLE	28031			ANSM	264-HYDROQUINIDINE.html	Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole	Precaution for use	Monitoring of the plasma concentrations of the antiarrythmic and possible decrease of its dosage if necessary.
L01XX05	HYDROXYCARBAMIDE 	5552						ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	265-HYDROXYCARBAMIDE.html	When indicated for a patient with drepanocytosis (sickle cell anemia), risk of general fatal vaccine disease. 	Not recommended	Administering these together should be considered only if the benefits are estimated to be higher than the this risk.
			HYPERKALEMIA INDUCING MEDICATIONS	M01A-001				HYPERKALEMIA INDUCING MEDICATIONS	M01A-001	ANSM	266-HYPERKALEMIA-INDUCING-MEDICATIONS.html	Risk of increase of hyperkalemia, potentially lethal. 	Take into account	
			HYPNOTICS	N05-R06				HYPNOTICS	N05-R06	ANSM	267-HYPNOTICS.html	Increase of central nervous system depression	Take into account	
			POTASSIUM LOWERING AGENTS	C03-001				POTASSIUM LOWERING AGENTS	C03-001	ANSM	268-POTASSIUM-LOWERING-MEDICATIONS.html	Increased risk of hypokalemia	Precaution for use	Monitoring of kalemia with correction if needed.
			POTASSIUM LOWERING AGENTS	C03-001				DIGITALIS GLYCOSIDES	C01AA0	ANSM	268-POTASSIUM-LOWERING-MEDICATIONS.html	Hypokalemia promoting the toxic effects of the digitalis glycosides	Precaution for use	Correct any pre-existing hypokalemia and maintain clinical monitoring, monitoring of electrolyte balance, and electrocardographic monitoring.
			POTASSIUM LOWERING AGENTS	C03-001				MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	268-POTASSIUM-LOWERING-MEDICATIONS.html	Increased risk of ventricular arrhythmias, especially torsades de pointes	Precaution for use	Correct any hypokalemia before administering the product and maintain clinical monitoring, electrolyte monitoring and electrocardiographic monitoring. 
			HYPONATREMIA INDUCING MEDICATIONS	C03EA				HYPONATREMIA INDUCING MEDICATIONS	C03EA	ANSM	269-HYPONATREMIA-INDUCING-MEDICATIONS.html	Increase of the risk of hyponatremia	Take into account	
A11HA03	ALPHA-TOCOPHEROL	11256						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	27-ALPHA-TOCOPHEROL.html	With the vitamin E used in doses greater than or equal to 500 mg per day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped. 
L01XE27	IBRUTINIB	1442981			C01BD01	AMIODARONE	703			ANSM	270-IBRUTINIB.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of these two drugs together.
L01XE27	IBRUTINIB	1442981			C08DB01	DILTIAZEM	3443			ANSM	270-IBRUTINIB.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time that these medications are administered together.
L01XE27	IBRUTINIB	1442981			C08DA01	VERAPAMIL	11170			ANSM	270-IBRUTINIB.html	Increase of the plasma concentrations of irutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140mg per day during the length of time these medications are administered together. 
L01XX47	IDELALISIB	1544460						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	271-IDELALISIB.html	Decrease of the plasma concentratioins of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer	Not recommended	
L01XX47	IDELALISIB	1544460						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	271-IDELALISIB.html	Increase of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor	Take into account	
L01XX47	IDELALISIB	1544460				ST JOHNS WORT	258326			ANSM	271-IDELALISIB.html	Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
L01XX47	IDELALISIB	1544460			J04AB02	RIFAMPICIN	9384			ANSM	271-IDELALISIB.html	Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.	Not recommended	
L01XX47	IDELALISIB	1544460			J04AM02	RIFAMPICIN	9384			ANSM	271-IDELALISIB.html	Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.	Not recommended	
L01XX47	IDELALISIB	1544460			J04AM05	RIFAMPICIN	9384			ANSM	271-IDELALISIB.html	Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.	Not recommended	
L01XX47	IDELALISIB	1544460			J04AM06	RIFAMPICIN	9384			ANSM	271-IDELALISIB.html	Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.	Not recommended	
L01XX47	IDELALISIB	1544460						SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	271-IDELALISIB.html	Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idelalisib.	Not recommended	
L01AA06	IFOSFAMIDE	5657			A04AD12	APREPITANT	358255			ANSM	272-IFOSFAMIDE.html	Risk of increase of the neurotoxicity of the ifosfamide	Take into account	
L01AA06	IFOSFAMIDE	5657						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	272-IFOSFAMIDE.html	Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital	Not recommended	
L01AA06	IFOSFAMIDE	5657			L01XE15	VEMURAFENIB	1147220			ANSM	272-IFOSFAMIDE.html	Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity	Take into account	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0		ALCOHOL (DRINK OR INGREDIENT)				ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the hypertensive and/or hyperthermic effects of the tyramine present in certain alcoholic drinks (chianti, certain beers, etc.)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N06AX12	BUPROPION	42347			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of hypertensive crises. From the fact of the length of action of the MAOI, this interaction is still theoretically possible two weeks after it is stopped	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	R05DA09	DEXTROMETHORPHAN	3289			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N07XX59	DEXTROMETHORPHAN	3289			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02CC02	GUANETHIDINE	5036			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	Contraindication 	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	S01EX01	GUANETHIDINE	5036			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	Contraindication 	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02LF01	GUANETHIDINE	5036			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	Contraindication 	Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT) 	COMT	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels, of the catecholamines due to the combined inhibition of their metabolism	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	Wait two weeks between the discontinuation of the MAOI andthe start of the treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the start. 
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N04BA01	LEVODOPA	6375			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	[no text in document]	[no text in document]	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N04BA02	LEVODOPA	6375			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	[no text in document]	[no text in document]	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N04BA03	LEVODOPA	6375			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	[no text in document]	[no text in document]	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication 	Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of the other treatment and the start of the MAOI.
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C01CA17	MIDODRINE	6963			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0		ST JOHNS WORT	258326			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N02AB02	PETHIDINE 	6754			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N02AB52	PETHIDINE 	6754			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N02AB72	PETHIDINE 	6754			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N02AG03	PETHIDINE 	6754			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02AA02	RESERPINE 	9260			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02LA01	RESERPINE 	9260			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02LA51	RESERPINE 	9260			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02LA71	RESERPINE 	9260			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	C02AA52	RESERPINE 	9260			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped	Not recommended	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the pressor action of the sympathomimetic, most often moderate.	Precaution for use	Only use under strict medical monitoring. 
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Paroxysmal hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N07XX06	TETRABENAZINE	10390			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after it is stopped	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N06AX14	TIANEPTINE	38252			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of drop in blood pressure, paroxysmal hypertension, hyperthermia, convulsions, death	Not recommended	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N02AX02	TRAMADOL	10689			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	N02AX5	TRAMADOL	10689			ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of arterial hypertension, of constriction of the coronary arteries 	Contraindication	
			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0				TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	273-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of arterial hypertension, of constriction of the coronary arteries 	Not recommended 	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N06AX12	BUPROPION	42347			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of hypertensive crises 	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	R05DA09	DEXTROMETHORPHAN	3289			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N07XX59	DEXTROMETHORPHAN	3289			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				MAOI-B 	N04BD0-001	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of rapid elevation of blood pressure, due to loss of selectivity on the monoamine oxydase, especially in case of eating food rich in tyramine (cheese, beer, ...)	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration at minimum recommended dosages.
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together at minimum recommended dosages. 
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001		ST JOHNS WORT	258326			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N02AB02	PETHIDINE 	6754			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N02AB52	PETHIDINE 	6754			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N02AB72	PETHIDINE 	6754			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N02AG03	PETHIDINE 	6754			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	By extrapolation from the non selective MAOIs: risk of increase of heart activation.	Precaution for use	To be used only under strict medical monitoring.
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N02AX02	TRAMADOL	10689			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	N02AX52	TRAMADOL	10689			ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of arterial hypertension, of constriction of coronary arteries	Contraindication	
			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001				TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	274-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of arterial hypertension, of constriction of coronary arteries	Not recommended	
			MAOI-B 	N04BD0-001	N06AX12	BUPROPION	42347			ANSM	275-MAOI-B.html	Risk of hypertensive crises	Contraindication	
			MAOI-B 	N04BD0-001				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	275-MAOI-B.html	Risk of rapid elevation of blood pressure, due to loss of selectivity on the monamine oydase, especially in case of consuming food rich in tyramine (cheese, beer,...)	Contraindication	
			MAOI-B 	N04BD0-001				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	275-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
			MAOI-B 	N04BD0-001	N04BA01	LEVODOPA	6375			ANSM	275-MAOI-B.html	Increased risk of orthostatic hypotension	Take into account	
			MAOI-B 	N04BD0-001	N04BA02	LEVODOPA	6375			ANSM	275-MAOI-B.html	Increased risk of orthostatic hypotension	Take into account	
			MAOI-B 	N04BD0-001	N04BA03	LEVODOPA	6375			ANSM	275-MAOI-B.html	Increased risk of orthostatic hypotension	Take into account	
			MAOI-B 	N04BD0-001	N02AB02	PETHIDINE 	6754			ANSM	275-MAOI-B.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			MAOI-B 	N04BD0-001	N02AB52	PETHIDINE 	6754			ANSM	275-MAOI-B.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			MAOI-B 	N04BD0-001	N02AB72	PETHIDINE 	6754			ANSM	275-MAOI-B.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			MAOI-B 	N04BD0-001	N02AG03	PETHIDINE 	6754			ANSM	275-MAOI-B.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
			MAOI-B 	N04BD0-001	N02AX02	TRAMADOL	10689			ANSM	275-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
			MAOI-B 	N04BD0-001	N02AX52	TRAMADOL	10689			ANSM	275-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
			MAOI-B 	N04BD0-001				TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	275-MAOI-B.html	Risk of arterial hypertension, of constriction of the coronary arteries	Contraindication	
			MAOI-B 	N04BD0-001				TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	275-MAOI-B.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
L01XE01	IMATINIB	282388						THYROID HORMONES	H03AA	ANSM	276-IMATINIB.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
			IMMUNOSUPPRESSANTS	L04A		GRAPEFRUIT JUICE				ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the bioavailability of the immunosuppressant and, as a result, of its undesirable effects	Not recommended	
			IMMUNOSUPPRESSANTS	L04A	J05AE12	BOCEPREVIR	1102129			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant (especially for the ciclosporin, extremely large for the tacrolimus)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the administration of the medications together and after it is stopped. 
			IMMUNOSUPPRESSANTS	L04A	J01FA09	CLARITHROMYCIN	21212			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these must be administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
			IMMUNOSUPPRESSANTS	L04A				CYTOTOXICS	L01	ANSM	277-IMMUNOSUPPRESSANTS.html	Excessive immunodepression with risk of lymphoproliferative syndrome	Take into account	
			IMMUNOSUPPRESSANTS	L04A	J01FG02	DALFOPRISTIN	229369			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
			IMMUNOSUPPRESSANTS	L04A	C08DB01	DILTIAZEM	3443			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.
			IMMUNOSUPPRESSANTS	L04A	C01BD07	DRONEDARONE	233698			ANSM	277-IMMUNOSUPPRESSANTS.html	Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Not recommended	
			IMMUNOSUPPRESSANTS	L04A	D10AF02	ERYTHROMYCIN	4053			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	D10AF52	ERYTHROMYCIN	4053			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	J01FA01	ERYTHROMYCIN	4053			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	S01AA17	ERYTHROMYCIN	4053			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	D01AC15	FLUCONAZOLE	4450			ANSM	277-IMMUNOSUPPRESSANTS.html	Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. 
			IMMUNOSUPPRESSANTS	L04A	J02AC01	FLUCONAZOLE	4450			ANSM	277-IMMUNOSUPPRESSANTS.html	Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. 
			IMMUNOSUPPRESSANTS	L04A				ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001	ANSM	277-IMMUNOSUPPRESSANTS.html	Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)	Take into account	
			IMMUNOSUPPRESSANTS	L04A				ENZYMATIC INDUCERS	N03-J05-001	ANSM	277-IMMUNOSUPPRESSANTS.html	Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer	Precaution for use	Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.
			IMMUNOSUPPRESSANTS	L04A				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.
			IMMUNOSUPPRESSANTS	L04A	J02AC02	ITRACONAZOLE	28031			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	D01AC08	KETOCONAZOLE	6135			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	G01AF11	KETOCONAZOLE	6135			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	J02AB02	KETOCONAZOLE	6135			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A		ST JOHNS WORT	258326			ANSM	277-IMMUNOSUPPRESSANTS.html	Decrease of the blood concentrations of the immunosuppressant, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect which can possibly have possibly serious consequences (rejection of a graft).	Contraindication	
			IMMUNOSUPPRESSANTS	L04A	J05AE04	NELFINAVIR	134527			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism 	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
			IMMUNOSUPPRESSANTS	L04A	C08CA04	NICARDIPINE	7396			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment and after it is stopped.
			IMMUNOSUPPRESSANTS	L04A	J02AC04	POSACONAZOLE	282446			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A	J01FG01	PRISTINAMYCIN	66958			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.
			IMMUNOSUPPRESSANTS	L04A	J01FG02	QUINUPRISTINE	135098			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism 	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped.
			IMMUNOSUPPRESSANTS	L04A	C01EB18	RANOLAZINE	35829			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the immunosuppressant.
			IMMUNOSUPPRESSANTS	L04A	N03AX17	STIRIPENTOL	37119			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)	Contraindication	
			IMMUNOSUPPRESSANTS	L04A	J05AE11	TELAPREVIR	1102261			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped. 
			IMMUNOSUPPRESSANTS	L04A	J01FA15	TELITHROMYCIN	274786			ANSM	277-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
			IMMUNOSUPPRESSANTS	L04A				ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	277-IMMUNOSUPPRESSANTS.html	Risk of general vaccinal disease, possibly fatal. 	Contraindication	And during the 3 months following the treatment. 
			IMMUNOSUPPRESSANTS	L04A	L01XE15	VEMURAFENIB	1147220			ANSM	277-IMMUNOSUPPRESSANTS.html	Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness	Not recommended	
			IMMUNOSUPPRESSANTS	L04A	J02AC03	VORICONAZOLE	121243			ANSM	277-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole	Not recommended	-with the everolimus, the sirolimus, and the temsirolimus
J05AE02	INDINAVIR	114289			J05AG03	EFAVIRENZ	195085			ANSM	278-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together. 
J05AE02	INDINAVIR	114289			J05AR06	EFAVIRENZ	195085			ANSM	278-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together. 
J05AE02	INDINAVIR	114289			J05AG01	NEVIRAPINE	53654			ANSM	278-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substancestogether. 
J05AE02	INDINAVIR	114289			J05AR07	NEVIRAPINE	53654			ANSM	278-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substancestogether. 
J05AE02	INDINAVIR	114289			J05AR05	NEVIRAPINE	53654			ANSM	278-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substancestogether. 
			ENZYMATIC INDUCERS	N03-J05-001				ANDROGENS	A14AA0	ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the androgen and as a result of its effectiveness, due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and laboratory tests during the administrations of these substances together and 1 to 2 weeks after the inducer is discontinued.
			ENZYMATIC INDUCERS	N03-J05-001	J04AK05	BEDAQUILINE	1364504			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	L01XX32	BORTEZOMIB	358258			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
			ENZYMATIC INDUCERS	N03-J05-001	L01CD04	CABAZITAXEL	996051			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
			ENZYMATIC INDUCERS	N03-J05-001	J05AX14	DACLATASVIR	1606218			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer	Contraindication	
			ENZYMATIC INDUCERS	N03-J05-001		DASABUVIR	1597381			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the dasabuvir by the inducer.	Contraindication	
			ENZYMATIC INDUCERS	N03-J05-001	L01CD02	DOCETAXEL	72962			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
			ENZYMATIC INDUCERS	N03-J05-001	L01XX41	ERIBULINE	1045453			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of eribuline by the inducer.	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001				COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used during the treatment with these substances together and a cycle following. 
			ENZYMATIC INDUCERS	N03-J05-001	A01AC03	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	A07EA02	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07XA01	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	H02AB09	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S01BA02	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S01CB03	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S02BA01	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07AC16	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07CA01	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S01CA03	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S02CA03	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S03CA04	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07BA04	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	S01BB01	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07AB11	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07AB02	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	D07BB04	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	R01AD60	HYDROCORTISONE	5492			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001				IMMUNOSUPPRESSANTS	L04A	ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer	Precaution for use	Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.
			ENZYMATIC INDUCERS	N03-J05-001	L01XX19	IRINOTECAN	51499			ANSM	279-ENZYMATIC-INDUCERS.html	Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Take into account	
			ENZYMATIC INDUCERS	N03-J05-001	J02AC02	ITRACONAZOLE	28031			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	R07AX02	IVACAFTOR	1243041			ANSM	279-ENZYMATIC-INDUCERS.html	Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	C02KX04	MACITENTAN	1442132			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	J05AX09	MARAVIROC	620216			ANSM	279-ENZYMATIC-INDUCERS.html	In the absence of co-administration with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer.	Precaution for use	The dose of maraviroc must be increased to 600mg twice a day in this situation. 
			ENZYMATIC INDUCERS	N03-J05-001	N02AC52	METHADONE	6813			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	Increase the frequency of the doses of methadone (2 to 3 times a day instead of a single dose per day).
			ENZYMATIC INDUCERS	N03-J05-001	N07BC02	METHADONE	6813			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	Increase the frequency of the doses of methadone (2 to 3 times a day instead of a single dose per day).
			ENZYMATIC INDUCERS	N03-J05-001	N06AX03	MIANSERIN	6929			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of ineffectiveness of the mianserin	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001				OMBITASVIR + PARITAPREVIR	OMPA	ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the bitherapy by increase of its hepatic metabolism by the inducer	Contraindication	
			ENZYMATIC INDUCERS	N03-J05-001				PROGESTIN CONTRACEPTIVES	G03-001	ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer. 	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used during the length of time that the two substances are administered together and one cycle following.
			ENZYMATIC INDUCERS	N03-J05-001				NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the effectiveness of the progestogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. 
			ENZYMATIC INDUCERS	N03-J05-001	L01XE21	REGORAFENIB	1312397			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the regorafenib due to increase of its metabolism by the inducer	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	J05AG05	RILPIVIRINE	1102270			ANSM	279-ENZYMATIC-INDUCERS.html	Significant decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer	Contratindication	
			ENZYMATIC INDUCERS	N03-J05-001	N06AB06	SERTRALINE	36437			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of ineffectiveness of the treatment by the antidepressant 	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	J05AE14	SIMEPREVIR	1482790			ANSM	279-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	J05AX15	SOFOSBUVIR	1484911			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer.	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	L01XE15	VEMURAFENIB	1147220			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the concentrations of the vermurafenib, with lower effectiveness	Not recommended	
			ENZYMATIC INDUCERS	N03-J05-001	L01XX43	VISMODEGIB	1242987			ANSM	279-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer	Not recommended	
			ALUMINUM (SALTS)	A02AD0-001				CITRATES	V09HX	ANSM	28-ALUMINUM-(SALTS).html	Risk of facilitating systemic uptake of the aluminum salts especially when there is altered renal function	Precaution for use	Take aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including the natural ones such as citrus fruits. 
			CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT) 	COMT				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	280-CATECHOL-O-METHYLTRANSFERASE-INHIBITORS-(COMT).html	Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels by the catecholamines due to the combined inhibition of their metabolism	Contraindication	
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE				ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of orthostatic hypotension, especially in older patients	Not recommended	-with doxazosin
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE				ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended 	-with the doxazosine
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	J01FA09	CLARITHROMYCIN	21212			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	- with avanafil
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	A02BD04	CLARITHROMYCIN	21212			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	- with avanafil
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	A02BD05	CLARITHROMYCIN	21212			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	- with avanafil
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	A02BD06	CLARITHROMYCIN	21212			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	- with avanafil
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	A02BD07	CLARITHROMYCIN	21212			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of PDE5, with risk of hypotension	Contraindication	- with avanafil
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE				NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and provoking an acute coronary accident	Contraindication	
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	D10AF02	ERYTHROMYCIN	4053			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	D10AF52	ERYTHROMYCIN	4053			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	J01FA01	ERYTHROMYCIN	4053			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	S01AA17	ERYTHROMYCIN	4053			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the inhibitor of the PDE5, with risk of hypotension	Precaution for use	Start the treatment with the PDE5 inhibitor at the minimum dose when administered with one of these medications. [sic]
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Large increase of the plasma concentrations of the PDE5 inhibitor, with risk of severe hypotension	Contraindication 	-- with the sildenafilindicated for pulmonary artery hypertension
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	J02AC02	ITRACONAZOLE	28031			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase (very large for the avanafil and the vardenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil Contraindication	With the vardenafil 
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	D01AC08	KETOCONAZOLE	6135			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil:	Contraindication
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	G01AF11	KETOCONAZOLE	6135			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil:	Contraindication
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	J02AB02	KETOCONAZOLE	6135			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil:	Contraindication
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	C02KX05	RIOCIGUAT	1439816			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of large drop in blood pressure (synergic effect)	Contraindication	
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	J05AE11	TELAPREVIR	1102261			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Large increase of the plasma concentrations of the PDE5 inhibitor, with risk of severe hypotension	Contraindication	-in cases of pulmonary artery hypertension
			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	J01FA15	TELITHROMYCIN	274786			ANSM	281-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase of the plasma concentrations of the type 5 inhibiter of phosphodiesterase with risk of severe hypotension	Contraindication	--with the avanafil
			XANTHINE OXYDASE INHIBITORS	M04AA0	L04AX01	AZATHIOPRINE	1256			ANSM	282-XANTHINE-OXYDASE-INHIBITORS.html	Bone marrow suppression, possibly serious	Contraindication	
			XANTHINE OXYDASE INHIBITORS	M04AA0	L01BB02	MERCAPTOPURINE	103			ANSM	282-XANTHINE-OXYDASE-INHIBITORS.html	Bone marrow suppression, reversible but possibly serious (overdose due to decrease of the hepatic metabolism of the mercaptopurine).	Not recommended	Reinforced hematological monitoring and adjustment of the dosage of the mercaptopurine. 
			XANTHINE OXYDASE INHIBITORS	M04AA0				THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	282-XANTHINE-OXYDASE-INHIBITORS.html	With large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism. 	Precaution for use	Clinical monitoring and testing of the theohyllinemia up to two or three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. 
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C09XA02	ALISKIREN 	325646			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication:	-for patients with diabetes or renal insufficiency
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C09XA52	ALISKIREN 	325646			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication:	-for patients with diabetes or renal insufficiency
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C09DX02	ALISKIREN 	325646			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication:	-for patients with diabetes or renal insufficiency
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA				ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	In situations where the administration of these medications together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness. 	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, or having altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of these substances together.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA				POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Except for the eplerenone and the spironolactone at doses between 12.5 mg and 50 mg/day in the treatment of heart failure, as well as in cases of hypokalemia: Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	If the administration of these medications together is justified, strict testing of the kalemia and of the renal function.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA				POTASSIUM LOWERING DIURETICS	C03	ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion 	Precaution for use	In arterial hypertension, when there is fluid depletion from a previous treatment with a diuretic, it is necessary:
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C03DA04	EPLERENONE	298869			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of hyperkalemia, especially with older patients.	Precaution for use	Strict testing of the kalemia and of renal function during the administration of these substances together. 
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	L01XX11	ESTRAMUSTINE	4089			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema) 	Not recommended	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA				GLIPTINS	A10B-001	ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of the onset of angioedema, due to reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the ACE inhibitor	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AC01	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AC02	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AC03	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AC04	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AD01	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AD02	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AD03	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AD04	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AD05	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AE01	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AE02	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AE03	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AE04	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AE05	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A10AF01	INSULIN	5856			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Reinforce self-monitoring of blood glucose
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	D11AX04	LITHIUM	6448			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the lithemia which can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If the use of an ACE inhibitor is indispensable, strict monitoring of the lithemia and adjustment of the dosage of the lithium. 
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01CB	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01CB01	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01CB02	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01CB03	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01CB04	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	M01CB05	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	V10AX06	GOLD	691572			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A12BA	POTASSIUM	8588			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Unless there is hypokalemia.
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	A07XA04	RACECADOTRIL	16738			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of increase of the undesirable effects of the angioedema type. 	Contraindication	--in case of preceding angioedema with ACE inhibitors
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	C03DA01	SPIRONOLACTONE	9997			ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the spironolactone at dosages from 12.5 to 50 mg per day, and with low doses of ACE inhibitorsIn the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescribed doses for this combination of medications.	Precaution for use	Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict laboratory testing of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter). 
			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA				BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	283-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)	Precaution for use	Reinforce self-monitoring of blood glucose.
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	D06AX01	FUSIDIC ACID	4608			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. 	Contraindication	Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid and use another antibiotic
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	D09AA02	FUSIDIC ACID	4608			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. 	Contraindication	Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid and use another antibiotic
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	J01XC01	FUSIDIC ACID	4608			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. 	Contraindication	Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid and use another antibiotic
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	S01AA13	FUSIDIC ACID	4608			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. 	Contraindication	Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid and use another antibiotic
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	M04AC01	COLCHICINE	2683			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	Clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together.
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	J01XX09	DAPTOMYCIN	22299			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of addition of the undesirable effects (dose dependent) of the rhabdomyolysis type.	Not recommended	If the administration of these medications together cannot be avoided, reinforce laboratory testing (dosage of the CPK once a week) and strict clinical monitoring.
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	B02BX05	ELTROMBOPAG	711942			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the statin.
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA				FIBRATES	C01AB-001	ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin	Contraindication	--for doses of 40mg of rosuvastatin
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA		LEDIPASVIR	1591922			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolosis type.	Contraindication	--with the rosuvastatin.
			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	L04AX04	LENALIDOMIDE	342369			ANSM	284-HMG--COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of the appearance of rhabdomyolysis	Precaution for use	Reinforce clinical monitoring and laboratory tests, especially during the first weeks of treatment.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	L01XE13	AFATINIB	1430438			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the protease inhibitor	Precaution for use	It is recommended that that the protease inhibitor be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	P02CA03	ALBENDAZOLE	430			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of reduction of its effectiveness.	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C10AA05	ATORVASTATIN	83367			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	Use lower doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	P01AX06	ATOVAQUONE	60212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				OTHER CORTICOIDES, NOTABLY INHALED	D07AC-001	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome, even of adrenal insufficiency 	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J05AE12	BOCEPREVIR	1102129			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure 	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N02AE01	BUPRENORPHINE	1819			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N07BC01	BUPRENORPHINE	1819			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N07BC51	BUPRENORPHINE	1819			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J01FA09	CLARITHROMYCIN	21212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment with these medications together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J01FA09	CLARITHROMYCIN	21212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment with these medications together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	A02BD04	CLARITHROMYCIN	21212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment with these medications together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	A02BD05	CLARITHROMYCIN	21212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment with these medications together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	A02BD06	CLARITHROMYCIN	21212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment with these medications together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	A02BD07	CLARITHROMYCIN	21212			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of treatment with these medications together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	M04AC01	COLCHICINE	2683			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	G04BD10	DARIFENACIN	136198			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	A01AC02	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C05AA09	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	D07AB19	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	D07XB05	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	D10AA03	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	H02AB02	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	R01AD03	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S01BA01	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S01CB01	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S02BA06	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S03BA01	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	D07CB04	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S01CA01	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S02CA06	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	S03CA01	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	R01AD53	DEXAMETHASONE	3264			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C01AA05	DIGOXIN 	3407			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	L01XX41	ERIBULINE	1045453			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of eribuline by the ritonavir	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive, because of the increase of its hepatic metabolism by the ritonavir.	Not recommended	Another method of contraception, in particular a barrier method (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	G04BD11	FESOTERODINE	797195			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	P01BX01	HALOFANTRINE	50749			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				THYROID HORMONES	H03AA	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the thyroid hormones due to increase of their hepatic metabolism by the ritonavir	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the thyroid hormones.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				IMMUNOSUPPRESSANTS	L04A	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Large increase of the plasma concentrations of the PDE5 inhibitor, with risk of severe hypotension	Contraindication	- with the sildenafil in the indication for pulmonary arterial hypertension
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N03AX09	LAMOTRIGINE	28439			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	-avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of lamotrigine
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	P01BF01	LUMEFANTRINE	847728			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N02AC52	METHADONE	6813			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N07BC02	METHADONE	6813			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N05CD08	MIDAZOLAM	6960			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use with	-midazolam by IV route
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002		ST JOHNS WORT	258326			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of the effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	Contraindication	In the case of the substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns wort is stopped. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	R06AX25	MIZOLASTINE	61455			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				PROGESTIN CONTRACEPTIVES	G03-001	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	Another method of contraception, in particular a barrier method (condom or IUD), should be used during the time the substances are administered together and one cycle following. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C01BA01	QUINIDINE	9068			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C01BA51	QUINIDINE	9068			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C01BA71	QUINIDINE	9068			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J04AB04	RIFABUTIN	55672			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin, for another thing.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J04AB02	RIFAMPICIN	9384			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional information about the ritonavir boosted protease inhibitors is available.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J04AM02	RIFAMPICIN	9384			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional information about the ritonavir boosted protease inhibitors is available.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J04AM	RIFAMPICIN	9384			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional information about the ritonavir boosted protease inhibitors is available.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J04AM06	RIFAMPICIN	9384			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional information about the ritonavir boosted protease inhibitors is available.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C10AA07	ROSUVASTATIN	301542			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	Clinical monitoring and laboratory tests.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	C10AA01	SIMVASTATIN	36567			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metoblism of the simvastatin).	Contraindication	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	G04BD08	SOLIFENACIN	322167			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	G04CA53	SOLIFENACIN	322167			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J05AE11	TELAPREVIR	1102261			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure.	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	G04BD07	TOLTERODINE	119565			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose.	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	G03AD02	ULIPRISTAL	1005921			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N06AX16	VENLAFAXINE	39786			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002				VINCA ALKALOIDS	L01CA	ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor. 	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic. 
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	J02AC03	VORICONAZOLE	121243			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N05CF02	ZOLPIDEM	39993			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Slight increase of the sedative effects of the zolpidem	Take into account 	
			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	N05CF01	ZOPICLONE	40001			ANSM	285-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Slight increase of the sedative effects of the zopiclone	Take into account	
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the enzymatic inducer	Not recommended	
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE				H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption	Take into account	-except with the vandetanib.
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE				PROTON PUMP INHIBITORS	A02BC-001	ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption	Take into account	-except with the vandetanib
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE				STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism	Not recommeded:	--with the bosutinib
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE		ST JOHNS WORT	258326			ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns wort	Contraindication	
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	J04AB02	RIFAMPICIN	9384			ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	J04AM02	RIFAMPICIN	9384			ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	J04AM05	RIFAMPICIN	9384			ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	J04AM06	RIFAMPICIN	9384			ANSM	286-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	N01AH02	ALFENTANIL	480			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism.	Precaution for use:	Clinical monitoring and adjustment of the dosage of the opioid analgesic when administered with a strong inhibitor of CYP3A4
			STRONG INHIBITORS OF CYP3A4	J02-J05	G04CA01	ALFUZOSIN	17300			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	G04CA51	ALFUZOSIN	17300			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05				CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.	Precaution for use	Clinical monitoring and dosage adjustment during the treatment with the enzyme inhibitor and after it is stopped
			STRONG INHIBITORS OF CYP3A4	J02-J05	B01AF02	APIXABAN	1364430			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the apixaban by the inhibitor, with increased risk of bleeding	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	J04AK05	BEDAQUILINE	1364504			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor.	Not recommended	If taking these medications together is necessary, more frequent EKG and monitoring of the transaminases are recommended.
			STRONG INHIBITORS OF CYP3A4	J02-J05	L01XX32	BORTEZOMIB	358258			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzyme inhibitor.
			STRONG INHIBITORS OF CYP3A4	J02-J05	L01CD04	CABAZITAXEL	996051			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzyme inhibitor
			STRONG INHIBITORS OF CYP3A4	J02-J05	J05AX14	DACLATASVIR	1606218			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of daclatasvir by the inhibitor	Precaution for use	The dose of daclatasvir should be decreased to 30mg once a day when it is administered with the inhibitor. 
			STRONG INHIBITORS OF CYP3A4	J02-J05	G04BX14	DAPOXETINE	69394			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially of the vertigo or syncope type. 	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	L01CD02	DOCETAXEL	72962			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.
			STRONG INHIBITORS OF CYP3A4	J02-J05	C01BD07	DRONEDARONE	233698			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of dronedarone due to decrease of its metabolism	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	C03DA04	EPLERENONE	298869			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	N01AH01	FENTANYL	4337			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
			STRONG INHIBITORS OF CYP3A4	J02-J05	N01AH51	FENTANYL	4337			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
			STRONG INHIBITORS OF CYP3A4	J02-J05	N02AB03	FENTANYL	4337			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
			STRONG INHIBITORS OF CYP3A4	J02-J05	L01XX47	IDELALISIB	1544460			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increaese of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor	Take into account	
			STRONG INHIBITORS OF CYP3A4	J02-J05				METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism	Not recommended	-with the bosutinib
			STRONG INHIBITORS OF CYP3A4	J02-J05	L01XX19	IRINOTECAN	51499			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	C01EB17	IVABRADINE	77417			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	R07AX02	IVACAFTOR	1243041			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by a fourth, that is 150 mg every other day. 
			STRONG INHIBITORS OF CYP3A4	J02-J05	C10AX12	LOMITAPIDE	1364479			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	J05AX09	MARAVIROC	620216			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of maraviroc by the inhibitor.	Precaution for use	The dose of maravirocmust be decreased to 150 mg twice a day when administered with this inhibitor.
			STRONG INHIBITORS OF CYP3A4	J02-J05				OMBITASVIR + PARITAPREVIR	OMPA	ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the ombitsavir + paritaprevir due to decrease of the hepatic metabolism by the inhibitor.	Contraindication	--except with ritonavir
			STRONG INHIBITORS OF CYP3A4	J02-J05	N02AA05	OXYCODONE	7804			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the oxycodone	Not recommended	Clinical monitoring and possible adjustment of the dosage of oxycodone during the length of the treatment with the enzyme inhibitor.
			STRONG INHIBITORS OF CYP3A4	J02-J05	N02AA55	OXYCODONE	7804			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the oxycodone	Not recommended	Clinical monitoring and possible adjustment of the dosage of oxycodone during the length of the treatment with the enzyme inhibitor.
			STRONG INHIBITORS OF CYP3A4	J02-J05	N05AG02	PIMOZIDE	8331			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increased difficulty with ventricular rhythm, especially of torsades de pointes	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	N05AH04	QUETIAPINE	51272			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of quetiapine, with risk of overdose	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	P01BC01	QUININE	9071			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).	Not recommended	-with the protease inhibitors
			STRONG INHIBITORS OF CYP3A4	J02-J05	M09AA72	QUININE	9071			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).	Not recommended	-with the protease inhibitors
			STRONG INHIBITORS OF CYP3A4	J02-J05	M09AA	QUININE	9071			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).	Not recommended	-with the protease inhibitors
			STRONG INHIBITORS OF CYP3A4	J02-J05	C01EB18	RANOLAZINE	35829			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	L01XE21	REGORAFENIB	1312397			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	C02KX05	RIOCIGUAT	1439816			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of riociquat due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	B01AF01	RIVAROXABAN	1114195			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	J05AE14	SIMEPREVIR	1482790			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of simeprevir due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05				SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects specific to each substrate, with frequently severe consequences	Take into account	
			STRONG INHIBITORS OF CYP3A4	J02-J05	N01AH03	SUFENTANIL	56795			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.
			STRONG INHIBITORS OF CYP3A4	J02-J05	G04CA02	TAMSULOSINE	77492			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism 	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	G04CA52	TAMSULOSINE	77492			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism 	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	G04CA53	TAMSULOSINE	77492			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism 	Not recommended	
			STRONG INHIBITORS OF CYP3A4	J02-J05	B01AC24	TICAGRELOR	1116632			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor	Contraindication	
			STRONG INHIBITORS OF CYP3A4	J02-J05	C08DA01	VERAPAMIL	11170			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires. 
			STRONG INHIBITORS OF CYP3A4	J02-J05	C08DA51	VERAPAMIL	11170			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires. 
			STRONG INHIBITORS OF CYP3A4	J02-J05	C09BB10	VERAPAMIL	11170			ANSM	287-STRONG-INHIBITORS-OF-CYP3A4.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires. 
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				ORAL ANTICOAGULANTS	B01A-001	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Precaution for use	Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and after it is stopped. 
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects	Precaution for use	Increased clinical monitoring and, if necessary, adjustment of the dosage
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	R06AX02	CYPROHEPTADINE	3013			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of decrease of the effectiveness of the antidepressant	Take into account 	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	Wait at least two weeks between the discontinuation of the irreversible MAOI and the start of treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the beginning [sic]. 
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration with minimum recommended dosages.
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				MAOI-B 	N04BD0-001	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	D11AX04	LITHIUM	6448			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB		ST JOHNS WORT	258326			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	A08AB01	ORLISTAT	37925			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	N02AX02	TRAMADOL	10689			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	N02AX52	TRAMADOL	10689			ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB				TRIPTANS	N02CC-001	ANSM	288-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of serotonin syndrome 	Take into account	
A10AC01	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AD05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE02	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE03	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE04	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AE05	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			DRINK	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AF01	INSULIN	5856			INGREDIE	ALCOHOL				ANSM	289-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol.
A10AC01	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AC02	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AC03	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AC04	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AD01	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AD02	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AD03	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AD04	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AD05	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AE01	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AE02	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AE03	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AE04	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AE05	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AF01	INSULIN	5856						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	289-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
A10AC01	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AC02	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AC03	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AC04	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AD01	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AD02	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AD03	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AD04	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AD05	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AE01	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AE02	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AE03	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AE04	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AE05	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AF01	INSULIN	5856						BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	289-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Strengthen blood and urine monitoring
A10AC01	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AC02	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AC03	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AC04	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AD01	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AD02	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AD03	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AD04	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AD05	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AE01	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AE02	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AE03	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AE04	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AE05	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AF01	INSULIN	5856						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 
A10AC01	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AC02	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AC03	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AC04	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AD01	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AD02	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AD03	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AD04	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AD05	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AE01	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AE02	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AE03	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AE04	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AE05	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AF01	INSULIN	5856						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	289-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose
A10AC01	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AC02	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AC03	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AC04	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AD01	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AD02	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AD03	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AD04	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AD05	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AE01	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AE02	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AE03	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AE04	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AE05	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AF01	INSULIN	5856			N05AA01	CHLORPROMAZINE	2403			ANSM	289-INSULIN.html	With large dosages (100 mg/day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 
A10AC01	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AC02	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AC03	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AC04	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AD01	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AD02	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AD03	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AD04	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AD05	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AE01	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AE02	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AE03	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AE04	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AE05	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AF01	INSULIN	5856			G03XA01	DANAZOL	3102			ANSM	289-INSULIN.html	Diabetes inducing effect of the danazol 	Not recommended	If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 
A10AC01	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AC02	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AC03	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AC04	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AD01	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AD02	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AD03	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AD04	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AD05	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AE01	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AE02	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AE03	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AE04	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AE05	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
A10AF01	INSULIN	5856						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	289-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	Strengthen self-monitoring of blood glucose
C02KX02	AMBRISENTAN	358274			L04AD01	CICLOSPORIN	3008			ANSM	29-AMBRISENTAN.html	Doubling of the concentrations of ambrisentan, with increase of its vasodilator effect (severe headaches )	Take into account	
C02KX02	AMBRISENTAN	358274			S01XA18	CICLOSPORIN	3008			ANSM	29-AMBRISENTAN.html	Doubling of the concentrations of ambrisentan, with increase of its vasodilator effect (severe headaches )	Take into account	
1431112	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
L03AB01	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
5879	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
L03AB04	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
5880	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
L03AB05	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
202912	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
L03AB06	INTERFERON ALFA							FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	290-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
L01XX19	IRINOTECAN	51499						ENZYMATIC INDUCERS	N03-J05-001	ANSM	291-IRINOTECAN.html	Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Take into account	
L01XX19	IRINOTECAN	51499						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	291-IRINOTECAN.html	Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite	Not recommended	
L01XX19	IRINOTECAN	51499				ST JOHNS WORT	258326			ANSM	291-IRINOTECAN.html	Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Contraindication	
J04AM03	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AC01	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AC51	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AM02	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AM05	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AM06	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AM01	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AM04	ISONIAZID	6038						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	292-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
J04AM03	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AC01	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AC51	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AM02	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AM05	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AM06	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AM01	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AM04	ISONIAZID	6038			N03AF01	CARBAMAZEPINE	2002			ANSM	292-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
J04AM03	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AC01	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AC51	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AM02	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AM05	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AM06	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AM01	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AM04	ISONIAZID	6038			N07BB01	DISULFIRAM	3554			ANSM	292-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
J04AM03	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AC01	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AC51	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AM02	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AM01	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AM04	ISONIAZID	6038						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	292-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	Clinical monitoring and laboratory tests.
J04AM03	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM03	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM03	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AC01	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AC01	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AC01	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AC51	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AC51	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AC51	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM02	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM02	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM02	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM05	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM05	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM05	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM06	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM06	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM06	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM01	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM01	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM01	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM04	ISONIAZID	6038			D01AC08	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM04	ISONIAZID	6038			G01AF11	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM04	ISONIAZID	6038			J02AB02	KETOCONAZOLE	6135			ANSM	292-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J04AM03	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AC01	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AC51	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AM02	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AM05	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AM06	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AM01	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AM04	ISONIAZID	6038						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	292-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
J04AM03	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM03	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM03	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AC01	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AC01	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AC01	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AC51	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AC51	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AC51	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM02	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM02	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM02	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM01	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM01	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM01	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM04	ISONIAZID	6038			J04AK01	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM04	ISONIAZID	6038			J04AM05	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM04	ISONIAZID	6038			J04AM06	PYRAZINAMIDE	8987			ANSM	292-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM03	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM03	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM03	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM03	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC01	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC01	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC01	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC01	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC51	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC51	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC51	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AC51	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM01	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM01	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM01	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM01	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM04	ISONIAZID	6038			J04AB02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM04	ISONIAZID	6038			J04AM02	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM04	ISONIAZID	6038			J04AM05	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM04	ISONIAZID	6038			J04AM06	RIFAMPICIN	9384			ANSM	292-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM03	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM03	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AC01	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AC01	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AC51	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AC51	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM02	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM02	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM05	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM05	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM06	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM06	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM01	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM01	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM04	ISONIAZID	6038			J05AF04	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM04	ISONIAZID	6038			J05AR07	STAVUDINE	59763			ANSM	292-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
C01CA02	ISOPRENALINE	6054						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	293-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization.	Not recommended	
R03AB02	ISOPRENALINE	6054						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	293-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization.	Not recommended	
R03CB01	ISOPRENALINE	6054						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	293-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization.	Not recommended	
R03AK02	ISOPRENALINE	6054						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	293-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization.	Not recommended	
R03CB51	ISOPRENALINE	6054						HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	293-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization.	Not recommended	
J02AC02	ITRACONAZOLE	28031			L01XE13	AFATINIB	1430438			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the itraconazole. 	Precaution for use	It is recommended to administer the itraconazole as far distant from the afatinib as possible, preferably at an interval of 6 to 12 hours away from the afatinib. 
J02AC02	ITRACONAZOLE	28031						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	294-ITRACONAZOLE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J02AC02	ITRACONAZOLE	28031			C09XA02	ALISKIREN	325646			ANSM	294-ITRACONAZOLE.html	Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Contraindication	
J02AC02	ITRACONAZOLE	28031			C09XA52	ALISKIREN	325646			ANSM	294-ITRACONAZOLE.html	Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Contraindication	
J02AC02	ITRACONAZOLE	28031			C09DX02	ALISKIREN	325646			ANSM	294-ITRACONAZOLE.html	Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Contraindication	
J02AC02	ITRACONAZOLE	28031						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	294-ITRACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
J02AC02	ITRACONAZOLE	28031						PROTON PUMP INHIBITORS	A02BC-001	ANSM	294-ITRACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory	Take into account	
J02AC02	ITRACONAZOLE	28031						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	294-ITRACONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped
J02AC02	ITRACONAZOLE	28031			A04AD12	APREPITANT	358255			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the intraconazole.	Take into account	
J02AC02	ITRACONAZOLE	28031			C10AA05	ATORVASTATIN	83367			ANSM	294-ITRACONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
J02AC02	ITRACONAZOLE	28031						OTHER CORTICOIDES, NOTABLY INHALED	D07AC-001	ANSM	294-ITRACONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency 	Take into account	
J02AC02	ITRACONAZOLE	28031			N02AE01	BUPRENORPHINE	1819			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is ended.
J02AC02	ITRACONAZOLE	28031			N07BC01	BUPRENORPHINE	1819			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is ended.
J02AC02	ITRACONAZOLE	28031			N07BC51	BUPRENORPHINE	1819			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is ended.
J02AC02	ITRACONAZOLE	28031			N05BE01	BUSPIRONE	1827			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
J02AC02	ITRACONAZOLE	28031			L01AB01	BUSULFAN	1828			ANSM	294-ITRACONAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole	Not recommended	
J02AC02	ITRACONAZOLE	28031			B01AE07	DABIGATRAN	1037042			ANSM	294-ITRACONAZOLE.html	Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
J02AC02	ITRACONAZOLE	28031			G04BD10	DARIFENACIN	136198			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J02AC02	ITRACONAZOLE	28031			A01AC02	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			C05AA09	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			D07AB19	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			D07XB05	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			D10AA03	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			H02AB02	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			R01AD03	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S01BA01	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S01CB01	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S02BA06	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S03BA01	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			D07CB04	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S01CA01	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S02CA06	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			S03CA01	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			R01AD53	DEXAMETHASONE	3264			ANSM	294-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC02	ITRACONAZOLE	28031			C01AA05	DIGOXIN 	3407			ANSM	294-ITRACONAZOLE.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.
J02AC02	ITRACONAZOLE	28031			R06AX22	EBASTINE	23796			ANSM	294-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
J02AC02	ITRACONAZOLE	28031			G04BD11	FESOTERODINE	797195			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
J02AC02	ITRACONAZOLE	28031				HYDROQUINIDINE	27220			ANSM	294-ITRACONAZOLE.html	Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole	Precaution for use	Monitoring of the plasma concentrations of the antiarrythmic and possible decrease of its dosage if necessary.
J02AC02	ITRACONAZOLE	28031						IMMUNOSUPPRESSANTS	L04A	ANSM	294-ITRACONAZOLE.html	Very large increase of the blood concentrations of the immusuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.
J02AC02	ITRACONAZOLE	28031						ENZYMATIC INDUCERS	N03-J05-001	ANSM	294-ITRACONAZOLE.html	Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer.	Not recommended	
J02AC02	ITRACONAZOLE	28031						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	294-ITRACONAZOLE.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the type 5 phosphodiesterase inhibitorwith risk of hypotension (severe with the vardenafil)	With the avanafil	contraindication
J02AC02	ITRACONAZOLE	28031			C09BB02	LERCANIDIPINE	135056			ANSM	294-ITRACONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
J02AC02	ITRACONAZOLE	28031			C08CA13	LERCANIDIPINE	135056			ANSM	294-ITRACONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
J02AC02	ITRACONAZOLE	28031			P01BF01	LUMEFANTRINE	847728			ANSM	294-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the torsadegenic medication. If administering these two together cannot be avoided, testing of the QT beforehand and EKG monitoring.
J02AC02	ITRACONAZOLE	28031				ST JOHNS WORT	258326			ANSM	294-ITRACONAZOLE.html	Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
J02AC02	ITRACONAZOLE	28031			R06AX25	MIZOLASTINE	61455			ANSM	294-ITRACONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J02AC02	ITRACONAZOLE	28031			C01BA01	QUINIDINE	9068			ANSM	294-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	Not recommended	If administering the two substances together cannot be avoided, strict clinical monitoring and EKG. 
J02AC02	ITRACONAZOLE	28031			C01BA51	QUINIDINE	9068			ANSM	294-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	Not recommended	If administering the two substances together cannot be avoided, strict clinical monitoring and EKG. 
J02AC02	ITRACONAZOLE	28031			C01BA71	QUINIDINE	9068			ANSM	294-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	Not recommended	If administering the two substances together cannot be avoided, strict clinical monitoring and EKG. 
J02AC02	ITRACONAZOLE	28031			R03AC12	SALMETEROL	36117			ANSM	294-ITRACONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
J02AC02	ITRACONAZOLE	28031			R03AK06	SALMETEROL	36117			ANSM	294-ITRACONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
J02AC02	ITRACONAZOLE	28031			C10AA01	SIMVASTATIN	36567			ANSM	294-ITRACONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type (decrease of the hepatic metabolism of the simvastatin)	Contraindication	
J02AC02	ITRACONAZOLE	28031			G04BD08	SOLIFENACIN	322167			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of the solfenacin with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
J02AC02	ITRACONAZOLE	28031			G04CA53	SOLIFENACIN	322167			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of the solfenacin with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
J02AC02	ITRACONAZOLE	28031			G04BD07	TOLTERODINE	119565			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
J02AC02	ITRACONAZOLE	28031			L01CX01	TRABECTEDINE	397736			ANSM	294-ITRACONAZOLE.html	Risk of increase of the plasma concentrations of the trabectedine by the itraconazole.	Not recommended	It administering these two medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedine during the length of the treatment with itraconazole. 
J02AC02	ITRACONAZOLE	28031			N06AX16	VENLAFAXINE	39786			ANSM	294-ITRACONAZOLE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
J02AC02	ITRACONAZOLE	28031						VINCA ALKALOIDS	L01CA	ANSM	294-ITRACONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole	Not recommended	
J02AC02	ITRACONAZOLE	28031			N05CF02	ZOLPIDEM	39993			ANSM	294-ITRACONAZOLE.html	Slight increase of the sedative effects of the zolpidem	Take into account	
J02AC02	ITRACONAZOLE	28031			N05CF01	ZOPICLONE	40001			ANSM	294-ITRACONAZOLE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
C01EB17	IVABRADINE	77417				GRAPEFRUIT JUICE				ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit juice)	Not recommended	
C01EB17	IVABRADINE	77417						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	295-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer.	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. 
C01EB17	IVABRADINE	77417			C08DB01	DILTIAZEM	3443			ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules	Contraindication	
C01EB17	IVABRADINE	77417						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).	Contraindication	
C01EB17	IVABRADINE	77417			J01FA07	JOSAMYCIN	6084			ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).	Contraindication	
C01EB17	IVABRADINE	77417				ST JOHNS WORT	258326			ANSM	295-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort	Not recommended	
C01EB17	IVABRADINE	77417			J04AB02	RIFAMPICIN	9384			ANSM	295-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin 	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after it is stopped.
C01EB17	IVABRADINE	77417			J04AM02	RIFAMPICIN	9384			ANSM	295-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin 	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after it is stopped.
C01EB17	IVABRADINE	77417			J04AM05	RIFAMPICIN	9384			ANSM	295-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin 	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after it is stopped.
C01EB17	IVABRADINE	77417			J04AM06	RIFAMPICIN	9384			ANSM	295-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin 	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after it is stopped.
C01EB17	IVABRADINE	77417			C08DA01	VERAPAMIL	11170			ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules	Contraindication	
C01EB17	IVABRADINE	77417			C08DA51	VERAPAMIL	11170			ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules	Contraindication	
C01EB17	IVABRADINE	77417			C09BB10	VERAPAMIL	11170			ANSM	295-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules	Contraindication	
R07AX02	IVACAFTOR	1243041			D01AC15	FLUCONAZOLE	4450			ANSM	296-IVACAFTOR.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by half, that is 150 mg/day.
R07AX02	IVACAFTOR	1243041			J02AC01	FLUCONAZOLE	4450			ANSM	296-IVACAFTOR.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by half, that is 150 mg/day.
R07AX02	IVACAFTOR	1243041						ENZYMATIC INDUCERS	N03-J05-001	ANSM	296-IVACAFTOR.html	Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness	Not recommended	
R07AX02	IVACAFTOR	1243041						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	296-IVACAFTOR.html	Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	Reduce the dose by a fourth, that is 150 mg every other day. 
J01FA07	JOSAMYCIN	6084			N03AF01	CARBAMAZEPINE	2002			ANSM	297-JOSAMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.
J01FA07	JOSAMYCIN	6084			L04AD01	CICLOSPORIN	3008			ANSM	297-JOSAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
J01FA07	JOSAMYCIN	6084			S01XA18	CICLOSPORIN	3008			ANSM	297-JOSAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.
J01FA07	JOSAMYCIN	6084			C01BA03	DISOPYRAMIDE	3541			ANSM	297-JOSAMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	Regular clinical monitoring, laboratory tests, and EKG
J01FA07	JOSAMYCIN	6084			R06AX22	EBASTINE	23796			ANSM	297-JOSAMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
J01FA07	JOSAMYCIN	6084			P01BX01	HALOFANTRINE	50749			ANSM	297-JOSAMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the macrolide. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
J01FA07	JOSAMYCIN	6084			C01EB17	IVABRADINE	77417			ANSM	297-JOSAMYCIN.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).	Contraindication	
J01FA07	JOSAMYCIN	6084			N05AG02	PIMOZIDE	8331			ANSM	297-JOSAMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J01FA07	JOSAMYCIN	6084			G04BE03	SILDENAFIL	136411			ANSM	297-JOSAMYCIN.html	Increase of the plasma concentrations of sildenafil, with risk of hypotension	Precaution for use	Start the treatment with sildenafil at the minimun dose when it is administered with josamycin.
J01FA07	JOSAMYCIN	6084			D11AH01	TACROLIMUS	42316			ANSM	297-JOSAMYCIN.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
J01FA07	JOSAMYCIN	6084			L04AD02	TACROLIMUS	42316			ANSM	297-JOSAMYCIN.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
J01FA07	JOSAMYCIN	6084			L04AD02	TACROLIMUS	42316			ANSM	297-JOSAMYCIN.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
J01FA07	JOSAMYCIN	6084						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	297-JOSAMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
D01AC08	KETOCONAZOLE	6135			L01XE13	AFATINIB	1430438			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as far from the afatinib as possible, preferably at an interval of 6 or 12 hours away from doses of the afatinib
G01AF11	KETOCONAZOLE	6135			L01XE13	AFATINIB	1430438			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as far from the afatinib as possible, preferably at an interval of 6 or 12 hours away from doses of the afatinib
J02AB02	KETOCONAZOLE	6135			L01XE13	AFATINIB	1430438			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.	Precaution for use	It is recommended that the ketoconazole be administered as far from the afatinib as possible, preferably at an interval of 6 or 12 hours away from doses of the afatinib
D01AC08	KETOCONAZOLE	6135						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	298-KETOCONAZOLE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
G01AF11	KETOCONAZOLE	6135						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	298-KETOCONAZOLE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J02AB02	KETOCONAZOLE	6135						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	298-KETOCONAZOLE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
D01AC08	KETOCONAZOLE	6135						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	298-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increaseof the gastric pH by the antisecretory	Take into account	
G01AF11	KETOCONAZOLE	6135						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	298-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increaseof the gastric pH by the antisecretory	Take into account	
J02AB02	KETOCONAZOLE	6135						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	298-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increaseof the gastric pH by the antisecretory	Take into account	
D01AC08	KETOCONAZOLE	6135						PROTON PUMP INHIBITORS	A02BC-001	ANSM	298-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory	Take into account	
G01AF11	KETOCONAZOLE	6135						PROTON PUMP INHIBITORS	A02BC-001	ANSM	298-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory	Take into account	
J02AB02	KETOCONAZOLE	6135						PROTON PUMP INHIBITORS	A02BC-001	ANSM	298-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory	Take into account	
D01AC08	KETOCONAZOLE	6135			C10AA05	ATORVASTATIN	83367			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
G01AF11	KETOCONAZOLE	6135			C10AA05	ATORVASTATIN	83367			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
J02AB02	KETOCONAZOLE	6135			C10AA05	ATORVASTATIN	83367			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
D01AC08	KETOCONAZOLE	6135						OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	ANSM	298-KETOCONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency 	Take into account	
G01AF11	KETOCONAZOLE	6135						OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	ANSM	298-KETOCONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency 	Take into account	
J02AB02	KETOCONAZOLE	6135						OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	ANSM	298-KETOCONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency 	Take into account	
D01AC08	KETOCONAZOLE	6135			N02AE01	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
D01AC08	KETOCONAZOLE	6135			N07BC01	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
D01AC08	KETOCONAZOLE	6135			N07BC51	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
G01AF11	KETOCONAZOLE	6135			N02AE01	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
G01AF11	KETOCONAZOLE	6135			N07BC01	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
G01AF11	KETOCONAZOLE	6135			N07BC51	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
J02AB02	KETOCONAZOLE	6135			N02AE01	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
J02AB02	KETOCONAZOLE	6135			N07BC01	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
J02AB02	KETOCONAZOLE	6135			N07BC51	BUPRENORPHINE	1819			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
D01AC08	KETOCONAZOLE	6135			1037042	DABIGATRAN				ANSM	298-KETOCONAZOLE.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
G01AF11	KETOCONAZOLE	6135			1037042	DABIGATRAN				ANSM	298-KETOCONAZOLE.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
J02AB02	KETOCONAZOLE	6135			1037042	DABIGATRAN				ANSM	298-KETOCONAZOLE.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
D01AC08	KETOCONAZOLE	6135			G04BD10	DARIFENACIN	136198			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
G01AF11	KETOCONAZOLE	6135			G04BD10	DARIFENACIN	136198			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J02AB02	KETOCONAZOLE	6135			G04BD10	DARIFENACIN	136198			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
D01AC08	KETOCONAZOLE	6135			A01AC02	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			C05AA09	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			D07AB19	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			D07XB05	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			D10AA03	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			H02AB02	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			R01AD03	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S01BA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S01CB01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S02BA06	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S03BA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			D07CB04	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S01CA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S02CA06	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			S03CA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			R01AD53	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			A01AC02	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			C05AA09	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			D07AB19	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			D07XB05	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			D10AA03	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			H02AB02	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			R01AD03	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S01BA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S01CB01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S02BA06	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S03BA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			D07CB04	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S01CA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S02CA06	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			S03CA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
G01AF11	KETOCONAZOLE	6135			R01AD53	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			A01AC02	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			C05AA09	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			D07AB19	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			D07XB05	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			D10AA03	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			H02AB02	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			R01AD03	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S01BA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S01CB01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S02BA06	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S03BA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			D07CB04	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S01CA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S02CA06	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			S03CA01	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J02AB02	KETOCONAZOLE	6135			R01AD53	DEXAMETHASONE	3264			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
D01AC08	KETOCONAZOLE	6135			R06AX22	EBASTINE	23796			ANSM	298-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)	Not recommended	
G01AF11	KETOCONAZOLE	6135			R06AX22	EBASTINE	23796			ANSM	298-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)	Not recommended	
J02AB02	KETOCONAZOLE	6135			R06AX22	EBASTINE	23796			ANSM	298-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)	Not recommended	
D01AC08	KETOCONAZOLE	6135			G04BD11	FESOTERODINE	797195			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
G01AF11	KETOCONAZOLE	6135			G04BD11	FESOTERODINE	797195			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
J02AB02	KETOCONAZOLE	6135			G04BD11	FESOTERODINE	797195			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of fesoterodine with patients who are slow metabolizers, with risk of overdose	Not recommended	
D01AC08	KETOCONAZOLE	6135			A07AA12	FIDAXOMICIN	1111103			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the fidaxomicine	Not recommended	
G01AF11	KETOCONAZOLE	6135			A07AA12	FIDAXOMICIN	1111103			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the fidaxomicine	Not recommended	
J02AB02	KETOCONAZOLE	6135			A07AA12	FIDAXOMICIN	1111103			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of the fidaxomicine	Not recommended	
D01AC08	KETOCONAZOLE	6135						IMMUNOSUPPRESSANTS	L04A	ANSM	298-KETOCONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict monitoring of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
G01AF11	KETOCONAZOLE	6135						IMMUNOSUPPRESSANTS	L04A	ANSM	298-KETOCONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict monitoring of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
J02AB02	KETOCONAZOLE	6135						IMMUNOSUPPRESSANTS	L04A	ANSM	298-KETOCONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	If these substances are administered together, strict monitoring of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.
D01AC08	KETOCONAZOLE	6135						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	298-KETOCONAZOLE.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil	Contraindication
G01AF11	KETOCONAZOLE	6135						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	298-KETOCONAZOLE.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil	Contraindication
J02AB02	KETOCONAZOLE	6135						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	298-KETOCONAZOLE.html	Increase (very large for the avanafil and the verdenafil) of the plasma concentrations of the PDE5, with risk of hypotension (severe with the vardenafil)	With the avanafil	Contraindication
D01AC08	KETOCONAZOLE	6135			J04AM03	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AC01	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AC51	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AM02	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AM05	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AM06	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AM01	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			J04AM04	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AM03	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AC01	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AC51	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AM02	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AM05	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AM06	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AM01	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
G01AF11	KETOCONAZOLE	6135			J04AM04	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AM03	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AC01	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AC51	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AM02	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AM05	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AM06	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AM01	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
J02AB02	KETOCONAZOLE	6135			J04AM04	ISONIAZID	6038			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 
D01AC08	KETOCONAZOLE	6135			C09BB02	LERCANIDIPINE	135056			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
D01AC08	KETOCONAZOLE	6135			C08CA13	LERCANIDIPINE	135056			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
G01AF11	KETOCONAZOLE	6135			C09BB02	LERCANIDIPINE	135056			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
G01AF11	KETOCONAZOLE	6135			C08CA13	LERCANIDIPINE	135056			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
J02AB02	KETOCONAZOLE	6135			C09BB02	LERCANIDIPINE	135056			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
J02AB02	KETOCONAZOLE	6135			C08CA13	LERCANIDIPINE	135056			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
D01AC08	KETOCONAZOLE	6135			P01BF01	LUMEFANTRINE	847728			ANSM	298-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand, and EKG monitoring. 
G01AF11	KETOCONAZOLE	6135			P01BF01	LUMEFANTRINE	847728			ANSM	298-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand, and EKG monitoring. 
J02AB02	KETOCONAZOLE	6135			P01BF01	LUMEFANTRINE	847728			ANSM	298-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand, and EKG monitoring. 
D01AC08	KETOCONAZOLE	6135			R06AX25	MIZOLASTINE	61455			ANSM	298-KETOCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
G01AF11	KETOCONAZOLE	6135			R06AX25	MIZOLASTINE	61455			ANSM	298-KETOCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J02AB02	KETOCONAZOLE	6135			R06AX25	MIZOLASTINE	61455			ANSM	298-KETOCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
D01AC08	KETOCONAZOLE	6135			J05AG01	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
D01AC08	KETOCONAZOLE	6135			J05AR07	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
D01AC08	KETOCONAZOLE	6135			J05AR05	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
G01AF11	KETOCONAZOLE	6135			J05AG01	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
G01AF11	KETOCONAZOLE	6135			J05AR07	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
G01AF11	KETOCONAZOLE	6135			J05AR05	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
J02AB02	KETOCONAZOLE	6135			J05AG01	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
J02AB02	KETOCONAZOLE	6135			J05AR07	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
J02AB02	KETOCONAZOLE	6135			J05AR05	NEVIRAPINE	53654			ANSM	298-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	Contraindication	
D01AC08	KETOCONAZOLE	6135			J04AB02	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC08	KETOCONAZOLE	6135			J04AM02	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC08	KETOCONAZOLE	6135			J04AM05	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC08	KETOCONAZOLE	6135			J04AM06	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
G01AF11	KETOCONAZOLE	6135			J04AB02	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
G01AF11	KETOCONAZOLE	6135			J04AM02	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
G01AF11	KETOCONAZOLE	6135			J04AM05	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
G01AF11	KETOCONAZOLE	6135			J04AM06	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AB02	KETOCONAZOLE	6135			J04AB02	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AB02	KETOCONAZOLE	6135			J04AM02	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AB02	KETOCONAZOLE	6135			J04AM05	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AB02	KETOCONAZOLE	6135			J04AM06	RIFAMPICIN	9384			ANSM	298-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
D01AC08	KETOCONAZOLE	6135			R03AC12	SALMETEROL	36117			ANSM	298-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
D01AC08	KETOCONAZOLE	6135			R03AK06	SALMETEROL	36117			ANSM	298-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
G01AF11	KETOCONAZOLE	6135			R03AC12	SALMETEROL	36117			ANSM	298-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
G01AF11	KETOCONAZOLE	6135			R03AK06	SALMETEROL	36117			ANSM	298-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
J02AB02	KETOCONAZOLE	6135			R03AC12	SALMETEROL	36117			ANSM	298-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
J02AB02	KETOCONAZOLE	6135			R03AK06	SALMETEROL	36117			ANSM	298-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
D01AC08	KETOCONAZOLE	6135			C10AA01	SIMVASTATIN	36567			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)	Contraindication	Use a statin not affected by this type of interaction.
G01AF11	KETOCONAZOLE	6135			C10AA01	SIMVASTATIN	36567			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)	Contraindication	Use a statin not affected by this type of interaction.
J02AB02	KETOCONAZOLE	6135			C10AA01	SIMVASTATIN	36567			ANSM	298-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)	Contraindication	Use a statin not affected by this type of interaction.
D01AC08	KETOCONAZOLE	6135			G04BD08	SOLIFENACIN	322167			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
D01AC08	KETOCONAZOLE	6135			G04CA53	SOLIFENACIN	322167			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
G01AF11	KETOCONAZOLE	6135			G04BD08	SOLIFENACIN	322167			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
G01AF11	KETOCONAZOLE	6135			G04CA53	SOLIFENACIN	322167			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
J02AB02	KETOCONAZOLE	6135			G04BD08	SOLIFENACIN	322167			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
J02AB02	KETOCONAZOLE	6135			G04CA53	SOLIFENACIN	322167			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
D01AC08	KETOCONAZOLE	6135			G04BD07	TOLTERODINE	119565			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
G01AF11	KETOCONAZOLE	6135			G04BD07	TOLTERODINE	119565			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
J02AB02	KETOCONAZOLE	6135			G04BD07	TOLTERODINE	119565			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of tolterodine in patients who are slow metabolizers, with risk of overdose	Not recommended	
D01AC08	KETOCONAZOLE	6135			N06AX16	VENLAFAXINE	39786			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of vanlafaxine with risk of overdose 	Take into account	
G01AF11	KETOCONAZOLE	6135			N06AX16	VENLAFAXINE	39786			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of vanlafaxine with risk of overdose 	Take into account	
J02AB02	KETOCONAZOLE	6135			N06AX16	VENLAFAXINE	39786			ANSM	298-KETOCONAZOLE.html	Increase of the concentrations of vanlafaxine with risk of overdose 	Take into account	
D01AC08	KETOCONAZOLE	6135						VINCA ALKALOIDS	L01CA	ANSM	298-KETOCONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
G01AF11	KETOCONAZOLE	6135						VINCA ALKALOIDS	L01CA	ANSM	298-KETOCONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
J02AB02	KETOCONAZOLE	6135						VINCA ALKALOIDS	L01CA	ANSM	298-KETOCONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
D01AC08	KETOCONAZOLE	6135			N05CF02	ZOLPIDEM	39993			ANSM	298-KETOCONAZOLE.html	Slight increase of the sedative effects of the zolpidem	Take into account	
G01AF11	KETOCONAZOLE	6135			N05CF02	ZOLPIDEM	39993			ANSM	298-KETOCONAZOLE.html	Slight increase of the sedative effects of the zolpidem	Take into account	
J02AB02	KETOCONAZOLE	6135			N05CF02	ZOLPIDEM	39993			ANSM	298-KETOCONAZOLE.html	Slight increase of the sedative effects of the zolpidem	Take into account	
D01AC08	KETOCONAZOLE	6135			N05CF01	ZOPICLONE	40001			ANSM	298-KETOCONAZOLE.html	Slight increase of the sedative effects of the zolpiclone	Take into account	
G01AF11	KETOCONAZOLE	6135			N05CF01	ZOPICLONE	40001			ANSM	298-KETOCONAZOLE.html	Slight increase of the sedative effects of the zolpiclone	Take into account	
J02AB02	KETOCONAZOLE	6135			N05CF01	ZOPICLONE	40001			ANSM	298-KETOCONAZOLE.html	Slight increase of the sedative effects of the zolpiclone	Take into account	
J05AF05	LAMIVUDINE	68244			L01BB04	CLADRIBINE	44157			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J05AR02	LAMIVUDINE	68244			L01BB04	CLADRIBINE	44157			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J05AR07	LAMIVUDINE	68244			L01BB04	CLADRIBINE	44157			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J05AR01	LAMIVUDINE	68244			L01BB04	CLADRIBINE	44157			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J05AR04	LAMIVUDINE	68244			L01BB04	CLADRIBINE	44157			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J05AR05	LAMIVUDINE	68244			L01BB04	CLADRIBINE	44157			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
J05AF05	LAMIVUDINE	68244			J05AF03	ZALCITABINE	3363			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR02	LAMIVUDINE	68244			J05AF03	ZALCITABINE	3363			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR07	LAMIVUDINE	68244			J05AF03	ZALCITABINE	3363			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR01	LAMIVUDINE	68244			J05AF03	ZALCITABINE	3363			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR04	LAMIVUDINE	68244			J05AF03	ZALCITABINE	3363			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR05	LAMIVUDINE	68244			J05AF03	ZALCITABINE	3363			ANSM	299-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
S01EC01	ACETAZOLAMIDE	167			N03AF01	CARBAMAZEPINE	2002			ANSM	3-ACETAZOLAMIDE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precautions for use	Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage. 
S01EC01	ACETAZOLAMIDE	167			D11AX04	LITHIUM	6448			ANSM	3-ACETAZOLAMIDE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precautions for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
L02BG01	AMINOGLUTETHIMIDE	677						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	30-AMINOGLUTETHIMIDE.html	Described for warfarin and acenocoumarol. Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped. 
L02BG01	AMINOGLUTETHIMIDE	677			A01AC02	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			C05AA09	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			D07AB19	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			D07XB05	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			D10AA03	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			H02AB02	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			R01AD03	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S01BA01	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S01CB01	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S02BA06	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S03BA01	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			D07CB04	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S01CA01	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S02CA06	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			S03CA01	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
L02BG01	AMINOGLUTETHIMIDE	677			R01AD53	DEXAMETHASONE	3264			ANSM	30-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	Adjustment of the dosage of the dexamethasone. 
N03AX09	LAMOTRIGINE	28439			N03AF01	CARBAMAZEPINE	2002			ANSM	300-LAMOTRIGINE.html	Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced	Precaution for use	Clinical monitoring and possible reduction of the dosage of the carbamazepine. 
N03AX09	LAMOTRIGINE	28439						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	300-LAMOTRIGINE.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism	Not recommended	-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.
N03AX09	LAMOTRIGINE	28439						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	300-LAMOTRIGINE.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	-Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of the lamotrigine
N03AX09	LAMOTRIGINE	28439			N03AF02	OXCARBAZEPINE	32624			ANSM	300-LAMOTRIGINE.html	Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.
N03AX09	LAMOTRIGINE	28439						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	300-LAMOTRIGINE.html	Increased risk of serious cutaneous reactions (Lyell's syndrome). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)	Not recommended	If this combination of medications is judged necessary, strict clinical monitoring.
A02BC03	LANSOPRAZOLE	17128			D11AH01	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BC03	LANSOPRAZOLE	17128			L04AD02	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BD07	LANSOPRAZOLE	17128			D11AH01	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BD07	LANSOPRAZOLE	17128			L04AD02	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BD03	LANSOPRAZOLE	17128			D11AH01	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BD03	LANSOPRAZOLE	17128			L04AD02	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BD02	LANSOPRAZOLE	17128			D11AH01	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
A02BD02	LANSOPRAZOLE	17128			L04AD02	TACROLIMUS	42316			ANSM	301-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testingof the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped.
	LEDIPASVIR	1591922			C01BD01	AMIODARONE	703			ANSM	302-LEDIPASVIR.html	Only when ledipasvir is combined with sofosbuvir, appearance of bradycardia, possibly abruptly, which can have fatal consequences.	Not recommended	If administering these together cannot be avoided, strictmonitoring of patients is recommended, in particular during the first weeks of treatment with the ledipasvir/sofosbuvir combination (clinical monitoring and EKG).
	LEDIPASVIR	1591922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	302-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.	Contraindication	
	LEDIPASVIR	1591922						PROTON PUMP INHIBITORS	A02BC-001	ANSM	302-LEDIPASVIR.html	Decrease of the concentrations of the ledipasvir when the proton pump is administered before the ledipasvir	Precaution for use	It is recommended that the proton pump inhibitor and the ledipasvir be administered simultaneously 
	LEDIPASVIR	1591922						HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	302-LEDIPASVIR.html	Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolysis type	Contraindication	--with the rosuvastatin
	LEDIPASVIR	1591922				ST JOHNS WORT	258326			ANSM	302-LEDIPASVIR.html	Risk of large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	LEDIPASVIR	1591922			J04AB02	RIFAMPICIN	9384			ANSM	302-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin	Contraindication	
	LEDIPASVIR	1591922			J04AM02	RIFAMPICIN	9384			ANSM	302-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin	Contraindication	
	LEDIPASVIR	1591922			J04AM05	RIFAMPICIN	9384			ANSM	302-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin	Contraindication	
	LEDIPASVIR	1591922			J04AM06	RIFAMPICIN	9384			ANSM	302-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin	Contraindication	
	LEDIPASVIR	1591922			J05AF07	TENOFOVIR DISOPROXIL	300195			ANSM	302-LEDIPASVIR.html	When administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvit	Precaution for use	Clinical monitoring and laboratory tests, especially of the renal function
L04AX04	LENALIDOMIDE	342369						HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	303-LENALIDOMIDE.html	Increased risk of onset of rhabdomyolysis	Precaution for use	Strengthen clinical monitoring and laboratory tests, especially during the first weeks of treatment.
C09BB02	LERCANIDIPINE	135056				GRAPEFRUIT JUICE				ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the intestinal metabolism of the dihyropyridine	Take into account	
C08CA13	LERCANIDIPINE	135056				GRAPEFRUIT JUICE				ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the intestinal metabolism of the dihyropyridine	Take into account	
C09BB02	LERCANIDIPINE	135056			L04AD01	CICLOSPORIN	3008			ANSM	304-LERCANIDIPINE.html	Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped
C09BB02	LERCANIDIPINE	135056			S01XA18	CICLOSPORIN	3008			ANSM	304-LERCANIDIPINE.html	Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped
C08CA13	LERCANIDIPINE	135056			L04AD01	CICLOSPORIN	3008			ANSM	304-LERCANIDIPINE.html	Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped
C08CA13	LERCANIDIPINE	135056			S01XA18	CICLOSPORIN	3008			ANSM	304-LERCANIDIPINE.html	Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine	Precaution for use	Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped
C09BB02	LERCANIDIPINE	135056			J02AC02	ITRACONAZOLE	28031			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
C08CA13	LERCANIDIPINE	135056			J02AC02	ITRACONAZOLE	28031			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
C09BB02	LERCANIDIPINE	135056			D01AC08	KETOCONAZOLE	6135			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
C09BB02	LERCANIDIPINE	135056			G01AF11	KETOCONAZOLE	6135			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
C09BB02	LERCANIDIPINE	135056			J02AB02	KETOCONAZOLE	6135			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
C08CA13	LERCANIDIPINE	135056			D01AC08	KETOCONAZOLE	6135			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
C08CA13	LERCANIDIPINE	135056			G01AF11	KETOCONAZOLE	6135			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
C08CA13	LERCANIDIPINE	135056			J02AB02	KETOCONAZOLE	6135			ANSM	304-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
N04BA01	LEVODOPA	6375			M03BX01	BACLOFEN	1292			ANSM	305-LEVODOPA.html	Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
N04BA02	LEVODOPA	6375			M03BX01	BACLOFEN	1292			ANSM	305-LEVODOPA.html	Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
N04BA03	LEVODOPA	6375			M03BX01	BACLOFEN	1292			ANSM	305-LEVODOPA.html	Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
N04BA01	LEVODOPA	6375			B03A	IRON	1431589			ANSM	305-LEVODOPA.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
N04BA02	LEVODOPA	6375			B03A	IRON	1431589			ANSM	305-LEVODOPA.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
N04BA03	LEVODOPA	6375			B03A	IRON	1431589			ANSM	305-LEVODOPA.html	Decrease of the digestive absorption of the levodopa	Precaution for use	Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).
N04BA01	LEVODOPA	6375						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	305-LEVODOPA.html	[no text on ANSM document]	[no text on ANSM document]	
N04BA02	LEVODOPA	6375						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	305-LEVODOPA.html	[no text on ANSM document]	[no text on ANSM document]	
N04BA03	LEVODOPA	6375						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	305-LEVODOPA.html	[no text on ANSM document]	[no text on ANSM document]	
N04BA01	LEVODOPA	6375						MAOI-B 	N04BD0-001	ANSM	305-LEVODOPA.html	Increase of the risk of orthostatic hypotension 	Take into account	
N04BA02	LEVODOPA	6375						MAOI-B 	N04BD0-001	ANSM	305-LEVODOPA.html	Increase of the risk of orthostatic hypotension 	Take into account	
N04BA03	LEVODOPA	6375						MAOI-B 	N04BD0-001	ANSM	305-LEVODOPA.html	Increase of the risk of orthostatic hypotension 	Take into account	
N04BA01	LEVODOPA	6375			C02AB	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA01	LEVODOPA	6375			C02LB	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA01	LEVODOPA	6375			C02AB01	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA01	LEVODOPA	6375			C02LB01	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA01	LEVODOPA	6375			C02AB02	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA02	LEVODOPA	6375			C02AB	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA02	LEVODOPA	6375			C02LB	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA02	LEVODOPA	6375			C02AB01	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA02	LEVODOPA	6375			C02LB01	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA02	LEVODOPA	6375			C02AB02	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA03	LEVODOPA	6375			C02AB	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA03	LEVODOPA	6375			C02LB	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA03	LEVODOPA	6375			C02AB01	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA03	LEVODOPA	6375			C02LB01	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA03	LEVODOPA	6375			C02AB02	METHYLDOPA	6876			ANSM	305-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possibly decrease of the doses of levodopa.
N04BA01	LEVODOPA	6375						ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptic 	Contraindication	Use an antiemitic without extrapyramidal effects.
N04BA02	LEVODOPA	6375						ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptic 	Contraindication	Use an antiemitic without extrapyramidal effects.
N04BA03	LEVODOPA	6375						ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptic 	Contraindication	Use an antiemitic without extrapyramidal effects.
N04BA01	LEVODOPA	6375						ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dosees of each of the medications. 
N04BA02	LEVODOPA	6375						ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dosees of each of the medications. 
N04BA03	LEVODOPA	6375						ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dosees of each of the medications. 
N04BA01	LEVODOPA	6375			C02AA02	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA01	LEVODOPA	6375			C02LA01	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA01	LEVODOPA	6375			C02LA51	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA01	LEVODOPA	6375			C02LA71	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA01	LEVODOPA	6375			C02AA52	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA02	LEVODOPA	6375			C02AA02	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA02	LEVODOPA	6375			C02LA01	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA02	LEVODOPA	6375			C02LA51	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA02	LEVODOPA	6375			C02LA71	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA02	LEVODOPA	6375			C02AA52	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA03	LEVODOPA	6375			C02AA02	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA03	LEVODOPA	6375			C02LA01	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA03	LEVODOPA	6375			C02LA51	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA03	LEVODOPA	6375			C02LA71	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA03	LEVODOPA	6375			C02AA52	RESERPINE	9260			ANSM	305-LEVODOPA.html	Inhibition of the effects of the levodopa	Contraindication	
N04BA01	LEVODOPA	6375			J01FA02	SPIRAMYCIN	9991			ANSM	305-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
N04BA01	LEVODOPA	6375			J01RA04	SPIRAMYCIN	9991			ANSM	305-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
N04BA02	LEVODOPA	6375			J01FA02	SPIRAMYCIN	9991			ANSM	305-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
N04BA02	LEVODOPA	6375			J01RA04	SPIRAMYCIN	9991			ANSM	305-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
N04BA03	LEVODOPA	6375			J01FA02	SPIRAMYCIN	9991			ANSM	305-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
N04BA03	LEVODOPA	6375			J01RA04	SPIRAMYCIN	9991			ANSM	305-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
N04BA01	LEVODOPA	6375			N07XX06	TETRABENAZINE	10390			ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
N04BA02	LEVODOPA	6375			N07XX06	TETRABENAZINE	10390			ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
N04BA03	LEVODOPA	6375			N07XX06	TETRABENAZINE	10390			ANSM	305-LEVODOPA.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
J01MA12	LEVOFLOXACINE	82122						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	306-LEVOFLOXACIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administrations of these substances together. 
S01AE05	LEVOFLOXACINE	82122						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	306-LEVOFLOXACIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administrations of these substances together. 
C01BB01	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C05AD01	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
D04AB01	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
N01BB02	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
R02AD02	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
S01HA07	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
S02DA01	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
N01BB52	LIDOCAINE	6387			C01BD01	AMIODARONE	703			ANSM	307-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BB01	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
C05AD01	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
D04AB01	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
N01BB02	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
R02AD02	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
S01HA07	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
S02DA01	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
N01BB52	LIDOCAINE	6387						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	307-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
C01BB01	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
C05AD01	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
D04AB01	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
N01BB02	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
R02AD02	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
S01HA07	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
S02DA01	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
N01BB52	LIDOCAINE	6387						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	307-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
C01BB01	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
C01BB01	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
C05AD01	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
C05AD01	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
D04AB01	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
D04AB01	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
N01BB02	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
N01BB02	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
R02AD02	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
R02AD02	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
S01HA07	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
S01HA07	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
S02DA01	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
S02DA01	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
N01BB52	LIDOCAINE	6387			A02BA01	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
N01BB52	LIDOCAINE	6387			A02BA51	CIMETIDINE	2541			ANSM	307-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 
C01BB01	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
C05AD01	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
D04AB01	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N01BB02	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
R02AD02	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
S01HA07	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
S02DA01	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
N01BB52	LIDOCAINE	6387			N06AB08	FLUVOXAMINE	42355			ANSM	307-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
			LINCOSANIDES	J01FF0				CURARES	M03A-001	ANSM	308-LINCOSANIDES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	Monitor the degree of curarisation at the end of anesthesia.
J01XX08	LINEZOLIDE	190376			J01FA09	CLARITHROMYCIN	21212			ANSM	309-LINEZOLIDE.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin, due to increase of its absorption	Take into account	
J01XX08	LINEZOLIDE	190376			J04AB02	RIFAMPICIN	9384			ANSM	309-LINEZOLIDE.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J01XX08	LINEZOLIDE	190376			J04AM02	RIFAMPICIN	9384			ANSM	309-LINEZOLIDE.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J01XX08	LINEZOLIDE	190376			J04AM05	RIFAMPICIN	9384			ANSM	309-LINEZOLIDE.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J01XX08	LINEZOLIDE	190376			J04AM06	RIFAMPICIN	9384			ANSM	309-LINEZOLIDE.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
			AMINOGLYCOSIDES	J01GB-001				AMINOGLYCOSIDES	J01GB-001	ANSM	31-AMINOGLYCOSIDES.html	Increased risk of nephrotoxicity and ototoxicity (the ototoxicity is cumulative in cases of successive administrations).	Contraindication	-in case of simultaneous administration
			AMINOGLYCOSIDES	J01GB-001	A01AB04	AMPHOTERICIN B 	732			ANSM	31-AMINOGLYCOSIDES.html	With the amphotericin B administered intravenously:increased risk of nephrotoxicity	Take into account	
			AMINOGLYCOSIDES	J01GB-001	A07AA07	AMPHOTERICIN B 	732			ANSM	31-AMINOGLYCOSIDES.html	With the amphotericin B administered intravenously:increased risk of nephrotoxicity	Take into account	
			AMINOGLYCOSIDES	J01GB-001	G01AA03	AMPHOTERICIN B 	732			ANSM	31-AMINOGLYCOSIDES.html	With the amphotericin B administered intravenously:increased risk of nephrotoxicity	Take into account	
			AMINOGLYCOSIDES	J01GB-001	J02AA01	AMPHOTERICIN B 	732			ANSM	31-AMINOGLYCOSIDES.html	With the amphotericin B administered intravenously:increased risk of nephrotoxicity	Take into account	
			AMINOGLYCOSIDES	J01GB-001		ATALUREN				ANSM	31-AMINOGLYCOSIDES.html	Risk of increase of renal toxicity of the aminoglycoside.	Contraindication	
			AMINOGLYCOSIDES	J01GB-001	M03AX01	BOTULINUM TOXIN	1716			ANSM	31-AMINOGLYCOSIDES.html	Risk of increase of the effects of the botulinum toxin with the aminoglycosides (by extrapolation from the effects observed during the course of the botulism)	Not recommended	Use another antibiotic
			AMINOGLYCOSIDES	J01GB-001	J01DB03	CEFALOTIN	2236			ANSM	31-AMINOGLYCOSIDES.html	Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion	Precaution for use	Monitoring of renal function
			AMINOGLYCOSIDES	J01GB-001	L04AD01	CICLOSPORIN	3008			ANSM	31-AMINOGLYCOSIDES.html	Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk 	Take into account	
			AMINOGLYCOSIDES	J01GB-001	S01XA18	CICLOSPORIN	3008			ANSM	31-AMINOGLYCOSIDES.html	Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk 	Take into account	
			AMINOGLYCOSIDES	J01GB-001				CURARES	M03A-001	ANSM	31-AMINOGLYCOSIDES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
			AMINOGLYCOSIDES	J01GB-001				LOOP DIURETICS	C03CA-001	ANSM	31-AMINOGLYCOSIDES.html	Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)	Precaution for use	The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and, possibly, of the plasma concentrations of the aminoglycoside.
			AMINOGLYCOSIDES	J01GB-001				PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA	ANSM	31-AMINOGLYCOSIDES.html	Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency	Take into account	
			AMINOGLYCOSIDES	J01GB-001	A07AA05	POLYMYXIN B	8536			ANSM	31-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
			AMINOGLYCOSIDES	J01GB-001	J01XB02	POLYMYXIN B	8536			ANSM	31-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
			AMINOGLYCOSIDES	J01GB-001	S01AA18	POLYMYXIN B	8536			ANSM	31-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
			AMINOGLYCOSIDES	J01GB-001	S02AA11	POLYMYXIN B	8536			ANSM	31-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
			AMINOGLYCOSIDES	J01GB-001	S03AA03	POLYMYXIN B	8536			ANSM	31-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
			AMINOGLYCOSIDES	J01GB-001	D11AH01	TACROLIMUS	42316			ANSM	31-AMINOGLYCOSIDES.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
			AMINOGLYCOSIDES	J01GB-001	L04AD02	TACROLIMUS	42316			ANSM	31-AMINOGLYCOSIDES.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
			AMINOGLYCOSIDES	J01GB-001	L04AD02	TACROLIMUS	42316			ANSM	31-AMINOGLYCOSIDES.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
D11AX04	LITHIUM	6448			S01EC01	ACETAZOLAMIDE	167			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precautions for use:	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
D11AX04	LITHIUM	6448						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	310-LITHIUM.html	Increase of the lithemia that can attain toxic values (decrease of the renal excretion of the lithium).	Not recommended	If the use of the angiotensis II antagonist is indispensable, strict monitoring of the lithemia and adjustment of the dosage
D11AX04	LITHIUM	6448						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	310-LITHIUM.html	Increase of the lithemia that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, monitor the lithemia strictly and adjust the dosage of the lithium during the administration of the substances together and after the NSAI is stopped.
D11AX04	LITHIUM	6448			N06BC01	CAFFEINE 	1886			ANSM	310-LITHIUM.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the lithemia	Take into account	
D11AX04	LITHIUM	6448			V04CG30	CAFFEINE 	1886			ANSM	310-LITHIUM.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the lithemia	Take into account	
D11AX04	LITHIUM	6448			H05BA	CALCITONIN	36118			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
D11AX04	LITHIUM	6448			H05BA03	CALCITONIN	36118			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
D11AX04	LITHIUM	6448			H05BA02	CALCITONIN	36118			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
D11AX04	LITHIUM	6448			H05BA01	CALCITONIN	36118			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
D11AX04	LITHIUM	6448			H05BA01	CALCITONIN	36118			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
D11AX04	LITHIUM	6448			N03AF01	CARBAMAZEPINE	2002			ANSM	310-LITHIUM.html	Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped	Not recommended	
D11AX04	LITHIUM	6448						LOOP DIURETICS	C03CA-001	ANSM	310-LITHIUM.html	Increase of the lithemia with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium) 	Not recommended	If administering these substances together cannot be avoided, strict monitoring of the lithemia and adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448						POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	310-LITHIUM.html	Increase of the lithemia with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448						THIAZIDE DIURETICS AND RELATED	C03-003	ANSM	310-LITHIUM.html	Increase of the lithemia with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium) 	Not recommended	If administering the substances together cannot be avoided, strict monitoring of the lithemia and adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			A06AG04	GLYCEROL	4910			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
D11AX04	LITHIUM	6448			A06AX01	GLYCEROL	4910			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
D11AX04	LITHIUM	6448			A16AX09	GLYCEROL	4910			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium.
D11AX04	LITHIUM	6448						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	310-LITHIUM.html	Increase of the lithemia which can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If the use of an ACE inhibitor is indispensable, strict monitoring of the lithemia and adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	310-LITHIUM.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together. 
D11AX04	LITHIUM	6448			A06AD16	MANNITOL	6628			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			B05BC01	MANNITOL	6628			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			B05CX04	MANNITOL	6628			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			R05CB16	MANNITOL	6628			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			C02AB	METHYLDOPA 	6876			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			C02LB	METHYLDOPA 	6876			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			C02AB01	METHYLDOPA 	6876			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			C02LB01	METHYLDOPA 	6876			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			C02AB02	METHYLDOPA 	6876			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
D11AX04	LITHIUM	6448			A02BD08	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			A02BD03	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			A02BD02	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			A01AB17	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			D06BX01	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			G01AF01	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			J01XD01	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			P01AB01	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448			A02BD01	METRONIDAZOLE	6922			ANSM	310-LITHIUM.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D11AX04	LITHIUM	6448						NEUROLEPTICS	N05AA-003	ANSM	310-LITHIUM.html	Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
D11AX04	LITHIUM	6448			A08AB01	ORLISTAT	37925			ANSM	310-LITHIUM.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
D11AX04	LITHIUM	6448			A02AH	SODIUM BICARBONATE	36676			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			B05CB04	SODIUM BICARBONATE	36676			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			B05XA02	SODIUM BICARBONATE	36676			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			A12CA01	SODIUM CHLORIDE	9863			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			B05CB01	SODIUM CHLORIDE	9863			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			B05XA03	SODIUM CHLORIDE	9863			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			S01XA03	SODIUM CHLORIDE	9863			ANSM	310-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.
D11AX04	LITHIUM	6448			R03DA04	THEOPHYLLINE 	10438			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
D11AX04	LITHIUM	6448			R03DB04	THEOPHYLLINE 	10438			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
D11AX04	LITHIUM	6448			R03DA54	THEOPHYLLINE 	10438			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
D11AX04	LITHIUM	6448			R03DA74	THEOPHYLLINE 	10438			ANSM	310-LITHIUM.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
D11AX04	LITHIUM	6448			38404	TOPIRAMATE	38404			ANSM	310-LITHIUM.html	For doses of topiramate >= 200 mg/day: increase of the lithemia that can reach toxic values, with signs of overdose of lithium.	Precaution for use	Clinical monitoring and laboratory tests. Adjustment of the dosage of the lithium. 
C10AX12	LOMITAPIDE	1364479						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	311-LOMITAPIDE.html	Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor	Contraindication	
C10AX12	LOMITAPIDE	1364479				ST JOHNS WORT	258326			ANSM	311-LOMITAPIDE.html	Risk of decrease of the plasma concentrations of the lomitapide	Not recommended	
L01AD02	LOMUSTINE	6466			A02BA01	CIMETIDINE	2541			ANSM	312-LOMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
L01AD02	LOMUSTINE	6466			A02BA51	CIMETIDINE	2541			ANSM	312-LOMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
C09CA01	LOSARTAN	52175			D01AC15	FLUCONAZOLE	4450			ANSM	313-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
C09CA01	LOSARTAN	52175			J02AC01	FLUCONAZOLE	4450			ANSM	313-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
C09DB06	LOSARTAN	52175			D01AC15	FLUCONAZOLE	4450			ANSM	313-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
C09DB06	LOSARTAN	52175			J02AC01	FLUCONAZOLE	4450			ANSM	313-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
C09DA01	LOSARTAN	52175			D01AC15	FLUCONAZOLE	4450			ANSM	313-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
C09DA01	LOSARTAN	52175			J02AC01	FLUCONAZOLE	4450			ANSM	313-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
P01BF01	LUMEFANTRINE	847728			J01FA09	CLARITHROMYCIN	21212			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the two together cannot be avoided, testing of the QT before hand and EKG monitoring. 
P01BF01	LUMEFANTRINE	847728			D10AF02	ERYTHROMYCIN	4053			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
P01BF01	LUMEFANTRINE	847728			D10AF52	ERYTHROMYCIN	4053			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
P01BF01	LUMEFANTRINE	847728			J01FA01	ERYTHROMYCIN	4053			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
P01BF01	LUMEFANTRINE	847728			S01AA17	ERYTHROMYCIN	4053			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 
P01BF01	LUMEFANTRINE	847728						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
P01BF01	LUMEFANTRINE	847728			J02AC02	ITRACONAZOLE	28031			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering these two together cannot be avoided, testing of the QT beforehand and EKG monitoring.
P01BF01	LUMEFANTRINE	847728			D01AC08	KETOCONAZOLE	6135			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
P01BF01	LUMEFANTRINE	847728			G01AF11	KETOCONAZOLE	6135			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
P01BF01	LUMEFANTRINE	847728			J02AB02	KETOCONAZOLE	6135			ANSM	314-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
C02KX04	MACITENTAN	1442132						ENZYMATIC INDUCERS	N03-J05-001	ANSM	315-MACITENTAN.html	Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer	Not recommended	
C02KX04	MACITENTAN	1442132				ST JOHNS WORT	258326			ANSM	315-MACITENTAN.html	Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort	Not recommended	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA				DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. 	Not recommended	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the macrolide and after it is stopped
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	L01CC	COLCHICINE	2683			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Contraindication	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	M04AC01	COLCHICINE	2683			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Contraindication	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	N02CA01	DIHYDROERGOTAMINE	3418			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	Contraindication	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	N02CA02	ERGOTAMINE	4025			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	N02CA51	ERGOTAMINE	4025			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	N02CA52	ERGOTAMINE	4025			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	N02CA72	ERGOTAMINE	4025			ANSM	316-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	Contraindication	
A06AD16	MANNITOL	6628			D11AX04	LITHIUM	6448			ANSM	317-MANNITOL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
B05BC01	MANNITOL	6628			D11AX04	LITHIUM	6448			ANSM	317-MANNITOL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
B05CX04	MANNITOL	6628			D11AX04	LITHIUM	6448			ANSM	317-MANNITOL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
R05CB16	MANNITOL	6628			D11AX04	LITHIUM	6448			ANSM	317-MANNITOL.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
J05AX09	MARAVIROC	620216			J05AE07	FOSAMPRENAVIR	358262			ANSM	318-MARAVIROC.html	Significant decrease of the concentrations of amprenavir that could lead to a loss of the virological response	Not recommended	
J05AX09	MARAVIROC	620216						ENZYMATIC INDUCERS	N03-J05-001	ANSM	318-MARAVIROC.html	In the absence of the administration at the same time with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer	Precaution for use	The dose of maraviroc must be increased to 600 mg twice a day in this situation. 
J05AX09	MARAVIROC	620216						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	318-MARAVIROC.html	Increase of the concentrations of maraviroc by the inhibitor	Precaution for use	The dose of maraviroc must be reduced to 150 mg twice a day if it is taken with this inhibitor.
J05AX09	MARAVIROC	620216				ST JOHNS WORT	258326			ANSM	318-MARAVIROC.html	Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of the virological response	Not recommended	
J05AX09	MARAVIROC	620216			J05AE03	RITONAVIR	85762			ANSM	318-MARAVIROC.html	In case of co-administered with foramprenavir, significant decrease of the concentratioins of ritonavir that could lead to a loss of the virological response	Not recommended	
			MEDICATIONS LEADING TO SEROTONIN SYNDROME	N06A-002				MEDICATIONS LEADING TO SEROTONIN SYNDROME	N06A-002	ANSM	319-MEDICATIONS-LEADING-TO-SEROTONIN-SYNDROME.html	Risk of appearance or of increased severity of a serotonin syndrome in case of administering any of these medications with any of the others.	Take into account	
C01BD01	AMIODARONE	703			L01XE13	AFATINIB	1430438			ANSM	32-AMIODARONE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the amiodarone.	Precaution for use	It is recommended that the amiodarone be administered as far away from the afatinib as possible, preferably at an interval of six to twelve hours from the administration of the amiodorone.
C01BD01	AMIODARONE	703						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	32-AMIODARONE.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodarone and a week after it is stopped.
C01BD01	AMIODARONE	703						BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	ANSM	32-AMIODARONE.html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
C01BD01	AMIODARONE	703						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	32-AMIODARONE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	Precaution for use	Clinical monitoring and regular EKG
C01BD01	AMIODARONE	703			L04AD01	CICLOSPORIN	3008			ANSM	32-AMIODARONE.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone
C01BD01	AMIODARONE	703			S01XA18	CICLOSPORIN	3008			ANSM	32-AMIODARONE.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone
C01BD01	AMIODARONE	703			V03AX03	COBICISTAT	1306284			ANSM	32-AMIODARONE.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	Contraindication	
C01BD01	AMIODARONE	703			J05AR09	COBICISTAT	1306284			ANSM	32-AMIODARONE.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	Contraindication	
C01BD01	AMIODARONE	703			1037042	DABIGATRAN				ANSM	32-AMIODARONE.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In post surgical indications:
C01BD01	AMIODARONE	703			J05AX14	DACLATASVIR	1606218			ANSM	32-AMIODARONE.html	Only when daclatasvir is combined with sofosbuvir: Onset of bradycardia, possibly abrupt, that can have fatal consequences.	Not recommended	If the administration of these two medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the daclatsavir/sofosbuvir combination. 
C01BD01	AMIODARONE	703						DIGITALIS GLYCOSIDES	C01AA0	ANSM	32-AMIODARONE.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. When digoxin is used, increase of the digoxinemia due to decrease of the renal clearance of the digoxin.	Precaution for use	Clinical monitoring, EKG, and, if there is reason to, test the digoxinemia and adjust the dosage of the digoxin. 
C01BD01	AMIODARONE	703			C08DB01	DILTIAZEM	3443			ANSM	32-AMIODARONE.html	For diltiazem by injection: risk of bradycardia and of atrioventricular blockFor diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.	Not recommended	-with deltiazem administered intravenously
C01BD01	AMIODARONE	703			C07AB09	ESMOLOL	49737			ANSM	32-AMIODARONE.html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
C01BD01	AMIODARONE	703			A07AA12	FIDAXOMICIN	1111103			ANSM	32-AMIODARONE.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
C01BD01	AMIODARONE	703			L01XE27	IBRUTINIB	1442981			ANSM	32-AMIODARONE.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone.	Precaution for use	Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of these two drugs together.
C01BD01	AMIODARONE	703				LEDIPASVIR	1591922			ANSM	32-AMIODARONE.html	Only when ledipasvir is combined with sofosbuvir, appearance of bradycardia, posssibly abrupt, that can have fatal consequences. 	Not recommended	If the administration ofthese drugs together cannot be avoided, it is recommended that patients be closely monitored, in particular during the first weeks of the treatment with the ledipasvir-sofosbuvir bitherapy (clinical monitoring and EKG).
C01BD01	AMIODARONE	703			C01BB01	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			C05AD01	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			D04AB01	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			N01BB02	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			R02AD02	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			S01HA07	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			S02DA01	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703			N01BB52	LIDOCAINE	6387			ANSM	32-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.
C01BD01	AMIODARONE	703						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	32-AMIODARONE.html	Increase of the plasma concentrations of the amiodarone due to decrease of its hepatice metabolism by the bitherapy.	Contraindication	
C01BD01	AMIODARONE	703			A08AB01	ORLISTAT	37925			ANSM	32-AMIODARONE.html	Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite	Precaution for use	Clinical monitoring and, if needed, EKG
C01BD01	AMIODARONE	703						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	32-AMIODARONE.html	Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phenytoin and possible adjustment of its dosage
C01BD01	AMIODARONE	703			C10AA01	SIMVASTATIN	36567			ANSM	32-AMIODARONE.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin).	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
C01BD01	AMIODARONE	703			J05AX15	SOFOSBUVIR	1484911			ANSM	32-AMIODARONE.html	Only for the combinations dalatasvir/sofosbuvir or ledipasvir/sofosbuvir:Appearance of bradycardia, possibly abrupt, that can have fatal consequences.	Not recommended	If the administration of these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of the treatment with the drug combinations containing sofosbuvir.
C01BD01	AMIODARONE	703			D11AH01	TACROLIMUS	42316			ANSM	32-AMIODARONE.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during the administration of it and the amiodarone together and when the amiodarone is stopped. 
C01BD01	AMIODARONE	703			L04AD02	TACROLIMUS	42316			ANSM	32-AMIODARONE.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during the administration of it and the amiodarone together and when the amiodarone is stopped. 
C01BD01	AMIODARONE	703			L04AD02	TACROLIMUS	42316			ANSM	32-AMIODARONE.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during the administration of it and the amiodarone together and when the amiodarone is stopped. 
C01BD01	AMIODARONE	703			G04CA02	TAMSULOSIN	77492			ANSM	32-AMIODARONE.html	Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C01BD01	AMIODARONE	703			G04CA52	TAMSULOSIN	77492			ANSM	32-AMIODARONE.html	Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C01BD01	AMIODARONE	703			G04CA53	TAMSULOSIN	77492			ANSM	32-AMIODARONE.html	Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C01BD01	AMIODARONE	703			J05AE11	TELAPREVIR	1102261			ANSM	32-AMIODARONE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	Contraindication	
C01BD01	AMIODARONE	703			C08DA01	VERAPAMIL	11170			ANSM	32-AMIODARONE.html	For verapamil by injection: -risk of bradycardia or of atrioventricular block. For verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older patients	Not recommended with:	-verapamil administered via IV
C01BD01	AMIODARONE	703			C08DA51	VERAPAMIL	11170			ANSM	32-AMIODARONE.html	For verapamil by injection: -risk of bradycardia or of atrioventricular block. For verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older patients	Not recommended with:	-verapamil administered via IV
C01BD01	AMIODARONE	703			C09BB10	VERAPAMIL	11170			ANSM	32-AMIODARONE.html	For verapamil by injection: -risk of bradycardia or of atrioventricular block. For verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older patients	Not recommended with:	-verapamil administered via IV
C01BD01	AMIODARONE	703			J02AC03	VORICONAZOLE	121243			ANSM	32-AMIODARONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone.	Precaution for use	Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone.
			MEDICATIONS LEADING TO ORTHOSTATIC HYPOTENSION	N05AA-001	G04BX14	DAPOXETINE	69394			ANSM	320-MEDICATIONS-LEADING-TO-ORTHOSTATIC-HYPOTENSION.html	Risk of increase of the undesirable effects, especially of the vertigo and fainting type	Not recommended	-with the type 5 phospohdisterase inhibitors
			MEDICATIONS LEADING TO ORTHOSTATIC HYPOTENSION	N05AA-001				MEDICATIONS THAT LOWER BLOOD PRESSURE 	MLBP	ANSM	320-MEDICATIONS-LEADING-TO-ORTHOSTATIC-HYPOTENSION.html	Risk of increase of hypotension, especially orthostatic	Take into account	
			MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO	N0-R0-002				NICOTINE SUBSTITUTION TREATMENT	N07BA	ANSM	321-MEDICATIONS-AT-RISK-WHEN-WITHDRAWING-FROM-TOBACCO.html	Risk of overdose when replacing tobacco by the replacement therapy	Take into account	
			MEDICATIONS THAT LOWER BLOOD PRESSURE 	MLBP				NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	322-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html	Increase of the risk of hypotension, especially orthostatic	Take into account	
			MEDICATIONS THAT LOWER BLOOD PRESSURE 	MLBP				MEDICATIONS LEADING TO ORTHOSTATIC HYPOTENSION	N05AA-001	ANSM	322-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html	Risk of increase of hypotension, especially orthostatic	Take into account	
			MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD	N05AA-002				MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD	N05AA-002	ANSM	323-MEDICATIONS-THAT-LOWER-THE-EPILEPTIC-THRESHOLD.html	Accrued risk of convulsions	Take into account	
			ATROPINIC MEDICATIONS	R06AA				ATROPINIC MEDICATIONS	R06AA	ANSM	324-ATROPINIC-MEDICATIONS.html	Addition of the undesirable atropinic effects such as urinary retention, constipation, dry mouth, ...	Take into account	
			METHEMOGLOBINIZING MEDICATIONS 	METGL				METHEMOGLOBINIZING MEDICATIONS 	METGL	ANSM	325-METHEMOGLOBINIZING MEDICATIONS.html	Risk of addition of the effects of the methomoglobinizing agents.	Take into account	
			METHEMOGLOBINIZING MEDICATIONS 	METGL				METHEMOGLOBINIZING MEDICATIONS 	METGL	ANSM	325-METHEMOGLOBINIZING-MEDICATIONS.html	Risk of addition of the effects of the methomoglobinizing agents.	Take into account	
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	A01AD01	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992			ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	B02BC09	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992			ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	C01CA24	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992			ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	C01CA03	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992			ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precautions for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI. 
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma	Not recommended	If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages.
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	A08AB01	ORLISTAT	37925			ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A				ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	326-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Paroxysmal hypertension with possibility of ventricular arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
			NEPHROTOXIC MEDICATIONS 	J01-J05				NEPHROTOXIC MEDICATIONS 	J01-J05	ANSM	327-NEPHROTOXIC-MEDICATIONS.html	Risk of increase of the nephrotoxicity	Take into account	
			OTOTOXIC MEDICATIONS	J01GB-J01XA				OTOTOXIC MEDICATIONS	J01GB-J01XA	ANSM	328-OTOTOXIC-MEDICATIONS.html	Increase of the ototoxicity	Take into account	
			SEDATIVE MEDICATIONS	N04-N05-N06		ALCHOHO (DRINK OR INGREDIENT)				ANSM	329-SEDATIVE-MEDICATIONS.html	Increase by the alcohol of the sedative effect of these substances. The alteration of alertness can make driving vehicles or using machines dangerous	Not recommended	Avoid taking alcoholic beverages or medications containing alcohol.
			SEDATIVE MEDICATIONS	N04-N05-N06				SEDATIVE MEDICATIONS	N04-N05-N06	ANSM	329-SEDATIVE-MEDICATIONS.html	Increase of central nervous center depression. The alteration of alertness can make driving vehicles or using machines dangerous	Take into account	
			SEDATIVE MEDICATIONS	N04-N05-N06	N01AX11	Sodium Oxybate	9899			ANSM	329-SEDATIVE-MEDICATIONS.html	Increase of central nervous center depression. The alteration of alertness can made driving vehicles or using machines dangerous	Not recommended	
			SEDATIVE MEDICATIONS	N04-N05-N06	N07XX04	Sodium Oxybate	9899			ANSM	329-SEDATIVE-MEDICATIONS.html	Increase of central nervous center depression. The alteration of alertness can made driving vehicles or using machines dangerous	Not recommended	
C08CA01	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09BB04	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09DB01	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09DB02	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10BX03	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09BB03	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09DB04	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09DX01	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C08GA02	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09BX01	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C09DB07	AMLODIPINE	17767			C10AA01	SIMVASTATIN	36567			ANSM	33-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	L01XX35	ANAGRELIDE	596724			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05				ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES	P01B-001	ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	- with domperidone, citalopram, escitalopram, and hydroxyzine
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01FA10	AZITHROMYCIN 	18631			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05				BRADYCARIA INDUCING DRUGS	C0N0S0	ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01MA02	CIPROFLOXACIN	2551			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	S01AE03	CIPROFLOXACIN	2551			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	S02AA15	CIPROFLOXACIN	2551			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	S03AA07	CIPROFLOXACIN	2551			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together.
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01FA09	CLARITHROMYCIN	21212			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01FA09	CLARITHROMYCIN	21212			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	A02BD04	CLARITHROMYCIN	21212			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	A02BD05	CLARITHROMYCIN	21212			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	A02BD06	CLARITHROMYCIN	21212			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	A02BD07	CLARITHROMYCIN	21212			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05				POTASSIUM LOWERING AGENTS	C03-001	ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Correct any hypokalemia before administering the product and do clinical monitoring, electrolyte monitoring and electrocardiographic monitoring. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01MA12	LEVOFLOXACINE	82122			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	S01AE05	LEVOFLOXACINE	82122			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	N02AC52	METHADONE	6813			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	-with citalopram, escitalopram, domperidone, or hydroxyzine
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	N07BC02	METHADONE	6813			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	-with citalopram, escitalopram, domperidone, or hydroxyzine
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05				NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES	N05A-002	ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	-with the citalopram, escitalopram, domperidone or hydroxyzine
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01MA06	NORFLOXACIN	7517			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	S01AE02	NORFLOXACIN	7517			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	A04AA01	ONDANSETRON	26225			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	J01FA06	ROXITHROMYCIN	9478			ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these substances together. 
			MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05				TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)	C01B	ANSM	330-MEDICATIONS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	For dolasetron, erythromycin, spiramycin, and vincamine, only the forms administered via IV route are concerned in this interaction. 
P01BF02	MEFLOQUINE	6694			P01BC01	QUININE	9071			ANSM	331-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BF02	MEFLOQUINE	6694			M09AA72	QUININE	9071			ANSM	331-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BF02	MEFLOQUINE	6694			M09AA	QUININE	9071			ANSM	331-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BC02	MEFLOQUINE	6694			P01BC01	QUININE	9071			ANSM	331-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BC02	MEFLOQUINE	6694			M09AA72	QUININE	9071			ANSM	331-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BC02	MEFLOQUINE	6694			M09AA	QUININE	9071			ANSM	331-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BF02	MEFLOQUINE	6694						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	331-MEFLOQUINE.html	Risk of onset of epileptic crises, due to increase of the metabolism of the sodium valproate and the convulsion producing effect of the mefloquine	Contraindication	
P01BC02	MEFLOQUINE	6694						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	331-MEFLOQUINE.html	Risk of onset of epileptic crises, due to increase of the metabolism of the sodium valproate and the convulsion producing effect of the mefloquine	Contraindication	
R06AD07	MEQUITAZINE	29528			N06AX12	BUPROPION	42347			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			H05BX01	CINACALCET	407990			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			N06AX21	DULOXETINE	72625			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			N06AB03	FLUOXETINE	4493			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			N06CA03	FLUOXETINE	4493			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			N06AB05	PAROXETINE	32937			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			D01AE15	TERBINAFINE	37801			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
R06AD07	MEQUITAZINE	29528			D01BA02	TERBINAFINE	37801			ANSM	332-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
L01BB02	MERCAPTOPURINE	103						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	333-MERCAPTOPURINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment with the immunosuppressant (or the cytotoxic) and after it is stopped
L01BB02	MERCAPTOPURINE	103						DERIVATIVES OF AMINOSALICYLIC ACID (ASA)	A07EC-001	ANSM	333-MERCAPTOPURINE.html	Risk of increase of the myelosuppressor effect of the mercatopurine due to inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TPMT)	Take into account	
L01BB02	MERCAPTOPURINE	103						XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	333-MERCAPTOPURINE.html	Bone marrow suppression, reversible but possibly serious (overdose due to decrease of the hepatic metabolism of the mercaptopurine).	Not recommended	Reinforced hematological monitoring and adjustment of the dosage of the mercaptopurine. 
A10BA02	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD13	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD11	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD05	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD03	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD10	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD07	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD02	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BD08	METFORMIN	6809				ALCOHOL (DRINK OR INGREDIENT)				ANSM	334-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
A10BA02	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD13	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD11	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD05	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD03	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD10	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD07	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD02	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BD08	METFORMIN	6809						LOOP DIURETICS	C03CA-001	ANSM	334-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	Do not use metformin when the creatinemia is greater than 15mg/l (135 umol/l) with men, and 12 mg/l (110umol/l) for women.
A10BA02	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD13	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD11	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD05	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD03	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD10	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD07	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD02	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
A10BD08	METFORMIN	6809						IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	334-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
N02AC52	METHADONE	6813						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir.	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of the methadone.
N07BC02	METHADONE	6813						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir.	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of the methadone.
N02AC52	METHADONE	6813						MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	335-METHADONE.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
N07BC02	METHADONE	6813						MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	335-METHADONE.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
N02AC52	METHADONE	6813						TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	335-METHADONE.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
N07BC02	METHADONE	6813						TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	335-METHADONE.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
N02AC52	METHADONE	6813			J05AE12	BOCEPREVIR	1102129			ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
N07BC02	METHADONE	6813			J05AE12	BOCEPREVIR	1102129			ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
N02AC52	METHADONE	6813			A02BA01	CIMETIDINE	2541			ANSM	335-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. 
N02AC52	METHADONE	6813			A02BA51	CIMETIDINE	2541			ANSM	335-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. 
N07BC02	METHADONE	6813			A02BA01	CIMETIDINE	2541			ANSM	335-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. 
N07BC02	METHADONE	6813			A02BA51	CIMETIDINE	2541			ANSM	335-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. 
N02AC52	METHADONE	6813			N06AB08	FLUVOXAMINE	42355			ANSM	335-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.
N07BC02	METHADONE	6813			N06AB08	FLUVOXAMINE	42355			ANSM	335-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.
N02AC52	METHADONE	6813						ENZYMATIC INDUCERS	N03-J05-001	ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	Increase the frequency of doses of methadone (2 to 3 times a day instead of a single dose per day).
N07BC02	METHADONE	6813						ENZYMATIC INDUCERS	N03-J05-001	ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	Increase the frequency of doses of methadone (2 to 3 times a day instead of a single dose per day).
N02AC52	METHADONE	6813						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone. 
N07BC02	METHADONE	6813						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone. 
N02AC52	METHADONE	6813						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	335-METHADONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindicated 	-with citalopram, escitalopram, domperidone, ot hydroxyzine
N07BC02	METHADONE	6813						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	335-METHADONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindicated 	-with citalopram, escitalopram, domperidone, ot hydroxyzine
N02AC52	METHADONE	6813						AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	ANSM	335-METHADONE.html	Decrease of the effect of the methadone due to competitive blocking of the receptors	Contraindication	
N07BC02	METHADONE	6813						AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	ANSM	335-METHADONE.html	Decrease of the effect of the methadone due to competitive blocking of the receptors	Contraindication	
N02AC52	METHADONE	6813			J05AE04	NELFINAVIR	134527			ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methodone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the nelfinavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone 
N07BC02	METHADONE	6813			J05AE04	NELFINAVIR	134527			ANSM	335-METHADONE.html	Decrease of the plasma concentrations of methodone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the nelfinavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone 
J01XX05	METHENAMINE	6832			B05CA04	SULFAMETHIZOLE	10179			ANSM	336-METHENAMINE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
J01XX05	METHENAMINE	6832			J01EB02	SULFAMETHIZOLE	10179			ANSM	336-METHENAMINE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
L01BA0	METHOTREXATE	6851			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L04AX03	METHOTREXATE	6851			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	337-METHOTREXATE.html	Increase of toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	Contraindication  with acetylsalicylic acid used in analgesic,antipyretic, or anti-inflammatory doses
L01BA0	METHOTREXATE	6851			D05BB02	ACITRETIN	16818			ANSM	337-METHOTREXATE.html	Risk of increase of the hepatoxicity of the methotrexate	Not recommended	If administering these substances together is judged necessary, strengthen liver function testing 
L04AX03	METHOTREXATE	6851			D05BB02	ACITRETIN	16818			ANSM	337-METHOTREXATE.html	Risk of increase of the hepatoxicity of the methotrexate	Not recommended	If administering these substances together is judged necessary, strengthen liver function testing 
L01BA0	METHOTREXATE	6851						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Contraindication	--with the phenylbutazone, regardless of the dose of methotrexate and for all the forms of phenylbutazone, including topical. 
L04AX03	METHOTREXATE	6851						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Contraindication	--with the phenylbutazone, regardless of the dose of methotrexate and for all the forms of phenylbutazone, including topical. 
L01BA0	METHOTREXATE	6851						PROTON PUMP INHIBITORS	A02BC-001	ANSM	337-METHOTREXATE.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	--with the methotrexate in doses > 20mg /week
L04AX03	METHOTREXATE	6851						PROTON PUMP INHIBITORS	A02BC-001	ANSM	337-METHOTREXATE.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	--with the methotrexate in doses > 20mg /week
L01BA0	METHOTREXATE	6851			L04AD01	CICLOSPORIN	3008			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
L01BA0	METHOTREXATE	6851			S01XA18	CICLOSPORIN	3008			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
L04AX03	METHOTREXATE	6851			L04AD01	CICLOSPORIN	3008			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
L04AX03	METHOTREXATE	6851			S01XA18	CICLOSPORIN	3008			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.
L01BA0	METHOTREXATE	6851			J01MA02	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L01BA0	METHOTREXATE	6851			S01AE03	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L01BA0	METHOTREXATE	6851			S02AA15	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L01BA0	METHOTREXATE	6851			S03AA07	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L04AX03	METHOTREXATE	6851			J01MA02	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L04AX03	METHOTREXATE	6851			S01AE03	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L04AX03	METHOTREXATE	6851			S02AA15	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L04AX03	METHOTREXATE	6851			S03AA07	CIPROFLOXACIN	2551			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
L01BA0	METHOTREXATE	6851						PENICILLINS	J01C	ANSM	337-METHOTREXATE.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
L04AX03	METHOTREXATE	6851						PENICILLINS	J01C	ANSM	337-METHOTREXATE.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
L01BA0	METHOTREXATE	6851			M04AB01	PROBENECID	8698			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	Contraindication	
L04AX03	METHOTREXATE	6851			M04AB01	PROBENECID	8698			ANSM	337-METHOTREXATE.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	Contraindication	
L01BA0	METHOTREXATE	6851						ANTIBACTERIAL SULFONAMIDES	JO1E	ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the time of the administration of the substances together and after it is stopped. 
L04AX03	METHOTREXATE	6851						ANTIBACTERIAL SULFONAMIDES	JO1E	ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the time of the administration of the substances together and after it is stopped. 
L01BA0	METHOTREXATE	6851			J01E	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EA	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE02	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE05	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE07	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE01	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE03	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EE04	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L01BA0	METHOTREXATE	6851			J01EA01	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01E	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EA	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE02	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE05	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE07	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE01	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE03	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EE04	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
L04AX03	METHOTREXATE	6851			J01EA01	TRIMETHOPRIM	10829			ANSM	337-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	Contraindication	
C02AB	METHYLDOPA	6876			B03A	IRON	1431589			ANSM	338-METHYLDOPA.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).
C02LB	METHYLDOPA	6876			B03A	IRON	1431589			ANSM	338-METHYLDOPA.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).
C02AB01	METHYLDOPA	6876			B03A	IRON	1431589			ANSM	338-METHYLDOPA.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).
C02LB01	METHYLDOPA	6876			B03A	IRON	1431589			ANSM	338-METHYLDOPA.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).
C02AB02	METHYLDOPA	6876			B03A	IRON	1431589			ANSM	338-METHYLDOPA.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).
C02AB	METHYLDOPA	6876			N04BA01	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB	METHYLDOPA	6876			N04BA02	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB	METHYLDOPA	6876			N04BA03	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02LB	METHYLDOPA	6876			N04BA01	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02LB	METHYLDOPA	6876			N04BA02	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02LB	METHYLDOPA	6876			N04BA03	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB01	METHYLDOPA	6876			N04BA01	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB01	METHYLDOPA	6876			N04BA02	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB01	METHYLDOPA	6876			N04BA03	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02LB01	METHYLDOPA	6876			N04BA01	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02LB01	METHYLDOPA	6876			N04BA02	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02LB01	METHYLDOPA	6876			N04BA03	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB02	METHYLDOPA	6876			N04BA01	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB02	METHYLDOPA	6876			N04BA02	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB02	METHYLDOPA	6876			N04BA03	LEVODOPA	6375			ANSM	338-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	Clinical monitoring and possible decrease of the doses of levodopa.
C02AB	METHYLDOPA	6876			D11AX04	LITHIUM	6448			ANSM	338-METHYLDOPA.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
C02LB	METHYLDOPA	6876			D11AX04	LITHIUM	6448			ANSM	338-METHYLDOPA.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
C02AB01	METHYLDOPA	6876			D11AX04	LITHIUM	6448			ANSM	338-METHYLDOPA.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
C02LB01	METHYLDOPA	6876			D11AX04	LITHIUM	6448			ANSM	338-METHYLDOPA.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
C02AB02	METHYLDOPA	6876			D11AX04	LITHIUM	6448			ANSM	338-METHYLDOPA.html	Increase of the lithemia which can attain toxic values, with signs of overdose of lithium	Precaution for use	Clinical monitoring and adjustment of the dosage of lithium. 
N02CA02	METHYLERGOMETRINE	6883			G02AD05	SULPROSTONE	37414			ANSM	339-METHYLERGOMETRINE.html	Risk of constriction of coronary blood vessels which can be fatal 	Contraindication	
N02CA51	METHYLERGOMETRINE	6883			G02AD05	SULPROSTONE	37414			ANSM	339-METHYLERGOMETRINE.html	Risk of constriction of coronary blood vessels which can be fatal 	Contraindication	
N02CA52	METHYLERGOMETRINE	6883			G02AD05	SULPROSTONE	37414			ANSM	339-METHYLERGOMETRINE.html	Risk of constriction of coronary blood vessels which can be fatal 	Contraindication	
N02CA72	METHYLERGOMETRINE	6883			G02AD05	SULPROSTONE	37414			ANSM	339-METHYLERGOMETRINE.html	Risk of constriction of coronary blood vessels which can be fatal 	Contraindication	
A01AB04	AMPHOTERICIN B 	732						AMINOGLYCOSIDES	J01GB-001	ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increased risk of nephrotoxicity.	Take into account	
A07AA07	AMPHOTERICIN B 	732						AMINOGLYCOSIDES	J01GB-001	ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increased risk of nephrotoxicity.	Take into account	
G01AA03	AMPHOTERICIN B 	732						AMINOGLYCOSIDES	J01GB-001	ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increased risk of nephrotoxicity.	Take into account	
J02AA01	AMPHOTERICIN B 	732						AMINOGLYCOSIDES	J01GB-001	ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increased risk of nephrotoxicity.	Take into account	
A01AB04	AMPHOTERICIN B 	732			L04AD01	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A01AB04	AMPHOTERICIN B 	732			S01XA18	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A07AA07	AMPHOTERICIN B 	732			L04AD01	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A07AA07	AMPHOTERICIN B 	732			S01XA18	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
G01AA03	AMPHOTERICIN B 	732			L04AD01	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
G01AA03	AMPHOTERICIN B 	732			S01XA18	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
J02AA01	AMPHOTERICIN B 	732			L04AD01	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
J02AA01	AMPHOTERICIN B 	732			S01XA18	CICLOSPORIN	3008			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A01AB04	AMPHOTERICIN B 	732			D11AH01	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A01AB04	AMPHOTERICIN B 	732			L04AD02	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A07AA07	AMPHOTERICIN B 	732			D11AH01	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A07AA07	AMPHOTERICIN B 	732			L04AD02	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
G01AA03	AMPHOTERICIN B 	732			D11AH01	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
G01AA03	AMPHOTERICIN B 	732			L04AD02	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
J02AA01	AMPHOTERICIN B 	732			D11AH01	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
J02AA01	AMPHOTERICIN B 	732			L04AD02	TACROLIMUS	42316			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
A01AB04	AMPHOTERICIN B 	732			J05AF01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A01AB04	AMPHOTERICIN B 	732			J05AR01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A01AB04	AMPHOTERICIN B 	732			J05AR04	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A01AB04	AMPHOTERICIN B 	732			J05AR05	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A07AA07	AMPHOTERICIN B 	732			J05AF01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A07AA07	AMPHOTERICIN B 	732			J05AR01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A07AA07	AMPHOTERICIN B 	732			J05AR04	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
A07AA07	AMPHOTERICIN B 	732			J05AR05	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
G01AA03	AMPHOTERICIN B 	732			J05AF01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
G01AA03	AMPHOTERICIN B 	732			J05AR01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
G01AA03	AMPHOTERICIN B 	732			J05AR04	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
G01AA03	AMPHOTERICIN B 	732			J05AR05	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J02AA01	AMPHOTERICIN B 	732			J05AF01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J02AA01	AMPHOTERICIN B 	732			J05AR01	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J02AA01	AMPHOTERICIN B 	732			J05AR04	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J02AA01	AMPHOTERICIN B 	732			J05AR05	ZIDOVUDINE	11413			ANSM	34-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
D07AA01	METHYLPREDNISOLONE	6902						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	340-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythyl-prednisolone or in the presence of signs of hemorrhage
D10AA02	METHYLPREDNISOLONE	6902						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	340-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythyl-prednisolone or in the presence of signs of hemorrhage
H02AB04	METHYLPREDNISOLONE	6902						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	340-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythyl-prednisolone or in the presence of signs of hemorrhage
D07CA02	METHYLPREDNISOLONE	6902						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	340-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythyl-prednisolone or in the presence of signs of hemorrhage
S01CA08	METHYLPREDNISOLONE	6902						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	340-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythyl-prednisolone or in the presence of signs of hemorrhage
H02BX01	METHYLPREDNISOLONE	6902						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	340-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythyl-prednisolone or in the presence of signs of hemorrhage
D07AA01	METHYLPREDNISOLONE	6902			L04AD01	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
D07AA01	METHYLPREDNISOLONE	6902			S01XA18	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
D10AA02	METHYLPREDNISOLONE	6902			L04AD01	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
D10AA02	METHYLPREDNISOLONE	6902			S01XA18	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
H02AB04	METHYLPREDNISOLONE	6902			L04AD01	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
H02AB04	METHYLPREDNISOLONE	6902			S01XA18	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
D07CA02	METHYLPREDNISOLONE	6902			L04AD01	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
D07CA02	METHYLPREDNISOLONE	6902			S01XA18	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01CA08	METHYLPREDNISOLONE	6902			L04AD01	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
S01CA08	METHYLPREDNISOLONE	6902			S01XA18	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
H02BX01	METHYLPREDNISOLONE	6902			L04AD01	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
H02BX01	METHYLPREDNISOLONE	6902			S01XA18	CICLOSPORIN	3008			ANSM	340-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
C07AB02	METOPROLOL	6918			L02BX03	ABIRATERONE	1100072			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
C07FB02	METOPROLOL	6918			L02BX03	ABIRATERONE	1100072			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
C07CB02	METOPROLOL	6918			L02BX03	ABIRATERONE	1100072			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
C07BB02	METOPROLOL	6918			L02BX03	ABIRATERONE	1100072			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
C07BB52	METOPROLOL	6918			L02BX03	ABIRATERONE	1100072			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
C07AB52	METOPROLOL	6918			L02BX03	ABIRATERONE	1100072			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone
C07AB02	METOPROLOL	6918			N06AX12	BUPROPION	42347			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
C07FB02	METOPROLOL	6918			N06AX12	BUPROPION	42347			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
C07CB02	METOPROLOL	6918			N06AX12	BUPROPION	42347			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
C07BB02	METOPROLOL	6918			N06AX12	BUPROPION	42347			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
C07BB52	METOPROLOL	6918			N06AX12	BUPROPION	42347			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
C07AB52	METOPROLOL	6918			N06AX12	BUPROPION	42347			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion
C07AB02	METOPROLOL	6918			A02BA01	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07AB02	METOPROLOL	6918			A02BA51	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07FB02	METOPROLOL	6918			A02BA01	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07FB02	METOPROLOL	6918			A02BA51	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07CB02	METOPROLOL	6918			A02BA01	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07CB02	METOPROLOL	6918			A02BA51	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07BB02	METOPROLOL	6918			A02BA01	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07BB02	METOPROLOL	6918			A02BA51	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07BB52	METOPROLOL	6918			A02BA01	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07BB52	METOPROLOL	6918			A02BA51	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07AB52	METOPROLOL	6918			A02BA01	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07AB52	METOPROLOL	6918			A02BA51	CIMETIDINE	2541			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Contraindication	Use another H2receptor antagonist
C07AB02	METOPROLOL	6918			H05BX01	CINACALCET	407990			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
C07FB02	METOPROLOL	6918			H05BX01	CINACALCET	407990			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
C07CB02	METOPROLOL	6918			H05BX01	CINACALCET	407990			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
C07BB02	METOPROLOL	6918			H05BX01	CINACALCET	407990			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
C07BB52	METOPROLOL	6918			H05BX01	CINACALCET	407990			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
C07AB52	METOPROLOL	6918			H05BX01	CINACALCET	407990			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.
C07AB02	METOPROLOL	6918			G04BD10	DARIFENACIN	136198			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
C07FB02	METOPROLOL	6918			G04BD10	DARIFENACIN	136198			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
C07CB02	METOPROLOL	6918			G04BD10	DARIFENACIN	136198			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
C07BB02	METOPROLOL	6918			G04BD10	DARIFENACIN	136198			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
C07BB52	METOPROLOL	6918			G04BD10	DARIFENACIN	136198			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
C07AB52	METOPROLOL	6918			G04BD10	DARIFENACIN	136198			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.
C07AB02	METOPROLOL	6918			N06AX21	DULOXETINE	72625			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
C07FB02	METOPROLOL	6918			N06AX21	DULOXETINE	72625			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
C07CB02	METOPROLOL	6918			N06AX21	DULOXETINE	72625			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
C07BB02	METOPROLOL	6918			N06AX21	DULOXETINE	72625			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
C07BB52	METOPROLOL	6918			N06AX21	DULOXETINE	72625			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
C07AB52	METOPROLOL	6918			N06AX21	DULOXETINE	72625			ANSM	341-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 
C07AB02	METOPROLOL	6918			N06AB03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07AB02	METOPROLOL	6918			N06CA03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07FB02	METOPROLOL	6918			N06AB03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07FB02	METOPROLOL	6918			N06CA03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07CB02	METOPROLOL	6918			N06AB03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07CB02	METOPROLOL	6918			N06CA03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07BB02	METOPROLOL	6918			N06AB03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07BB02	METOPROLOL	6918			N06CA03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07BB52	METOPROLOL	6918			N06AB03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07BB52	METOPROLOL	6918			N06CA03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07AB52	METOPROLOL	6918			N06AB03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07AB52	METOPROLOL	6918			N06CA03	FLUOXETINE	4493			ANSM	341-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of its undesirable effects, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Contraindication	
C07AB02	METOPROLOL	6918			N06AB05	PAROXETINE	32937			ANSM	341-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Contraindication	-with the metoprolol used for heart failure
C07FB02	METOPROLOL	6918			N06AB05	PAROXETINE	32937			ANSM	341-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Contraindication	-with the metoprolol used for heart failure
C07CB02	METOPROLOL	6918			N06AB05	PAROXETINE	32937			ANSM	341-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Contraindication	-with the metoprolol used for heart failure
C07BB02	METOPROLOL	6918			N06AB05	PAROXETINE	32937			ANSM	341-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Contraindication	-with the metoprolol used for heart failure
C07BB52	METOPROLOL	6918			N06AB05	PAROXETINE	32937			ANSM	341-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Contraindication	-with the metoprolol used for heart failure
C07AB52	METOPROLOL	6918			N06AB05	PAROXETINE	32937			ANSM	341-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Contraindication	-with the metoprolol used for heart failure
C07AB02	METOPROLOL	6918						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07FB02	METOPROLOL	6918						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07CB02	METOPROLOL	6918						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07BB02	METOPROLOL	6918						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07BB52	METOPROLOL	6918						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07AB52	METOPROLOL	6918						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07AB02	METOPROLOL	6918			J04AB02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB02	METOPROLOL	6918			J04AM02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB02	METOPROLOL	6918			J04AM05	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB02	METOPROLOL	6918			J04AM06	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07FB02	METOPROLOL	6918			J04AB02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07FB02	METOPROLOL	6918			J04AM02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07FB02	METOPROLOL	6918			J04AM05	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07FB02	METOPROLOL	6918			J04AM06	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07CB02	METOPROLOL	6918			J04AB02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07CB02	METOPROLOL	6918			J04AM02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07CB02	METOPROLOL	6918			J04AM05	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07CB02	METOPROLOL	6918			J04AM06	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB02	METOPROLOL	6918			J04AB02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB02	METOPROLOL	6918			J04AM02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB02	METOPROLOL	6918			J04AM05	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB02	METOPROLOL	6918			J04AM06	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB52	METOPROLOL	6918			J04AB02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB52	METOPROLOL	6918			J04AM02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB52	METOPROLOL	6918			J04AM05	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07BB52	METOPROLOL	6918			J04AM06	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB52	METOPROLOL	6918			J04AB02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB52	METOPROLOL	6918			J04AM02	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB52	METOPROLOL	6918			J04AM05	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB52	METOPROLOL	6918			J04AM06	RIFAMPICIN	9384			ANSM	341-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AB02	METOPROLOL	6918			D01AE15	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07AB02	METOPROLOL	6918			D01BA02	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07FB02	METOPROLOL	6918			D01AE15	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07FB02	METOPROLOL	6918			D01BA02	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07CB02	METOPROLOL	6918			D01AE15	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07CB02	METOPROLOL	6918			D01BA02	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07BB02	METOPROLOL	6918			D01AE15	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07BB02	METOPROLOL	6918			D01BA02	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07BB52	METOPROLOL	6918			D01AE15	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07BB52	METOPROLOL	6918			D01BA02	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07AB52	METOPROLOL	6918			D01AE15	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
C07AB52	METOPROLOL	6918			D01BA02	TERBINAFINE	37801			ANSM	341-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
A02BD08	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
A02BD03	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
A02BD02	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
A01AB17	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
D06BX01	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
G01AF01	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
J01XD01	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
P01AB01	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
A02BD01	METRONIDAZOLE	6922						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 
A02BD08	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
A02BD03	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
A02BD02	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
A01AB17	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
D06BX01	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
G01AF01	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
J01XD01	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
P01AB01	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
A02BD01	METRONIDAZOLE	6922			L01AB01	BUSULFAN	1828			ANSM	342-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
A02BD08	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
A02BD03	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
A02BD02	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
A01AB17	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
D06BX01	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
G01AF01	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
J01XD01	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
P01AB01	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
A02BD01	METRONIDAZOLE	6922			N07BB01	DISULFIRAM	3554			ANSM	342-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
A02BD08	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
A02BD03	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
A02BD02	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
A01AB17	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
D06BX01	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
G01AF01	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
J01XD01	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
P01AB01	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
A02BD01	METRONIDAZOLE	6922						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	342-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
A02BD08	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
A02BD03	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
A02BD02	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
A01AB17	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
D06BX01	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
G01AF01	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
J01XD01	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
P01AB01	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
A02BD01	METRONIDAZOLE	6922			D11AX04	LITHIUM	6448			ANSM	342-METRONIDAZOLE.html	Increase of the lithemia which can attain toxic values with signs of overdose of lithium.	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium. 
A02BD08	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD08	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD08	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD08	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD03	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD03	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD03	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD03	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD02	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD02	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD02	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD02	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A01AB17	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A01AB17	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A01AB17	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A01AB17	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
D06BX01	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
D06BX01	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
D06BX01	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
D06BX01	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
G01AF01	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
G01AF01	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
G01AF01	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
G01AF01	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J01XD01	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J01XD01	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J01XD01	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J01XD01	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
P01AB01	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
P01AB01	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
P01AB01	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
P01AB01	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD01	METRONIDAZOLE	6922			J04AB02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD01	METRONIDAZOLE	6922			J04AM02	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD01	METRONIDAZOLE	6922			J04AM05	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
A02BD01	METRONIDAZOLE	6922			J04AM06	RIFAMPICIN	9384			ANSM	342-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
V04CD01	METYRAPONE	6923						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	343-METYRAPONE.html	Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.	Precaution for use	Double the dosage of the metyrapone.
C01BB02	MEXILETINE	6926			N06BC01	CAFFEINE 	1886			ANSM	344-MEXILETINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
C01BB02	MEXILETINE	6926			V04CG30	CAFFEINE 	1886			ANSM	344-MEXILETINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
C01BB02	MEXILETINE	6926			N06AB08	FLUVOXAMINE	42355			ANSM	344-MEXILETINE.html	Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.
C01BB02	MEXILETINE	6926						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	344-MEXILETINE.html	Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.
C01BB02	MEXILETINE	6926						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	344-MEXILETINE.html	Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped.
N06AX03	MIANSERIN	6929						ENZYMATIC INDUCERS	N03-J05-001	ANSM	345-MIANSERIN.html	Risk of ineffectiveness of the mianserin 	Not recommended	
A01AB09	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
A07AC01	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
D01AC02	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
G01AF04	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
J02AB01	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
S02AA13	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
D01AC52	MICONAZOLE	6932						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-MICONAZOLE.html	With the miconazole by general route and oral gel: unpredictable hemorrhages, possibly serious	Contraindication	
A01AB09	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
A07AC01	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
D01AC02	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
G01AF04	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
J02AB01	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
S02AA13	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
D01AC52	MICONAZOLE	6932			P01BX01	HALOFANTRINE	50749			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	If this is possible, interrupt the azole antifungal. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.
A01AB09	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
A07AC01	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
D01AC02	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
G01AF04	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
J02AB01	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
S02AA13	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
D01AC52	MICONAZOLE	6932						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	346-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
A01AB09	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A07AC01	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
D01AC02	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
G01AF04	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J02AB01	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
S02AA13	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
D01AC52	MICONAZOLE	6932			N05AG02	PIMOZIDE	8331			ANSM	346-MICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A01AB09	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
A07AC01	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
D01AC02	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
G01AF04	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
J02AB01	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
S02AA13	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
D01AC52	MICONAZOLE	6932						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	346-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
N05CD08	MIDAZOLAM	6960						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	347-MIDAZOLAM.html	Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant	Take into account	
N05CD08	MIDAZOLAM	6960						AZOLE ANTIFUNGALS	J02AC-001	ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.	Precaution for use 	- with midazolam via IV route
N05CD08	MIDAZOLAM	6960			J01FA09	CLARITHROMYCIN	21212			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism with increase of sedation.	Precaution for use	Clinical monitoring and reduction of the dosage of the midazolam during the treatment with the clarithromycin
N05CD08	MIDAZOLAM	6960			C08DB01	DILTIAZEM	3443			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the diltiazem
N05CD08	MIDAZOLAM	6960			D10AF02	ERYTHROMYCIN	4053			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
N05CD08	MIDAZOLAM	6960			D10AF52	ERYTHROMYCIN	4053			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
N05CD08	MIDAZOLAM	6960			J01FA01	ERYTHROMYCIN	4053			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
N05CD08	MIDAZOLAM	6960			S01AA17	ERYTHROMYCIN	4053			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation, especially with children	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the erythromycin.
N05CD08	MIDAZOLAM	6960						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	- with midazolam via IV route
N05CD08	MIDAZOLAM	6960				ST JOHNS WORT	258326			ANSM	347-MIDAZOLAM.html	Risk of decrease of the plasma concentrations of midazolam by the St Johns wort	Take into account	
N05CD08	MIDAZOLAM	6960						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir	Contraindication	
N05CD08	MIDAZOLAM	6960			J04AM02	RIFAMPICIN	9384			ANSM	347-MIDAZOLAM.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
N05CD08	MIDAZOLAM	6960			J04AM05	RIFAMPICIN	9384			ANSM	347-MIDAZOLAM.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
N05CD08	MIDAZOLAM	6960			J04AM06	RIFAMPICIN	9384			ANSM	347-MIDAZOLAM.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
N05CD08	MIDAZOLAM	6960			J01FA06	ROXITHROMYCIN	9478			ANSM	347-MIDAZOLAM.html	Slight increase of sedation	Take into account	
N05CD08	MIDAZOLAM	6960			N03AX17	STIRIPENTOL	37119			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.
N05CD08	MIDAZOLAM	6960			J05AE11	TELAPREVIR	1102261			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Contraindication 	- with the midazolam by mouth
N05CD08	MIDAZOLAM	6960			C08DA01	VERAPAMIL	11170			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
N05CD08	MIDAZOLAM	6960			C08DA51	VERAPAMIL	11170			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
N05CD08	MIDAZOLAM	6960			C09BB10	VERAPAMIL	11170			ANSM	347-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
J01FA05	MIDECAMYCIN	30005			L04AD01	CICLOSPORIN	3008			ANSM	348-MIDECAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. 
J01FA05	MIDECAMYCIN	30005			S01XA18	CICLOSPORIN	3008			ANSM	348-MIDECAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. 
C01CA17	MIDODRINE	6963						DIGITALIS GLYCOSIDES	C01AA0	ANSM	349-MIDODRINE.html	Disorders of autoregulation (increase of the bradycardia inducing effect of the midodrine) and disorders of atrioventricular conduction	Not recommended	If administering these substances together cannot be avoided, strengthen clinical monitoring and EKG.
C01CA17	MIDODRINE	6963						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	349-MIDODRINE.html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.	Contraindication	
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	N02AE01	BUPRENORPHINE	1819			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of increase or decrease of the effects of the buprenorphine, due to the simultaneous inhibition and acceleration of its metabolism by the protease inhibitor.	Take into account	
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	N07BC01	BUPRENORPHINE	1819			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of increase or decrease of the effects of the buprenorphine, due to the simultaneous inhibition and acceleration of its metabolism by the protease inhibitor.	Take into account	
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	N07BC51	BUPRENORPHINE	1819			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of increase or decrease of the effects of the buprenorphine, due to the simultaneous inhibition and acceleration of its metabolism by the protease inhibitor.	Take into account	
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	J05AG03	EFAVIRENZ	195085			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	J05AR06	EFAVIRENZ	195085			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	N02AC52	METHADONE	6813			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir.	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	N07BC02	METHADONE	6813			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir.	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	J05AG01	NEVIRAPINE	53654			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	J05AR07	NEVIRAPINE	53654			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
			AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	J05AR05	NEVIRAPINE	53654			ANSM	35-AMPRENAVIR-(AND-BY-EXTRAPOLATION-FOSAMPRENAVIR).html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
	ST JOHNS WORT	258326						METABOLIZED ANTICONVULSANTS	N03A-002	ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant.	Contraindication	
	ST JOHNS WORT	258326						PROTON PUMP INHIBITORS	A02BC-001	ANSM	350-ST-JOHNS-WORT.html	Risk of ineffectiveness of the treatment by the proton pump inhibitor due to decrease of its metabolism by the St Johns wort	Take into account	
	ST JOHNS WORT	258326						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)	Contraindication	In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped.
	ST JOHNS WORT	258326			J04AK05	BEDAQUILINE	1364504			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
	ST JOHNS WORT	258326			N03AF01	CARBAMAZEPINE	2002			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine	Not recommended	
	ST JOHNS WORT	258326			V03AX03	COBICISTAT	1306284			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
	ST JOHNS WORT	258326			J05AR09	COBICISTAT	1306284			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
	ST JOHNS WORT	258326			G03HA01	CYPROTERONE	3014			ANSM	350-ST-JOHNS-WORT.html	Decrease of the effectiveness of the progestin, due to increase of its hepatic metabolism by the St Johns Wort	Not recommended	
	ST JOHNS WORT	258326			G03HB01	CYPROTERONE	3014			ANSM	350-ST-JOHNS-WORT.html	Decrease of the effectiveness of the progestin, due to increase of its hepatic metabolism by the St Johns Wort	Not recommended	
	ST JOHNS WORT	258326			J05AX14	DACLATASVIR	1606218			ANSM	350-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326				DASABUVIR	1597381			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326			C01AA05	DIGOXIN	3407			ANSM	350-ST-JOHNS-WORT.html	Decrease of the digoxinemia, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).	Contraindication	In the case of the two substances being taken by accident, do not stop the St Johns Wort abruptly but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns Wort is stopped. 
	ST JOHNS WORT	258326			J05AX12	DOLUTEGRAVIR	1433868			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326			C01BD07	DRONEDARONE	233698			ANSM	350-ST-JOHNS-WORT.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
	ST JOHNS WORT	258326			L01XX41	ERIBULINE	1045453			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of eribuline by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can have possibly serious consequences (pregnancy).	Contraindication	
	ST JOHNS WORT	258326			L01XX47	IDELALISIB	1544460			ANSM	350-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	350-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
	ST JOHNS WORT	258326						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	350-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
	ST JOHNS WORT	258326						IMMUNOSUPPRESSANTS	L04A	ANSM	350-ST-JOHNS-WORT.html	Decrease of the blood concentrations of the immunosuppressant, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (rejection of a graft)	Contraindication	
	ST JOHNS WORT	258326						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	Contraindication	In the case of the substances being taken together by accident, do not stop the St Johns Wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns Wort is stopped. 
	ST JOHNS WORT	258326						METABOLIZED TYROSINE-KINASE INHIBITORS 	L01XE	ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns Wort	Contraindication	
	ST JOHNS WORT	258326						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	350-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
	ST JOHNS WORT	258326			L01XX19	IRINOTECAN	51499			ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Contraindication	
	ST JOHNS WORT	258326			J02AC02	ITRACONAZOLE	28031			ANSM	350-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326			C01EB17	IVABRADINE	77417			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the ivabradine due to increase of its metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326				LEDIPASVIR	1591922			ANSM	350-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolidm by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326			C10AX12	LOMITAPIDE	1364479			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of the lomitapide	Not recommended	
	ST JOHNS WORT	258326			C02KX0	MACITENTAN	1442132			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326			J05AX09	MARAVIROC	620216			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of maraviroc that cound lead to a loss of virological response	Not recommended	
	ST JOHNS WORT	258326			N05CD08	MIDAZOLAM	6960			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of midazolam by the St Johns wort	Take into account	
	ST JOHNS WORT	258326			J05AG01	NEVIRAPINE	53654			ANSM	350-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326			J05AR07	NEVIRAPINE	53654			ANSM	350-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326			J05AR05	NEVIRAPINE	53654			ANSM	350-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)	Contraindication	
	ST JOHNS WORT	258326			C01BC03	PROPAFENONE	8754			ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped. 
	ST JOHNS WORT	258326			N05AH04	QUETIAPINE	51272			ANSM	350-ST-JOHNS-WORT.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
	ST JOHNS WORT	258326			L01XE21	REGORAFENIB	1312397			ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326			J05AG05	RILPIVIRINE	1102270			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
	ST JOHNS WORT	258326			J05AE14	SIMEPREVIR	1482790			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326			C10AA01	SIMVASTATIN	36567			ANSM	350-ST-JOHNS-WORT.html	Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326			J05AX15	SOFOSBUVIR	1484911			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of sofobusvir due to decrease of its intestinal absorption by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326			J05AE11	TELAPREVIR	1102261			ANSM	350-ST-JOHNS-WORT.html	Risk of very large decrease of the concentrations of telaprevir	Contraindication	
	ST JOHNS WORT	258326			J01FA15	TELITHROMYCIN	274786			ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort	Not recommended	
	ST JOHNS WORT	258326						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	350-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the theophylline, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome) 	Contraindication	In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the substance taken with it before and then after stopping the St Johns wort. 
	ST JOHNS WORT	258326			B01AC24	TICAGRELOR	1116632			ANSM	350-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with risk of decrease of its therapeutic effect	Contraindication	
	ST JOHNS WORT	258326			G03AD02	ULIPRISTAL	1005921			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not metabolized.
	ST JOHNS WORT	258326			C08DA01	VERAPAMIL	11170			ANSM	350-ST-JOHNS-WORT.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect	Contraindication	
	ST JOHNS WORT	258326			C08DA51	VERAPAMIL	11170			ANSM	350-ST-JOHNS-WORT.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect	Contraindication	
	ST JOHNS WORT	258326			C09BB10	VERAPAMIL	11170			ANSM	350-ST-JOHNS-WORT.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect	Contraindication	
	ST JOHNS WORT	258326			L01XX43	VISMODEGIB	1242987			ANSM	350-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of vismodegib	Contraindication	
	ST JOHNS WORT	258326			J02AC03	VORICONAZOLE	121243			ANSM	350-ST-JOHNS-WORT.html	Large reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect	Contraindication	
			MINERALOCORTICOIDS	H02AA0				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	351-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addison's disease treated with the hydrocortisone and in the case of organ transplants.	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 
			MINERALOCORTICOIDS	H02AA0	J04AB02	RIFAMPICIN	9384			ANSM	351-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
			MINERALOCORTICOIDS	H02AA0	J04AM02	RIFAMPICIN	9384			ANSM	351-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
			MINERALOCORTICOIDS	H02AA0	J04AM05	RIFAMPICIN	9384			ANSM	351-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
			MINERALOCORTICOIDS	H02AA0	J04AM06	RIFAMPICIN	9384			ANSM	351-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
L01DC03	MITOMYCIN C	632						VINCA ALKALOIDS	L01CA	ANSM	352-MITOMYCIN-C.html	Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca-alkaloids	Take into account	
L01XX23	MITOTANE	7004				DASABUVIR	1597381			ANSM	353-MITOTANE.html	Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane	Contraindication	
L01XX23	MITOTANE	7004			C03DA01	SPIRONOLACTONE	9997			ANSM	353-MITOTANE.html	Risk of blockage of the action of the mitotane by the spironolactone	Contraindication	
R06AX25	MIZOLASTINE	61455			J01FA09	CLARITHROMYCIN	21212			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			D10AF02	ERYTHROMYCIN	4053			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			D10AF52	ERYTHROMYCIN	4053			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			J01FA01	ERYTHROMYCIN	4053			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			S01AA17	ERYTHROMYCIN	4053			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			J02AC02	ITRACONAZOLE	28031			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			D01AC08	KETOCONAZOLE	6135			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			G01AF11	KETOCONAZOLE	6135			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			J02AB02	KETOCONAZOLE	6135			ANSM	354-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
R06AX25	MIZOLASTINE	61455			J01FA15	TELITHROMYCIN	274786			ANSM	354-MIZOLASTINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N06AG02	MOCLOBEMIDE	30121			A02BA01	CIMETIDINE	2541			ANSM	355-MOCLOBEMIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring with possible adjustment of the dosage of moclobemide
N06AG02	MOCLOBEMIDE	30121			A02BA51	CIMETIDINE	2541			ANSM	355-MOCLOBEMIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring with possible adjustment of the dosage of moclobemide
N06BA07	MODAFINIL	30125			L04AD01	CICLOSPORIN	3008			ANSM	356-MODAFINIL.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
N06BA07	MODAFINIL	30125			S01XA18	CICLOSPORIN	3008			ANSM	356-MODAFINIL.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
N06BA07	MODAFINIL	30125						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	356-MODAFINIL.html	Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential	Not recommended	Use oral contraceptives containing estrogens and progestins that have 50 micrograms of estrogen or another method of contraception. 
N06BA07	MODAFINIL	30125			J05AX15	SOFOSBUVIR	1484911			ANSM	356-MODAFINIL.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil	Not recommended	
R03DC03	MONTELUKAST	88249						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	357-MONTELUKAST.html	Risk of loss of the effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoruing and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped. 
R03DC03	MONTELUKAST	88249			J04AB02	RIFAMPICIN	9384			ANSM	357-MONTELUKAST.html	Risk of loss of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
R03DC03	MONTELUKAST	88249			J04AM02	RIFAMPICIN	9384			ANSM	357-MONTELUKAST.html	Risk of loss of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
R03DC03	MONTELUKAST	88249			J04AM05	RIFAMPICIN	9384			ANSM	357-MONTELUKAST.html	Risk of loss of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
R03DC03	MONTELUKAST	88249			J04AM06	RIFAMPICIN	9384			ANSM	357-MONTELUKAST.html	Risk of loss of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
A07DA52	MORPHINE	7052			J04AB02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
A07DA52	MORPHINE	7052			J04AM02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
A07DA52	MORPHINE	7052			J04AM05	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
A07DA52	MORPHINE	7052			J04AM06	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA01	MORPHINE	7052			J04AB02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA01	MORPHINE	7052			J04AM02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA01	MORPHINE	7052			J04AM05	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA01	MORPHINE	7052			J04AM06	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA51	MORPHINE	7052			J04AB02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA51	MORPHINE	7052			J04AM02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA51	MORPHINE	7052			J04AM05	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AA51	MORPHINE	7052			J04AM06	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AG01	MORPHINE	7052			J04AB02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AG01	MORPHINE	7052			J04AM02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AG01	MORPHINE	7052			J04AM05	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
N02AG01	MORPHINE	7052			J04AM06	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
R05DA05	MORPHINE	7052			J04AB02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
R05DA05	MORPHINE	7052			J04AM02	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
R05DA05	MORPHINE	7052			J04AM05	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
R05DA05	MORPHINE	7052			J04AM06	RIFAMPICIN	9384			ANSM	358-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
			OPIOIDS	N0-R0				BARBITURATES	N05CA-001	ANSM	359-OPIOIDS.html	Increased risk of respiratory depression, which could be fatal in case of overdose	Take into account	
			OPIOIDS	N0-R0				BENZODIAZEPINES AND RELATED	N05-001	ANSM	359-OPIOIDS.html	Increased risk of respiratory depression, which could be fatal in case of overdose	Take into account	
L01XX35	ANAGRELIDE	596724			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events 	Not recommended	
L01XX35	ANAGRELIDE	596724						PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	36-ANAGRELIDE.html	Increase of hemorraghic events 	Not recommended	
L01XX35	ANAGRELIDE	596724						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	36-ANAGRELIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
			AGONIST-ANTAGONIST OPIOIDS 	NO2A-001				STEP II OPIOID ANALGESICS	N02A-003	ANSM	360-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome. 	Not recommended	
			AGONIST-ANTAGONIST OPIOIDS 	NO2A-001				STEP III OPIOID ANALGESICS	N02A-002	ANSM	360-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Contraindication	
			AGONIST-ANTAGONIST OPIOIDS 	NO2A-001				TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	360-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended 	
			AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	N02AC52	METHADONE	6813			ANSM	360-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the effect of the methadone due to competitive blocking of the receptors	Contraindication	
			AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	N07BC02	METHADONE	6813			ANSM	360-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the effect of the methadone due to competitive blocking of the receptors	Contraindication	
			AGONIST-ANTAGONIST OPIOIDS 	NO2A-001				PARTIAL AGONIST OPIOIDS	PARAG	ANSM	360-AGONIST-ANTAGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect and/or of appearance of a withdrawal syndrome	Contraindication	
			PARTIAL AGONIST OPIOIDS	PARAG				STEP II OPIOID ANALGESICS	N02A-003	ANSM	361-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect	Not Recommended	
			PARTIAL AGONIST OPIOIDS	PARAG				STEP III OPIOID ANALGESICS	N02A-002	ANSM	361-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect	Contraindication	
			PARTIAL AGONIST OPIOIDS	PARAG				AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	ANSM	361-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect and/or appearance of a withdrawal syndrome	Contraindication	
			PARTIAL AGONIST OPIOIDS	PARAG				OPIOIDS FOR REPLACEMENT THERAPY	N07BC	ANSM	361-PARTIAL-AGONIST-OPIOIDS.html	Risk of appearance of a withdrawal syndrome	Contraindication	
			OPIOIDS FOR REPLACEMENT THERAPY	N07BC				PARTIAL AGONIST OPIOIDS	PARAG	ANSM	362-OPIOIDS-FOR-REPLACEMENT-THERAPY.html	Risk of appearance of a withdrawal syndrome 	Contraindication	
L04AA06	MYCOPHENOLATE MOFETIL	7145						PROTON PUMP INHIBITORS	A02BC-001	ANSM	363-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
L04AA06	MYCOPHENOLATE MOFETIL	7145						FLUOROQUINOLONES	J01MA-001	ANSM	363-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
L04AA06	MYCOPHENOLATE MOFETIL	7145						AMINOPENICILLINS	J01CA	ANSM	363-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
L04AA06	MYCOPHENOLATE MOFETIL	7145						ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	363-MYCOPHENOLATE-MOFETIL.html	Risk of general vaccin disease, possibly fatal.	Contraindication	And during the 3 months following the end of the treatment
	MYCOPHENOLATE SODIUM 	408142						ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	364-MYCOPHENOLATE-SODIUM.html	Risk of general vaccine disease, possibly fatal 	Contraindication	And during the 3 months following the end of the treatment
C07AB12	NEBIVOLOL	31555			N06AB03	FLUOXETINE	4493			ANSM	365-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
C07AB12	NEBIVOLOL	31555			N06CA03	FLUOXETINE	4493			ANSM	365-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
C07BB12	NEBIVOLOL	31555			N06AB03	FLUOXETINE	4493			ANSM	365-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
C07BB12	NEBIVOLOL	31555			N06CA03	FLUOXETINE	4493			ANSM	365-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.
C07AB12	NEBIVOLOL	31555			N06AB05	PAROXETINE	32937			ANSM	365-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with notably excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. 
C07BB12	NEBIVOLOL	31555			N06AB05	PAROXETINE	32937			ANSM	365-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with notably excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. 
J05AE04	NELFINAVIR	134527						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	366-NELFINAVIR.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J05AE04	NELFINAVIR	134527			N02AE01	BUPRENORPHINE	1819			ANSM	366-NELFINAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
J05AE04	NELFINAVIR	134527			N07BC01	BUPRENORPHINE	1819			ANSM	366-NELFINAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
J05AE04	NELFINAVIR	134527			N07BC51	BUPRENORPHINE	1819			ANSM	366-NELFINAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
J05AE04	NELFINAVIR	134527			G04BD10	DARIFENACIN	136198			ANSM	366-NELFINAVIR.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J05AE04	NELFINAVIR	134527			A01AC02	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			C05AA09	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			D07AB19	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			D07XB05	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			D10AA03	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			H02AB02	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			R01AD03	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S01BA01	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S01CB01	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S02BA06	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S03BA01	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			D07CB04	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S01CA01	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S02CA06	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			S03CA01	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527			R01AD53	DEXAMETHASONE	3264			ANSM	366-NELFINAVIR.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J05AE04	NELFINAVIR	134527						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	366-NELFINAVIR.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive	Not recommended	Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these substances together and a cycle after. 
J05AE04	NELFINAVIR	134527						IMMUNOSUPPRESSANTS	L04A	ANSM	366-NELFINAVIR.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 
J05AE04	NELFINAVIR	134527			N02AC52	METHADONE	6813			ANSM	366-NELFINAVIR.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the nelfinavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone. 
J05AE04	NELFINAVIR	134527			N07BC02	METHADONE	6813			ANSM	366-NELFINAVIR.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the nelfinavir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone. 
J05AE04	NELFINAVIR	134527			A02BC01	OMEPRAZOLE	7646			ANSM	366-NELFINAVIR.html	Risk of large decrease of the plasma concentrations of the nelfinavir and of its active metabolite due to decrease of its digestive absorption by the omeprazole	Contraindication	
J05AE04	NELFINAVIR	134527			A02BD05	OMEPRAZOLE	7646			ANSM	366-NELFINAVIR.html	Risk of large decrease of the plasma concentrations of the nelfinavir and of its active metabolite due to decrease of its digestive absorption by the omeprazole	Contraindication	
J05AE04	NELFINAVIR	134527			A02BD01	OMEPRAZOLE	7646			ANSM	366-NELFINAVIR.html	Risk of large decrease of the plasma concentrations of the nelfinavir and of its active metabolite due to decrease of its digestive absorption by the omeprazole	Contraindication	
J05AE04	NELFINAVIR	134527						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	366-NELFINAVIR.html	Risk of decrease of the plasma concentrations of the phenytoin due to increase of its hepatic metabolism by the nelfinavir	Precaution for use	Clinical monitoring and laboratory tests. Possible adjustment of the dosage of the phenytoin during the treatment with nelfinavir.
J05AE04	NELFINAVIR	134527						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	366-NELFINAVIR.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of hormonal contraceptive	Not recommended	Another contraceptive method, in particular of the barrier type (condom or IUD), should be used during the length of the administration of the substances together and one cycle following.
J05AE04	NELFINAVIR	134527			G04BD08	SOLIFENACIN	322167			ANSM	366-NELFINAVIR.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J05AE04	NELFINAVIR	134527			G04CA53	SOLIFENACIN	322167			ANSM	366-NELFINAVIR.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J05AE04	NELFINAVIR	134527			N06AX16	VENLAFAXINE	39786			ANSM	366-NELFINAVIR.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
J05AE04	NELFINAVIR	134527			N05CF02	ZOLPIDEM	39993			ANSM	366-NELFINAVIR.html	Slight increase of the sedative effects of the zolpidem	Take into account	
J05AE04	NELFINAVIR	134527			N05CF01	ZOPICLONE	40001			ANSM	366-NELFINAVIR.html	Slight increase of the sedative effects of the zopiclone	Take into account	
			NEUROLEPTICS	N05AA-003				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	367-NEUROLEPTICS.html	Vasidilator effect and risks of hypotension, especially orthostatic (additive effect)	Take into account	
			NEUROLEPTICS	N05AA-003	D11AX04	LITHIUM	6448			ANSM	367-NEUROLEPTICS.html	Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
			NEUROLEPTICS	N05AA-003	A08AB01	ORLISTAT	37925			ANSM	367-NEUROLEPTICS.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
			ANTIEMITIC NEUROLEPTICS	A03FA-001				DOPAMINERGICS	N04B-002	ANSM	368-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the dopaminergic and the neuropleptic	Contraindication	Use an antiemetic without extrapyramidal effects. 
			ANTIEMITIC NEUROLEPTICS	A03FA-001	N04BA01	LEVODOPA	6375			ANSM	368-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the levodopa and the neuroleptic	Contraindication	Use an antiemitic without extrapyramidal effects.
			ANTIEMITIC NEUROLEPTICS	A03FA-001	N04BA02	LEVODOPA	6375			ANSM	368-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the levodopa and the neuroleptic	Contraindication	Use an antiemitic without extrapyramidal effects.
			ANTIEMITIC NEUROLEPTICS	A03FA-001	N04BA03	LEVODOPA	6375			ANSM	368-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the levodopa and the neuroleptic	Contraindication	Use an antiemitic without extrapyramidal effects.
			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001				ANTIPARKINSONIAN DOPAMINERGICS	N04B-001	ANSM	369-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).	Not recommended	
			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001				DOPAMINERGICS, EXCEPT PARKINSON	G02CB-002	ANSM	369-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the dopamine agonist and the neuroleptics	Contraindication	
			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	N04BA01	LEVODOPA	6375			ANSM	369-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dose of each of the medications. 
			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	N04BA02	LEVODOPA	6375			ANSM	369-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dose of each of the medications. 
			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	N04BA03	LEVODOPA	6375			ANSM	369-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the levodopa and the neuroleptics	Not recommended	With a parkinsons patient, use the minimum effective dose of each of the medications. 
L04AC03	ANAKINRA	72435			L04AB01	ETANERCEPT	214555			ANSM	37-ANAKINRA.html	Increased risk of serious infections and neutropenia	Not recommended	
			NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES	N05A-002				MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	370-NEUROLEPTICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	-with the citalopram, the escitalopram, the domperidone, or the hydroxyzine
J05AG01	NEVIRAPINE	53654						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AR07	NEVIRAPINE	53654						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AR05	NEVIRAPINE	53654						AMPRENAVIR (AND, BY EXTRAPOLATION, FOSAMPRENAVIR)	J05AE0-001	ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AG01	NEVIRAPINE	53654						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	371-NEVIRAPINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
J05AR07	NEVIRAPINE	53654						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	371-NEVIRAPINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
J05AR05	NEVIRAPINE	53654						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	371-NEVIRAPINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
J05AG01	NEVIRAPINE	53654			J05AE08	ATAZANAVIR	343047			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AR07	NEVIRAPINE	53654			J05AE08	ATAZANAVIR	343047			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AR05	NEVIRAPINE	53654			J05AE08	ATAZANAVIR	343047			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AG01	NEVIRAPINE	53654			D01AC15	FLUCONAZOLE	4450			ANSM	371-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J05AG01	NEVIRAPINE	53654			J02AC01	FLUCONAZOLE	4450			ANSM	371-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J05AR07	NEVIRAPINE	53654			D01AC15	FLUCONAZOLE	4450			ANSM	371-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J05AR07	NEVIRAPINE	53654			J02AC01	FLUCONAZOLE	4450			ANSM	371-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J05AR05	NEVIRAPINE	53654			D01AC15	FLUCONAZOLE	4450			ANSM	371-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J05AR05	NEVIRAPINE	53654			J02AC01	FLUCONAZOLE	4450			ANSM	371-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the nevirapine.
J05AG01	NEVIRAPINE	53654			J05AE02	INDINAVIR	114289			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
J05AR07	NEVIRAPINE	53654			J05AE02	INDINAVIR	114289			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
J05AR05	NEVIRAPINE	53654			J05AE02	INDINAVIR	114289			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together.
J05AG01	NEVIRAPINE	53654			D01AC08	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AG01	NEVIRAPINE	53654			G01AF11	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AG01	NEVIRAPINE	53654			J02AB02	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AR07	NEVIRAPINE	53654			D01AC08	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AR07	NEVIRAPINE	53654			G01AF11	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AR07	NEVIRAPINE	53654			J02AB02	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AR05	NEVIRAPINE	53654			D01AC08	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AR05	NEVIRAPINE	53654			G01AF11	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AR05	NEVIRAPINE	53654			J02AB02	KETOCONAZOLE	6135			ANSM	371-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 	Contraindication	
J05AG01	NEVIRAPINE	53654				ST JOHNS WORT	258326			ANSM	371-NEVIRAPINE.html	Risk of significant decrease of the plasma concentrations of the nevirapiine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
J05AR07	NEVIRAPINE	53654				ST JOHNS WORT	258326			ANSM	371-NEVIRAPINE.html	Risk of significant decrease of the plasma concentrations of the nevirapiine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
J05AR05	NEVIRAPINE	53654				ST JOHNS WORT	258326			ANSM	371-NEVIRAPINE.html	Risk of significant decrease of the plasma concentrations of the nevirapiine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
J05AG01	NEVIRAPINE	53654			J04AB02	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AG01	NEVIRAPINE	53654			J04AM02	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AG01	NEVIRAPINE	53654			J04AM05	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AG01	NEVIRAPINE	53654			J04AM06	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR07	NEVIRAPINE	53654			J04AB02	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR07	NEVIRAPINE	53654			J04AM02	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR07	NEVIRAPINE	53654			J04AM05	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR07	NEVIRAPINE	53654			J04AM06	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR05	NEVIRAPINE	53654			J04AB02	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR05	NEVIRAPINE	53654			J04AM02	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR05	NEVIRAPINE	53654			J04AM05	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AR05	NEVIRAPINE	53654			J04AM06	RIFAMPICIN	9384			ANSM	371-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J05AG01	NEVIRAPINE	53654			J02AC03	VORICONAZOLE	121243			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.
J05AR07	NEVIRAPINE	53654			J02AC03	VORICONAZOLE	121243			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.
J05AR05	NEVIRAPINE	53654			J02AC03	VORICONAZOLE	121243			ANSM	371-NEVIRAPINE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.
C08CA04	NICARDIPINE	7396						IMMUNOSUPPRESSANTS	L04A	ANSM	372-NICARDIPINE.html	Increase of the blood concentrations of the immunosuppressant, due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment with nicardipine and after it is stopped.
C08CA05	NIFEDIPINE	7417			L04AD01	CICLOSPORIN	3008			ANSM	373-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
C08CA05	NIFEDIPINE	7417			S01XA18	CICLOSPORIN	3008			ANSM	373-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
C08GA01	NIFEDIPINE	7417			L04AD01	CICLOSPORIN	3008			ANSM	373-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
C08GA01	NIFEDIPINE	7417			S01XA18	CICLOSPORIN	3008			ANSM	373-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
C08CA55	NIFEDIPINE	7417			L04AD01	CICLOSPORIN	3008			ANSM	373-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
C08CA55	NIFEDIPINE	7417			S01XA18	CICLOSPORIN	3008			ANSM	373-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	Use another dihydropyridine
C08CA05	NIFEDIPINE	7417			A02BA01	CIMETIDINE	2541			ANSM	373-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
C08CA05	NIFEDIPINE	7417			A02BA51	CIMETIDINE	2541			ANSM	373-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
C08GA01	NIFEDIPINE	7417			A02BA01	CIMETIDINE	2541			ANSM	373-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
C08GA01	NIFEDIPINE	7417			A02BA51	CIMETIDINE	2541			ANSM	373-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
C08CA55	NIFEDIPINE	7417			A02BA01	CIMETIDINE	2541			ANSM	373-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
C08CA55	NIFEDIPINE	7417			A02BA51	CIMETIDINE	2541			ANSM	373-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 
C08CA05	NIFEDIPINE	7417			C08DB01	DILTIAZEM	3443			ANSM	373-NIFEDIPINE.html	Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08GA01	NIFEDIPINE	7417			C08DB01	DILTIAZEM	3443			ANSM	373-NIFEDIPINE.html	Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08CA55	NIFEDIPINE	7417			C08DB01	DILTIAZEM	3443			ANSM	373-NIFEDIPINE.html	Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	Contraindication	
C08CA06	NIMODIPINE	7426						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	374-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped
C08CA06	NIMODIPINE	7426			J04AB02	RIFAMPICIN	9384			ANSM	374-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
C08CA06	NIMODIPINE	7426			J04AM02	RIFAMPICIN	9384			ANSM	374-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
C08CA06	NIMODIPINE	7426			J04AM05	RIFAMPICIN	9384			ANSM	374-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
C08CA06	NIMODIPINE	7426			J04AM06	RIFAMPICIN	9384			ANSM	374-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
C08CA06	NIMODIPINE	7426						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	374-NIMODIPINE.html	With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid).	Take into account	
J01MA06	NORFLOXACIN	7517			N06BC01	CAFFEINE 	1886			ANSM	375-NORFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
J01MA06	NORFLOXACIN	7517			V04CG30	CAFFEINE 	1886			ANSM	375-NORFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
S01AE02	NORFLOXACIN	7517			N06BC01	CAFFEINE 	1886			ANSM	375-NORFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
S01AE02	NORFLOXACIN	7517			V04CG30	CAFFEINE 	1886			ANSM	375-NORFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
J01MA06	NORFLOXACIN	7517						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	375-NORFLOXACIN.html	Increased risk of ventricular arrhythmias, especially of torsades de points. 	Precaution for use	Clinical monitoring and EKG during the administration of theses substances together. 
S01AE02	NORFLOXACIN	7517						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	375-NORFLOXACIN.html	Increased risk of ventricular arrhythmias, especially of torsades de points. 	Precaution for use	Clinical monitoring and EKG during the administration of theses substances together. 
J01MA06	NORFLOXACIN	7517						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	375-NORFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. 
S01AE02	NORFLOXACIN	7517						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	375-NORFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. 
N06AA10	NORTRIPTYLINE	7531			N06AX12	BUPROPION	42347			ANSM	376-NORTRIPTYLINE.html	Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.
R05DA07	NOSCAPINE	7533						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	377-NOSCAPINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
N05AH03	OLANZAPINE	61381			N03AF01	CARBAMAZEPINE	2002			ANSM	378-OLANZAPINE.html	Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine. 
N05AH03	OLANZAPINE	61381			N06AB08	FLUVOXAMINE	42355			ANSM	378-OLANZAPINE.html	Increase of the concentrations of the olanzapine, with risk of increase of its undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.
			OMBITASVIR + PARITAPREVIR 	OMPA	D06AX01	FUSIDIC ACID	4608			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	D09AA02	FUSIDIC ACID	4608			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	J01XC01	FUSIDIC ACID	4608			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	S01AA13	FUSIDIC ACID	4608			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA				VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G04CA01	ALFUZOSIN	17300			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	C01BD01	AMIODARONE	703			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	C10AA05	ATORVASTATIN	83367			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	M04AC01	COLCHICINE	2683			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the bitherapy.	Contraindication	with patients having renal and/or hepatic insufficiency
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA15	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AB07	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA09	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AB05	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA12	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03CA01	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	L02AA03	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA01	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA10	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AB06	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA07	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AB03	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AA03	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G03AB02	ETHINYLESTRADIOL	4124			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA				ENZYMATIC INDUCERS	N03-J05-001	ANSM	379-OMBITASVIR + PARITAPREVIR.html	Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA				STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the bitherapy due to decrease of its hepatic metabolism by the inhibitor	Contraindication	-except with the ritonavir
			OMBITASVIR + PARITAPREVIR 	OMPA	N05CD08	MIDAZOLAM	6960			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	N05AG02	PIMOZIDE	8331			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	N05AH04	QUETIAPINE	51272			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	C01BA01	QUINIDINE	9068			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	C01BA51	QUINIDINE	9068			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	C01BA71	QUINIDINE	9068			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	G04BE03	SILDENAFIL	136411			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	C10AA01	SIMVASTATIN	36567			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			OMBITASVIR + PARITAPREVIR 	OMPA	B01AC24	TICAGRELOR	1116632			ANSM	379-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the bitherapy	Contraindication	
			AGONIST OPIOID ANALGESICS	N01A-N02A				AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
			AGONIST OPIOID ANALGESICS	N01A-N02A				MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
			AGONIST OPIOID ANALGESICS	N01A-N02A				TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression which can be fatal in cases of overdose	Take into account	
A02BC01	OMEPRAZOLE	7646			C01AA05	DIGOXIN 	3407			ANSM	380-OMEPRAZOLE.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 
A02BD05	OMEPRAZOLE	7646			C01AA05	DIGOXIN 	3407			ANSM	380-OMEPRAZOLE.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 
A02BD01	OMEPRAZOLE	7646			C01AA05	DIGOXIN 	3407			ANSM	380-OMEPRAZOLE.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 
A02BC01	OMEPRAZOLE	7646			J05AE04	NELFINAVIR	134527			ANSM	380-OMEPRAZOLE.html	Risk of large decrease of the plasma concentrations of the nelfinavir and of its active metabolite due to decrease of its digestive absorption by the omeprazole	Contraindication	
A02BD05	OMEPRAZOLE	7646			J05AE04	NELFINAVIR	134527			ANSM	380-OMEPRAZOLE.html	Risk of large decrease of the plasma concentrations of the nelfinavir and of its active metabolite due to decrease of its digestive absorption by the omeprazole	Contraindication	
A02BD01	OMEPRAZOLE	7646			J05AE04	NELFINAVIR	134527			ANSM	380-OMEPRAZOLE.html	Risk of large decrease of the plasma concentrations of the nelfinavir and of its active metabolite due to decrease of its digestive absorption by the omeprazole	Contraindication	
A02BC01	OMEPRAZOLE	7646			D11AH01	TACROLIMUS	42316			ANSM	380-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
A02BC01	OMEPRAZOLE	7646			L04AD02	TACROLIMUS	42316			ANSM	380-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
A02BD05	OMEPRAZOLE	7646			D11AH01	TACROLIMUS	42316			ANSM	380-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
A02BD05	OMEPRAZOLE	7646			L04AD02	TACROLIMUS	42316			ANSM	380-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
A02BD01	OMEPRAZOLE	7646			D11AH01	TACROLIMUS	42316			ANSM	380-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
A02BD01	OMEPRAZOLE	7646			L04AD02	TACROLIMUS	42316			ANSM	380-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
A04AA01	ONDANSETRON	26225			G04BE07	APOMORPHINE	1043			ANSM	381-ONDANSETRON.html	Severe hypotension and loss of consciousness have been reported when ondansetron is administered with apomorphine	Contraindication	
A04AA01	ONDANSETRON	26225			N04BC07	APOMORPHINE	1043			ANSM	381-ONDANSETRON.html	Severe hypotension and loss of consciousness have been reported when ondansetron is administered with apomorphine	Contraindication	
A04AA01	ONDANSETRON	26225			N02AX02	TRAMADOL	10689			ANSM	381-ONDANSETRON.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemetic effect of the ondansetron	Take into account	
A04AA01	ONDANSETRON	26225			N02AX52	TRAMADOL	10689			ANSM	381-ONDANSETRON.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemetic effect of the ondansetron	Take into account	
A04AA01	ONDANSETRON	26225						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	382-ONDANSTRON.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes 	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
M01CB	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
M01CB01	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
M01CB02	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
M01CB03	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
M01CB04	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
M01CB05	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
V10AX06	GOLD	691572						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	383-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA				AMINOGLYCOSIDES	J01GB-001	ANSM	384-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html	Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency	Take into account	
			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA				LOOP DIURETICS	C03CA-001	ANSM	384-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html	Risk of addition of the ototoxic and/or nephrotoxic effects	Take into account	
A08AB01	ORLISTAT	37925			C01BD01	AMIODARONE	703			ANSM	385-ORLISTAT.html	Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite	Precaution for use	Clinical monitoring and, if needed, EKG
A08AB01	ORLISTAT	37925						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	385-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
A08AB01	ORLISTAT	37925						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	385-ORLISTAT.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped. 
A08AB01	ORLISTAT	37925			L04AD01	CICLOSPORIN	3008			ANSM	385-ORLISTAT.html	Decrease of the blood concentrations of the ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	Take the orlistat at a different time from the ciclosporin (at least three hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the two medications together, and at the time of a possible increase in the dosage of the orlistat.
A08AB01	ORLISTAT	37925			S01XA18	CICLOSPORIN	3008			ANSM	385-ORLISTAT.html	Decrease of the blood concentrations of the ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	Take the orlistat at a different time from the ciclosporin (at least three hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the two medications together, and at the time of a possible increase in the dosage of the orlistat.
A08AB01	ORLISTAT	37925						THYROID HORMONES	H03AA	ANSM	385-ORLISTAT.html	Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat	Take into account 	
A08AB01	ORLISTAT 	37925						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	385-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
A08AB01	ORLISTAT	37925			D11AX04	LITHIUM	6448			ANSM	385-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
A08AB01	ORLISTAT	37925						MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	385-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
A08AB01	ORLISTAT	37925						NEUROLEPTICS	N05AA-003	ANSM	385-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
A08AB01	ORLISTAT	37925						VITAMIN D	A11CC	ANSM	385-ORLISTAT.html	Decrease of the absorption of the vitamin D	Take into account	
G01AF06	ORNIDAZOLE	7701						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	386-ORNIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
J01XD03	ORNIDAZOLE	7701						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	386-ORNIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
P01AB03	ORNIDAZOLE	7701						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	386-ORNIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
N03AF02	OXCARBAZEPINE	32624						NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	387-OXCARBAZEPINE.html	Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with the oxcarbazepine and after it is stopped.
N03AF02	OXCARBAZEPINE	32624			N03AX09	LAMOTRIGINE	28439			ANSM	387-OXCARBAZEPINE.html	Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.
N03AF02	OXCARBAZEPINE	32624			N03AX22	PERAMPANEL	1356552			ANSM	387-OXCARBAZEPINE.html	Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.	Take into account	
N03AF02	OXCARBAZEPINE	32624			38404	TOPIRAMATE	38404			ANSM	387-OXCARBAZEPINE.html	Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped. 
C07AA02	OXPRENOLOL	7801			N02CA02	ERGOTAMINE	4025			ANSM	388-OXPRENOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together. 
C07AA02	OXPRENOLOL	7801			N02CA51	ERGOTAMINE	4025			ANSM	388-OXPRENOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together. 
C07AA02	OXPRENOLOL	7801			N02CA52	ERGOTAMINE	4025			ANSM	388-OXPRENOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together. 
C07AA02	OXPRENOLOL	7801			N02CA72	ERGOTAMINE	4025			ANSM	388-OXPRENOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together. 
N02AA05	OXYCODONE	7804						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	389-OXYCODONE.html	Increase of the plasma concentrations of the oxycodone	Not recommended	Clinical monitoring and possible adjustment of the dosage of oxycodone during the length of the treatment with the enzyme inhibitor.
N02AA55	OXYCODONE	7804						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	389-OXYCODONE.html	Increase of the plasma concentrations of the oxycodone	Not recommended	Clinical monitoring and possible adjustment of the dosage of oxycodone during the length of the treatment with the enzyme inhibitor.
			STEP II OPIOID ANALGESICS	N02A-003				AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	ANSM	39-STEP-II-OPIOID-ANALGESICS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
			STEP II OPIOID ANALGESICS	N02A-003				PARTIAL AGONIST OPIOIDS	PARAG	ANSM	39-STEP-II-OPIOID-ANALGESICS.html	Risk of decrease of the antalgic effect	Not recommended	
N02BE01	PARACETAMOL	161						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	390-PARACETAMOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the paracetamol and after it is stopped. 
N02BE51	PARACETAMOL	161						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	390-PARACETAMOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the paracetamol and after it is stopped. 
N02BE71	PARACETAMOL	161						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	390-PARACETAMOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the paracetamol and after it is stopped. 
N06AB05	PAROXETINE	32937			N06BA09	ATOMOXETINE	38400			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the atomoxetine due to substantial decrease of its hepatic metabolism 	Not recommended	If it is not possible to avoid administering the two medications together, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped
N06AB05	PAROXETINE	32937			N03AF01	CARBAMAZEPINE	2002			ANSM	391-PAROXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 
N06AB05	PAROXETINE	32937			R06AD07	MEQUITAZINE	29528			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
N06AB05	PAROXETINE	32937			C07AB02	METOPROLOL	6918			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Contraindication:	-with the metoprolol used for heart failure
N06AB05	PAROXETINE	32937			C07FB02	METOPROLOL	6918			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Contraindication:	-with the metoprolol used for heart failure
N06AB05	PAROXETINE	32937			C07CB02	METOPROLOL	6918			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Contraindication:	-with the metoprolol used for heart failure
N06AB05	PAROXETINE	32937			C07BB02	METOPROLOL	6918			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Contraindication:	-with the metoprolol used for heart failure
N06AB05	PAROXETINE	32937			C07BB52	METOPROLOL	6918			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Contraindication:	-with the metoprolol used for heart failure
N06AB05	PAROXETINE	32937			C07AB52	METOPROLOL	6918			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with notably excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Contraindication:	-with the metoprolol used for heart failure
N06AB05	PAROXETINE	32937			C07AB12	NEBIVOLOL	31555			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with notably excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. 
N06AB05	PAROXETINE	32937			C07BB12	NEBIVOLOL	31555			ANSM	391-PAROXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with notably excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. 
N06AB05	PAROXETINE	32937			N05AG02	PIMOZIDE	8331			ANSM	391-PAROXETINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N06AB05	PAROXETINE	32937			N05AX08	RISPERIDONE	35636			ANSM	391-PAROXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. 	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. 
N06AB05	PAROXETINE	32937			L02BA01	TAMOXIFEN	10324			ANSM	391-PAROXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine	Not recommended	
J01MA03	PEFLOXACIN	7960						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	392-PEFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
L03AB11	PEG-INTERFERON ALFA-2A	120608			J05AF11	TELBIVUDINE	474128			ANSM	393-PEG-INTERFERON-ALFA-2A.html	Increased risk of peripheral neuropathy	Contraindication	
L03AB61	PEG-INTERFERON ALFA-2A	120608			J05AF11	TELBIVUDINE	474128			ANSM	393-PEG-INTERFERON-ALFA-2A.html	Increased risk of peripheral neuropathy	Contraindication	
L01BA04	PEMETREXED	68446			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	-with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml/min).
L01BA04	PEMETREXED	68446						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	394-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)	Not recommended	with patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml.min)
			PENEMS	J01DH				VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	395-PENEMS.html	Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable.	Not recommended	
M01CC01	PENICILLAMINE	7975			B03A	IRON	1431589			ANSM	396-PENICILLAMINE.html	Decrease of the digestive absorption of the penicillamine	Precaution for use	Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).
			PENICILLINS	J01C	L01BA01	METHOTREXATE	6851			ANSM	397-PENICILLINS.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
			PENICILLINS	J01C	L04AX03	METHOTREXATE	6851			ANSM	397-PENICILLINS.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
			AMINOPENICILLINS	J01CA	M04AA01	ALLOPURINOL	519			ANSM	398-AMINOPENICILLINS.html	Increased risk of cutaneous reactions	Take into account	
			AMINOPENICILLINS	J01CA	L04AA06	MYCOPHENOLATE MOFETIL	7145			ANSM	398-AMINOPENICILLINS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
P01CX01	PENTAMIDINE	7994			J05AF02	DIDANOSINE	3364			ANSM	399-PENTAMIDINE.html	Increased risk of onset of pancreatitis due to addition of undesirable effects	Precaution for use	Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. 
P01CX01	PENTAMIDINE	7994			J05AD01	FOSCARNET	33562			ANSM	399-PENTAMIDINE.html	Risk of severe hypocalcemia	Precaution for use	Monitoring of the calcemia and supplementation if necessary.
P01CX01	PENTAMIDINE	7994			J05AF04	STAVUDINE	59763			ANSM	399-PENTAMIDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together
P01CX01	PENTAMIDINE	7994			J05AR07	STAVUDINE	59763			ANSM	399-PENTAMIDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together
P01CX01	PENTAMIDINE	7994			J05AF03	ZALCITABINE	3363			ANSM	399-PENTAMIDINE.html	Increased risk of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together
G04BX03	ACETOHYDROXAMIC ACID	16728			B03A	IRON	1431589			ANSM	4-ACETOHYDROXAMIC ACID.html	Decrease of the digestive absorption of these two medications due to chelation of the iron	Take into account	
			STEP III OPIOID ANALGESICS	N02A-002				AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	ANSM	40-STEP-III-OPIOID-ANALGESICS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Contraindication	
			STEP III OPIOID ANALGESICS	N02A-002				PARTIAL AGONIST OPIOIDS	PARAG	ANSM	40-STEP-III-OPIOID-ANALGESICS.html	Risk of decrease of the antalgic effect	Contraindication	
L01XX08	PENTOSTATIN	8011			L01AA01	CYCLOPHOSPHAMIDE	3002			ANSM	400-PENTOSTATIN.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
L01XX08	PENTOSTATIN	8011			L01BB05	FLUDARABINE	24698			ANSM	400-PENTOSTATIN.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
C04AD03	PENTOXIFYLLINE	8013						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	401-PENTOXIFYLLINE.html	Increase of the hemorrhagic risk	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped.
C04AD03	PENTOXIFYLLINE	8013						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	401-PENTOXIFYLLINE.html	Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped.
N03AX22	PERAMPANEL	1356552						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	402-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
N03AX22	PERAMPANEL	1356552			N03AF02	OXCARBAZEPINE	32624			ANSM	402-PERAMPANEL.html	Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.	Take into account	
N03AX22	PERAMPANEL	1356552						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	402-PERAMPANEL.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used.
N03AX22	PERAMPANEL	1356552			J04AB02	RIFAMPICIN	9384			ANSM	402-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
N03AX22	PERAMPANEL	1356552			J04AM02	RIFAMPICIN	9384			ANSM	402-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
N03AX22	PERAMPANEL	1356552			J04AM05	RIFAMPICIN	9384			ANSM	402-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
N03AX22	PERAMPANEL	1356552			J04AM06	RIFAMPICIN	9384			ANSM	402-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
N02AB02	PETHIDINE 	6754						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AB52	PETHIDINE 	6754						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AB72	PETHIDINE 	6754						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AG03	PETHIDINE 	6754						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AB02	PETHIDINE 	6754						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
N02AB52	PETHIDINE 	6754						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
N02AB72	PETHIDINE 	6754						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
N02AG03	PETHIDINE 	6754						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	403-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	Contraindication	
N02AB02	PETHIDINE 	6754						MAOI-B 	N04BD0-001	ANSM	403-PETHIDINE.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AB52	PETHIDINE 	6754						MAOI-B 	N04BD0-001	ANSM	403-PETHIDINE.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AB72	PETHIDINE 	6754						MAOI-B 	N04BD0-001	ANSM	403-PETHIDINE.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N02AG03	PETHIDINE 	6754						MAOI-B 	N04BD0-001	ANSM	403-PETHIDINE.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Contraindication	
N03AA02	PHENOBARBITAL	8134			A05AA03	CHOLIC ACID	1440856			ANSM	404-PHENOBARBITAL.html	Antagonist effect of the phenobarbital	Contraindication	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	N03AF01	CARBAMAZEPINE	2002			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness	Take into account	Use prudence with respect to the interpretation of the plasma concentrations.
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C01AA04	DIGITOXIN	3403			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations and of the effectiveness of the digotoxin (increase of its hepatic metabolism)	Precaution for use	Clinical monitoring, EKG, and, possibly, monitoring of the digitoxinemia. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after the phenobarbital is stopped, or choose digoxin, less metabolized by the liver. 
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	N03AX10	FELBAMATE	24812			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed. 
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001				FOLATES	V03-	ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	L01AA06	IFOSFAMIDE	5657			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital	Not recommended	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07AB02	METOPROLOL	6918			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07FB02	METOPROLOL	6918			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07CB02	METOPROLOL	6918			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07BB02	METOPROLOL	6918			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07BB52	METOPROLOL	6918			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07AB52	METOPROLOL	6918			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001				PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)In cases of previous treatment with the pheyntoin and the addition of phenobarbital or of primidone, unpredictable changes:--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	C07AA05	PROPRANOLOL	8787			ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001				VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	405-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Increase of the plasma concentrations of the phenobarbital, with signs of overdose, due to inhibition of the hepatic metabolism, most often with children. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the phenobarbital	Precaution for use	Clinical monitoring during the first two weeks of the administration of these substances together and immediate reduction of the doses of phenobarbital at the appearance of the signs of sedation, test especially the plasma concentrations of the two anticonvulsants. 
M01AA01	PHENYLBUTAZONE	8160						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the NSAI)	Contraindication	
M02AA01	PHENYLBUTAZONE	8160						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the NSAI)	Contraindication	
M01BA01	PHENYLBUTAZONE	8160						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the NSAI)	Contraindication	
M01AA01	PHENYLBUTAZONE	8160			AUROTIOP	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M01AA01	PHENYLBUTAZONE	8160			46680	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M01AA01	PHENYLBUTAZONE	8160			M01CB05	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M02AA01	PHENYLBUTAZONE	8160			AUROTIOP	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M02AA01	PHENYLBUTAZONE	8160			46680	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M02AA01	PHENYLBUTAZONE	8160			M01CB05	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M01BA01	PHENYLBUTAZONE	8160			AUROTIOP	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M01BA01	PHENYLBUTAZONE	8160			46680	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M01BA01	PHENYLBUTAZONE	8160			M01CB05	SODIUM AUROTHIOPROPANOL-SULFONATE				ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia. 	Not recommended	Another NSAI that is less interactive should be used. 
M01AA01	PHENYLBUTAZONE	8160						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the hypoglycemic effect of the sulfonamides due to decrease of their hepatic metabolism	Not recommended	Another anti-inflammatory that is less interactive should be used: if not, inform the patient and reinforce self-monitoring of blood glucose; possibly adjust the dosage during the treatment with the anti-inflammatory and after it is stopped. 
M02AA01	PHENYLBUTAZONE	8160						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the hypoglycemic effect of the sulfonamides due to decrease of their hepatic metabolism	Not recommended	Another anti-inflammatory that is less interactive should be used: if not, inform the patient and reinforce self-monitoring of blood glucose; possibly adjust the dosage during the treatment with the anti-inflammatory and after it is stopped. 
M01BA01	PHENYLBUTAZONE	8160						BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	406-PHENYLBUTAZONE.html	For all the forms of phenylbutazone, including topical: increase of the hypoglycemic effect of the sulfonamides due to decrease of their hepatic metabolism	Not recommended	Another anti-inflammatory that is less interactive should be used: if not, inform the patient and reinforce self-monitoring of blood glucose; possibly adjust the dosage during the treatment with the anti-inflammatory and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	C01BD01	AMIODARONE	703			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)	Precaution for use	Clinical monitoring, testing of plasma concentrations of phenytoin, and possible adjustment of its dosage 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N03AF01	CARBAMAZEPINE	2002			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)	Take into account	Use prudence in the interpretation of the plasma concentrations. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	A02BA01	CIMETIDINE	2541			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	A02BA51	CIMETIDINE	2541			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J01MA02	CIPROFLOXACIN	2551			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	S01AE03	CIPROFLOXACIN	2551			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	S02AA15	CIPROFLOXACIN	2551			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	S03AA07	CIPROFLOXACIN	2551			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin	Precaution for use	Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	B01AC04	CLOPIDOGREL	32968			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N05AH02	CLOZAPINE	2626			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB				CYTOTOXICS	L01	ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of the effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin	Not recommended	
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N05BA01	DIAZEPAM	3322			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N07BB01	DISULFIRAM	3554			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)	Not recommended	If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phentoin during the treatment with the disulfiram and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N03AX10	FELBAMATE	24812			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate	Precaution for use	Clinical monitoring, testing of the plasma concentrations of phentoin, and if needed adjustment of its dosage during the treatment with the felbamate.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	D01AC15	FLUCONAZOLE	4450			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	Strict clinical monitoring and laboratory tests.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J02AC01	FLUCONAZOLE	4450			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	Strict clinical monitoring and laboratory tests.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N06AB03	FLUOXETINE	4493			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with fluoxetine and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N06CA03	FLUOXETINE	4493			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with fluoxetine and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	N06AB08	FLUVOXAMINE	42355			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdosage, due to inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Cinical monitoring and possibly testing of the plasmatic concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB				FOLATES	V03-	ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	C03CA01	FUROSEMIDE	460			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	C03CB01	FUROSEMIDE	460			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	C03EB01	FUROSEMIDE	460			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the diuretic effect which can reach 50%	Precaution for use	Possibly use higher doses of furosemide.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AM03	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AC01	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AC51	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AM02	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AM05	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AM06	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AM01	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J04AM04	ISONIAZID	6038			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	V04CD01	METYRAPONE	6923			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.	Precaution for use	Double the dosage of the metyrapone.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	C01BB02	MEXILETINE	6926			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)	Precaution for use	Clinical monitoring, EKG, and, possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	A01AB09	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	A07AC01	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	D01AC02	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	G01AF04	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J02AB01	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	S02AA13	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	D01AC52	MICONAZOLE	6932			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	Strict clinical monitoring. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J05AE04	NELFINAVIR	134527			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of decrease of the plasma concentrations of the phenytoin due to increase of its hepatic metabolism by the nelfinavir	Precaution for use	Clinical monitoring and laboratory tests. Possible adjustment of the dosage of the phenytoin during the treatment with nelfinavir.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB				PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)In cases of previous treatment with the phenytoin and the addition of phenobarbital or of primidone, unpredictable changes:--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)	Take into account	
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	A02BX02	SUCRALFATE	10156			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the digestive absorption of the phenytoin.	Precaution for use	Take the sucralfate at a different time from the phenytoin (more than 2 hours apart if possible).
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J01EB05	SULFAFURAZOLE	10207			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	S01AB02	SULFAFURAZOLE	10207			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	B05CA04	SULFAMETHIZOLE	10179			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	D06BA04	SULFAMETHIZOLE	10179			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J01EB02	SULFAMETHIZOLE	10179			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	S01AB01	SULFAMETHIZOLE	10179			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J01EC01	SULFAMETHOXAZOLE	10180			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism). 	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	J01EE01	SULFAMETHOXAZOLE	10180			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism). 	Not recommended	Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	B01AC05	TICLOPIDINE	10594			ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin).	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB				VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	407-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation of the plasma concentrations of phenytoin. In addition, risk of decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the phenytoin.	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the two anticonvulsants. 
N07AX01	PILOCARPINE	8328						ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	ANSM	408-PILOCARPINE.html	Risk of addition of the undesirable cholinergic effects, especially digestive 	Take into account	
S01EB01	PILOCARPINE	8328						ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	ANSM	408-PILOCARPINE.html	Risk of addition of the undesirable cholinergic effects, especially digestive 	Take into account	
S01EB51	PILOCARPINE	8328						ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	ANSM	408-PILOCARPINE.html	Risk of addition of the undesirable cholinergic effects, especially digestive 	Take into account	
N05AG02	PIMOZIDE	8331			A04AD12	APREPITANT	358255			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J01FG02	DALFOPRISTIN	229369			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
N05AG02	PIMOZIDE	8331			C08DB01	DILTIAZEM	3443			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J05AG03	EFAVIRENZ	195085			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J05AR06	EFAVIRENZ	195085			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			D01AC15	FLUCONAZOLE	4450			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J02AC01	FLUCONAZOLE	4450			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J01FA07	JOSAMYCIN	6084			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			A01AB09	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			A07AC01	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			D01AC02	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			G01AF04	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J02AB01	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			S02AA13	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			D01AC52	MICONAZOLE	6932			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331						OMBITASVIR + PARITAPREVIR 	OMPA	ANSM	409-PIMOZIDE.html	Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the combination ombitasvir + paritaprevir	Contraindication	
N05AG02	PIMOZIDE	8331			N06AB05	PAROXETINE	32937			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			J01FG02	QUINUPRISTINE	135098			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
N05AG02	PIMOZIDE	8331			N06AB06	SERTRALINE	36437			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			N03AX17	STIRIPENTOL	37119			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N05AG02	PIMOZIDE	8331			P02BX04	TRICLABENDAZOLE	38608			ANSM	409-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the medication that tends to produce torsades de pointes).	Contraindication	Wait 24 hours between the end of the triclabendazole and the administration of the medication that tends to produce torsades de pointes and vice versa.
			SOMATOSTATIN ANALOGS	H01CB0-001				GLITAZONE ANTIDIABETICS	A10BG0	ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for glitazone due to decrease or increase of the secretion of endogenous glucagon.	Precaution for use	Strengthen self- monitoring of blood glucose and adjust the dosage of the glitazone if needed during the treatment with the somatostatin analog. 
			SOMATOSTATIN ANALOGS	H01CB0-001	L04AD01	CICLOSPORIN	3008			ANSM	41-SOMATOSTATIN-ANALOGS.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	Increase the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analogue is stopped.
			SOMATOSTATIN ANALOGS	H01CB0-001	S01XA18	CICLOSPORIN	3008			ANSM	41-SOMATOSTATIN-ANALOGS.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	Increase the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analogue is stopped.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AC01	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AC02	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AC03	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AC04	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AD01	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AD02	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AD03	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AD04	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AD05	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AE01	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AE02	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AE03	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AE04	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AE05	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10AF01	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001	A10BX02	REPAGLINIDE	73044			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for repaglinde due to decrease or increase of the secretion of endogenous glucagon .	Precaution for use	Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog.
			SOMATOSTATIN ANALOGS	H01CB0-001				BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Strengthen self-monitoring of blood glucose, and adjust the dosage of the sulfonamide if needed during the treatment with the somatostatin analog. 
L04AX05	PIRFENIDONE	88221			N06AB08	FLUVOXAMINE	42355			ANSM	410-PIRFENIDONE.html	Increase of the plasma concentrations of pirfenidone with signs of overdose	Contraindication	
C10AA08	PITAVASTATIN	861634			L04AD01	CICLOSPORIN	3008			ANSM	411-PITAVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	Contraindication	
C10AA08	PITAVASTATIN	861634			S01XA18	CICLOSPORIN	3008			ANSM	411-PITAVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	Contraindication	
A07AA05	POLYMYXIN B	8536						AMINOGLYCOSIDES	J01GB-001	ANSM	412-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
J01XB02	POLYMYXIN B	8536						AMINOGLYCOSIDES	J01GB-001	ANSM	412-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
S01AA18	POLYMYXIN B	8536						AMINOGLYCOSIDES	J01GB-001	ANSM	412-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
S02AA11	POLYMYXIN B	8536						AMINOGLYCOSIDES	J01GB-001	ANSM	412-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
S03AA03	POLYMYXIN B	8536						AMINOGLYCOSIDES	J01GB-001	ANSM	412-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification
A07AA05	POLYMYXIN B	8536						CURARES	M03A-001	ANSM	412-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
J01XB02	POLYMYXIN B	8536						CURARES	M03A-001	ANSM	412-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
S01AA18	POLYMYXIN B	8536						CURARES	M03A-001	ANSM	412-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
S02AA11	POLYMYXIN B	8536						CURARES	M03A-001	ANSM	412-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
S03AA03	POLYMYXIN B	8536						CURARES	M03A-001	ANSM	412-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	Monitor the degree of curarization at the end of anesthesia
J02AC04	POSACONAZOLE	282446						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	413-POSACONAZOLE.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J02AC04	POSACONAZOLE	282446						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	413-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the posaconazole	Precaution for use	Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.
J02AC04	POSACONAZOLE	282446						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	413-POSACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the H2 receptor antagonist	Not recommended	
J02AC04	POSACONAZOLE	282446						PROTON PUMP INHIBITORS	A02BC-001	ANSM	413-POSACONAZOLE.html	Decrease of the absorption of the azole antifungal, due to increase of the gastric pH by the inhibitor	Not recommended	
J02AC04	POSACONAZOLE	282446			C10AA05	ATORVASTATIN	83367			ANSM	413-POSACONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	Contraindication	
J02AC04	POSACONAZOLE	282446			G04BD10	DARIFENACIN	136198			ANSM	413-POSACONAZOLE.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J02AC04	POSACONAZOLE	282446			A01AC02	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			C05AA09	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			D07AB19	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			D07XB05	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			D10AA03	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			H02AB02	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			R01AD03	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S01BA01	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S01CB01	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S02BA06	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S03BA01	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			D07CB04	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S01CA01	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S02CA06	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			S03CA01	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			R01AD53	DEXAMETHASONE	3264			ANSM	413-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC04	POSACONAZOLE	282446			C01AA05	DIGOXIN 	3407			ANSM	413-POSACONAZOLE.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digoxin during the treatment with the posaconazole and after it is stopped.
J02AC04	POSACONAZOLE	282446						IMMUNOSUPPRESSANTS	L04A	ANSM	413-POSACONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	If these medications are administered together, strict testing of renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.
J02AC04	POSACONAZOLE	282446			J04AB04	RIFABUTIN	55672			ANSM	413-POSACONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Not recommended	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together. 
J02AC04	POSACONAZOLE	282446			J04AB02	RIFAMPICIN	9384			ANSM	413-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC04	POSACONAZOLE	282446			J04AM02	RIFAMPICIN	9384			ANSM	413-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC04	POSACONAZOLE	282446			J04AM05	RIFAMPICIN	9384			ANSM	413-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC04	POSACONAZOLE	282446			J04AM06	RIFAMPICIN	9384			ANSM	413-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J02AC04	POSACONAZOLE	282446			C10AA01	SIMVASTATIN	36567			ANSM	413-POSACONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	Contraindication	
J02AC04	POSACONAZOLE	282446			G04BD08	SOLIFENACIN	322167			ANSM	413-POSACONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J02AC04	POSACONAZOLE	282446			G04CA53	SOLIFENACIN	322167			ANSM	413-POSACONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J02AC04	POSACONAZOLE	282446						VINCA ALKALOIDS	L01CA	ANSM	413-POSACONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole	Not recommended	
A12BA	POTASSIUM	8588						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	414-POTASSIUM.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).	Not recommended	Avoid administering these substances together unless there is pre-existing hypokalemia. 
A12BA	POTASSIUM	8588			L04AD01	CICLOSPORIN	3008			ANSM	414-POTASSIUM.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid the administration of these two substances together unless there is a pre-existing hypokalemia.
A12BA	POTASSIUM	8588			S01XA18	CICLOSPORIN	3008			ANSM	414-POTASSIUM.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Avoid the administration of these two substances together unless there is a pre-existing hypokalemia.
A12BA	POTASSIUM	8588						POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	414-POTASSIUM.html	Potentially lethal hyperkalemia, especially with renal insufficiency (addition of the hyperkaliemia producing effects)	Contraindication:	-aside from hypokalemia or in case of parenteral use of the potassium salts
A12BA	POTASSIUM	8588						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	414-POTASSIUM.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	Unless there is hypokalemia.
A12BA	POTASSIUM	8588			D11AH01	TACROLIMUS	42316			ANSM	414-POTASSIUM.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects) 	Not recommended	Avoid administering these substances together unless there is a preexisting hypokalemia. 
A12BA	POTASSIUM	8588			L04AD02	TACROLIMUS	42316			ANSM	414-POTASSIUM.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects) 	Not recommended	Avoid administering these substances together unless there is a preexisting hypokalemia. 
D08AG02	POVIDONE-IODINE	8611						MERCURIAL ANTISEPTICS	D08AK0	ANSM	415-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
D09AA09	POVIDONE-IODINE	8611						MERCURIAL ANTISEPTICS	D08AK0	ANSM	415-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
D11AC06	POVIDONE-IODINE	8611						MERCURIAL ANTISEPTICS	D08AK0	ANSM	415-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
G01AX11	POVIDONE-IODINE	8611						MERCURIAL ANTISEPTICS	D08AK0	ANSM	415-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
R02AA15	POVIDONE-IODINE	8611						MERCURIAL ANTISEPTICS	D08AK0	ANSM	415-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
S01AX18	POVIDONE-IODINE	8611						MERCURIAL ANTISEPTICS	D08AK0	ANSM	415-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
C10AA03	PRAVASTATIN	42463			J01FA09	CLARITHROMYCIN	21212			ANSM	416-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
C10AA03	PRAVASTATIN	42463			A02BD06	CLARITHROMYCIN	21212			ANSM	416-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
C10AA03	PRAVASTATIN	42463			A02BD07	CLARITHROMYCIN	21212			ANSM	416-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
C10AA03	PRAVASTATIN	42463			A02BD05	CLARITHROMYCIN	21212			ANSM	416-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
C10AA03	PRAVASTATIN	42463			A02BD04	CLARITHROMYCIN	21212			ANSM	416-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic
C10AA03	PRAVASTATIN	42463			D10AF02	ERYTHROMYCIN	4053			ANSM	416-PRAVASTATIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
C10AA03	PRAVASTATIN	42463			D10AF52	ERYTHROMYCIN	4053			ANSM	416-PRAVASTATIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
C10AA03	PRAVASTATIN	42463			J01FA01	ERYTHROMYCIN	4053			ANSM	416-PRAVASTATIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
C10AA03	PRAVASTATIN	42463			S01AA17	ERYTHROMYCIN	4053			ANSM	416-PRAVASTATIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	Clinical monitoring and laboratory tests during the treatment with the antibiotic.
P02BA01	PRAZIQUANTEL	8628						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	417-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
P02BA01	PRAZIQUANTEL	8628			A01AC02	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			C05AA09	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			D07AB19	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			D07XB05	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			D10AA03	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			H02AB02	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			R01AD03	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S01BA01	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S01CB01	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S02BA06	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S03BA01	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			D07CB04	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S01CA01	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S02CA06	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			S03CA01	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			R01AD53	DEXAMETHASONE	3264			ANSM	417-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	Separate the administration of the two medications by at least a week.
P02BA01	PRAZIQUANTEL	8628			J04AB02	RIFAMPICIN	9384			ANSM	417-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
P02BA01	PRAZIQUANTEL	8628			J04AM02	RIFAMPICIN	9384			ANSM	417-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
P02BA01	PRAZIQUANTEL	8628			J04AM05	RIFAMPICIN	9384			ANSM	417-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
P02BA01	PRAZIQUANTEL	8628			J04AM06	RIFAMPICIN	9384			ANSM	417-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
A07EA01	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
A07EA01	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
C05AA04	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
C05AA04	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07AA03	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07AA03	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07XA02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07XA02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
H02AB06	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
H02AB06	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
R01AD02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
R01AD02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01BA04	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01BA04	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01CB02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01CB02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S02BA03	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S02BA03	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S03BA02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S03BA02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07CA03	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07CA03	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01CA02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01CA02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S02CA01	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S02CA01	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S03CA02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S03CA02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07BA01	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
D07BA01	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01BB02	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
S01BB02	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
V03AB05	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
V03AB05	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
A01AC54	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
A01AC54	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
R01AD52	PREDNISOLONE	8638			L04AD01	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
R01AD52	PREDNISOLONE	8638			S01XA18	CICLOSPORIN	3008			ANSM	418-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic Cushing's appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
	LATEX CONDOMS							MINERAL OILS	A06AA-	ANSM	419-LATEX-CONDOMS.html	Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)	Contraindication	Use a hydrosoluble lubricant (glycerin, polyacrylamide...).
			ANDROGENS	A14AA0				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	42-ANDROGENS.html	Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the Vitamin K antagonist during the treatment with the androgen and after it is stopped. 
			ANDROGENS	A14AA0				ENZYMATIC INDUCERS	N03-J05-001	ANSM	42-ANDROGENS.html	Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and laboratory tests during the administration of these substances together and 1 to 2 weeks after the inducer is stopped. 
J01FG01	PRISTINAMYCIN	66958						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	420-PRISTINAMYCIN.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped
J01FG01	PRISTINAMYCIN	66958			M04AC01	COLCHICINE	2683			ANSM	420-PRISTINAMYCIN.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	Contraindication	
J01FG01	PRISTINAMYCIN	66958						IMMUNOSUPPRESSANTS	L04A	ANSM	420-PRISTINAMYCIN.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.
M04AB01	PROBENECID	8698			R03DA01	DIPROPHYLLINE	3714			ANSM	421-PROBENECID.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
M04AB01	PROBENECID	8698			R03DB01	DIPROPHYLLINE	3714			ANSM	421-PROBENECID.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
M04AB01	PROBENECID	8698			R03DA51	DIPROPHYLLINE	3714			ANSM	421-PROBENECID.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	Reduce the dosage of diprophylline during the treatment with the probenicid
M04AB01	PROBENECID	8698			L01BA01	METHOTREXATE	6851			ANSM	421-PROBENECID.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	Contraindication	
M04AB01	PROBENECID	8698			L04AX03	METHOTREXATE	6851			ANSM	421-PROBENECID.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	Contraindication	
L01XB01	PROCARBAZINE	8702						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	422-PROCARBAZINE.html	Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer	Take into account	
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	L03AC01	ALDESLEUKIN	70223			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: skin rash or more rarely low blood pressure, oliguria, or even renal failure	Take into account	
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001				DIURETICS	C0E-001	ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used	Precaution for use	Rehydrate before administration of the iodinated product
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BA02	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD13	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD11	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD05	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD03	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD10	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD07	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD02	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	A10BD08	METFORMIN	6809			ANSM	423-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 	Contraindication	The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
			PROGESTIN CONTRACEPTIVES	G03-001	A04AD12	APREPITANT	358255			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	(Except IUD), decrease of the progestin, with risk of lower contraceptive effectiveness 	Precaution for use	Use another method of contraception, in particular a barrier method or IUD, during the length of time that these are administered togetherand one cycle after.
			PROGESTIN CONTRACEPTIVES	G03-001	J05AE12	BOCEPREVIR	1102129			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together. 
			PROGESTIN CONTRACEPTIVES	G03-001	C02KX01	BOSENTAN	75207			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism 	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. 
			PROGESTIN CONTRACEPTIVES	G03-001	D01AA08	GRISEOFULVIN	5021			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. 
			PROGESTIN CONTRACEPTIVES	G03-001	D01BA01	GRISEOFULVIN	5021			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. 
			PROGESTIN CONTRACEPTIVES	G03-001				ENZYMATIC INDUCERS	N03-J05-001	ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its metabolism by the inducer	Not recommended	Use an additional or alternative, reliable contraceptive method, in particular a barrier type, during the administration of these medications together and a cycle after. 
			PROGESTIN CONTRACEPTIVES	G03-001				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir 	Not recommended	Another method of contraception, in particular a condom or IUD, should be used during the time the substances are administered together and one cycle following. 
			PROGESTIN CONTRACEPTIVES	G03-001		ST JOHNS WORT	258326			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy) 	Contraindication	
			PROGESTIN CONTRACEPTIVES	G03-001	J05AE04	NELFINAVIR	134527			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of hormonal contraceptive	Not recommended	Another contraceptive method, in particular of the barrier type (condom or IUD), should be used during the length of the administration of the substances together and one cycle following.
			PROGESTIN CONTRACEPTIVES	G03-001	N03AX22	PERAMPANEL	1356552			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used.
			PROGESTIN CONTRACEPTIVES	G03-001	G03AD02	ULIPRISTAL	1005921			ANSM	424-PROGESTIN-CONTRACEPTIVES.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	Do not restart the progestin contraceptive treatment fewer than 12 days after stopping the ulipristal.
			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003				ENZYMATIC INDUCERS	N03-J05-001	ANSM	425-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Decrease of the effectiveness of the progestogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. 
			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	G03AD02	ULIPRISTAL	1005921			ANSM	425-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Risk of antagonism of the effects of the progestogen	Not recommended	Do not restart a progestogen treatment fewer than 12 days after stopping the ulipristal. 
P01BB01	PROGUANIL	2382						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	426-PROGUANIL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. 
P01BB51	PROGUANIL	2382						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	426-PROGUANIL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. 
P01BB01	PROGUANIL	2382						THYROID HORMONES	H03AA	ANSM	426-PROGUANIL.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. 
P01BB51	PROGUANIL	2382						THYROID HORMONES	H03AA	ANSM	426-PROGUANIL.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. 
C01BC03	PROPAFENONE	8754			L02BX03	ABIRATERONE	1100072			ANSM	427-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone
C01BC03	PROPAFENONE	8754						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	427-PROPAFENONE.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer	Precaution of use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of it and the inducer together and after the inducer is stopped.
C01BC03	PROPAFENONE	8754						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	427-PROPAFENONE.html	Increase of the anticoagulant effect and of the risk of hemorrhage. Mechanism proposed: inhibition of the metabolism of the vitamin K antagonist	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. 
C01BC03	PROPAFENONE	8754						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	427-PROPAFENONE.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
C01BC03	PROPAFENONE	8754			N06AX12	BUPROPION	42347			ANSM	427-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.
C01BC03	PROPAFENONE	8754			H05BX01	CINACALCET	407990			ANSM	427-PROPAFENONE.html	Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.
C01BC03	PROPAFENONE	8754			G04BD10	DARIFENACIN	136198			ANSM	427-PROPAFENONE.html	Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use.	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.
C01BC03	PROPAFENONE	8754			C01AA05	DIGOXIN 	3407			ANSM	427-PROPAFENONE.html	Risk of increase of the digoxinemia, especially with older patients	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.
C01BC03	PROPAFENONE	8754			N06AX21	DULOXETINE	72625			ANSM	427-PROPAFENONE.html	Increase of the plasma concentrations of propafenone with risk of overdosage due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. 
C01BC03	PROPAFENONE	8754			C07AB09	ESMOLOL	49737			ANSM	427-PROPAFENONE.html	Disorders of contractility, autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
C01BC03	PROPAFENONE	8754				ST JOHNS WORT	258326			ANSM	427-PROPAFENONE.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped.
C01BC03	PROPAFENONE	8754			J04AB02	RIFAMPICIN	9384			ANSM	427-PROPAFENONE.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.
C01BC03	PROPAFENONE	8754			J04AM02	RIFAMPICIN	9384			ANSM	427-PROPAFENONE.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.
C01BC03	PROPAFENONE	8754			J04AM05	RIFAMPICIN	9384			ANSM	427-PROPAFENONE.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.
C01BC03	PROPAFENONE	8754			J04AM06	RIFAMPICIN	9384			ANSM	427-PROPAFENONE.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.
C01BC03	PROPAFENONE	8754			D01AE15	TERBINAFINE	37801			ANSM	427-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. 
C01BC03	PROPAFENONE	8754			D01BA02	TERBINAFINE	37801			ANSM	427-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. 
C01BC03	PROPAFENONE	8754			R03DA04	THEOPHYLLINE 	10438			ANSM	427-PROPAFENONE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone. 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
C01BC03	PROPAFENONE	8754			R03DB04	THEOPHYLLINE 	10438			ANSM	427-PROPAFENONE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone. 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
C01BC03	PROPAFENONE	8754			R03DA54	THEOPHYLLINE 	10438			ANSM	427-PROPAFENONE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone. 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
C01BC03	PROPAFENONE	8754			R03DA74	THEOPHYLLINE 	10438			ANSM	427-PROPAFENONE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone. 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
C07AA05	PROPRANOLOL	8787			N02CA02	ERGOTAMINE	4025			ANSM	428-PROPRANOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
C07AA05	PROPRANOLOL	8787			N02CA51	ERGOTAMINE	4025			ANSM	428-PROPRANOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
C07AA05	PROPRANOLOL	8787			N02CA52	ERGOTAMINE	4025			ANSM	428-PROPRANOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
C07AA05	PROPRANOLOL	8787			N02CA72	ERGOTAMINE	4025			ANSM	428-PROPRANOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 
C07AA05	PROPRANOLOL	8787			N06AB08	FLUVOXAMINE	42355			ANSM	428-PROPRANOLOL.html	Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia	Precaution for use	Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped. 
C07AA05	PROPRANOLOL	8787						PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	428-PROPRANOLOL.html	Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
C07AA05	PROPRANOLOL	8787			J04AB02	RIFAMPICIN	9384			ANSM	428-PROPRANOLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AA05	PROPRANOLOL	8787			J04AM02	RIFAMPICIN	9384			ANSM	428-PROPRANOLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AA05	PROPRANOLOL	8787			J04AM05	RIFAMPICIN	9384			ANSM	428-PROPRANOLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
C07AA05	PROPRANOLOL	8787			J04AM06	RIFAMPICIN	9384			ANSM	428-PROPRANOLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
J04AK01	PYRAZINAMIDE	8987			J04AM03	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AC01	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AC51	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AM02	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AM05	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AM06	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AM01	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AK01	PYRAZINAMIDE	8987			J04AM04	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AM03	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AC01	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AC51	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AM02	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AM05	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AM06	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AM01	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM05	PYRAZINAMIDE	8987			J04AM04	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AM03	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AC01	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AC51	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AM02	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AM05	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AM06	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AM01	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
J04AM06	PYRAZINAMIDE	8987			J04AM04	ISONIAZID	6038			ANSM	429-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	Clinical monitoring and laboratory tests.
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001				ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	Limit the amount of adrenaline, for example: less then 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-andrenergic inhibition can be elevated by the beta-mimetics during surgery. 	Precaution for use	As a general rule, do not stop the treatment with the beta-blocking agent and, in any event, avoid stopping it abruptly. Inform the anesthesiologist of this treatment. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-adrenergic inhibition can be elevated during the surgery by the beta-stimulants.	Precaution for use	As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AM03	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AC01	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AC51	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AM02	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AM05	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AM06	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AM01	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	J04AM04	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	C01CA02	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization 	Not recommended	
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	R03AB02	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization 	Not recommended	
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	R03CB01	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization 	Not recommended	
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	R03AK02	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization 	Not recommended	
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	R03CB51	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization 	Not recommended	
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001				ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001				INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Perioperative hypertension 	Precaution for use	In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery. 
P01BD01	PYRIMETHAMINE	9010			J01E	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EA	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE02	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE05	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE07	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE01	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE03	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EE04	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD01	PYRIMETHAMINE	9010			J01EA01	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01E	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EA	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE02	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE05	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE07	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE01	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE03	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EE04	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BD51	PYRIMETHAMINE	9010			J01EA01	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01E	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EA	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE02	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE05	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE07	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE01	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE03	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EE04	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
P01BF04	PYRIMETHAMINE	9010			J01EA01	TRIMETHOPRIM	10829			ANSM	430-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
N05AH04	QUETIAPINE	51272						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	431-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
N05AH04	QUETIAPINE 	51272						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	431-QUETIAPINE.html	Large increase of the concentrations of quetiapine, with risk of overdose	Contraindication	
N05AH04	QUETIAPINE	51272				ST JOHNS WORT	258326			ANSM	431-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
N05AH04	QUETIAPINE	51272						OMBITASVIR + PARITAPREVIR 	OMPA	ANSM	431-QUETIAPINE.html	Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	Contraindication	
N05AH04	QUETIAPINE	51272			J04AB02	RIFAMPICIN	9384			ANSM	431-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
N05AH04	QUETIAPINE	51272			J04AM02	RIFAMPICIN	9384			ANSM	431-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
N05AH04	QUETIAPINE	51272			J04AM05	RIFAMPICIN	9384			ANSM	431-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
N05AH04	QUETIAPINE	51272			J04AM06	RIFAMPICIN	9384			ANSM	431-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
C01BA01	QUINIDINE	9068						URINARY ALKALIZERS	B05-001	ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
C01BA51	QUINIDINE	9068						URINARY ALKALIZERS	B05-001	ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
C01BA71	QUINIDINE	9068						URINARY ALKALIZERS	B05-001	ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
C01BA01	QUINIDINE	9068			C09XA02	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA01	QUINIDINE	9068			C09XA52	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA01	QUINIDINE	9068			C09DX02	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA51	QUINIDINE	9068			C09XA02	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA51	QUINIDINE	9068			C09XA52	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA51	QUINIDINE	9068			C09DX02	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA71	QUINIDINE	9068			C09XA02	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA71	QUINIDINE	9068			C09XA52	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA71	QUINIDINE	9068			C09DX02	ALISKIREN	325646			ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Contraindication	
C01BA01	QUINIDINE	9068			N06BA09	ATOMOXETINE	38400			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism 	Not recommended	If administering the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped
C01BA51	QUINIDINE	9068			N06BA09	ATOMOXETINE	38400			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism 	Not recommended	If administering the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped
C01BA71	QUINIDINE	9068			N06BA09	ATOMOXETINE	38400			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism 	Not recommended	If administering the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped
C01BA01	QUINIDINE	9068			V03AX03	COBICISTAT	1306284			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
C01BA01	QUINIDINE	9068			J05AR09	COBICISTAT	1306284			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
C01BA51	QUINIDINE	9068			V03AX03	COBICISTAT	1306284			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
C01BA51	QUINIDINE	9068			J05AR09	COBICISTAT	1306284			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
C01BA71	QUINIDINE	9068			V03AX03	COBICISTAT	1306284			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
C01BA71	QUINIDINE	9068			J05AR09	COBICISTAT	1306284			ANSM	432-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	Contraindication	
C01BA01	QUINIDINE	9068			1037042	DABIGATRAN				ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
C01BA51	QUINIDINE	9068			1037042	DABIGATRAN				ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
C01BA71	QUINIDINE	9068			1037042	DABIGATRAN				ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.
C01BA01	QUINIDINE	9068			C01AA05	DIGOXIN 	3407			ANSM	432-QUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 
C01BA51	QUINIDINE	9068			C01AA05	DIGOXIN 	3407			ANSM	432-QUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 
C01BA71	QUINIDINE	9068			C01AA05	DIGOXIN 	3407			ANSM	432-QUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 
C01BA01	QUINIDINE	9068			C01BD07	DRONEDARONE	233698			ANSM	432-QUINIDINE.html	Risk of bradycardia or of atrioventricular block especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG. 
C01BA51	QUINIDINE	9068			C01BD07	DRONEDARONE	233698			ANSM	432-QUINIDINE.html	Risk of bradycardia or of atrioventricular block especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG. 
C01BA71	QUINIDINE	9068			C01BD07	DRONEDARONE	233698			ANSM	432-QUINIDINE.html	Risk of bradycardia or of atrioventricular block especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG. 
C01BA01	QUINIDINE	9068						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA51	QUINIDINE	9068						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA71	QUINIDINE	9068						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA01	QUINIDINE	9068			J02AC02	ITRACONAZOLE	28031			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	Not recommended	If administering the two substances together cannot be avoided, strict clinical monitoring and EKG. 
C01BA51	QUINIDINE	9068			J02AC02	ITRACONAZOLE	28031			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	Not recommended	If administering the two substances together cannot be avoided, strict clinical monitoring and EKG. 
C01BA71	QUINIDINE	9068			J02AC02	ITRACONAZOLE	28031			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	Not recommended	If administering the two substances together cannot be avoided, strict clinical monitoring and EKG. 
C01BA01	QUINIDINE	9068						OMBITASVIR + PARITAPREVIR 	OMPA	ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	Contraindication	
C01BA51	QUINIDINE	9068						OMBITASVIR + PARITAPREVIR 	OMPA	ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	Contraindication	
C01BA71	QUINIDINE	9068						OMBITASVIR + PARITAPREVIR 	OMPA	ANSM	432-QUINIDINE.html	Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	Contraindication	
C01BA01	QUINIDINE	9068			N03AX17	STIRIPENTOL	37119			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA51	QUINIDINE	9068			N03AX17	STIRIPENTOL	37119			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA71	QUINIDINE	9068			N03AX17	STIRIPENTOL	37119			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA01	QUINIDINE	9068			L02BA01	TAMOXIFEN	10324			ANSM	432-QUINIDINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
C01BA51	QUINIDINE	9068			L02BA01	TAMOXIFEN	10324			ANSM	432-QUINIDINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
C01BA71	QUINIDINE	9068			L02BA01	TAMOXIFEN	10324			ANSM	432-QUINIDINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
C01BA01	QUINIDINE	9068			P02BX04	TRICLABENDAZOLE	38608			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse.
C01BA51	QUINIDINE	9068			P02BX04	TRICLABENDAZOLE	38608			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse.
C01BA71	QUINIDINE	9068			P02BX04	TRICLABENDAZOLE	38608			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse.
C01BA01	QUINIDINE	9068			C08DA01	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA01	QUINIDINE	9068			C08DA51	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA01	QUINIDINE	9068			C09BB10	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA51	QUINIDINE	9068			C08DA01	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA51	QUINIDINE	9068			C08DA51	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA51	QUINIDINE	9068			C09BB10	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA71	QUINIDINE	9068			C08DA01	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA71	QUINIDINE	9068			C08DA51	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA71	QUINIDINE	9068			C09BB10	VERAPAMIL	11170			ANSM	432-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C01BA01	QUINIDINE	9068			J02AC03	VORICONAZOLE	121243			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA51	QUINIDINE	9068			J02AC03	VORICONAZOLE	121243			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
C01BA71	QUINIDINE	9068			J02AC03	VORICONAZOLE	121243			ANSM	432-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
P01BC01	QUININE	9071						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped. 
M09AA72	QUININE	9071						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped. 
M09AA	QUININE	9071						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped. 
P01BC01	QUININE	9071			C01AA05	DIGOXIN 	3407			ANSM	433-QUININE.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
M09AA72	QUININE	9071			C01AA05	DIGOXIN 	3407			ANSM	433-QUININE.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
M09AA	QUININE	9071			C01AA05	DIGOXIN 	3407			ANSM	433-QUININE.html	Moderate increase of the digoxinemia	Precaution for use	Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.
P01BC01	QUININE	9071						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	433-QUININE.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism) 	Not recommended	-with the protease inhibitors 
M09AA72	QUININE	9071						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	433-QUININE.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism) 	Not recommended	-with the protease inhibitors 
M09AA	QUININE	9071						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	433-QUININE.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism) 	Not recommended	-with the protease inhibitors 
P01BC01	QUININE	9071			P01BF02	MEFLOQUINE	6694			ANSM	433-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BC01	QUININE	9071			P01BC02	MEFLOQUINE	6694			ANSM	433-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
M09AA72	QUININE	9071			P01BF02	MEFLOQUINE	6694			ANSM	433-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
M09AA72	QUININE	9071			P01BC02	MEFLOQUINE	6694			ANSM	433-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
M09AA	QUININE	9071			P01BF02	MEFLOQUINE	6694			ANSM	433-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
M09AA	QUININE	9071			P01BC02	MEFLOQUINE	6694			ANSM	433-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
P01BC01	QUININE	9071			J04AB02	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
P01BC01	QUININE	9071			J04AM02	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
P01BC01	QUININE	9071			J04AM05	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
P01BC01	QUININE	9071			J04AM06	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA72	QUININE	9071			J04AB02	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA72	QUININE	9071			J04AM02	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA72	QUININE	9071			J04AM05	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA72	QUININE	9071			J04AM06	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA	QUININE	9071			J04AB02	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA	QUININE	9071			J04AM02	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA	QUININE	9071			J04AM05	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
M09AA	QUININE	9071			J04AM06	RIFAMPICIN	9384			ANSM	433-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J01FG02	QUINUPRISTINE	135098			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	434-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	QUINUPRISTINE	135098			N02CA02	ERGOTAMINE	4025			ANSM	434-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	QUINUPRISTINE	135098			N02CA51	ERGOTAMINE	4025			ANSM	434-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	QUINUPRISTINE	135098			N02CA52	ERGOTAMINE	4025			ANSM	434-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	QUINUPRISTINE	135098			N02CA72	ERGOTAMINE	4025			ANSM	434-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	Contraindication	
J01FG02	QUINUPRISTINE	135098						IMMUNOSUPPRESSANTS	L04A	ANSM	434-QUINUPRISTINE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism 	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. 
J01FG02	QUINUPRISTINE	135098			N05AG02	PIMOZIDE	8331			ANSM	434-QUINUPRISTINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
A07XA04	RACECADOTRIL	16738						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	435-RACECADOTRIL.html	Risk of increase of the undesirable effects of the angioedema type. 	Contraindication	-when there was previous angioedema with ACE inhibitors
J05AX08	RALTEGRAVIR	719872			J04AB02	RIFAMPICIN	9384			ANSM	436-RALTEGRAVIR.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered 
J05AX08	RALTEGRAVIR	719872			J04AM02	RIFAMPICIN	9384			ANSM	436-RALTEGRAVIR.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered 
J05AX08	RALTEGRAVIR	719872			J04AM05	RIFAMPICIN	9384			ANSM	436-RALTEGRAVIR.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered 
J05AX08	RALTEGRAVIR	719872			J04AM06	RIFAMPICIN	9384			ANSM	436-RALTEGRAVIR.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered 
C01EB18	RANOLAZINE	35829						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	437-RANOLAZINE.html	Risk of large decrease of the concentrations of ranolazine	Not recommended	
C01EB18	RANOLAZINE	35829			C10AA05	ATORVASTATIN	83367			ANSM	437-RANOLAZINE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine	Precaution for use	Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.
C01EB18	RANOLAZINE	35829			C01AA05	DIGOXIN 	3407			ANSM	437-RANOLAZINE.html	Increase of the digoxinemia	Precaution for use	Clinical monitoring, laboratory tests, and, possibly EKG. Adjustment of the dosage of the digoxin if needed.
C01EB18	RANOLAZINE	35829						IMMUNOSUPPRESSANTS	L04A	ANSM	437-RANOLAZINE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine	Precaution for use	Clinical monitoring, laboratory tests, and possible adjustment of the dosage of the immunosuppressant.
C01EB18	RANOLAZINE	35829						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	437-RANOLAZINE.html	Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor	Contraindication	
C01EB18	RANOLAZINE	35829			J04AB02	RIFAMPICIN	9384			ANSM	437-RANOLAZINE.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
C01EB18	RANOLAZINE	35829			J04AM02	RIFAMPICIN	9384			ANSM	437-RANOLAZINE.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
C01EB18	RANOLAZINE	35829			J04AM05	RIFAMPICIN	9384			ANSM	437-RANOLAZINE.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
C01EB18	RANOLAZINE	35829			J04AM06	RIFAMPICIN	9384			ANSM	437-RANOLAZINE.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
C01EB18	RANOLAZINE	35829			C10AA01	SIMVASTATIN	36567			ANSM	437-RANOLAZINE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine	Precaution for use	Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction.
L01XE21	REGORAFENIB	1312397				GRAPEFRUIT JUICE				ANSM	438-REGORAFENIB.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit juice	Not recommended	
L01XE21	REGORAFENIB	1312397						ENZYMATIC INDUCERS	N03-J05-001	ANSM	438-REGORAFENIB.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer 	Not recommended	
L01XE21	REGORAFENIB	1312397						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	438-REGORAFENIB.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
L01XE21	REGORAFENIB	1312397				ST JOHNS WORT	258326			ANSM	438-REGORAFENIB.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort	Not recommended	
A10BX02	REPAGLINIDE	73044						SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	439-REPAGLINIDE.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the need for repaglinde due to decrease or increase of the secretion of endogenous glucagon .	Precaution for use	Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog
A10BX02	REPAGLINIDE	73044			L04AD01	CICLOSPORIN	3008			ANSM	439-REPAGLINIDE.html	The concentrations of repaglinide more than doubled due to increase of its absorption	Not recommended	
A10BX02	REPAGLINIDE	73044			S01XA18	CICLOSPORIN	3008			ANSM	439-REPAGLINIDE.html	The concentrations of repaglinide more than doubled due to increase of its absorption	Not recommended	
A10BX02	REPAGLINIDE	73044			J01FA09	CLARITHROMYCIN	21212			ANSM	439-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.
A10BX02	REPAGLINIDE	73044			A02BD06	CLARITHROMYCIN	21212			ANSM	439-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.
A10BX02	REPAGLINIDE	73044			A02BD07	CLARITHROMYCIN	21212			ANSM	439-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.
A10BX02	REPAGLINIDE	73044			A02BD05	CLARITHROMYCIN	21212			ANSM	439-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.
A10BX02	REPAGLINIDE	73044			A02BD04	CLARITHROMYCIN	21212			ANSM	439-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.
A10BX02	REPAGLINIDE	73044			V03AC03	DEFERASIROX	614373			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide, due to inhibition of its hepatic metabolism by the deferasirox	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			C10AB04	GEMFIBROZIL	4719			ANSM	439-REPAGLINIDE.html	Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfibrozil	Contraindication	
A10BX02	REPAGLINIDE	73044			J01E	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EA	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE02	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE05	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE07	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE01	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE03	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EE04	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
A10BX02	REPAGLINIDE	73044			J01EA01	TRIMETHOPRIM	10829			ANSM	439-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If the administration of these together cannot be avoided, strict clinical monitoring and laboratory tests.
			ANTABUSE (REACTION)	123-ANT	DRINK	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
			ANTABUSE (REACTION)	123-ANT	INGREDIE	ALCOHOL 				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect: (heat, redness, vomiting, tachycardia)	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of these medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
C02AA02	RESERPINE	9260						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	440-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	Contraindication	
C02LA01	RESERPINE	9260						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	440-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	Contraindication	
C02LA51	RESERPINE	9260						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	440-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	Contraindication	
C02LA71	RESERPINE	9260						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	440-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	Contraindication	
C02AA52	RESERPINE	9260						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	440-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	Contraindication	
C02AA02	RESERPINE	9260			N04BA01	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02AA02	RESERPINE	9260			N04BA02	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02AA02	RESERPINE	9260			N04BA03	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA01	RESERPINE	9260			N04BA01	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA01	RESERPINE	9260			N04BA02	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA01	RESERPINE	9260			N04BA03	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA51	RESERPINE	9260			N04BA01	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA51	RESERPINE	9260			N04BA02	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA51	RESERPINE	9260			N04BA03	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA71	RESERPINE	9260			N04BA01	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA71	RESERPINE	9260			N04BA02	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02LA71	RESERPINE	9260			N04BA03	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02AA52	RESERPINE	9260			N04BA01	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02AA52	RESERPINE	9260			N04BA02	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
C02AA52	RESERPINE	9260			N04BA03	LEVODOPA	6375			ANSM	440-RESERPINE.html	Inhibition of the effects of the levodopa	Contraindication	
			CHELATING RESINS	C10-V0		MEDICATIONS ADMINISTERED BY ORAL ROUTE				ANSM	441-CHELATING-RESINS.html	Taking chelating resins can decrease the intestinal absorption and, potentially, the effectiveness of other medications taken simultaneously	Precaution for use	As a general rule, the doses of the resin should be taken at a different time from that of other medications, at an interval of more than 2 hours apart, if possible
			CHELATING RESINS	C10-V0				THYROID HORMONES	H03AA	ANSM	441-CHELATING-RESINS.html	Decrease of the digestive absorption of the thyroid hormones 	Precaution for use	Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).
			RETINOIDS	D05-D10				RETINOIDS	D05-D10	ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			RETINOIDS	D05-D10				TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	442-RETINOIDS.html	Risk of intracranial hypertension	Contraindication	
			RETINOIDS	D05-D10	A11C	VITAMIN A	11246			ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			RETINOIDS	D05-D10	A11CA	VITAMIN A	11246			ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			RETINOIDS	D05-D10	A11CA01	VITAMIN A	11246			ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			RETINOIDS	D05-D10	A11CA02	VITAMIN A	11246			ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			RETINOIDS	D05-D10	A11CB	VITAMIN A	11246			ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			RETINOIDS	D05-D10	V04CB01	VITAMIN A	11246			ANSM	442-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
J05AB04	RIBAVIRIN	9344			L04AX01	AZATHIOPRINE	1256			ANSM	443-RIBAVIRIN.html	Increased risk of serious undesirable hematological effects due to inhibition of the metabolism of the azothioprine by the ribavirin	Not recommended	
J05AB04	RIBAVIRIN	9344			J05AF02	DIDANOSINE	3364			ANSM	443-RIBAVIRIN.html	Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite	Not recommended	
J05AB04	RIBAVIRIN	9344			J05AF04	STAVUDINE	59763			ANSM	443-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AB04	RIBAVIRIN	9344			J05AR07	STAVUDINE	59763			ANSM	443-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AB04	RIBAVIRIN	9344			J05AF01	ZIDOVUDINE 	11413			ANSM	443-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AB04	RIBAVIRIN	9344			J05AR01	ZIDOVUDINE 	11413			ANSM	443-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AB04	RIBAVIRIN	9344			J05AR04	ZIDOVUDINE 	11413			ANSM	443-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AB04	RIBAVIRIN	9344			J05AR05	ZIDOVUDINE 	11413			ANSM	443-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J04AB04	RIFABUTIN	55672			P01AX06	ATOVAQUONE	60212			ANSM	444.RIFABUTIN.html	Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Take into account	
J04AB04	RIFABUTIN	55672			J01FA09	CLARITHROMYCIN	21212			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together.
J04AB04	RIFABUTIN	55672			A02BD04	CLARITHROMYCIN	21212			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together.
J04AB04	RIFABUTIN	55672			A02BD05	CLARITHROMYCIN	21212			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together.
J04AB04	RIFABUTIN	55672			A02BD06	CLARITHROMYCIN	21212			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together.
J04AB04	RIFABUTIN	55672			A02BD07	CLARITHROMYCIN	21212			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together.
J04AB04	RIFABUTIN	55672			V03AX03	COBICISTAT	1306284			ANSM	444.RIFABUTIN.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half). 
J04AB04	RIFABUTIN	55672			J05AR09	COBICISTAT	1306284			ANSM	444.RIFABUTIN.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half). 
J04AB04	RIFABUTIN	55672			J05AG03	EFAVIRENZ	195085			ANSM	444.RIFABUTIN.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	Adjustment of the dosage of the rifabutin during the treatment with efavirenz.
J04AB04	RIFABUTIN	55672			J05AR06	EFAVIRENZ	195085			ANSM	444.RIFABUTIN.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	Adjustment of the dosage of the rifabutin during the treatment with efavirenz.
J04AB04	RIFABUTIN	55672			J05AX11	ELVITEGRAVIR	1306286			ANSM	444.RIFABUTIN.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
J04AB04	RIFABUTIN	55672			J05AR09	ELVITEGRAVIR	1306286			ANSM	444.RIFABUTIN.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
J04AB04	RIFABUTIN	55672			D01AC15	FLUCONAZOLE	4450			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the treatment with the two medications together. 
J04AB04	RIFABUTIN	55672			J02AC01	FLUCONAZOLE	4450			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the treatment with the two medications together. 
J04AB04	RIFABUTIN	55672						THYROID HORMONES	H03AA	ANSM	444.RIFABUTIN.html	Described for phenytoin, rifampicin, and carbamazepine. Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4	Precaution for use	Monitoring of serum concentrations of T3 and of T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.
J04AB04	RIFABUTIN	55672						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	444.RIFABUTIN.html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another. 	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J04AB04	RIFABUTIN	55672			J02AC04	POSACONAZOLE	282446			ANSM	444.RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Not recommended	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together. 
J04AB04	RIFABUTIN	55672			J02AC03	VORICONAZOLE	121243			ANSM	444.RIFABUTIN.html	Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing; and risk of increase of the undesirable effects (uveitis) of the rifabutin for another	Not recommended	If the administration of these substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin. 
J04AB02	RIFAMPICIN	9384			L02BX03	ABIRATERONE	1100072			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
J04AM02	RIFAMPICIN	9384			L02BX03	ABIRATERONE	1100072			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
J04AM05	RIFAMPICIN	9384			L02BX03	ABIRATERONE	1100072			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
J04AM06	RIFAMPICIN	9384			L02BX03	ABIRATERONE	1100072			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
J04AB02	RIFAMPICIN	9384			P02CA03	ALBENDAZOLE	430			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
J04AM02	RIFAMPICIN	9384			P02CA03	ALBENDAZOLE	430			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
J04AM05	RIFAMPICIN	9384			P02CA03	ALBENDAZOLE	430			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
J04AM06	RIFAMPICIN	9384			P02CA03	ALBENDAZOLE	430			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.
J04AB02	RIFAMPICIN	9384						CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
J04AM02	RIFAMPICIN	9384						CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
J04AM05	RIFAMPICIN	9384						CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
J04AM06	RIFAMPICIN	9384						CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
J04AB02	RIFAMPICIN	9384						CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic)
J04AM02	RIFAMPICIN	9384						CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic)
J04AM05	RIFAMPICIN	9384						CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic)
J04AM06	RIFAMPICIN	9384						CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic)
J04AB02	RIFAMPICIN	9384						GLITAZONE ANTIDIABETICS	A10BG0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384						GLITAZONE ANTIDIABETICS	A10BG0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384						GLITAZONE ANTIDIABETICS	A10BG0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384						GLITAZONE ANTIDIABETICS	A10BG0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	445-RIFAMPICIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
J04AM02	RIFAMPICIN	9384						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	445-RIFAMPICIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
J04AM05	RIFAMPICIN	9384						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	445-RIFAMPICIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
J04AM06	RIFAMPICIN	9384						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	445-RIFAMPICIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
J04AB02	RIFAMPICIN	9384			B01AF02	APIXABAN	1364430			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
J04AM02	RIFAMPICIN	9384			B01AF02	APIXABAN	1364430			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
J04AM05	RIFAMPICIN	9384			B01AF02	APIXABAN	1364430			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
J04AM06	RIFAMPICIN	9384			B01AF02	APIXABAN	1364430			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
J04AB02	RIFAMPICIN	9384			A04AD12	APREPITANT	358255			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of aprepitant	Not recommended	
J04AM02	RIFAMPICIN	9384			A04AD12	APREPITANT	358255			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of aprepitant	Not recommended	
J04AM05	RIFAMPICIN	9384			A04AD12	APREPITANT	358255			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of aprepitant	Not recommended	
J04AM06	RIFAMPICIN	9384			A04AD12	APREPITANT	358255			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of aprepitant	Not recommended	
J04AB02	RIFAMPICIN	9384			C10AA05	ATORVASTATIN	83367			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM02	RIFAMPICIN	9384			C10AA05	ATORVASTATIN	83367			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM05	RIFAMPICIN	9384			C10AA05	ATORVASTATIN	83367			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM06	RIFAMPICIN	9384			C10AA05	ATORVASTATIN	83367			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AB02	RIFAMPICIN	9384			P01AX06	ATOVAQUONE	60212			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer	Not recommended	
J04AM02	RIFAMPICIN	9384			P01AX06	ATOVAQUONE	60212			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer	Not recommended	
J04AM05	RIFAMPICIN	9384			P01AX06	ATOVAQUONE	60212			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer	Not recommended	
J04AM06	RIFAMPICIN	9384			P01AX06	ATOVAQUONE	60212			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer	Not recommended	
J04AB02	RIFAMPICIN	9384			J05AE12	BOCEPREVIR	1102129			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together. 
J04AM02	RIFAMPICIN	9384			J05AE12	BOCEPREVIR	1102129			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together. 
J04AM05	RIFAMPICIN	9384			J05AE12	BOCEPREVIR	1102129			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together. 
J04AM06	RIFAMPICIN	9384			J05AE12	BOCEPREVIR	1102129			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together. 
J04AB02	RIFAMPICIN	9384			C02KX01	BOSENTAN	75207			ANSM	445-RIFAMPICIN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
J04AM02	RIFAMPICIN	9384			C02KX01	BOSENTAN	75207			ANSM	445-RIFAMPICIN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
J04AM05	RIFAMPICIN	9384			C02KX01	BOSENTAN	75207			ANSM	445-RIFAMPICIN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
J04AM06	RIFAMPICIN	9384			C02KX01	BOSENTAN	75207			ANSM	445-RIFAMPICIN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
J04AB02	RIFAMPICIN	9384			N05BE01	BUSPIRONE	1827			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
J04AM02	RIFAMPICIN	9384			N05BE01	BUSPIRONE	1827			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
J04AM05	RIFAMPICIN	9384			N05BE01	BUSPIRONE	1827			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
J04AM06	RIFAMPICIN	9384			N05BE01	BUSPIRONE	1827			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.
J04AB02	RIFAMPICIN	9384			N03AF01	CARBAMAZEPINE	2002			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
J04AM02	RIFAMPICIN	9384			N03AF01	CARBAMAZEPINE	2002			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
J04AM05	RIFAMPICIN	9384			N03AF01	CARBAMAZEPINE	2002			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
J04AM06	RIFAMPICIN	9384			N03AF01	CARBAMAZEPINE	2002			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.
J04AB02	RIFAMPICIN	9384			C07AG02	CARVEDILOL	20352			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
J04AM02	RIFAMPICIN	9384			C07AG02	CARVEDILOL	20352			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
J04AM05	RIFAMPICIN	9384			C07AG02	CARVEDILOL	20352			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
J04AM06	RIFAMPICIN	9384			C07AG02	CARVEDILOL	20352			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
J04AB02	RIFAMPICIN	9384			N05AH02	CLOZAPINE	2626			ANSM	445-RIFAMPICIN.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
J04AM02	RIFAMPICIN	9384			N05AH02	CLOZAPINE	2626			ANSM	445-RIFAMPICIN.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
J04AM05	RIFAMPICIN	9384			N05AH02	CLOZAPINE	2626			ANSM	445-RIFAMPICIN.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
J04AM06	RIFAMPICIN	9384			N05AH02	CLOZAPINE	2626			ANSM	445-RIFAMPICIN.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
J04AB02	RIFAMPICIN	9384			V03AX03	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AB02	RIFAMPICIN	9384			J05AR09	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AM02	RIFAMPICIN	9384			V03AX03	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AM02	RIFAMPICIN	9384			J05AR09	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AM05	RIFAMPICIN	9384			V03AX03	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AM05	RIFAMPICIN	9384			J05AR09	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AM06	RIFAMPICIN	9384			V03AX03	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AM06	RIFAMPICIN	9384			J05AR09	COBICISTAT	1306284			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
J04AB02	RIFAMPICIN	9384			1037042	DABIGATRAN				ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
J04AM02	RIFAMPICIN	9384			1037042	DABIGATRAN				ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
J04AM05	RIFAMPICIN	9384			1037042	DABIGATRAN				ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
J04AM06	RIFAMPICIN	9384			1037042	DABIGATRAN				ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
J04AB02	RIFAMPICIN	9384			V03AC03	DEFERASIROX	614373			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
J04AM02	RIFAMPICIN	9384			V03AC03	DEFERASIROX	614373			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
J04AM05	RIFAMPICIN	9384			V03AC03	DEFERASIROX	614373			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
J04AM06	RIFAMPICIN	9384			V03AC03	DEFERASIROX	614373			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
J04AB02	RIFAMPICIN	9384			J04AK06	DELAMANID	1344662			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AM02	RIFAMPICIN	9384			J04AK06	DELAMANID	1344662			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AM05	RIFAMPICIN	9384			J04AK06	DELAMANID	1344662			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AM06	RIFAMPICIN	9384			J04AK06	DELAMANID	1344662			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	Contraindication	
J04AB02	RIFAMPICIN	9384			C01AA04	DIGITOXIN	3403			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the digitoxinemia. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after the rifampicin is stopped, or choose digoxin, less metabolized by the liver. 
J04AM02	RIFAMPICIN	9384			C01AA04	DIGITOXIN	3403			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the digitoxinemia. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after the rifampicin is stopped, or choose digoxin, less metabolized by the liver. 
J04AM05	RIFAMPICIN	9384			C01AA04	DIGITOXIN	3403			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the digitoxinemia. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after the rifampicin is stopped, or choose digoxin, less metabolized by the liver. 
J04AM06	RIFAMPICIN	9384			C01AA04	DIGITOXIN	3403			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the digitoxin due to increase of its hepatic metabolism. 	Precaution for use. 	Clinical monitoring, EKG, and, possibly, monitoring of the digitoxinemia. If there is reason for it, adjustment of the dosage of the digitoxin during the administration of these substances together and after the rifampicin is stopped, or choose digoxin, less metabolized by the liver. 
J04AB02	RIFAMPICIN	9384			J05AX12	DOLUTEGRAVIR	1433868			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	--in case of resistance to the class of integrase inhibitors
J04AM02	RIFAMPICIN	9384			J05AX12	DOLUTEGRAVIR	1433868			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	--in case of resistance to the class of integrase inhibitors
J04AM05	RIFAMPICIN	9384			J05AX12	DOLUTEGRAVIR	1433868			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	--in case of resistance to the class of integrase inhibitors
J04AM06	RIFAMPICIN	9384			J05AX12	DOLUTEGRAVIR	1433868			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	--in case of resistance to the class of integrase inhibitors
J04AB02	RIFAMPICIN	9384			C01BD07	DRONEDARONE	233698			ANSM	445-RIFAMPICIN.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
J04AM02	RIFAMPICIN	9384			C01BD07	DRONEDARONE	233698			ANSM	445-RIFAMPICIN.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
J04AM05	RIFAMPICIN	9384			C01BD07	DRONEDARONE	233698			ANSM	445-RIFAMPICIN.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
J04AM06	RIFAMPICIN	9384			C01BD07	DRONEDARONE	233698			ANSM	445-RIFAMPICIN.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
J04AB02	RIFAMPICIN	9384			J05AG03	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AB02	RIFAMPICIN	9384			J05AR06	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM02	RIFAMPICIN	9384			J05AG03	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM02	RIFAMPICIN	9384			J05AR06	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM05	RIFAMPICIN	9384			J05AG03	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM05	RIFAMPICIN	9384			J05AR06	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM06	RIFAMPICIN	9384			J05AG03	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AM06	RIFAMPICIN	9384			J05AR06	EFAVIRENZ	195085			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J04AB02	RIFAMPICIN	9384			L02BG06	EXEMESTANE	258494			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
J04AM02	RIFAMPICIN	9384			L02BG06	EXEMESTANE	258494			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
J04AM05	RIFAMPICIN	9384			L02BG06	EXEMESTANE	258494			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
J04AM06	RIFAMPICIN	9384			L02BG06	EXEMESTANE	258494			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
J04AB02	RIFAMPICIN	9384			N01AH01	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AB02	RIFAMPICIN	9384			N02AB03	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AB02	RIFAMPICIN	9384			N01AH51	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM02	RIFAMPICIN	9384			N01AH01	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM02	RIFAMPICIN	9384			N02AB03	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM02	RIFAMPICIN	9384			N01AH51	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM05	RIFAMPICIN	9384			N01AH01	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM05	RIFAMPICIN	9384			N02AB03	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM05	RIFAMPICIN	9384			N01AH51	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM06	RIFAMPICIN	9384			N01AH01	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM06	RIFAMPICIN	9384			N02AB03	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AM06	RIFAMPICIN	9384			N01AH51	FENTANYL	4337			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	Choose another opioid.
J04AB02	RIFAMPICIN	9384			D01AC15	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AB02	RIFAMPICIN	9384			J02AC01	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM02	RIFAMPICIN	9384			D01AC15	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM02	RIFAMPICIN	9384			J02AC01	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM05	RIFAMPICIN	9384			D01AC15	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM05	RIFAMPICIN	9384			J02AC01	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM06	RIFAMPICIN	9384			D01AC15	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM06	RIFAMPICIN	9384			J02AC01	FLUCONAZOLE	4450			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AB02	RIFAMPICIN	9384						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			N05AD01	HALOPERIDOL	5093			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			N05AD01	HALOPERIDOL	5093			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			N05AD01	HALOPERIDOL	5093			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			N05AD01	HALOPERIDOL	5093			ANSM	445-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384						THYROID HORMONES	H03AA	ANSM	445-RIFAMPICIN.html	Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384						THYROID HORMONES	H03AA	ANSM	445-RIFAMPICIN.html	Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384						THYROID HORMONES	H03AA	ANSM	445-RIFAMPICIN.html	Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384						THYROID HORMONES	H03AA	ANSM	445-RIFAMPICIN.html	Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.	Precaution for use	Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			L01XX47	IDELALISIB	1544460			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM02	RIFAMPICIN	9384			L01XX47	IDELALISIB	1544460			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM05	RIFAMPICIN	9384			L01XX47	IDELALISIB	1544460			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM06	RIFAMPICIN	9384			L01XX47	IDELALISIB	1544460			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AB02	RIFAMPICIN	9384						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional data about the ritonavir boosted inhibitors is available.
J04AM02	RIFAMPICIN	9384						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional data about the ritonavir boosted inhibitors is available.
J04AM05	RIFAMPICIN	9384						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional data about the ritonavir boosted inhibitors is available.
J04AM06	RIFAMPICIN	9384						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	Contraindication	Until additional data about the ritonavir boosted inhibitors is available.
J04AB02	RIFAMPICIN	9384						METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
J04AM02	RIFAMPICIN	9384						METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
J04AM05	RIFAMPICIN	9384						METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
J04AM06	RIFAMPICIN	9384						METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
J04AB02	RIFAMPICIN	9384			J04AM03	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AC01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AC51	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AM02	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AM05	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AM06	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AM01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			J04AM04	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AM03	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AC01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AC51	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AM02	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AM05	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AM06	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AM01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM02	RIFAMPICIN	9384			J04AM04	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AM03	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AC01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AC51	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AM02	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AM05	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AM06	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AM01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM05	RIFAMPICIN	9384			J04AM04	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AM03	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AC01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AC51	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AM02	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AM05	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AM06	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AM01	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AM06	RIFAMPICIN	9384			J04AM04	ISONIAZID	6038			ANSM	445-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	Clinical monitoring and laboratory tests of this classic combination. In case of hepatitis, stop the isoniazid.
J04AB02	RIFAMPICIN	9384			C01EB17	IVABRADINE	77417			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.
J04AM02	RIFAMPICIN	9384			C01EB17	IVABRADINE	77417			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.
J04AM05	RIFAMPICIN	9384			C01EB17	IVABRADINE	77417			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.
J04AM06	RIFAMPICIN	9384			C01EB17	IVABRADINE	77417			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.
J04AB02	RIFAMPICIN	9384			D01AC08	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AB02	RIFAMPICIN	9384			G01AF11	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AB02	RIFAMPICIN	9384			J02AB02	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM02	RIFAMPICIN	9384			D01AC08	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM02	RIFAMPICIN	9384			G01AF11	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM02	RIFAMPICIN	9384			J02AB02	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM05	RIFAMPICIN	9384			D01AC08	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM05	RIFAMPICIN	9384			G01AF11	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM05	RIFAMPICIN	9384			J02AB02	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM06	RIFAMPICIN	9384			D01AC08	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM06	RIFAMPICIN	9384			G01AF11	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM06	RIFAMPICIN	9384			J02AB02	KETOCONAZOLE	6135			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AB02	RIFAMPICIN	9384				LEDIPASVIR	1591922			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AM02	RIFAMPICIN	9384				LEDIPASVIR	1591922			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AM05	RIFAMPICIN	9384				LEDIPASVIR	1591922			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AM06	RIFAMPICIN	9384				LEDIPASVIR	1591922			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AB02	RIFAMPICIN	9384			J01XX08	LINEZOLIDE	190376			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J04AM02	RIFAMPICIN	9384			J01XX08	LINEZOLIDE	190376			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J04AM05	RIFAMPICIN	9384			J01XX08	LINEZOLIDE	190376			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J04AM06	RIFAMPICIN	9384			J01XX08	LINEZOLIDE	190376			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
J04AB02	RIFAMPICIN	9384			C07AB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			C07FB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			C07CB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			C07BB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			C07BB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			C07AB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07AB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07FB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07CB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07BB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07BB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07AB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07AB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07FB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07CB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07BB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07BB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07AB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07AB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07FB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07CB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07BB02	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07BB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07AB52	METOPROLOL	6918			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			A02BD08	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			A02BD03	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			A02BD02	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			A01AB17	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			D06BX01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			G01AF01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			J01XD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			P01AB01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			A02BD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			A02BD08	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			A02BD03	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			A02BD02	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			A01AB17	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			D06BX01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			G01AF01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			J01XD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			P01AB01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			A02BD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			A02BD08	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			A02BD03	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			A02BD02	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			A01AB17	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			D06BX01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			G01AF01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			J01XD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			P01AB01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			A02BD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			A02BD08	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			A02BD03	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			A02BD02	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			A01AB17	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			D06BX01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			G01AF01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			J01XD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			P01AB01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			A02BD01	METRONIDAZOLE	6922			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			N05CD08	MIDAZOLAM	6960			ANSM	445-RIFAMPICIN.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
J04AM02	RIFAMPICIN	9384			N05CD08	MIDAZOLAM	6960			ANSM	445-RIFAMPICIN.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
J04AM05	RIFAMPICIN	9384			N05CD08	MIDAZOLAM	6960			ANSM	445-RIFAMPICIN.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
J04AM06	RIFAMPICIN	9384			N05CD08	MIDAZOLAM	6960			ANSM	445-RIFAMPICIN.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
J04AB02	RIFAMPICIN	9384						MINERALOCORTICOIDS	H02AA0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384						MINERALOCORTICOIDS	H02AA0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384						MINERALOCORTICOIDS	H02AA0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384						MINERALOCORTICOIDS	H02AA0	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			R03DC03	MONTELUKAST	88249			ANSM	445-RIFAMPICIN.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			R03DC03	MONTELUKAST	88249			ANSM	445-RIFAMPICIN.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			R03DC03	MONTELUKAST	88249			ANSM	445-RIFAMPICIN.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			R03DC03	MONTELUKAST	88249			ANSM	445-RIFAMPICIN.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			A07DA52	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			N02AA01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			N02AA51	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			N02AG01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			R05DA05	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			A07DA52	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			N02AA01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			N02AA51	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			N02AG01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384			R05DA05	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			A07DA52	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			N02AA01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			N02AA51	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			N02AG01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384			R05DA05	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			A07DA52	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			N02AA01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			N02AA51	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			N02AG01	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384			R05DA05	MORPHINE	7052			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			J05AG01	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AB02	RIFAMPICIN	9384			J05AR07	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AB02	RIFAMPICIN	9384			J05AR05	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM02	RIFAMPICIN	9384			J05AG01	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM02	RIFAMPICIN	9384			J05AR07	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM02	RIFAMPICIN	9384			J05AR05	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM05	RIFAMPICIN	9384			J05AG01	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM05	RIFAMPICIN	9384			J05AR07	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM05	RIFAMPICIN	9384			J05AR05	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM06	RIFAMPICIN	9384			J05AG01	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM06	RIFAMPICIN	9384			J05AR07	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AM06	RIFAMPICIN	9384			J05AR05	NEVIRAPINE	53654			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
J04AB02	RIFAMPICIN	9384			C08CA06	NIMODIPINE	7426			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
J04AM02	RIFAMPICIN	9384			C08CA06	NIMODIPINE	7426			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
J04AM05	RIFAMPICIN	9384			C08CA06	NIMODIPINE	7426			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
J04AM06	RIFAMPICIN	9384			C08CA06	NIMODIPINE	7426			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.
J04AB02	RIFAMPICIN	9384			N03AX22	PERAMPANEL	1356552			ANSM	445-RIFAMPICIN.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
J04AM02	RIFAMPICIN	9384			N03AX22	PERAMPANEL	1356552			ANSM	445-RIFAMPICIN.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
J04AM05	RIFAMPICIN	9384			N03AX22	PERAMPANEL	1356552			ANSM	445-RIFAMPICIN.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
J04AM06	RIFAMPICIN	9384			N03AX22	PERAMPANEL	1356552			ANSM	445-RIFAMPICIN.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
J04AB02	RIFAMPICIN	9384			J02AC04	POSACONAZOLE	282446			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM02	RIFAMPICIN	9384			J02AC04	POSACONAZOLE	282446			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM05	RIFAMPICIN	9384			J02AC04	POSACONAZOLE	282446			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AM06	RIFAMPICIN	9384			J02AC04	POSACONAZOLE	282446			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
J04AB02	RIFAMPICIN	9384			P02BA01	PRAZIQUANTEL	8628			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
J04AM02	RIFAMPICIN	9384			P02BA01	PRAZIQUANTEL	8628			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
J04AM05	RIFAMPICIN	9384			P02BA01	PRAZIQUANTEL	8628			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
J04AM06	RIFAMPICIN	9384			P02BA01	PRAZIQUANTEL	8628			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	Contraindication	
J04AB02	RIFAMPICIN	9384			C01BC03	PROPAFENONE	8754			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.
J04AM02	RIFAMPICIN	9384			C01BC03	PROPAFENONE	8754			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.
J04AM05	RIFAMPICIN	9384			C01BC03	PROPAFENONE	8754			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.
J04AM06	RIFAMPICIN	9384			C01BC03	PROPAFENONE	8754			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.
J04AB02	RIFAMPICIN	9384			C07AA05	PROPRANOLOL	8787			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM02	RIFAMPICIN	9384			C07AA05	PROPRANOLOL	8787			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM05	RIFAMPICIN	9384			C07AA05	PROPRANOLOL	8787			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
J04AM06	RIFAMPICIN	9384			C07AA05	PROPRANOLOL	8787			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
J04AB02	RIFAMPICIN	9384			N05AH04	QUETIAPINE	51272			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
J04AM02	RIFAMPICIN	9384			N05AH04	QUETIAPINE	51272			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
J04AM05	RIFAMPICIN	9384			N05AH04	QUETIAPINE	51272			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
J04AM06	RIFAMPICIN	9384			N05AH04	QUETIAPINE	51272			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
J04AB02	RIFAMPICIN	9384			P01BC01	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AB02	RIFAMPICIN	9384			M09AA72	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AB02	RIFAMPICIN	9384			M09AA	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM02	RIFAMPICIN	9384			P01BC01	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM02	RIFAMPICIN	9384			M09AA72	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM02	RIFAMPICIN	9384			M09AA	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM05	RIFAMPICIN	9384			P01BC01	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM05	RIFAMPICIN	9384			M09AA72	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM05	RIFAMPICIN	9384			M09AA	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM06	RIFAMPICIN	9384			P01BC01	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM06	RIFAMPICIN	9384			M09AA72	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AM06	RIFAMPICIN	9384			M09AA	QUININE	9071			ANSM	445-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
J04AB02	RIFAMPICIN	9384			J05AX08	RALTEGRAVIR	719872			ANSM	445-RIFAMPICIN.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these together cannot be avoided, doubling the dose of raltegravir can be considered
J04AM02	RIFAMPICIN	9384			J05AX08	RALTEGRAVIR	719872			ANSM	445-RIFAMPICIN.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these together cannot be avoided, doubling the dose of raltegravir can be considered
J04AM05	RIFAMPICIN	9384			J05AX08	RALTEGRAVIR	719872			ANSM	445-RIFAMPICIN.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these together cannot be avoided, doubling the dose of raltegravir can be considered
J04AM06	RIFAMPICIN	9384			J05AX08	RALTEGRAVIR	719872			ANSM	445-RIFAMPICIN.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	If administering these together cannot be avoided, doubling the dose of raltegravir can be considered
J04AB02	RIFAMPICIN	9384			C01EB18	RANOLAZINE	35829			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
J04AM02	RIFAMPICIN	9384			C01EB18	RANOLAZINE	35829			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
J04AM05	RIFAMPICIN	9384			C01EB18	RANOLAZINE	35829			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
J04AM06	RIFAMPICIN	9384			C01EB18	RANOLAZINE	35829			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of ranolazine. 	Not recommended	
J04AB02	RIFAMPICIN	9384			B01AF01	RIVAROXABAN	1114195			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
J04AM02	RIFAMPICIN	9384			B01AF01	RIVAROXABAN	1114195			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
J04AM05	RIFAMPICIN	9384			B01AF01	RIVAROXABAN	1114195			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
J04AM06	RIFAMPICIN	9384			B01AF01	RIVAROXABAN	1114195			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
J04AB02	RIFAMPICIN	9384			C10AA01	SIMVASTATIN	36567			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
J04AM02	RIFAMPICIN	9384			C10AA01	SIMVASTATIN	36567			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
J04AM05	RIFAMPICIN	9384			C10AA01	SIMVASTATIN	36567			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
J04AM06	RIFAMPICIN	9384			C10AA01	SIMVASTATIN	36567			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
J04AB02	RIFAMPICIN	9384			J05AE11	TELAPREVIR	1102261			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J04AM02	RIFAMPICIN	9384			J05AE11	TELAPREVIR	1102261			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J04AM05	RIFAMPICIN	9384			J05AE11	TELAPREVIR	1102261			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J04AM06	RIFAMPICIN	9384			J05AE11	TELAPREVIR	1102261			ANSM	445-RIFAMPICIN.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J04AB02	RIFAMPICIN	9384			J01FA15	TELITHROMYCIN	274786			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin. 	Not recommended	
J04AM02	RIFAMPICIN	9384			J01FA15	TELITHROMYCIN	274786			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin. 	Not recommended	
J04AM05	RIFAMPICIN	9384			J01FA15	TELITHROMYCIN	274786			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin. 	Not recommended	
J04AM06	RIFAMPICIN	9384			J01FA15	TELITHROMYCIN	274786			ANSM	445-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the anti-infective treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin. 	Not recommended	
J04AB02	RIFAMPICIN	9384			D01AE15	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AB02	RIFAMPICIN	9384			D01BA02	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AM02	RIFAMPICIN	9384			D01AE15	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AM02	RIFAMPICIN	9384			D01BA02	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AM05	RIFAMPICIN	9384			D01AE15	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AM05	RIFAMPICIN	9384			D01BA02	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AM06	RIFAMPICIN	9384			D01AE15	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AM06	RIFAMPICIN	9384			D01BA02	TERBINAFINE	37801			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
J04AB02	RIFAMPICIN	9384						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			N03AG06	TIAGABINE	31914			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.
J04AM02	RIFAMPICIN	9384			N03AG06	TIAGABINE	31914			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.
J04AM05	RIFAMPICIN	9384			N03AG06	TIAGABINE	31914			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.
J04AM06	RIFAMPICIN	9384			N03AG06	TIAGABINE	31914			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.
J04AB02	RIFAMPICIN	9384			B01AC24	TICAGRELOR	1116632			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
J04AM02	RIFAMPICIN	9384			B01AC24	TICAGRELOR	1116632			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
J04AM05	RIFAMPICIN	9384			B01AC24	TICAGRELOR	1116632			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
J04AM06	RIFAMPICIN	9384			B01AC24	TICAGRELOR	1116632			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
J04AB02	RIFAMPICIN	9384			G03AD02	ULIPRISTAL	1005921			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
J04AM02	RIFAMPICIN	9384			G03AD02	ULIPRISTAL	1005921			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
J04AM05	RIFAMPICIN	9384			G03AD02	ULIPRISTAL	1005921			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
J04AM06	RIFAMPICIN	9384			G03AD02	ULIPRISTAL	1005921			ANSM	445-RIFAMPICIN.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized.
J04AB02	RIFAMPICIN	9384						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	445-RIFAMPICIN.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped. 
J04AM02	RIFAMPICIN	9384						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	445-RIFAMPICIN.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped. 
J04AM05	RIFAMPICIN	9384						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	445-RIFAMPICIN.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped. 
J04AM06	RIFAMPICIN	9384						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	445-RIFAMPICIN.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped. 
J04AB02	RIFAMPICIN	9384			J02AC03	VORICONAZOLE	121243			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AM02	RIFAMPICIN	9384			J02AC03	VORICONAZOLE	121243			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AM05	RIFAMPICIN	9384			J02AC03	VORICONAZOLE	121243			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AM06	RIFAMPICIN	9384			J02AC03	VORICONAZOLE	121243			ANSM	445-RIFAMPICIN.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J04AB02	RIFAMPICIN	9384			N05CF02	ZOLPIDEM	39993			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AM02	RIFAMPICIN	9384			N05CF02	ZOLPIDEM	39993			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AM05	RIFAMPICIN	9384			N05CF02	ZOLPIDEM	39993			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AM06	RIFAMPICIN	9384			N05CF02	ZOLPIDEM	39993			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AB02	RIFAMPICIN	9384			N05CF01	ZOPICLONE	40001			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AM02	RIFAMPICIN	9384			N05CF01	ZOPICLONE	40001			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AM05	RIFAMPICIN	9384			N05CF01	ZOPICLONE	40001			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J04AM06	RIFAMPICIN	9384			N05CF01	ZOPICLONE	40001			ANSM	445-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
J05AG05	RILPIVIRINE	1102270						PROTON PUMP INHIBITORS	A02BC-001	ANSM	446-RILPIVIRINE.html	Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption because of increase of the gastric pH)	Contraindication	
J05AG05	RILPIVIRINE	1102270			A01AC02	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			C05AA09	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			D07AB19	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			D07XB05	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			D10AA03	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			H02AB02	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			R01AD03	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S01BA01	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S01CB01	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S02BA06	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S03BA01	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			D07CB04	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S01CA01	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S02CA06	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			S03CA01	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270			R01AD53	DEXAMETHASONE	3264			ANSM	446-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	Contraindication	With the exception of dexamethasone administered in a single dose
J05AG05	RILPIVIRINE	1102270						ENZYMATIC INDUCERS	N03-J05-001	ANSM	446-RILPIVIRINE.html	Large decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer	Contraindication	
J05AG05	RILPIVIRINE	1102270				ST JOHNS WORT	258326			ANSM	446-RILPIVIRINE.html	Risk of decrease of the plasma concentratons of rilpivirine due to increase of its hepatic metabolism by the St Johns wort	Contraindication	
C02KX05	RIOCIGUAT	1439816						NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	447-RIOCIGUAT.html	Risk of serious hypotension (synergic effect)	Contraindication	
C02KX05	RIOCIGUAT	1439816						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	447-RIOCIGUAT.html	Risk of serious hypotension (synergic effect)	Contraidication	
C02KX05	RIOCIGUAT	1439816						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	447-RIOCIGUAT.html	Increase of the plasma concentrations of riociguat due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
N05AX08	RISPERIDONE	35636			N03AF01	CARBAMAZEPINE	2002			ANSM	448-RISPERIDONE.html	Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.
N05AX08	RISPERIDONE	35636			N06AB03	FLUOXETINE	4493			ANSM	448-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of the undesirable effects	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. 
N05AX08	RISPERIDONE	35636			N06CA03	FLUOXETINE	4493			ANSM	448-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of the undesirable effects	Precaution for use	Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. 
N05AX08	RISPERIDONE	35636			N06AB05	PAROXETINE	32937			ANSM	448-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. 	Precaution for use	Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. 
J05AE03	RITONAVIR	85762			J05AX09	MARAVIROC	620216			ANSM	449-RITONAVIR.html	In the case of administration with fosamprenavir, significant decrease of the concentrations of ritonavir which can lead to a loss of the virological response	Not recommended	
			CALCIUM CHANNEL BLOCKERS	CO8CA-001				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	with the nimodipine
			CALCIUM CHANNEL BLOCKERS	CO8CA-001				STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.	Precaution for use	Clinical monitoring and adjustment of the dosage during the treatment with the enzyme inhibitor and after it is stopped. 
			CALCIUM CHANNEL BLOCKERS	CO8CA-001	J04AB02	RIFAMPICIN	9384			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
			CALCIUM CHANNEL BLOCKERS	CO8CA-001	J04AM02	RIFAMPICIN	9384			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
			CALCIUM CHANNEL BLOCKERS	CO8CA-001	J04AM05	RIFAMPICIN	9384			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
			CALCIUM CHANNEL BLOCKERS	CO8CA-001	J04AM06	RIFAMPICIN	9384			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended with the nimodipine	Precaution for use
B01AF01	RIVAROXABAN	1114195						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	450-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.	Not recommended	
B01AF01	RIVAROXABAN	1114195						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	450-RIVAROXABAN.html	Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding	Not recommended	
B01AF01	RIVAROXABAN	1114195			J04AB02	RIFAMPICIN	9384			ANSM	450-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
B01AF01	RIVAROXABAN	1114195			J04AM02	RIFAMPICIN	9384			ANSM	450-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
B01AF01	RIVAROXABAN	1114195			J04AM05	RIFAMPICIN	9384			ANSM	450-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
B01AF01	RIVAROXABAN	1114195			J04AM06	RIFAMPICIN	9384			ANSM	450-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
N04BC04	ROPINIROLE	72302						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	451-ROPINIROLE.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped. 
N04BC04	ROPINIROLE	72302			J01MA02	CIPROFLOXACIN	2551			ANSM	451-ROPINIROLE.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
N04BC04	ROPINIROLE	72302			S01AE03	CIPROFLOXACIN	2551			ANSM	451-ROPINIROLE.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
N04BC04	ROPINIROLE	72302			S02AA15	CIPROFLOXACIN	2551			ANSM	451-ROPINIROLE.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
N04BC04	ROPINIROLE	72302			S03AA07	CIPROFLOXACIN	2551			ANSM	451-ROPINIROLE.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 
N04BC04	ROPINIROLE	72302			J01MA04	ENOXACIN	3925			ANSM	451-ROPINIROLE.html	Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. 
N04BC04	ROPINIROLE	72302			N06AB08	FLUVOXAMINE	42355			ANSM	451-ROPINIROLE.html	Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. 
C10AA07	ROSUVASTATIN	301542			L04AD01	CICLOSPORIN	3008			ANSM	452-ROSUVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	Contraindication	
C10AA07	ROSUVASTATIN	301542			S01XA18	CICLOSPORIN	3008			ANSM	452-ROSUVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	Contraindication	
C10AA07	ROSUVASTATIN	301542						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	452-ROSUVASTATIN.html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	Clinical monitoring and laboratory tests.
J01FA06	ROXITHROMYCIN	9478			C10AA05	ATORVASTATIN	83367			ANSM	453-ROXITHROMYCIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	Use weaker doses of the cholesterol lowering medication
J01FA06	ROXITHROMYCIN	9478			L04AD01	CICLOSPORIN	3008			ANSM	453-ROXITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. 
J01FA06	ROXITHROMYCIN	9478			S01XA18	CICLOSPORIN	3008			ANSM	453-ROXITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. 
J01FA06	ROXITHROMYCIN	9478						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	453-ROXITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of these medications together. 
J01FA06	ROXITHROMYCIN	9478			N05CD08	MIDAZOLAM	6960			ANSM	453-ROXITHROMYCIN.html	Slight increase of sedation	Take into account	
J01FA06	ROXITHROMYCIN	9478			C10AA01	SIMVASTATIN	36567			ANSM	453-ROXITHROMYCIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	Use lower doses of the cholesterol lowering medication
J01FA06	ROXITHROMYCIN	9478						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	453-ROXITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
N03AF03	RUFINAMIDE	69036						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	454-RUFINAMIDE.html	Moderate decrease of the concentrations of ethinylestradiol	Precaution for use	Another contraceptive method, in particular a barrier type or IUD, should be used. 
N03AF03	RUFINAMIDE	69036						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	454-RUFINAMIDE.html	Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg.	Precaution for use	With children who weigh less than 30 kg: do not exceed the total dose of 600mg/day after the period of titration. 
R03AC12	SALMETEROL	36117			J02AC02	ITRACONAZOLE	28031			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
R03AK06	SALMETEROL	36117			J02AC02	ITRACONAZOLE	28031			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
R03AC12	SALMETEROL	36117			D01AC08	KETOCONAZOLE	6135			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
R03AC12	SALMETEROL	36117			G01AF11	KETOCONAZOLE	6135			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
R03AC12	SALMETEROL	36117			J02AB02	KETOCONAZOLE	6135			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
R03AK06	SALMETEROL	36117			D01AC08	KETOCONAZOLE	6135			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
R03AK06	SALMETEROL	36117			G01AF11	KETOCONAZOLE	6135			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
R03AK06	SALMETEROL	36117			J02AB02	KETOCONAZOLE	6135			ANSM	455-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
N06AB06	SERTRALINE	36437				GRAPEFRUIT JUICE 				ANSM	456-SERTRALINE.html	Increase, sometimes large, of the concentrations of the antidepressant with some patients due to decrease of its intestinal metabolism	Not recommended	
N06AB06	SERTRALINE	36437						ENZYMATIC INDUCERS	N03-J05-001	ANSM	456-SERTRALINE.html	Risk of ineffectiveness of the treatment with the antidepressant	Not recommended	
N06AB06	SERTRALINE	36437			N05AG02	PIMOZIDE	8331			ANSM	456-SERTRALINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
G04BE03	SILDENAFIL	136411			J01FA07	JOSAMYCIN	6084			ANSM	457-SILDENAFIL.html	Increase of the plasma concentrations of sildenafil, with risk of hypotension	Precaution for use	Start the treatment with sildenafil at the minimum dose when it is administered with the josamycin
G04BE03	SILDENAFIL	136411						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	457-SILDENAFIL.html	Increase of he plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir	Contraindication	
J05AE14	SIMEPREVIR	1482790			A01AC02	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			C05AA09	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			D07AB19	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			D07XB05	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			D10AA03	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			H02AB02	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			R01AD03	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S01BA01	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S01CB01	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S02BA06	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S03BA01	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			D07CB04	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S01CA01	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S02CA06	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			S03CA01	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790			R01AD53	DEXAMETHASONE	3264			ANSM	458-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	With the exception of dexamethasone administered in a single dose
J05AE14	SIMEPREVIR	1482790						ENZYMATIC INDUCERS	N03-J05-001	ANSM	458-SIMEPREVIR.html	Decrease of he plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer	Not recommended	
J05AE14	SIMEPREVIR	1482790						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	458-SIMEPREVIR.html	Risk of increase of the plasma concentrations of simeprevir due to decrease of its heptatic metabolism by the inhibitor	Not recommended	
J05AE14	SIMEPREVIR	1482790				ST JOHNS WORT	258326			ANSM	458-SIMEPREVIR.html	Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
C10AA01	SIMVASTATIN	36567				GRAPEFRUIT JUICE				ANSM	459-SIMVASTATIN.html	Significant increase of the plasma concentrations of the cholesterol lowering agent, with risk of onset of undesirable effects, especially muscular	Not recommended	
C10AA01	SIMVASTATIN	36567			C01BD01	AMIODARONE	703			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C08CA01	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09BB04	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09DB01	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09DB02	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C10BX03	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09BB03	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09DB04	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09DX01	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C08GA02	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09BX01	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09DB07	AMLODIPINE	17767			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 	Precaution for use	Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			J01FA10	AZITHROMYCIN 	18631			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Precaution for use	Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			N03AF01	CARBAMAZEPINE	2002			ANSM	459-SIMVASTATIN.html	Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism	Not recommended	
C10AA01	SIMVASTATIN	36567			L04AD01	CICLOSPORIN	3008			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	Precaution for use	Do not exceed the dosage of 10 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
C10AA01	SIMVASTATIN	36567			S01XA18	CICLOSPORIN	3008			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	Precaution for use	Do not exceed the dosage of 10 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction.
C10AA01	SIMVASTATIN	36567			J01FA09	CLARITHROMYCIN	21212			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Contraindication	
C10AA01	SIMVASTATIN	36567			A02BD04	CLARITHROMYCIN	21212			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Contraindication	
C10AA01	SIMVASTATIN	36567			A02BD05	CLARITHROMYCIN	21212			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Contraindication	
C10AA01	SIMVASTATIN	36567			A02BD06	CLARITHROMYCIN	21212			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Contraindication	
C10AA01	SIMVASTATIN	36567			A02BD07	CLARITHROMYCIN	21212			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Contraindication	
C10AA01	SIMVASTATIN	36567			G03XA01	DANAZOL	3102			ANSM	459-SIMVASTATIN.html	Increased risk of onset of rhabdomyolysis	Not recommended	If administering these medications together is deemed necessary, do not exceed the dose of 10 mg of simvastatin. 
C10AA01	SIMVASTATIN	36567			C08DB01	DILTIAZEM	3443			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction. 
C10AA01	SIMVASTATIN	36567			C01BD07	DRONEDARONE	233698			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Not recommended	
C10AA01	SIMVASTATIN	36567			D10AF02	ERYTHROMYCIN	4053			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication	
C10AA01	SIMVASTATIN	36567			D10AF52	ERYTHROMYCIN	4053			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication	
C10AA01	SIMVASTATIN	36567			J01FA01	ERYTHROMYCIN	4053			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication	
C10AA01	SIMVASTATIN	36567			S01AA17	ERYTHROMYCIN	4053			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication	
C10AA01	SIMVASTATIN	36567						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Contraindication	
C10AA01	SIMVASTATIN	36567			J02AC02	ITRACONAZOLE	28031			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Contraindication	
C10AA01	SIMVASTATIN	36567			D01AC08	KETOCONAZOLE	6135			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication 	Use a statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			G01AF11	KETOCONAZOLE	6135			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication 	Use a statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			J02AB02	KETOCONAZOLE	6135			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication 	Use a statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567				ST JOHNS WORT	258326			ANSM	459-SIMVASTATIN.html	Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
C10AA01	SIMVASTATIN	36567						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	459-SIMVASTATIN.html	Increase of the plasma concentrations of simvastatin due to decrease of its hepatic metabolism by the therapy with ombitavir+paritaprevir	Not recommended	
C10AA01	SIMVASTATIN	36567			J02AC04	POSACONAZOLE	282446			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor).	Contraindication	
C10AA01	SIMVASTATIN	36567			C01EB18	RANOLAZINE	35829			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine	Precaution for use	Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			J04AB02	RIFAMPICIN	9384			ANSM	459-SIMVASTATIN.html	Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
C10AA01	SIMVASTATIN	36567			J04AM02	RIFAMPICIN	9384			ANSM	459-SIMVASTATIN.html	Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
C10AA01	SIMVASTATIN	36567			J04AM05	RIFAMPICIN	9384			ANSM	459-SIMVASTATIN.html	Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
C10AA01	SIMVASTATIN	36567			J04AM06	RIFAMPICIN	9384			ANSM	459-SIMVASTATIN.html	Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
C10AA01	SIMVASTATIN	36567			J01FA06	ROXITHROMYCIN	9478			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	Use weaker doses of the cholesterol lowering agent.
C10AA01	SIMVASTATIN	36567			N03AX17	STIRIPENTOL	37119			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication	
C10AA01	SIMVASTATIN	36567			J05AE11	TELAPREVIR	1102261			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Contraindication	
C10AA01	SIMVASTATIN	36567			J01FA15	TELITHROMYCIN	274786			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)	Contraindication	
C10AA01	SIMVASTATIN	36567			C08DA01	VERAPAMIL	11170			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C08DA51	VERAPAMIL	11170			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			C09BB10	VERAPAMIL	11170			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction
C10AA01	SIMVASTATIN	36567			J02AC03	VORICONAZOLE	121243			ANSM	459-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin	Contraindication	
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C09XA02	ALISKIREN	325646			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication	- for patients with diabetes or renal insufficiency
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C09XA52	ALISKIREN	325646			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication	- for patients with diabetes or renal insufficiency
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C09DX02	ALISKIREN	325646			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication	- for patients with diabetes or renal insufficiency
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilater prostaglandins due to the non steroidal anti-inflammatories.) These effects are generally reversible. In addition, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001				POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Except for the eplerenone and the spironolactone in doses between 12.5mg and 50mg/day for the treatment of heart failure as well as in cases of hypokalemia: Risk of hyperkalemia (possibly lethal) especially when there is renal insufficiency (addition of the effects of the hyperkalemia inducing substances).	Not recommended	If administering these medications together is justified, strict testing of the kalemia and of the renal function.
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001				POTASSIUM LOWERING DIURETICS	C03	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning or at an increase of the dosage of a treatment with an angiotensin II antagonist in cases where there is pre-existing fluid depletion. 	Precaution for use	With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	C03DA04	EPLERENONE	298869			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Increase of the risk of hyperkalemia, especially with older patients	Precaution for use	Strict testing of the kalemia and of the renal function during the administration of these substances together. 
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001				ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	In situations where the administration of these substances together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness. 	Take into account	
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	D11AX04	LITHIUM	6448			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Increase of the lithemia that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If the use of an angiotensin II antagonist is indispensable, strict monitoring of the lithemia and adjustment of the dosage
			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	A12BA	POTASSIUM	8588			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).	Not recommended	Avoid administering these substances together unless there is pre-existing hypokelimia. 
L04AA10	SIROLIMUS	35302			L04AD01	CICLOSPORIN	3008			ANSM	460-SIROLIMUS.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together 	Precaution for use	It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped
L04AA10	SIROLIMUS	35302			S01XA18	CICLOSPORIN	3008			ANSM	460-SIROLIMUS.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together 	Precaution for use	It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped
L04AA10	SIROLIMUS	35302			C08DA01	VERAPAMIL	11170			ANSM	460-SIROLIMUS.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
L04AA10	SIROLIMUS	35302			C08DA51	VERAPAMIL	11170			ANSM	460-SIROLIMUS.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
L04AA10	SIROLIMUS	35302			C09BB10	VERAPAMIL	11170			ANSM	460-SIROLIMUS.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
AUROTIOP	SODIUM AUROTHIO-PROPANOL-SULFONATE				M01AA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
AUROTIOP	SODIUM AUROTHIO-PROPANOL-SULFONATE				M02AA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
AUROTIOP	SODIUM AUROTHIO-PROPANOL-SULFONATE				M01BA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
46680	SODIUM AUROTHIO-PROPANOL-SULFONATE				M01AA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
46680	SODIUM AUROTHIO-PROPANOL-SULFONATE				M02AA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
46680	SODIUM AUROTHIO-PROPANOL-SULFONATE				M01BA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
M01CB05	SODIUM AUROTHIO-PROPANOL-SULFONATE				M01AA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
M01CB05	SODIUM AUROTHIO-PROPANOL-SULFONATE				M02AA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
M01CB05	SODIUM AUROTHIO-PROPANOL-SULFONATE				M01BA01	PHENYLBUTAZONE	8160			ANSM	461-SODIUM-AUROTHIOPROPANOLSULFONATE.html	For all the forms of phenylbutazone, including topical: increase of the risk of aplastic anemia	Not recommended	Choose another NSAI that is less interactive.
A02AH	SODIUM BICARBONATE	36676			D11AX04	LITHIUM	6448			ANSM	462-SODIUM-BICARBONATE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts. 	Precaution for use	Avoid excess amounts of sodium and take into account the presence of sodium in certain medications such as antacids.
B05CB04	SODIUM BICARBONATE	36676			D11AX04	LITHIUM	6448			ANSM	462-SODIUM-BICARBONATE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts. 	Precaution for use	Avoid excess amounts of sodium and take into account the presence of sodium in certain medications such as antacids.
B05XA02	SODIUM BICARBONATE	36676			D11AX04	LITHIUM	6448			ANSM	462-SODIUM-BICARBONATE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts. 	Precaution for use	Avoid excess amounts of sodium and take into account the presence of sodium in certain medications such as antacids.
A12CA01	SODIUM CHLORIDE	9863			D11AX04	LITHIUM	6448			ANSM	463-SODIUM-CHLORIDE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.
B05CB01	SODIUM CHLORIDE	9863			D11AX04	LITHIUM	6448			ANSM	463-SODIUM-CHLORIDE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.
B05XA03	SODIUM CHLORIDE	9863			D11AX04	LITHIUM	6448			ANSM	463-SODIUM-CHLORIDE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.
S01XA03	SODIUM CHLORIDE	9863			D11AX04	LITHIUM	6448			ANSM	463-SODIUM-CHLORIDE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.
N01AX11	SODIUM OXYBATE	9899				ALCOHOL (DRINK OF INGREDIENT)				ANSM	464-SODIUM-OXYBATE.html	Increase by the alcohol of the sedative effect of these substances. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	Avoid taking alcohol beverages and medications containing alcohol
ATCL	SODIUM OXYBATE	9899				ALCOHOL (DRINK OF INGREDIENT)				ANSM	464-SODIUM-OXYBATE.html	Increase by the alcohol of the sedative effect of these substances. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	Avoid taking alcohol beverages and medications containing alcohol
N07XX04	SODIUM OXYBATE	9899				ALCOHOL (DRINK OF INGREDIENT)				ANSM	464-SODIUM-OXYBATE.html	Increase by the alcohol of the sedative effect of these substances. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	Avoid taking alcohol beverages and medications containing alcohol
N01AX11	SODIUM OXYBATE	9899						SEDATIVE MEDICATIONS	N04-N05-N06	ANSM	464-SODIUM-OXYBATE.html	Increase of central depression. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	
ATCL	SODIUM OXYBATE	9899						SEDATIVE MEDICATIONS	N04-N05-N06	ANSM	464-SODIUM-OXYBATE.html	Increase of central depression. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	
N07XX04	SODIUM OXYBATE	9899						SEDATIVE MEDICATIONS	N04-N05-N06	ANSM	464-SODIUM-OXYBATE.html	Increase of central depression. The alteration of vigilence can make driving vehicles or operating machinery dangerous	Not recommended	
J05AX15	SOFOSBUVIR	1484911			C01BD01	AMIODARONE	703			ANSM	465-SOFOSBUVIR.html	Only for interactions with the combinatons daclatasvir/sofosbuvir or ledispavir/sofosbuvir:Onset of possibly abrupt bradycardia, that can have fatal consequences 	Not recommended	If administering these together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the combination.
J05AX15	SOFOSBUVIR	1484911						ENZYMATIC INDUCERS	N03-J05-001	ANSM	465-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of his intestinal absorption by the enzymatic inducer	Not recommended	
J05AX15	SOFOSBUVIR	1484911				ST JOHNS WORT	258326			ANSM	465-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the St Johns wort	Not recommended	
J05AX15	SOFOSBUVIR	1484911			N06BA07	MODAFINIL	30125			ANSM	465-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil	Not recommended	
G04BD08	SOLIFENACIN	322167			J01FA09	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04BD08	SOLIFENACIN	322167			A02BD04	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04BD08	SOLIFENACIN	322167			A02BD05	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04BD08	SOLIFENACIN	322167			A02BD06	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04BD08	SOLIFENACIN	322167			A02BD07	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04CA53	SOLIFENACIN	322167			J01FA09	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04CA53	SOLIFENACIN	322167			A02BD04	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04CA53	SOLIFENACIN	322167			A02BD05	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04CA53	SOLIFENACIN	322167			A02BD06	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04CA53	SOLIFENACIN	322167			A02BD07	CLARITHROMYCIN	21212			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the solifenacin.
G04BD08	SOLIFENACIN	322167			D10AF02	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			D10AF52	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J01FA01	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			S01AA17	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			D10AF02	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			D10AF52	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J01FA01	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			S01AA17	ERYTHROMYCIN	4053			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J02AC02	ITRACONAZOLE	28031			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J02AC02	ITRACONAZOLE	28031			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			D01AC08	KETOCONAZOLE	6135			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			G01AF11	KETOCONAZOLE	6135			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J02AB02	KETOCONAZOLE	6135			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			D01AC08	KETOCONAZOLE	6135			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			G01AF11	KETOCONAZOLE	6135			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J02AB02	KETOCONAZOLE	6135			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J05AE04	NELFINAVIR	134527			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J05AE04	NELFINAVIR	134527			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J02AC04	POSACONAZOLE	282446			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J02AC04	POSACONAZOLE	282446			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J01FA15	TELITHROMYCIN	274786			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J01FA15	TELITHROMYCIN	274786			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04BD08	SOLIFENACIN	322167			J02AC03	VORICONAZOLE	121243			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
G04CA53	SOLIFENACIN	322167			J02AC03	VORICONAZOLE	121243			ANSM	466-SOLIFENACIN.html	Increase of the concentrations of solifenacin, with risk of overdose.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
A06AD18	SORBITOL	9945			2161	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
A06AD18	SORBITOL	9945			V04CG01	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
A06AG07	SORBITOL	9945			2161	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
A06AG07	SORBITOL	9945			V04CG01	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
B05CX02	SORBITOL	9945			2161	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
B05CX02	SORBITOL	9945			V04CG01	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
V04CC01	SORBITOL	9945			2161	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
V04CC01	SORBITOL	9945			V04CG01	CATION EXCHANGE RESINS				ANSM	467-SORBITOL.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal. 	Not recommended	
			SPERMICIDES	R02AA		MEDICATIONS USED BY VAGINAL ROUTE				ANSM	468-SPERMICIDES.html	All topical vaginal treatment is susceptible to disrupting the action of a topical spermicidal contraceptive	Not recommended	
J01FA02	SPIRAMYCIN	9991			N04BA01	LEVODOPA	6375			ANSM	469-SPIRAMYCIN.html	In cases of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
J01FA02	SPIRAMYCIN	9991			N04BA02	LEVODOPA	6375			ANSM	469-SPIRAMYCIN.html	In cases of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
J01FA02	SPIRAMYCIN	9991			N04BA03	LEVODOPA	6375			ANSM	469-SPIRAMYCIN.html	In cases of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
J01RA04	SPIRAMYCIN	9991			N04BA01	LEVODOPA	6375			ANSM	469-SPIRAMYCIN.html	In cases of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
J01RA04	SPIRAMYCIN	9991			N04BA02	LEVODOPA	6375			ANSM	469-SPIRAMYCIN.html	In cases of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
J01RA04	SPIRAMYCIN	9991			N04BA03	LEVODOPA	6375			ANSM	469-SPIRAMYCIN.html	In cases of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the levodopa. 
			PLATELET AGGREGATION INHIBITORS	B01AC-001	L01XX3	ANAGRELIDE	596724			ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of hemorrhagic events 	Not recommended	
			PLATELET AGGREGATION INHIBITORS	B01AC-001				ORAL ANTICOAGULANTS	B01A-001	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage 	Take into account	
			PLATELET AGGREGATION INHIBITORS	B01AC-001	B01AX01	DEFIBROTIDE	1311089			ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increased risk of hemorrhage	Not recommended	
			PLATELET AGGREGATION INHIBITORS	B01AC-001				HEPARINS	B01AB	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage 	Take into account	
			PLATELET AGGREGATION INHIBITORS	B01AC-001				THROMBOLYTICS	B01AD	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
C03DA01	SPIRONOLACTONE	9997						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	470-SPIRONOLACTONE.html	With the spironolactone in dosages from 12.5 to 50 mg per day, and with low doses of the ACE inhibitor.In the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescribed doses for this combination of medications. 	Precaution for use	Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict laboratory testing of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter).
C03DA01	SPIRONOLACTONE	9997			L01XX23	MITOTANE	7004			ANSM	470-SPIRONOLACTONE.html	Risk of blocking of the action of the mitotane by the spironolactone	Contraindication	
J05AF04	STAVUDINE	59763			J04AM03	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AC01	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AC51	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AM02	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AM05	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AM06	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AM01	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			J04AM04	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AM03	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AC01	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AC51	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AM02	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AM05	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AM06	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AM01	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AR07	STAVUDINE	59763			J04AM04	ISONIAZID	6038			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
J05AF04	STAVUDINE	59763			P01CX01	PENTAMIDINE	7994			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects. 	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together. 
J05AR07	STAVUDINE	59763			P01CX01	PENTAMIDINE	7994			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects. 	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together. 
J05AF04	STAVUDINE	59763			J05AB04	RIBAVIRIN	9344			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites 	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AR07	STAVUDINE	59763			J05AB04	RIBAVIRIN	9344			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites 	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AF04	STAVUDINE	59763			L04AX02	THALIDOMIDE	10432			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AR07	STAVUDINE	59763			L04AX02	THALIDOMIDE	10432			ANSM	471-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AF04	STAVUDINE	59763			J05AF03	ZALCITABINE	3363			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AR07	STAVUDINE	59763			J05AF03	ZALCITABINE	3363			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AF04	STAVUDINE	59763			J05AF01	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AF04	STAVUDINE	59763			J05AR01	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AF04	STAVUDINE	59763			J05AR04	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AF04	STAVUDINE	59763			J05AR05	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AR07	STAVUDINE	59763			J05AF01	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AR07	STAVUDINE	59763			J05AR01	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AR07	STAVUDINE	59763			J05AR04	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
J05AR07	STAVUDINE	59763			J05AR05	ZIDOVUDINE 	11413			ANSM	471-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 	Not recommended	
N03AX17	STIRIPENTOL	37119						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	472-STIRIPENTOL.html	Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of its dosage. 
N03AX17	STIRIPENTOL	37119			C10AA05	ATORVASTATIN	83367			ANSM	472-STIRIPENTOL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the chlosterol lowering medication)	Contraindication	
N03AX17	STIRIPENTOL	37119			N06BC01	CAFFEINE 	1886			ANSM	472-STIRIPENTOL.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of caffeine. 
N03AX17	STIRIPENTOL	37119			V04CG30	CAFFEINE 	1886			ANSM	472-STIRIPENTOL.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and possible adjustment of the dosage of caffeine. 
N03AX17	STIRIPENTOL	37119			N05BA09	CLOBAZAM	21241			ANSM	472-STIRIPENTOL.html	Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of that anticonvulsant as well.
N03AX17	STIRIPENTOL	37119			N05BA01	DIAZEPAM	3322			ANSM	472-STIRIPENTOL.html	Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of the anticonvulsant as well.
N03AX17	STIRIPENTOL	37119			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	472-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	Contraindication	
N03AX17	STIRIPENTOL	37119			N02CA02	ERGOTAMINE	4025			ANSM	472-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	Contraindication	
N03AX17	STIRIPENTOL	37119			N02CA51	ERGOTAMINE	4025			ANSM	472-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	Contraindication	
N03AX17	STIRIPENTOL	37119			N02CA52	ERGOTAMINE	4025			ANSM	472-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	Contraindication	
N03AX17	STIRIPENTOL	37119			N02CA72	ERGOTAMINE	4025			ANSM	472-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	Contraindication	
N03AX17	STIRIPENTOL	37119			P01BX01	HALOFANTRINE	50749			ANSM	472-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades doe pointes. 	Not recommended	
N03AX17	STIRIPENTOL	37119						IMMUNOSUPPRESSANTS	L04A	ANSM	472-STIRIPENTOL.html	Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)	Contraindication	
N03AX17	STIRIPENTOL	37119			N05CD08	MIDAZOLAM	6960			ANSM	472-STIRIPENTOL.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation	Precaution for use	Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.
N03AX17	STIRIPENTOL	37119			N05AG02	PIMOZIDE	8331			ANSM	472-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N03AX17	STIRIPENTOL	37119			C01BA01	QUINIDINE	9068			ANSM	472-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N03AX17	STIRIPENTOL	37119			C01BA51	QUINIDINE	9068			ANSM	472-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N03AX17	STIRIPENTOL	37119			C01BA71	QUINIDINE	9068			ANSM	472-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
N03AX17	STIRIPENTOL	37119			C10AA01	SIMVASTATIN	36567			ANSM	472-STIRIPENTOL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Contraindication	
N03AX17	STIRIPENTOL	37119						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	472-STIRIPENTOL.html	Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism 	Precaution for use	Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline.
V10BX01	STRONTIUM	81638			A12AA	CALCIUM	1428011			ANSM	473-STRONTIUM .html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).
M05BX03	STRONTIUM	81638			A12AA	CALCIUM	1428011			ANSM	473-STRONTIUM .html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).
V10BX01	STRONTIUM	81638						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the tetracycline antibiotic (more than two hours apart, if possible).
M05BX03	STRONTIUM	81638						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the tetracycline antibiotic (more than two hours apart, if possible).
V10BX01	STRONTIUM	81638			B03A	IRON	1431589			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the iron salts (more than two hours apart, if possible).
M05BX03	STRONTIUM	81638			B03A	IRON	1431589			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the iron salts (more than two hours apart, if possible).
V10BX01	STRONTIUM	81638						FLUOROQUINOLONES	J01MA-001	ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the fluoroquinolones (more than two hours apart, if possible).
M05BX03	STRONTIUM	81638						FLUOROQUINOLONES	J01MA-001	ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the fluoroquinolones (more than two hours apart, if possible).
V10BX01	STRONTIUM	81638			A12CB	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
V10BX01	STRONTIUM	81638			A12CB01	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
V10BX01	STRONTIUM	81638			A12CB02	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
V10BX01	STRONTIUM	81638			A12CB03	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
V10BX01	STRONTIUM	81638			B05X	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
V10BX01	STRONTIUM	81638			B05XA	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
V10BX01	STRONTIUM	81638			B05XA12	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			A12CB	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			A12CB01	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			A12CB02	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			A12CB03	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			B05X	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			B05XA	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
M05BX03	STRONTIUM	81638			B05XA12	ZINC	1431163			ANSM	473-STRONTIUM .html	Decrease of the digestive absorption of the strontium.	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
			SUBSTRATES AT RISK OF CYP3A4	L01N01	L01XE16	CRIZOTINIB	1148495			ANSM	474-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib	Not recommended	
			SUBSTRATES AT RISK OF CYP3A4	L01N01	L01XX47	IDELALISIB	1544460			ANSM	474-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idealisib	Not recommended	
			SUBSTRATES AT RISK OF CYP3A4	L01N01				STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	474-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Increase of the undesirable effects particular to each substrate, with frequently severe consequences	Take into account	
A02BX02	SUCRALFATE	10156						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	475-SUCRALFATE.html	Decrease of the digestive absorption of the vitamin K antagonist	Precaution for use	Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible).
A02BX02	SUCRALFATE	10156			C01AA05	DIGOXIN 	3407			ANSM	475-SUCRALFATE.html	Decrease of the digestive absorption of the digoxin	Precaution for use	Take the sucralfate at a different time from the digoxin (more that 2 hours apart, if possible).
A02BX02	SUCRALFATE	10156						FLUOROQUINOLONES	J01MA-001	ANSM	475-SUCRALFATE.html	Decrease of the digestive absorption of the fluorquinolone	Precaution for use	Take the sucralfate at a different time from the fluoroquinolone (more than 2 hours apart, if possible). 
A02BX02	SUCRALFATE	10156						THYROID HORMONES	H03AA	ANSM	475-SUCRALFATE.html	Decrease of the digestive absorption of the thyroid hormones. 	Precaution for use	Take the thyroid hormones at a different time from the sucralfate (more than 2 hours apart, if possible).
A02BX02	SUCRALFATE	10156						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	475-SUCRALFATE.html	Decrease of the digestive absorption of the phenytoin	Precaution for use	Take the sucalfate at a different time from the phenytoin (more than 2 hours apart, if possible).
A02BX02	SUCRALFATE	10156			N05AL01	SULPIRIDE	10239			ANSM	475-SUCRALFATE.html	Decrease of the digestive absorption of the sulpiride	Precaution for use	Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible).
N01AH03	SUFENTANIL	56795						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	476-SUFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4. 
J01EB05	SULFAFURAZOLE	10207						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	477-SULFAFURAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.
S01AB02	SULFAFURAZOLE	10207						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	477-SULFAFURAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.
J01EB05	SULFAFURAZOLE	10207						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	477-SULFAFURAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	The use of another class of antibiotic is preferred; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-biotic and after it is stopped.
S01AB02	SULFAFURAZOLE	10207						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	477-SULFAFURAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	The use of another class of antibiotic is preferred; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-biotic and after it is stopped.
B05CA04	SULFAMETHIZOLE	10179						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	478-SULFAMETHIZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the anti-infective treatment and a week after it is stopped. 
D06BA04	SULFAMETHIZOLE	10179						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	478-SULFAMETHIZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the anti-infective treatment and a week after it is stopped. 
J01EB02	SULFAMETHIZOLE	10179						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	478-SULFAMETHIZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the anti-infective treatment and a week after it is stopped. 
S01AB01	SULFAMETHIZOLE	10179						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	478-SULFAMETHIZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the anti-infective treatment and a week after it is stopped. 
B05CA04	SULFAMETHIZOLE	10179			J01XX05	METHENAMINE	6832			ANSM	478-SULFAMETHIZOLE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
D06BA04	SULFAMETHIZOLE	10179			J01XX05	METHENAMINE	6832			ANSM	478-SULFAMETHIZOLE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
J01EB02	SULFAMETHIZOLE	10179			J01XX05	METHENAMINE	6832			ANSM	478-SULFAMETHIZOLE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
S01AB01	SULFAMETHIZOLE	10179			J01XX05	METHENAMINE	6832			ANSM	478-SULFAMETHIZOLE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
B05CA04	SULFAMETHIZOLE	10179						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	478-SULFAMETHIZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-infective and after it is stopped.
D06BA04	SULFAMETHIZOLE	10179						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	478-SULFAMETHIZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-infective and after it is stopped.
J01EB02	SULFAMETHIZOLE	10179						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	478-SULFAMETHIZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-infective and after it is stopped.
S01AB01	SULFAMETHIZOLE	10179						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	478-SULFAMETHIZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-infective and after it is stopped.
J01EC01	SULFAMETHOXAZOLE	10180						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	479-SULFAMETHOXAZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If the administration of the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. 
J01EE01	SULFAMETHOXAZOLE	10180						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	479-SULFAMETHOXAZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If the administration of the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. 
J01EC01	SULFAMETHOXAZOLE	10180						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	479-SULFAMETHOXAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-infective and after it is stopped.
J01EE01	SULFAMETHOXAZOLE	10180						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	479-SULFAMETHOXAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	Another class of anti-infective should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide anti-infective and after it is stopped.
			ANTIARRHYTHMIC AGENTS	C01B-001				OTHER ANTIARRHYTHMIC AGENTS	C01B-001	ANSM	48-ANTIARRHYTHMIC-AGENTS.html	The combination of two antiarrhythmic agents is very delicate. In the majority of cases, it is contraindicated or not recommended.	Contraindication	Not recommended 
			ANTIBACTERIAL SULFONAMIDES	JO1E	L01BA01	METHOTREXATE	6851			ANSM	480-ANTIBACTERIAL-SULFONAMIDES.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped. 
			ANTIBACTERIAL SULFONAMIDES	JO1E	L04AX03	METHOTREXATE	6851			ANSM	480-ANTIBACTERIAL-SULFONAMIDES.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB		ALCOHOL (DRINK OF INGREDIENT)				ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Antabuse effect, especially for glibenclamide, glipizide, tolbutamide. Increase of the hypoglycemic reaction (inhibition of the compensation reactions) that can make possible the onset of hypoglycemic coma	Not recommended	Avoid taking alcoholic beverages and medications containing alcohol. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB				SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the need for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	Reinforce self-monitoring of blood glucose and adjust the dosage of the blood glucose lowering sulfonamide if needed during the treatment with the somatostatin analog. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB				BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring. Possibly change to insulin if the situation requires. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of the treatment.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	N05AA01	CHLORPROMAZINE	2403			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With large doses (100mg per day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin) 	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the neuroleptic during the treatment and after it is stopped. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	J01FA09	CLARITHROMYCIN	21212			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	A02BD04	CLARITHROMYCIN	21212			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	A02BD05	CLARITHROMYCIN	21212			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	A02BD06	CLARITHROMYCIN	21212			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	A02BD07	CLARITHROMYCIN	21212			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	G03XA01	DANAZOL	3102			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Diabetes inducing effect of the danazol	Not recommended	If the administration of the substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	D01AC15	FLUCONAZOLE	4450			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Increase of the half life of the sulfonamide with possible onset of hypoglymemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	J02AC01	FLUCONAZOLE	4450			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Increase of the half life of the sulfonamide with possible onset of hypoglymemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB				ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)	Precaution for use	Reinforce self -monitoring of blood glucose.
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	A01AB09	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	A07AC01	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	D01AC02	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	G01AF04	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	J02AB01	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	S02AA13	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	D01AC52	MICONAZOLE	6932			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	Contraindication	
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	M01AA01	PHENYLBUTAZONE	8160			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	For all the forms of phenylbutazone, including topical: increase of the hypoglycemic effect of the sulfonamides due to decrease of their hepatic metabolism	Not recommended	Choose another anti-inflammatory that is less interactive; if not, inform the patient, reinforce self-monitoring of blood glucose; possibly adjust the dosage during the treatment with the anti-inflammatoryand after it is stopped. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	M02AA01	PHENYLBUTAZONE	8160			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	For all the forms of phenylbutazone, including topical: increase of the hypoglycemic effect of the sulfonamides due to decrease of their hepatic metabolism	Not recommended	Choose another anti-inflammatory that is less interactive; if not, inform the patient, reinforce self-monitoring of blood glucose; possibly adjust the dosage during the treatment with the anti-inflammatoryand after it is stopped. 
			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	M01BA01	PHENYLBUTAZONE	8160			ANSM	481-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	For all the forms of phenylbutazone, including topical: increase of the hypoglycemic effect of the sulfonamides due to decrease of their hepatic metabolism	Not recommended	Choose another anti-inflammatory that is less interactive; if not, inform the patient, reinforce self-monitoring of blood glucose; possibly adjust the dosage during the treatment with the anti-inflammatoryand after it is stopped. 
A07EC01	SULFASALAZINE	9524			C01AA05	DIGOXIN 	3407			ANSM	482-SULFASALAZINE.html	Decrease of the digoxinemia that can reach 50%	Precaution for use	Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.
M04AB02	SULFINPYRAZONE	10205			L04AD01	CICLOSPORIN	3008			ANSM	483-SULFINPYRAZONE.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped. 
M04AB02	SULFINPYRAZONE	10205			S01XA18	CICLOSPORIN	3008			ANSM	483-SULFINPYRAZONE.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped. 
N05AL01	SULPIRIDE	10239			A02BX02	SUCRALFATE	10156			ANSM	484-SULPIRIDE.html	Decrease of the digestive absorption of the sulpiride	Precaution for use	Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible). 
G02AD05	SULPROSTONE	37414			N02CA02	METHYLERGOMETRINE	6883			ANSM	485-SULPROSTONE.html	Risk of constriction of coronary blood vessels which can be fatal	Contraindication	
G02AD05	SULPROSTONE	37414			N02CA51	METHYLERGOMETRINE	6883			ANSM	485-SULPROSTONE.html	Risk of constriction of coronary blood vessels which can be fatal	Contraindication	
G02AD05	SULPROSTONE	37414			N02CA52	METHYLERGOMETRINE	6883			ANSM	485-SULPROSTONE.html	Risk of constriction of coronary blood vessels which can be fatal	Contraindication	
G02AD05	SULPROSTONE	37414			N02CA72	METHYLERGOMETRINE	6883			ANSM	485-SULPROSTONE.html	Risk of constriction of coronary blood vessels which can be fatal	Contraindication	
L01XE04	SUNITINIB	357977						THYROID HORMONES	H03AA	ANSM	486-SUNITINIB.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
M03AB01	SUXAMETHONIUM	10154						ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	ANSM	487-SUXAMETHONIUM.html	Risk of lengthening of the motor block, increased in the case of partial deficit of pseudo-cholinesterase 	Take into account	
			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA				DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	488-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA				VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	488-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	488-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped	Not recommended	
			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA				INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	488-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Contraindication	
			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA				HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	489-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA				TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	489-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Paroxysmal hypertension with the possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	489-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Increase of the pressor action of the sympathomimetic, most often moderate. 	Precaution for use	Only use under strict medical monitoring.
			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	489-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	By extrapolation from the non selective MAOIs: risk of increase of heart activation. 	Precaution for use	To be used only under strict medical monitoring.
			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA				MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	489-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html	Paroxysmal hypertension with possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003				BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	ANSM	49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html	Negative inotropic effect with risk of decompensated heart failure 	Contraindication	
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of hypertensive crises.	Contraindication	
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Perioperative hypertension	Precaution for use	In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery.
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Paroxystic hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped	Contraindication	
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA				ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	490-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Contraindication	
D11AH01	TACROLIMUS	42316						AMINOGLYCOSIDES	J01GB-001	ANSM	491-TACROLIMUS.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD02	TACROLIMUS	42316						AMINOGLYCOSIDES	J01GB-001	ANSM	491-TACROLIMUS.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
D11AH01	TACROLIMUS	42316			C01BD01	AMIODARONE	703			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during its administration with the amiodarone and when the amiodarone is stopped.
L04AD02	TACROLIMUS	42316			C01BD01	AMIODARONE	703			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone	Precaution for use	Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during its administration with the amiodarone and when the amiodarone is stopped.
D11AH01	TACROLIMUS	42316			A01AB04	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
D11AH01	TACROLIMUS	42316			A07AA07	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
D11AH01	TACROLIMUS	42316			G01AA03	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
D11AH01	TACROLIMUS	42316			J02AA01	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD02	TACROLIMUS	42316			A01AB04	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD02	TACROLIMUS	42316			A07AA07	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD02	TACROLIMUS	42316			G01AA03	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
L04AD02	TACROLIMUS	42316			J02AA01	AMPHOTERICIN B 	732			ANSM	491-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
D11AH01	TACROLIMUS	42316						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	491-TACROLIMUS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	Monitor renal function at the beginning of treatment with the NSAI.
L04AD02	TACROLIMUS	42316						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	491-TACROLIMUS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	Monitor renal function at the beginning of treatment with the NSAI.
D11AH01	TACROLIMUS	42316			D10AF01	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
D11AH01	TACROLIMUS	42316			G01AA10	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
D11AH01	TACROLIMUS	42316			J01FF01	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
D11AH01	TACROLIMUS	42316			D10AF51	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
L04AD02	TACROLIMUS	42316			D10AF01	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
L04AD02	TACROLIMUS	42316			G01AA10	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
L04AD02	TACROLIMUS	42316			J01FF01	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
L04AD02	TACROLIMUS	42316			D10AF51	CLINDAMYCIN	2582			ANSM	491-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 	Precaution for use	Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 
D11AH01	TACROLIMUS	42316			1037042	DABIGATRAN				ANSM	491-TACROLIMUS.html	Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
L04AD02	TACROLIMUS	42316			1037042	DABIGATRAN				ANSM	491-TACROLIMUS.html	Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Contraindication	
D11AH01	TACROLIMUS	42316			G03XA01	DANAZOL	3102			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.
L04AD02	TACROLIMUS	42316			G03XA01	DANAZOL	3102			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.
D11AH01	TACROLIMUS	42316						POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	491-TACROLIMUS.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
L04AD02	TACROLIMUS	42316						POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	491-TACROLIMUS.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
D11AH01	TACROLIMUS	42316			J01FA07	JOSAMYCIN	6084			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
L04AD02	TACROLIMUS	42316			J01FA07	JOSAMYCIN	6084			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
D11AH01	TACROLIMUS	42316			A02BC03	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
D11AH01	TACROLIMUS	42316			A02BD07	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
D11AH01	TACROLIMUS	42316			A02BD03	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
D11AH01	TACROLIMUS	42316			A02BD02	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
L04AD02	TACROLIMUS	42316			A02BC03	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
L04AD02	TACROLIMUS	42316			A02BD07	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
L04AD02	TACROLIMUS	42316			A02BD03	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
L04AD02	TACROLIMUS	42316			A02BD02	LANSOPRAZOLE	17128			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 
D11AH01	TACROLIMUS	42316			A02BC01	OMEPRAZOLE	7646			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
D11AH01	TACROLIMUS	42316			A02BD05	OMEPRAZOLE	7646			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
D11AH01	TACROLIMUS	42316			A02BD01	OMEPRAZOLE	7646			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
L04AD02	TACROLIMUS	42316			A02BC01	OMEPRAZOLE	7646			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
L04AD02	TACROLIMUS	42316			A02BD05	OMEPRAZOLE	7646			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
L04AD02	TACROLIMUS	42316			A02BD01	OMEPRAZOLE	7646			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.
D11AH01	TACROLIMUS	42316			A12BA	POTASSIUM	8588			ANSM	491-TACROLIMUS.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended 	Avoid administering these substances together unless there is preexisting hypokalemia.
L04AD02	TACROLIMUS	42316			A12BA	POTASSIUM	8588			ANSM	491-TACROLIMUS.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended 	Avoid administering these substances together unless there is preexisting hypokalemia.
D11AH01	TACROLIMUS	42316			C08DA01	VERAPAMIL	11170			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
D11AH01	TACROLIMUS	42316			C08DA51	VERAPAMIL	11170			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
D11AH01	TACROLIMUS	42316			C09BB10	VERAPAMIL	11170			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
L04AD02	TACROLIMUS	42316			C08DA01	VERAPAMIL	11170			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
L04AD02	TACROLIMUS	42316			C08DA51	VERAPAMIL	11170			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
L04AD02	TACROLIMUS	42316			C09BB10	VERAPAMIL	11170			ANSM	491-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
L02BA01	TAMOXIFEN	10324						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	492-TAMOXIFEN.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist.
L02BA01	TAMOXIFEN	10324			N06AX12	BUPROPION	42347			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic] 	Not recommended	
L02BA01	TAMOXIFEN	10324			N06AX21	DULOXETINE	72625			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine	Not recommended	
L02BA01	TAMOXIFEN	10324			N06AB03	FLUOXETINE	4493			ANSM	492-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine	Not recommended	
L02BA01	TAMOXIFEN	10324			N06CA03	FLUOXETINE	4493			ANSM	492-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine	Not recommended	
L02BA01	TAMOXIFEN	10324			N06AB05	PAROXETINE	32937			ANSM	492-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine	Not recommended	
L02BA01	TAMOXIFEN	10324			C01BA01	QUINIDINE	9068			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
L02BA01	TAMOXIFEN	10324			C01BA51	QUINIDINE	9068			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
L02BA01	TAMOXIFEN	10324			C01BA71	QUINIDINE	9068			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
L02BA01	TAMOXIFEN	10324			D01AE15	TERBINAFINE	37801			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine	Not recommended	
L02BA01	TAMOXIFEN	10324			D01BA02	TERBINAFINE	37801			ANSM	492-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine	Not recommended	
G04CA02	TAMSULOSINE	77492			C01BD01	AMIODARONE	703			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use 	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA52	TAMSULOSINE	77492			C01BD01	AMIODARONE	703			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use 	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA53	TAMSULOSINE	77492			C01BD01	AMIODARONE	703			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use 	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA02	TAMSULOSINE	77492			C08DB01	DILTIAZEM	3443			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA52	TAMSULOSINE	77492			C08DB01	DILTIAZEM	3443			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA53	TAMSULOSINE	77492			C08DB01	DILTIAZEM	3443			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA02	TAMSULOSINE	77492						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Not recommended	
G04CA52	TAMSULOSINE	77492						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Not recommended	
G04CA53	TAMSULOSINE	77492						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Not recommended	
G04CA02	TAMSULOSINE	77492			C08DA01	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA02	TAMSULOSINE	77492			C08DA51	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA02	TAMSULOSINE	77492			C09BB10	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA52	TAMSULOSINE	77492			C08DA01	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA52	TAMSULOSINE	77492			C08DA51	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA52	TAMSULOSINE	77492			C09BB10	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA53	TAMSULOSINE	77492			C08DA01	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA53	TAMSULOSINE	77492			C08DA51	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
G04CA53	TAMSULOSINE	77492			C09BB10	VERAPAMIL	11170			ANSM	493-TAMSULOSINE.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
J05AE11	TELAPREVIR	1102261						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	494-TELAPREVIR.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
J05AE11	TELAPREVIR	1102261			C01BD01	AMIODARONE	703			ANSM	494-TELAPREVIR.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	Contraindication	
J05AE11	TELAPREVIR	1102261						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	494-TELAPREVIR.html	Risk of very large decrease of the concentrations of telaprevir.	Contraindication	
J05AE11	TELAPREVIR	1102261			C10AA05	ATORVASTATIN	83367			ANSM	494-TELAPREVIR.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
J05AE11	TELAPREVIR	1102261			M04AC01	COLCHICINE	2683			ANSM	494-TELAPREVIR.html	Risk of increase of the undesirable effects of the colchicine, due to decrease of its metabolism	Not recommended	In particular with renal and hepatic insufficiency.
J05AE11	TELAPREVIR	1102261			C01AA05	DIGOXIN 	3407			ANSM	494-TELAPREVIR.html	Increase of the digoxinemia	Precaution for use	Clinical monitoring, laboratory tests, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped. 
J05AE11	TELAPREVIR	1102261						NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	494-TELAPREVIR.html	Decrease of the effectiveness of the estrogen	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped. 
J05AE11	TELAPREVIR	1102261						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	494-TELAPREVIR.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir	Precaution for use	Use an additional or alternative, reliable contraceptive method during the administration of the substances together and two cycles after. 
J05AE11	TELAPREVIR	1102261						IMMUNOSUPPRESSANTS	L04A	ANSM	494-TELAPREVIR.html	Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and afterit is stopped.
J05AE11	TELAPREVIR	1102261						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	494-TELAPREVIR.html	Large increase of the plasma concentrations of the PDE5 inhibitor, with risk of severe hypotension	Contraindication	-in cases of pulmonary artery hypertension
J05AE11	TELAPREVIR	1102261						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	494-TELAPREVIR.html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure	Not recommended	
J05AE11	TELAPREVIR	1102261			N05CD08	MIDAZOLAM	6960			ANSM	494-TELAPREVIR.html	Increase of the plasma concentrations of medazolam due to decrease of its hepatic metabolism, with increase of sedation	Contraindication	-with the midazolam by mouth
J05AE11	TELAPREVIR	1102261				ST JOHNS WORT	258326			ANSM	494-TELAPREVIR.html	Risk of very large decrease of the concentrations of telaprevir	Contraindication	
J05AE11	TELAPREVIR	1102261			J04AB02	RIFAMPICIN	9384			ANSM	494-TELAPREVIR.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J05AE11	TELAPREVIR	1102261			J04AM02	RIFAMPICIN	9384			ANSM	494-TELAPREVIR.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J05AE11	TELAPREVIR	1102261			J04AM05	RIFAMPICIN	9384			ANSM	494-TELAPREVIR.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J05AE11	TELAPREVIR	1102261			J04AM06	RIFAMPICIN	9384			ANSM	494-TELAPREVIR.html	Very large decrease of the concentrations of telaprevir	Contraindication	
J05AE11	TELAPREVIR	1102261			C10AA01	SIMVASTATIN	36567			ANSM	494-TELAPREVIR.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin	Contraindication	
J05AF11	TELBIVUDINE	474128			L03AB11	PEG-INTERFERON ALFA-2A	120608			ANSM	495-TELBIVUDINE.html	Increased risk of peripheral neuropathy	Contraindication	
J05AF11	TELBIVUDINE	474128			L03AB61	PEG-INTERFERON ALFA-2A	120608			ANSM	495-TELBIVUDINE.html	Increased risk of peripheral neuropathy	Contraindication	
J01FA15	TELITHROMYCIN	274786						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	496-TELITHROMYCIN.html	Risk of constriction of the coronary arteries or of the extremities (ergotism), or of rapid elevation of blood pressure 	Contrainication	
J01FA15	TELITHROMYCIN	274786						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	496-TELITHROMYCIN.html	Decrease of the plasma concentrations of telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the inducerr	Not recommended	
J01FA15	TELITHROMYCIN	274786			C10AA05	ATORVASTATIN	83367			ANSM	496-TELITHROMYCIN.html	Risk of increase of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication	Contraindication	
J01FA15	TELITHROMYCIN	274786			G04BD10	DARIFENACIN	136198			ANSM	496-TELITHROMYCIN.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin
J01FA15	TELITHROMYCIN	274786			A01AC02	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			C05AA09	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			D07AB19	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			D07XB05	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			D10AA03	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			H02AB02	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			R01AD03	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S01BA01	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S01CB01	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S02BA06	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S03BA01	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			D07CB04	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S01CA01	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S02CA06	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			S03CA01	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			R01AD53	DEXAMETHASONE	3264			ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
J01FA15	TELITHROMYCIN	274786			C01AA05	DIGOXIN 	3407			ANSM	496-TELITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the doginemia as well during the treatment with the telithromycin and after it is stopped.
J01FA15	TELITHROMYCIN	274786						IMMUNOSUPPRESSANTS	L04A	ANSM	496-TELITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	In case these are taken together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.
J01FA15	TELITHROMYCIN	274786						TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	496-TELITHROMYCIN.html	Increase of the plasma concentrations of the inhibitor of type 5 phosphodiesterase with risk of severe hypotension	Contraindication	--with the avanafil
J01FA15	TELITHROMYCIN	274786				ST JOHNS WORT	258326			ANSM	496-TELITHROMYCIN.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort	Not recommended	
J01FA15	TELITHROMYCIN	274786			R06AX25	MIZOLASTINE	61455			ANSM	496-TELITHROMYCIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Contraindication	
J01FA15	TELITHROMYCIN	274786			J04AB02	RIFAMPICIN	9384			ANSM	496-TELITHROMYCIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the telithromycin	Not recommended	
J01FA15	TELITHROMYCIN	274786			J04AM02	RIFAMPICIN	9384			ANSM	496-TELITHROMYCIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the telithromycin	Not recommended	
J01FA15	TELITHROMYCIN	274786			J04AM05	RIFAMPICIN	9384			ANSM	496-TELITHROMYCIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the telithromycin	Not recommended	
J01FA15	TELITHROMYCIN	274786			J04AM06	RIFAMPICIN	9384			ANSM	496-TELITHROMYCIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the telithromycin	Not recommended	
J01FA15	TELITHROMYCIN	274786			C10AA01	SIMVASTATIN	36567			ANSM	496-TELITHROMYCIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering drug). 	Contraindication	
J01FA15	TELITHROMYCIN	274786			G04BD08	SOLIFENACIN	322167			ANSM	496-TELITHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
J01FA15	TELITHROMYCIN	274786			G04CA53	SOLIFENACIN	322167			ANSM	496-TELITHROMYCIN.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin
J01FA15	TELITHROMYCIN	274786			N06AX16	VENLAFAXINE	39786			ANSM	496-TELITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
J01FA15	TELITHROMYCIN	274786						VINCA ALKALOIDS	L01CA	ANSM	496-TELITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic.
J01FA15	TELITHROMYCIN	274786			N05CF02	ZOLPIDEM	39993			ANSM	496-TELITHROMYCIN.html	Slight increase of the sedative effects of the zolpidem	Take into account	
J01FA15	TELITHROMYCIN	274786			N05CF01	ZOPICLONE	40001			ANSM	496-TELITHROMYCIN.html	Slight increase of the sedative effects of the zopiclone.	Take into account	
J05AR06	TENOFOVIR DISOPROXIL	300195						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir	Precaution for use	In case these are administered together, monitor renal function.
J05AR08	TENOFOVIR DISOPROXIL	300195						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir	Precaution for use	In case these are administered together, monitor renal function.
J05AR09	TENOFOVIR DISOPROXIL	300195						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir	Precaution for use	In case these are administered together, monitor renal function.
J05AF07	TENOFOVIR DISOPROXIL	300195						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir	Precaution for use	In case these are administered together, monitor renal function.
J05AR03	TENOFOVIR DISOPROXIL	300195						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir	Precaution for use	In case these are administered together, monitor renal function.
J05AR06	TENOFOVIR DISOPROXIL	300195			J05AE08	ATAZANAVIR	343047			ANSM	497-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	Do not administer the atazanavir with the tenofovir without ritonavir. 
J05AR08	TENOFOVIR DISOPROXIL	300195			J05AE08	ATAZANAVIR	343047			ANSM	497-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	Do not administer the atazanavir with the tenofovir without ritonavir. 
J05AR09	TENOFOVIR DISOPROXIL	300195			J05AE08	ATAZANAVIR	343047			ANSM	497-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	Do not administer the atazanavir with the tenofovir without ritonavir. 
J05AF07	TENOFOVIR DISOPROXIL	300195			J05AE08	ATAZANAVIR	343047			ANSM	497-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	Do not administer the atazanavir with the tenofovir without ritonavir. 
J05AR03	TENOFOVIR DISOPROXIL	300195			J05AE08	ATAZANAVIR	343047			ANSM	497-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	Do not administer the atazanavir with the tenofovir without ritonavir. 
J05AR06	TENOFOVIR DISOPROXIL	300195			J05AF02	DIDANOSINE	3364			ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
J05AR08	TENOFOVIR DISOPROXIL	300195			J05AF02	DIDANOSINE	3364			ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
J05AR09	TENOFOVIR DISOPROXIL	300195			J05AF02	DIDANOSINE	3364			ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
J05AF07	TENOFOVIR DISOPROXIL	300195			J05AF02	DIDANOSINE	3364			ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
J05AR03	TENOFOVIR DISOPROXIL	300195			J05AF02	DIDANOSINE	3364			ANSM	497-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
J05AR06	TENOFOVIR DISOPROXIL	300195				LEDIPASVIR	1591922			ANSM	497-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical monitoring and laboratory tests, especially of the renal function.
J05AR08	TENOFOVIR DISOPROXIL	300195				LEDIPASVIR	1591922			ANSM	497-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical monitoring and laboratory tests, especially of the renal function.
J05AR09	TENOFOVIR DISOPROXIL	300195				LEDIPASVIR	1591922			ANSM	497-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical monitoring and laboratory tests, especially of the renal function.
J05AF07	TENOFOVIR DISOPROXIL	300195				LEDIPASVIR	1591922			ANSM	497-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical monitoring and laboratory tests, especially of the renal function.
J05AR03	TENOFOVIR DISOPROXIL	300195				LEDIPASVIR	1591922			ANSM	497-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	Clinical monitoring and laboratory tests, especially of the renal function.
D01AE15	TERBINAFINE	37801			N06BA09	ATOMOXETINE	38400			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to large decrease of its hepatic metabolism	Not recommeded	If the administration of the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped. 
D01BA02	TERBINAFINE	37801			N06BA09	ATOMOXETINE	38400			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to large decrease of its hepatic metabolism	Not recommeded	If the administration of the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped. 
D01AE15	TERBINAFINE	37801			L04AD01	CICLOSPORIN	3008			ANSM	498-TERBINAFINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
D01AE15	TERBINAFINE	37801			S01XA18	CICLOSPORIN	3008			ANSM	498-TERBINAFINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
D01BA02	TERBINAFINE	37801			L04AD01	CICLOSPORIN	3008			ANSM	498-TERBINAFINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
D01BA02	TERBINAFINE	37801			S01XA18	CICLOSPORIN	3008			ANSM	498-TERBINAFINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 
D01AE15	TERBINAFINE	37801			C01BC04	FLECAINIDE	4441			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecaidine during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C01BC04	FLECAINIDE	4441			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the flecaidine during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			R06AD07	MEQUITAZINE	29528			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
D01BA02	TERBINAFINE	37801			R06AD07	MEQUITAZINE	29528			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
D01AE15	TERBINAFINE	37801			C07AB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			C07FB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			C07CB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			C07BB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			C07BB52	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			C07AB52	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C07AB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C07FB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C07CB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C07BB02	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C07BB52	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C07AB52	METOPROLOL	6918			ANSM	498-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			C01BC03	PROPAFENONE	8754			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. 
D01BA02	TERBINAFINE	37801			C01BC03	PROPAFENONE	8754			ANSM	498-TERBINAFINE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. 
D01AE15	TERBINAFINE	37801			J04AB02	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01AE15	TERBINAFINE	37801			J04AM02	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01AE15	TERBINAFINE	37801			J04AM05	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01AE15	TERBINAFINE	37801			J04AM06	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01BA02	TERBINAFINE	37801			J04AB02	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01BA02	TERBINAFINE	37801			J04AM02	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01BA02	TERBINAFINE	37801			J04AM05	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01BA02	TERBINAFINE	37801			J04AM06	RIFAMPICIN	9384			ANSM	498-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.
D01AE15	TERBINAFINE	37801			L02BA01	TAMOXIFEN	10324			ANSM	498-TERBINAFINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine. 	Nor recommended	
D01BA02	TERBINAFINE	37801			L02BA01	TAMOXIFEN	10324			ANSM	498-TERBINAFINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine. 	Nor recommended	
L04AA31	TERIFLUNOMIDE	1310520						ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	499-TERIFLUNOMIDE.html	Risk of general vaccine disease, possible fatal 	Not recommended	
A01AD05	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
B01AC06	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
B01AC56	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
C10BX01	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
C10BX02	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
C10BX04	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
M01BA03	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
N02BA01	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
N02BA51	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
N02BA71	ACETYLSALICYLIC ACID	1191			L01XX35	ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events 	Not recommended	
A01AD05	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
B01AC06	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
B01AC56	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
C10BX01	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
C10BX02	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
C10BX04	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
M01BA03	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
N02BA01	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
N02BA51	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
N02BA71	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect. 	Precautions for use	Hydrate the patient and monitor renal function at the beginning of treatment.
A01AD05	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
B01AC06	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
B01AC56	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
C10BX01	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
C10BX02	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
C10BX04	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
M01BA03	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
N02BA01	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
N02BA51	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
N02BA71	ACETYLSALICYLIC ACID	1191						ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, notably in cases with a previous gastroduodenal ulcer. 	Contraindication with	-anti-inflammatory doses of acetylsalicylic acid (>=1 gr per dose and/or >= 3gr per day)
A01AD05	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
B01AC06	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
B01AC56	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
C10BX01	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
C10BX02	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
C10BX04	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
M01BA03	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
N02BA01	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
N02BA51	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
N02BA71	ACETYLSALICYLIC ACID	1191						NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
A01AD05	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
B01AC06	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
B01AC56	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
C10BX01	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
C10BX02	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
C10BX04	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
M01BA03	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
N02BA01	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
N02BA51	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
N02BA71	ACETYLSALICYLIC ACID	1191			B01AC04	CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to increase of the action of the action of the platelet aggregation inhibitors	Not recommended	Except in the presence of validated indications for this combination of drugs in acute coronary syndromes. 
A01AD05	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
B01AC06	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
B01AC56	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
C10BX01	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
C10BX02	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
C10BX04	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
M01BA03	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
N02BA01	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
N02BA51	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
N02BA71	ACETYLSALICYLIC ACID	1191			V03AC03	DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Increase of the risk of digestive ulceration and hemorrhage	Take into account	
A01AD05	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
B01AC06	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
B01AC56	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
C10BX01	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
C10BX02	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
C10BX04	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
M01BA03	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
N02BA01	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
N02BA51	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
N02BA71	ACETYLSALICYLIC ACID	1191						DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease in the renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
A01AD05	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
B01AC06	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
B01AC56	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
C10BX01	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
C10BX02	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
C10BX04	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
M01BA03	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
N02BA01	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
N02BA51	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
N02BA71	ACETYLSALICYLIC ACID	1191						GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)
A01AD05	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
B01AC06	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
B01AC56	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
C10BX01	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
C10BX02	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
C10BX04	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
M01BA03	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
N02BA01	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
N02BA51	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
N02BA71	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended	-with anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
A01AD05	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
B01AC06	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
B01AC56	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
C10BX01	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
C10BX02	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
C10BX04	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
M01BA03	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
N02BA01	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
N02BA51	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
N02BA71	ACETYLSALICYLIC ACID	1191						LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin or similar substances in preventive doses, to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
A01AD05	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
B01AC06	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
B01AC56	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
C10BX01	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
C10BX02	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
C10BX04	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
M01BA03	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
N02BA01	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
N02BA51	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
N02BA71	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr
A01AD05	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
B01AC06	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
B01AC56	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
C10BX01	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
C10BX02	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
C10BX04	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
M01BA03	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
N02BA01	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
N02BA51	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
N02BA71	ACETYLSALICYLIC ACID	1191						UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 	Take into account	
A01AD05	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
B01AC06	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
B01AC56	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
C10BX01	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
C10BX02	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
C10BX04	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
M01BA03	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
N02BA01	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
N02BA51	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
N02BA71	ACETYLSALICYLIC ACID	1191						ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of renal prostaglandin synthesis. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment.
A01AD05	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
B01AC06	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
B01AC56	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
C10BX01	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
C10BX02	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
C10BX04	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
M01BA03	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
N02BA01	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
N02BA51	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
N02BA71	ACETYLSALICYLIC ACID	1191						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage 	Take into account	
A01AD05	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
B01AC06	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
B01AC56	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
C10BX01	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
C10BX02	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
C10BX04	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
M01BA03	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
N02BA01	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
N02BA51	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
N02BA71	ACETYLSALICYLIC ACID	1191			L04AX03	METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, notably hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	-Contraindication 
A01AD05	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
B01AC06	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
B01AC56	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
C10BX01	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
C10BX02	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
C10BX04	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
M01BA03	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
N02BA01	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
N02BA51	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
N02BA71	ACETYLSALICYLIC ACID	1191			L01BA04	PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	-With patients having weak to moderate renal function (elimination of the creatinine between 45 ml/min and 80 ml/min).
A01AD05	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
B01AC06	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
B01AC56	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
C10BX01	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
C10BX02	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
C10BX04	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
M01BA03	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
N02BA01	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
N02BA51	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
N02BA71	ACETYLSALICYLIC ACID	1191						THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
A01AD05	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
B01AC06	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
B01AC56	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
C10BX01	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
C10BX02	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
C10BX04	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
M01BA03	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
N02BA01	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
N02BA51	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
N02BA71	ACETYLSALICYLIC ACID	1191			B01AC24	TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	--except for validated indications for this combination in acute coronary syndromes
A01AD05	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
B01AC06	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
B01AC56	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
C10BX01	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
C10BX02	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
C10BX04	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
M01BA03	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
N02BA01	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
N02BA51	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
N02BA71	ACETYLSALICYLIC ACID	1191			B01AC05	TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring.
A01AD05	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
B01AC06	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
B01AC56	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
C10BX01	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
C10BX02	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
C10BX04	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
M01BA03	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
N02BA01	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
N02BA51	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
N02BA71	ACETYLSALICYLIC ACID	1191						URICOSURICS	M04AB0	ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the effect of the uricosuric due to competitive elimination of the uric acid at the level of the renal tubules	Not recommended	
			CLASS IA ANTIARRHYTHMICS	C01B-002				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrhythmic during the treatment with the inducer and after it is stopped. 
			CLASS IA ANTIARRHYTHMICS	C01B-002	C07AB09	ESMOLOL	49737			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
			CLASS IA ANTIARRHYTHMICS	C01B-002	J04AB02	RIFAMPICIN	9384			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)
			CLASS IA ANTIARRHYTHMICS	C01B-002	J04AM02	RIFAMPICIN	9384			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)
			CLASS IA ANTIARRHYTHMICS	C01B-002	J04AM05	RIFAMPICIN	9384			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)
			CLASS IA ANTIARRHYTHMICS	C01B-002	J04AM06	RIFAMPICIN	9384			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism). 	Precaution for use	Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)
N07XX06	TETRABENAZINE	10390						DOPAMINERGICS	N04B-002	ANSM	500-TETRABENAZINE.html	Reciprocal antagonism between the dopaminergic and the tetrabenazine	Not recommended	
N07XX06	TETRABENAZINE	10390						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	500-TETRABENAZINE.html	Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after it is stopped	Contraindication	
N07XX06	 TETRABENAZINE	10390			N04BA01	LEVODOPA	6375			ANSM	500-TETRABENAZINE.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
N07XX06	 TETRABENAZINE	10390			N04BA02	LEVODOPA	6375			ANSM	500-TETRABENAZINE.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
N07XX06	 TETRABENAZINE	10390			N04BA03	LEVODOPA	6375			ANSM	500-TETRABENAZINE.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
L04AX02	THALIDOMIDE	10432			J05AF02	DIDANOSINE	3364			ANSM	501-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
L04AX02	THALIDOMIDE	10432			J05AF04	STAVUDINE	59763			ANSM	501-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
L04AX02	THALIDOMIDE	10432			J05AR07	STAVUDINE	59763			ANSM	501-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
L04AX02	THALIDOMIDE	10432			J05AF03	ZALCITABINE	3363			ANSM	501-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together.
R03DA04	THEOPHYLLINE 	10438			D11AX04	LITHIUM	6448			ANSM	502-THEOPHYLLINE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
R03DB04	THEOPHYLLINE 	10438			D11AX04	LITHIUM	6448			ANSM	502-THEOPHYLLINE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
R03DA54	THEOPHYLLINE 	10438			D11AX04	LITHIUM	6448			ANSM	502-THEOPHYLLINE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
R03DA74	THEOPHYLLINE 	10438			D11AX04	LITHIUM	6448			ANSM	502-THEOPHYLLINE.html	Decrease of the lithemia with risk of reduction of the therapeutic effectiveness	Precaution for use	Strict monitoring of the lithemia and possible adjustment of the dosage of the lithium.
R03DA04	THEOPHYLLINE 	10438			C01BC03	PROPAFENONE	8754			ANSM	502-THEOPHYLLINE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
R03DB04	THEOPHYLLINE 	10438			C01BC03	PROPAFENONE	8754			ANSM	502-THEOPHYLLINE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
R03DA54	THEOPHYLLINE 	10438			C01BC03	PROPAFENONE	8754			ANSM	502-THEOPHYLLINE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
R03DA74	THEOPHYLLINE 	10438			C01BC03	PROPAFENONE	8754			ANSM	502-THEOPHYLLINE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
R03DA04	THEOPHYLLINE 	10438			L01XE1	VEMURAFENIB	1147220			ANSM	502-THEOPHYLLINE.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
R03DB04	THEOPHYLLINE 	10438			L01XE1	VEMURAFENIB	1147220			ANSM	502-THEOPHYLLINE.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
R03DA54	THEOPHYLLINE 	10438			L01XE1	VEMURAFENIB	1147220			ANSM	502-THEOPHYLLINE.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
R03DA74	THEOPHYLLINE 	10438			L01XE1	VEMURAFENIB	1147220			ANSM	502-THEOPHYLLINE.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer	 Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	A02BA01	CIMETIDINE	2541			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	A02BA51	CIMETIDINE	2541			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01MA02	CIPROFLOXACIN	2551			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	S01AE03	CIPROFLOXACIN	2551			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	S02AA15	CIPROFLOXACIN	2551			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	S03AA07	CIPROFLOXACIN	2551			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01FA09	CLARITHROMYCIN	21212			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	A02BD06	CLARITHROMYCIN	21212			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	A02BD07	CLARITHROMYCIN	21212			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	A02BD05	CLARITHROMYCIN	21212			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	A02BD04	CLARITHROMYCIN	21212			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	B01AC07	DIPYRIDAMOLE	3521			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline	Precaution for use	Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01MA04	ENOXACIN	3925			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to substantial decrease of its metabolism	Contraindication	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	D10AF02	ERYTHROMYCIN	4053			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiromycin) whose interference at the clinical level is now considered minimal or nonexistant. However, in the case of legionnaires' disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	D10AF52	ERYTHROMYCIN	4053			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiromycin) whose interference at the clinical level is now considered minimal or nonexistant. However, in the case of legionnaires' disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01FA01	ERYTHROMYCIN	4053			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiromycin) whose interference at the clinical level is now considered minimal or nonexistant. However, in the case of legionnaires' disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	S01AA17	ERYTHROMYCIN	4053			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	It is possible to use other macrolides (except spiromycin) whose interference at the clinical level is now considered minimal or nonexistant. However, in the case of legionnaires' disease, erythromycin remains the antibiotic of choice; clinical monitoring, with testing of the plasma concentrations of theophylline, is thus desirable in this special instance. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	D01AC15	FLUCONAZOLE	4450			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	Clinical monitoring and, possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J02AC01	FLUCONAZOLE	4450			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	Clinical monitoring and, possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	N06AB08	FLUVOXAMINE	42355			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with fluvoxamine and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	N01AB01	HALOTHANE	5095			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA				XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	In cases of large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism	Precaution for use	Clinical monitoring and testing of the theophyllinemia up to two or three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01FA07	JOSAMYCIN	6084			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	C01BB02	MEXILETINE	6926			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA		ST JOHNS WORT	258326			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations of the theophylline, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)	Contraindication 	In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the other substance taken with it before and then after stopping the St Johns wort.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01MA06	NORFLOXACIN	7517			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring, and possibly monitoring of the theophyllinemia. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	S01AE02	NORFLOXACIN	7517			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring, and possibly monitoring of the theophyllinemia. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01MA03	PEFLOXACIN	7960			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	Clinical monitoring and, possibly monitoring of the theophyllinemia.
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	C04AD03	PENTOXIFYLLINE	8013			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline) 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J04AB02	RIFAMPICIN	9384			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction) 	Precaution for use	Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J04AM02	RIFAMPICIN	9384			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction) 	Precaution for use	Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J04AM05	RIFAMPICIN	9384			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction) 	Precaution for use	Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J04AM06	RIFAMPICIN	9384			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction) 	Precaution for use	Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	J01FA06	ROXITHROMYCIN	9478			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children.	Take into account	
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	N03AX17	STIRIPENTOL	37119			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline. 
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	D01AC06	TIABENDAZOLE	10450			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	P02CA02	TIABENDAZOLE	10450			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	B01AC05	TICLOPIDINE	10594			ANSM	503-THEOPHYLLINE-(AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline)	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. 
			THROMBOLYTICS	B01AD	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD				PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD	B01AX01	DEFIBROTIDE	1311089			ANSM	504-THROMBOLYTICS.html	Accrued risk of hemorrhage	Contraindication	
			THROMBOLYTICS	B01AD				LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
			THROMBOLYTICS	B01AD				UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	504-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
D01AC06	TIABENDAZOLE	10450						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	505-TIABENDAZOLE.html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
P02CA02	TIABENDAZOLE	10450						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	505-TIABENDAZOLE.html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
N03AG06	TIAGABINE	31914						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	506-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with an anticonvulsant enzymatic inducer.
N03AG06	TIAGABINE	31914			J04AB02	RIFAMPICIN	9384			ANSM	506-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.
N03AG06	TIAGABINE	31914			J04AM02	RIFAMPICIN	9384			ANSM	506-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.
N03AG06	TIAGABINE	31914			J04AM05	RIFAMPICIN	9384			ANSM	506-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.
N03AG06	TIAGABINE	31914			J04AM06	RIFAMPICIN	9384			ANSM	506-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.
N06AX14	TIANEPTINE	38252						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	507-TIANEPTINE.html	Risk of drop in blood pressure, paroxystic hypertension, hyperthermia, convulsions, death	Not recommended	
G03CX01	TIBOLONE	38260						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	508-TIBOLONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped. 
B01AC24	TICAGRELOR	1116632				GRAPEFRUIT JUICE				ANSM	509-TICAGRELOR.html	Doubling of the plasma concentrations of the platelet aggregation inhibitor, with risk of increase of the undesirable effects, especially hemorrhagic	Not recommended	
B01AC24	TICAGRELOR	1116632			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	509-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	--except for validated indications for this combination in acute coronary syndromes.
B01AC24	TICAGRELOR	1116632						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	509-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect	Not recommended	
B01AC24	TICAGRELOR	1116632			1037042	DABIGATRAN				ANSM	509-TICAGRELOR.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Take into account	
B01AC24	TICAGRELOR	1116632			C08DB01	DILTIAZEM	3443			ANSM	509-TICAGRELOR.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
B01AC24	TICAGRELOR	1116632						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	509-TICAGRELOR.html	Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor	Contraindication	
B01AC24	TICAGRELOR	1116632				ST JOHNS WORT	258326			ANSM	509-TICAGRELOR.html	Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect.	Contraindication	
B01AC24	TICAGRELOR	1116632						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	509-TICAGRELOR.html	Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	Contraindication	
B01AC24	TICAGRELOR	1116632			J04AB02	RIFAMPICIN	9384			ANSM	509-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
B01AC24	TICAGRELOR	1116632			J04AM02	RIFAMPICIN	9384			ANSM	509-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
B01AC24	TICAGRELOR	1116632			J04AM05	RIFAMPICIN	9384			ANSM	509-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
B01AC24	TICAGRELOR	1116632			J04AM06	RIFAMPICIN	9384			ANSM	509-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
B01AC24	TICAGRELOR	1116632			C08DA01	VERAPAMIL	11170			ANSM	509-TICAGRELOR.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of excessive bradycardia (addition of the bradycardia inducing effects)	Precaution for use	Regular clinical monitoring, especially at the beginning of the administration of the substances together 
			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	N07AX01	PILOCARPINE	8328			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of addition of the undesirable cholinergic effects, especially digestive ones	Take into account	
			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	S01EB01	PILOCARPINE	8328			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of addition of the undesirable cholinergic effects, especially digestive ones	Take into account	
			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	S01EB51	PILOCARPINE	8328			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of addition of the undesirable cholinergic effects, especially digestive ones	Take into account	
			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	M03AB01	SUXAMETHONIUM	10154			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of lengthening of the motor block, increased in the case of partial deficit of pseudocholinesterase	Take into account	
B01AC05	TICLOPIDINE	10594			A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	510-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring.
B01AC05	TICLOPIDINE	10594			L04AD01	CICLOSPORIN	3008			ANSM	510-TICLOPIDINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage if the ticlopidine is stopped. 
B01AC05	TICLOPIDINE	10594			S01XA18	CICLOSPORIN	3008			ANSM	510-TICLOPIDINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage if the ticlopidine is stopped. 
B01AC05	TICLOPIDINE	10594						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	510-TICLOPIDINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	Clinical monitoring and testing of the plasma concentrations of phenytoin.
B01AC05	TICLOPIDINE	10594						THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	510-TICLOPIDINE.html	Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline). 	Precaution for use	Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. 
G04BD07	TOLTERODINE	119565			J01FA09	CLARITHROMYCIN	21212			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			A02BD04	CLARITHROMYCIN	21212			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			A02BD05	CLARITHROMYCIN	21212			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			A02BD06	CLARITHROMYCIN	21212			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			A02BD07	CLARITHROMYCIN	21212			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			D10AF02	ERYTHROMYCIN	4053			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			D10AF52	ERYTHROMYCIN	4053			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			J01FA01	ERYTHROMYCIN	4053			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			S01AA17	ERYTHROMYCIN	4053			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			J02AC02	ITRACONAZOLE	28031			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			D01AC08	KETOCONAZOLE	6135			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			G01AF11	KETOCONAZOLE	6135			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
G04BD07	TOLTERODINE	119565			J02AB02	KETOCONAZOLE	6135			ANSM	511-TOLTERODINE.html	Increase of the concentrations of tolterodine in patients who are slow metabolisers, with risk of overdose	Not recommended	
			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD		MEDICATIONS ADMINISTERED BY ORAL ROUTE				ANSM	512-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of certain other medications ingested simultaneously	Precaution for use	As a precaution, it is preferable to take these gastrointestinal targeted medications, antacids, and absorbent medications at a different time from any other medication (more than 2 hours apart, if possible).
N03AX11	TOPIRAMATE	38404			N03AF01	CARBAMAZEPINE	2002			ANSM	513-TOPIRAMATE.html	Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of the toprimate during the treatment with the carbamazepine and after it is stopped.
N03AX11	TOPIRAMATE	38404						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	513-TOPIRAMATE.html	For doses of topiramate >= 200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concontrations of estrogen	Not recommended	Another method of contraception, in particular a barrier method or IUD, should be used. 
N03AX11	TOPIRAMATE	38404			D11AX04	LITHIUM	6448			ANSM	513-TOPIRAMATE.html	For doses of topiramate >=200mg/day: increase of the lithemia that can reach toxic levels, with signs of overdose of lithium	Precaution for use	Clinical monitoring and laboratory tests. Adjustment of the dosage of lithium.
N03AX11	TOPIRAMATE	38404			N03AF02	OXCARBAZEPINE	32624			ANSM	513-TOPIRAMATE.html	Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	Clinical monitoring, and if needed, adjustment of the dosage of topiramate during the treatment with the oxcarbazepine and after it is stopped. 
N03AX11	TOPIRAMATE	38404						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	513-TOPIRAMATE.html	Risk of onset of hyperammonemia or encephalopathy, generally attributed to the valproic acid, when it is taken at the same time as the topiramate	Precaution for use	Reinforced clinical monitoring at the beginning of treatment and laboratory tests in case of suggestive symptoms. 
			TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)	C01B				MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	514-TORSADES-DE-POINTES-INDUCING-MEDICATIONS-(EXCEPT-ANTIPARASITICS,-NEUROLEPTICS,-METHADONE).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	For dolasetron, erythromycin, spiramycin, and vincamine, only the forms administered by IV route are affected by this interaction. 
L01CX0	TRABECTEDINE	397736			J02AC02	ITRACONAZOLE	28031			ANSM	515-TRABECTEDINE.html	Risk of increase of the plasma concentrations of the itraconazole	Not recommended	If administering these medications together is necessary, clinical monitoring and adjustment of the dosage of the trabectedine during the length of the treatment with the itraconazole
			NICOTINE SUBSTITUION TREATMENT	N07BA				MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO	N0-R0-002	ANSM	516-NICOTINE-SUBSTITUTION-TREATMENT.html	Risk of overdose when replacing tobacco due to the replacement therapy	Take into account	
N02AX02	TRAMADOL	10689						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	517-TRAMADOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped. 
N02AX52	TRAMADOL	10689						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	517-TRAMADOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped. 
N02AX02	TRAMADOL	10689			N06AX12	BUPROPION	42347			ANSM	517-TRAMADOL.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
N02AX52	TRAMADOL	10689			N06AX12	BUPROPION	42347			ANSM	517-TRAMADOL.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
N02AX02	TRAMADOL	10689						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	517-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
N02AX52	TRAMADOL	10689						IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	517-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
N02AX02	TRAMADOL	10689						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	517-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
N02AX52	TRAMADOL	10689						REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	517-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Contraindication	
N02AX02	TRAMADOL	10689						MAOI-B 	N04BD0-001	ANSM	517-TRAMADOL.html	Risk of appearance of a serotonin syndrome	Take into account	
N02AX52	TRAMADOL	10689						MAOI-B 	N04BD0-001	ANSM	517-TRAMADOL.html	Risk of appearance of a serotonin syndrome	Take into account	
N02AX02	TRAMADOL	10689						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	517-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
N02AX52	TRAMADOL	10689						SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	517-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
N02AX02	TRAMADOL	10689			A04AA01	ONDANSETRON	26225			ANSM	517-TRAMADOL.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemitic effect of the ondansetron	Take into account	
N02AX52	TRAMADOL	10689			A04AA01	ONDANSETRON	26225			ANSM	517-TRAMADOL.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemitic effect of the ondansetron	Take into account	
N02AX02	TRAMADOL	10689			N06AX16	VENLAFAXINE	39786			ANSM	517-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
N02AX52	TRAMADOL	10689			N06AX16	VENLAFAXINE	39786			ANSM	517-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
P02BX04	TRICLABENDAZOLE	38608			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	518-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the medication derived from ergot of rye, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			N02CA02	ERGOTAMINE	4025			ANSM	518-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			N02CA51	ERGOTAMINE	4025			ANSM	518-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			N02CA52	ERGOTAMINE	4025			ANSM	518-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			N02CA72	ERGOTAMINE	4025			ANSM	518-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			N05AG02	PIMOZIDE	8331			ANSM	518-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse. 
P02BX04	TRICLABENDAZOLE	38608			C01BA01	QUINIDINE	9068			ANSM	518-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			C01BA51	QUINIDINE	9068			ANSM	518-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse.
P02BX04	TRICLABENDAZOLE	38608			C01BA71	QUINIDINE	9068			ANSM	518-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	Contraindication	Wait 24 hours between stopping the triclabendazole and taking the torsade inducing medication, and the reverse.
J01E	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01E	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EA	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EA	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE02	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE02	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE05	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE05	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE07	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE07	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE01	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE01	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE03	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE03	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE04	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EE04	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EA01	TRIMETHOPRIM	10829			L04AD01	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01EA01	TRIMETHOPRIM	10829			S01XA18	CICLOSPORIN	3008			ANSM	519.TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
J01E	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01E	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EA	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EA	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE02	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE02	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE05	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE05	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE07	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE07	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE01	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE01	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE03	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE03	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE04	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EE04	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EA01	TRIMETHOPRIM	10829			L01BA01	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01EA01	TRIMETHOPRIM	10829			L04AX03	METHOTREXATE	6851			ANSM	519.TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	Contraindication	
J01E	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01E	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01E	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EA	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EA	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EA	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE02	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE02	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE02	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE05	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE05	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE05	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE07	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE07	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE07	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE01	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE01	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE01	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE03	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE03	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE03	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE04	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE04	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EE04	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EA01	TRIMETHOPRIM	10829			P01BD01	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EA01	TRIMETHOPRIM	10829			P01BD51	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01EA01	TRIMETHOPRIM	10829			P01BF04	PYRIMETHAMINE	9010			ANSM	519.TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines	Precaution for use	Regular CBC and addition of a treatment with folic acid (regular IM injections). 
J01E	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EA	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE02	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE05	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE07	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE01	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE03	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EE04	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
J01EA01	TRIMETHOPRIM	10829			A10BX02	REPAGLINIDE	73044			ANSM	519.TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	If administering these medications together cannot be avoided, strict clinical monitoring and laboratory tests. 
			ORAL ANTICOAGULANTS	B01A-001	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication	- with anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)
			ORAL ANTICOAGULANTS	B01A-001				PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Take into account	
			ORAL ANTICOAGULANTS	B01A-001				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the oral anticoagulant's risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)	Contraindication 	- with phenylbutazone
			ORAL ANTICOAGULANTS	B01A-001	B01AX01	DEFIBROTIDE	1311089			ANSM	52-ORAL-ANTICOAGULANTS.html	Increased risk of hemorrhage	Not recommended	
			ORAL ANTICOAGULANTS	B01A-001				GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the antivitamin K and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) with large doses or in treatment prolonged beyond 10 days. 	Precaution for use	When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the antivitamines K, laboratory tests on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped. 
			ORAL ANTICOAGULANTS	B01A-001				LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Precaution for use	Strengthen clinical monitoring and, if the situation requires, laboratory tests. 
			ORAL ANTICOAGULANTS	B01A-001				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Precaution for use	Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and after it is stopped. 
			TRIPTANS	N02CC-001				VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	520-TRIPTANS.html	Risk of arterial hypertension, of constriction of coronary arteries	Contraindication	Wait 6 to 24 hours, depending on the triptan, between taking it and the ergot alkaloid.
			TRIPTANS	N02CC-001				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	520-TRIPTANS.html	Risk of appearance of serotonin syndrome	Take into account	
			TRIPTANS METABOLIZED BY THE MAO	N02CC-002				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	521-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries 	Contraindication	
			TRIPTANS METABOLIZED BY THE MAO	N02CC-002				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	521-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries 	Contraindication	
			TRIPTANS METABOLIZED BY THE MAO	N02CC-002				MAOI-B 	N04BD0-001	ANSM	521-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Contraindication	
			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003				IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	522-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003				REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	522-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003				MAOI-B 	N04BD0-001	ANSM	522-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
G03AD02	ULIPRISTAL	1005921						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not metabolized. 
G03AD02	ULIPRISTAL	1005921						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
G03AD02	ULIPRISTAL	1005921						PROTON PUMP INHIBITORS	A02BC-001	ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
G03AD02	ULIPRISTAL	1005921						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir 	Not recommended	Choose a therapeutic alternative that is little or not metabolized.
G03AD02	ULIPRISTAL	1005921				ST JOHNS WORT	258326			ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not metabolized. 
G03AD02	ULIPRISTAL	1005921						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	523-ULIPRISTAL.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	Do not restart a progestin treatment fewer than 12 days after stopping the ulipristal.
G03AD02	ULIPRISTAL	1005921						NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	523-ULIPRISTAL.html	Risk of antagonism of the effects of the progestogen	Not recommended	Do not restart a progestogen treatment fewer than 12 days after stopping the ulipristal.
G03AD02	ULIPRISTAL	1005921			J04AB02	RIFAMPICIN	9384			ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Chose a therapeutic alternative that is little or not metabolized.
G03AD02	ULIPRISTAL	1005921			J04AM02	RIFAMPICIN	9384			ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Chose a therapeutic alternative that is little or not metabolized.
G03AD02	ULIPRISTAL	1005921			J04AM05	RIFAMPICIN	9384			ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Chose a therapeutic alternative that is little or not metabolized.
G03AD02	ULIPRISTAL	1005921			J04AM06	RIFAMPICIN	9384			ANSM	523-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Chose a therapeutic alternative that is little or not metabolized.
			URICOSURICS	M04AB0	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			URICOSURICS	M04AB0	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	524-URICOSURICS.html	Decrease of the effect of the uricosuric due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	L04AA24	ABATACEPT 	614391			ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	Not recommended	as well as during the 3 months following the treatment
			ATTENUATED LIVE VIRUS VACCINES	J07B-001				ANTI-TNF ALPHA	LO4AB	ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	-And during the 3 months following the end of the treatment
			ATTENUATED LIVE VIRUS VACCINES	J07B-001				CYTOTOXICS	L01	ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	Contraindication 	--And during the 6 months following the end of the chemotherapy
			ATTENUATED LIVE VIRUS VACCINES	J07B-001				ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001	ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease. This risk is increased in older patients already immunodepressed by the underlying disease.	Take into account	In particular, use an inactive vaccine when one exists (poliomyelitis).
			ATTENUATED LIVE VIRUS VACCINES	J07B-001				GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	With the exception of inhaled and local routes and for dosages greater than 10mg/day of prednisone equivalent (or >2mg/kg/day[sic] with children or >20 mg/day for children weighing more than 10 kg) for more than two weeks and for administration in "bolus" of the corticoids:Risk of general vaccine disease, possibly fatal	Contraindication	And during the 3 months following the end of the corticotherapy
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	L01XX05	HYDROXYCARBAMIDE 	5552			ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	In an indication for the patient with drepanocytosis, risk of general fatal vaccine disease.	Not recommended	Administering these medications together should only be considered if the benefits are estimated to be superior to this risk.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001				IMMUNOSUPPRESSANTS	L04A	ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal.	Contraindication	And during the 3 months following the treatment
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	OLATE	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MOFETIL	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	7145	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	L04AA06	MYCOPHENOLATE MOFETIL				ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease 	Contraindication	And during the 3 months following the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001		MYCOPHENOLATE SODIUM 	408142			ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	Contraindication	And during the 3 months after the end of the treatment.
			ATTENUATED LIVE VIRUS VACCINES	J07B-001	L04AA31	TERIFLUNOMIDE	1310520			ANSM	525-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	Not recommended	
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J01DF01	AZTREONAM	1272			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	N03AF01	CARBAMAZEPINE	2002			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	Clinical monitoring, plasma dosages and adjustment of the dosage of the two anticonvulsants.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	N03AX10	FELBAMATE	24812			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the valproic acid, with risk of overdose. 	Precaution for use	Clinical monitoring, laboratory tests, and possible adjustment of the dosage of the valproic acid or of the valpromide during the treatment with the felbamate and after it is stopped. 
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	N03AX09	LAMOTRIGINE	28439			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increased risk of serious cutaneous reactions (Lyell's syndorme). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)	Not recommended	If this combination of medications is judged necessary, strict clinical monitoring.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	P01BF02	MEFLOQUINE	6694			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of epileptic crises due to increase of the metabolism of the sodium valproate and the convulsion producing effect of the mefloquine	Contraindication	
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	P01BC02	MEFLOQUINE	6694			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of epileptic crises due to increase of the metabolism of the sodium valproate and the convulsion producing effect of the mefloquine	Contraindication	
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	C08CA06	NIMODIPINE	7426			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid)	Take into account	
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0				PENEMS	J01DH	ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable	Not recommended	
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0				PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the phenobarbital, with signs of overdose, due to inhibition of the hepatic metabolism, most often with children. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the phenobarbital	Precaution for use	Clinical monitoring during the first two weeks of the administration of these substances together and immediate reduction of the doses of phenobarbital at the appearance of signs of sedation, test especially the plasma concentrations of the two anticonvulsants. 
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0				PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Variation of the plasma concentrations of phenytoin. In addition, risk of decrease of the plasma concentrations of the valproic acid due to increase of its hepatic metabolism by the phenytoin.	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the two anticonvulsants.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J04AB02	RIFAMPICIN	9384			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J04AM02	RIFAMPICIN	9384			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J04AM05	RIFAMPICIN	9384			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J04AM06	RIFAMPICIN	9384			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	N03AF03	RUFINAMIDE	69036			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg	Precaution for use	With children weighing less than 30kg: do not exceed the total dose of 600 mg/day after the period of titration.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	38404	TOPIRAMATE	38404			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of hyperammonemia or encephalopathy, generally attributed to the valproic acid, when it is taken at the same time as the topiramate	Precaution for use	Reinforced clinical monitoring at the beginning of treatment and laboratory tests in case of suggestive symptoms. 
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J05AF01	ZIDOVUDINE (AZT)	11413			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first months of the administration of these substances together.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J05AR01	ZIDOVUDINE (AZT)	11413			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first months of the administration of these substances together.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J05AR04	ZIDOVUDINE (AZT)	11413			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first months of the administration of these substances together.
			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	J05AR05	ZIDOVUDINE (AZT)	11413			ANSM	526-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first months of the administration of these substances together.
G04BE0	VARDENAFIL	306674				GRAPEFRUIT JUICE				ANSM	527-VARDENAFIL.html	Increase of the plasma concentrations of the vardenafil, with risk of hypotension.	Not recommended	
L01XE15	VEMURAFENIB	1147220			N06AX12	BUPROPION	42347			ANSM	528-VEMURAFENIB.html	Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity	Take into account	
L01XE15	VEMURAFENIB	1147220						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	528-VEMURAFENIB.html	Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness	Not recommended	
L01XE15	VEMURAFENIB	1147220			L01AA06	IFOSFAMIDE	5657			ANSM	528-VEMURAFENIB.html	Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity	Take into account	
L01XE15	VEMURAFENIB	1147220						IMMUNOSUPPRESSANTS	L04A	ANSM	528-VEMURAFENIB.html	Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness	Not recommended	
L01XE15	VEMURAFENIB	1147220						ENZYMATIC INDUCERS	N03-J05-001	ANSM	528-VEMURAFENIB.html	Risk of decrease of the concentrations of the vemurafenib, with lower effectiveness	Not recommended	
L01XE15	VEMURAFENIB	1147220			R03DA04	THEOPHYLLINE 	10438			ANSM	528-VEMURAFENIB.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
L01XE15	VEMURAFENIB	1147220			R03DB04	THEOPHYLLINE 	10438			ANSM	528-VEMURAFENIB.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
L01XE15	VEMURAFENIB	1147220			R03DA54	THEOPHYLLINE 	10438			ANSM	528-VEMURAFENIB.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
L01XE15	VEMURAFENIB	1147220			R03DA74	THEOPHYLLINE 	10438			ANSM	528-VEMURAFENIB.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
N06AX16	VENLAFAXINE	39786			J01FA09	CLARITHROMYCIN	21212			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			A02BD04	CLARITHROMYCIN	21212			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			A02BD05	CLARITHROMYCIN	21212			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			A02BD06	CLARITHROMYCIN	21212			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			A02BD07	CLARITHROMYCIN	21212			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			D10AF02	ERYTHROMYCIN	4053			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			D10AF52	ERYTHROMYCIN	4053			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			J01FA01	ERYTHROMYCIN	4053			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			S01AA17	ERYTHROMYCIN	4053			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose. 	Take into account	
N06AX16	VENLAFAXINE	39786			J02AC02	ITRACONAZOLE	28031			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			D01AC08	KETOCONAZOLE	6135			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			G01AF11	KETOCONAZOLE	6135			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			J02AB02	KETOCONAZOLE	6135			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			J05AE04	NELFINAVIR	134527			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			J01FA15	TELITHROMYCIN	274786			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
N06AX16	VENLAFAXINE	39786			N02AX02	TRAMADOL	10689			ANSM	529-VENLAFAXINE.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
N06AX16	VENLAFAXINE	39786			N02AX52	TRAMADOL	10689			ANSM	529-VENLAFAXINE.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
N06AX16	VENLAFAXINE	39786			J02AC03	VORICONAZOLE	121243			ANSM	529-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	L02BX03	ABIRATERONE	1100072			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	P02CA03	ALBENDAZOLE	430			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness. .	Precaution for use	Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism 	Not recommended 	with the nimodipine
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic, due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrythmic during the treatment with the inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				VITAMIN K ANTAGONISTS	B01AA-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	B01AF02	APIXABAN	1364430			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A04AD12	APREPITANT	358255			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of very large decrease of the concentrations of aprepitant	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J05AE12	BOCEPREVIR	1102129			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these substances together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of the administration of them together
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	C02KX01	BOSENTAN	75207			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of bosentan	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	V03AX03	COBICISTAT	1306284			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J05AR09	COBICISTAT	1306284			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	Contraindication	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	1037042	DABIGATRAN				ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	V03AC03	DEFERASIROX	614373			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J04AK06	DELAMANID				ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentratioins of delamanid due to increase of its hepatic metabolism by the inducer. 	Contraindication	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J05AX12	DOLUTEGRAVIR	1433868			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A01AB22	DOXYCYCLINE	3640			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the doxycycline
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J01AA02	DOXYCYCLINE	3640			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the doxycycline
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	C01BD07	DRONEDARONE	233698			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the concentrations of dronedarone due to decrease of its metabolism, without significant modification of the active metabolite	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the effectiveness of the estrogen .	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N01AH01	FENTANYL	4337			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N01AH51	FENTANYL	4337			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N02AB03	FENTANYL	4337			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	Choose another opioid.
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addison's disease treated with hydrocortisone and in cases of organ transplants	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				THYROID HORMONES	H03AA	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4	Precaution for use	Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	L01XX47	IDELALISIB	1544460			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				TYROSINE-KINASE INHIBITORS	L01XE	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	C01EB17	IVABRADINE	77417			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer	Precaution for use	Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001		LEDIPASVIR	1591922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.	Contraindication	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A02BD08	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A02BD03	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A02BD02	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A01AB17	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	D06BX01	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	G01AF01	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J01XD01	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	P01AB01	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	A02BD01	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the enzymatic inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N05CD08	MIDAZOLAM	6960			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant	Take into account	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				MINERALOCORTICOIDS	H02AA0	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addison's disease treated with the hydrocortisone and in the case of transplants.	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	R03DC03	MONTELUKAST	88249			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	C08CA06	NIMODIPINE	7426			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer	Not recommended	Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N03AX22	PERAMPANEL	1356552			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J02AC04	POSACONAZOLE	282446			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the posaconazole	Precaution for use	Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	P02BA01	PRAZIQUANTEL	8628			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	L01XB01	PROCARBAZINE	8702			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer	Take into account	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	C01BC03	PROPAFENONE	8754			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer	Precaution of use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N05AH04	QUETIAPINE	51272			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	P01BC01	QUININE	9071			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	M09AA72	QUININE	9071			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	M09AA	QUININE	9071			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 	Precaution for use	Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	C01EB18	RANOLAZINE	35829			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of large decrease of the concentrations of ranolazine	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	B01AF01	RIVAROXABAN	1114195			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N03AX17	STIRIPENTOL	37119			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol.	Precaution for use	Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of its dosage. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J05AE11	TELAPREVIR	1102261			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of very large decrease of the concentrations of telaprevir	Contraindication	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J01FA15	TELITHROMYCIN	274786			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001				THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer	Precaution for use	Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	N03AG06	TIAGABINE	31914			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer	Precaution for use	An increase of the dosage of the tiagabine can prove necessary when it is administered with an anticonvulsant enzymatic inducer
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	B01AC24	TICAGRELOR	1116632			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Large decrease of the plasma concentrations of the ticagrelor due to increase of its hepatic metabolsim by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.	Not recommended	
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	G03AD02	ULIPRISTAL	1005921			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	Choose a therapeutic alternative that is little or not at all metabolized. 
			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	J02AC03	VORICONAZOLE	121243			ANSM	53-ANTICONVULSANT-ENZYMATIC-INDUCERS.html	-for carbamazipine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducerFor phenytoin, fosphenytoin:Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole for another thing	Contraindication	 -for carbamazepine, phenobarbital, primidone
C08DA01	VERAPAMIL	11170				GRAPEFRUIT JUICE				ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of verapamil, with risk of onset of undesirable effects	Take into account	
C08DA51	VERAPAMIL	11170				GRAPEFRUIT JUICE				ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of verapamil, with risk of onset of undesirable effects	Take into account	
C09BB10	VERAPAMIL	11170				GRAPEFRUIT JUICE				ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of verapamil, with risk of onset of undesirable effects	Take into account	
C08DA01	VERAPAMIL	11170			L01XE13	AFATINIB	1430438			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil	Precaution for use	It is recommended that the verapamil be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours distant from the afatinib.
C08DA51	VERAPAMIL	11170			L01XE13	AFATINIB	1430438			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil	Precaution for use	It is recommended that the verapamil be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours distant from the afatinib.
C09BB10	VERAPAMIL	11170			L01XE13	AFATINIB	1430438			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil	Precaution for use	It is recommended that the verapamil be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours distant from the afatinib.
C08DA01	VERAPAMIL	11170			C09XA02	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C08DA01	VERAPAMIL	11170			C09XA52	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C08DA01	VERAPAMIL	11170			C09DX02	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C08DA51	VERAPAMIL	11170			C09XA02	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C08DA51	VERAPAMIL	11170			C09XA52	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C08DA51	VERAPAMIL	11170			C09DX02	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C09BB10	VERAPAMIL	11170			C09XA02	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C09BB10	VERAPAMIL	11170			C09XA52	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C09BB10	VERAPAMIL	11170			C09DX02	ALISKIREN	325646			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	Clinical monitoring.
C08DA01	VERAPAMIL	11170			C01BD01	AMIODARONE	703			ANSM	530-VERAPAMIL.html	For verapamil by injection:-risk of bradycardia or of atrioventricular blockFor verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older persons	Not recommended with	-the verapamil via IV
C08DA51	VERAPAMIL	11170			C01BD01	AMIODARONE	703			ANSM	530-VERAPAMIL.html	For verapamil by injection:-risk of bradycardia or of atrioventricular blockFor verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older persons	Not recommended with	-the verapamil via IV
C09BB10	VERAPAMIL	11170			C01BD01	AMIODARONE	703			ANSM	530-VERAPAMIL.html	For verapamil by injection:-risk of bradycardia or of atrioventricular blockFor verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older persons	Not recommended with	-the verapamil via IV
C08DA01	VERAPAMIL	11170			C10AA05	ATORVASTATIN	83367			ANSM	530-VERAPAMIL.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
C08DA51	VERAPAMIL	11170			C10AA05	ATORVASTATIN	83367			ANSM	530-VERAPAMIL.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
C09BB10	VERAPAMIL	11170			C10AA05	ATORVASTATIN	83367			ANSM	530-VERAPAMIL.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.
C08DA01	VERAPAMIL	11170						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	530-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure 	Not recommended	The administration of these medications together should only be undertaken under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment. 
C08DA51	VERAPAMIL	11170						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	530-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure 	Not recommended	The administration of these medications together should only be undertaken under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment. 
C09BB10	VERAPAMIL	11170						BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	530-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure 	Not recommended	The administration of these medications together should only be undertaken under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment. 
C08DA01	VERAPAMIL	11170						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	530-VERAPAMIL.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	Not recommended	
C08DA51	VERAPAMIL	11170						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	530-VERAPAMIL.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	Not recommended	
C09BB10	VERAPAMIL	11170						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	530-VERAPAMIL.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	Not recommended	
C08DA01	VERAPAMIL	11170			N05BE01	BUSPIRONE	1827			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
C08DA51	VERAPAMIL	11170			N05BE01	BUSPIRONE	1827			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
C09BB10	VERAPAMIL	11170			N05BE01	BUSPIRONE	1827			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects	Precaution for use	Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
C08DA01	VERAPAMIL	11170			L04AD01	CICLOSPORIN	3008			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C08DA01	VERAPAMIL	11170			S01XA18	CICLOSPORIN	3008			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C08DA51	VERAPAMIL	11170			L04AD01	CICLOSPORIN	3008			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C08DA51	VERAPAMIL	11170			S01XA18	CICLOSPORIN	3008			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C09BB10	VERAPAMIL	11170			L04AD01	CICLOSPORIN	3008			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C09BB10	VERAPAMIL	11170			S01XA18	CICLOSPORIN	3008			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 	Precaution for use	Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C08DA01	VERAPAMIL	11170			C02AC01	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA01	VERAPAMIL	11170			N02CX02	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA01	VERAPAMIL	11170			S01EA04	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA01	VERAPAMIL	11170			C02LC01	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA01	VERAPAMIL	11170			C02LC51	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA51	VERAPAMIL	11170			C02AC01	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA51	VERAPAMIL	11170			N02CX02	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA51	VERAPAMIL	11170			S01EA04	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA51	VERAPAMIL	11170			C02LC01	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA51	VERAPAMIL	11170			C02LC51	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C09BB10	VERAPAMIL	11170			C02AC01	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C09BB10	VERAPAMIL	11170			N02CX02	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C09BB10	VERAPAMIL	11170			S01EA04	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C09BB10	VERAPAMIL	11170			C02LC01	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C09BB10	VERAPAMIL	11170			C02LC51	CLONIDINE	2599			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
C08DA01	VERAPAMIL	11170			M04AC01	COLCHICINE	2683			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
C08DA51	VERAPAMIL	11170			M04AC01	COLCHICINE	2683			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
C09BB10	VERAPAMIL	11170			M04AC01	COLCHICINE	2683			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
C08DA01	VERAPAMIL	11170			1037042	DABIGATRAN				ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose, or even 75 mg/day in case of moderate renal insufficiency
C08DA51	VERAPAMIL	11170			1037042	DABIGATRAN				ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose, or even 75 mg/day in case of moderate renal insufficiency
C09BB10	VERAPAMIL	11170			1037042	DABIGATRAN				ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose, or even 75 mg/day in case of moderate renal insufficiency
C08DA01	VERAPAMIL	11170			M03CA	DANTROLENE	3105			ANSM	530-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Contraindication	
C08DA01	VERAPAMIL	11170			M03CA01	DANTROLENE	3105			ANSM	530-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Contraindication	
C08DA51	VERAPAMIL	11170			M03CA	DANTROLENE	3105			ANSM	530-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Contraindication	
C08DA51	VERAPAMIL	11170			M03CA01	DANTROLENE	3105			ANSM	530-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Contraindication	
C09BB10	VERAPAMIL	11170			M03CA	DANTROLENE	3105			ANSM	530-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Contraindication	
C09BB10	VERAPAMIL	11170			M03CA01	DANTROLENE	3105			ANSM	530-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Contraindication	
C08DA01	VERAPAMIL	11170			C01AA05	DIGOXIN 	3407			ANSM	530-VERAPAMIL.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped. 
C08DA51	VERAPAMIL	11170			C01AA05	DIGOXIN 	3407			ANSM	530-VERAPAMIL.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped. 
C09BB10	VERAPAMIL	11170			C01AA05	DIGOXIN 	3407			ANSM	530-VERAPAMIL.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin	Precaution for use	Clinical monitoring, EKG and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped. 
C08DA01	VERAPAMIL	11170			L01DB01	DOXORUBICIN	3639			ANSM	530-VERAPAMIL.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
C08DA51	VERAPAMIL	11170			L01DB01	DOXORUBICIN	3639			ANSM	530-VERAPAMIL.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
C09BB10	VERAPAMIL	11170			L01DB01	DOXORUBICIN	3639			ANSM	530-VERAPAMIL.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
C08DA01	VERAPAMIL	11170			C01BD07	DRONEDARONE	233698			ANSM	530-VERAPAMIL.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.
C08DA51	VERAPAMIL	11170			C01BD07	DRONEDARONE	233698			ANSM	530-VERAPAMIL.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.
C09BB10	VERAPAMIL	11170			C01BD07	DRONEDARONE	233698			ANSM	530-VERAPAMIL.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.
C08DA01	VERAPAMIL	11170			L01XX41	ERIBULINE	1045453			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
C08DA51	VERAPAMIL	11170			L01XX41	ERIBULINE	1045453			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
C09BB10	VERAPAMIL	11170			L01XX41	ERIBULINE	1045453			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
C08DA01	VERAPAMIL	11170			D10AF02	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA01	VERAPAMIL	11170			D10AF52	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA01	VERAPAMIL	11170			J01FA01	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA01	VERAPAMIL	11170			S01AA17	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA51	VERAPAMIL	11170			D10AF02	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA51	VERAPAMIL	11170			D10AF52	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA51	VERAPAMIL	11170			J01FA01	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA51	VERAPAMIL	11170			S01AA17	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C09BB10	VERAPAMIL	11170			D10AF02	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C09BB10	VERAPAMIL	11170			D10AF52	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C09BB10	VERAPAMIL	11170			J01FA01	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C09BB10	VERAPAMIL	11170			S01AA17	ERYTHROMYCIN	4053			ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 
C08DA01	VERAPAMIL	11170			C07AB09	ESMOLOL	49737			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of the left ventricular function.
C08DA51	VERAPAMIL	11170			C07AB09	ESMOLOL	49737			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of the left ventricular function.
C09BB10	VERAPAMIL	11170			C07AB09	ESMOLOL	49737			ANSM	530-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	-in case of alteration of the left ventricular function.
C08DA01	VERAPAMIL	11170			L01XE10	EVEROLIMUS	141704			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
C08DA01	VERAPAMIL	11170			L04AA18	EVEROLIMUS	141704			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
C08DA51	VERAPAMIL	11170			L01XE10	EVEROLIMUS	141704			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
C08DA51	VERAPAMIL	11170			L04AA18	EVEROLIMUS	141704			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
C09BB10	VERAPAMIL	11170			L01XE10	EVEROLIMUS	141704			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
C09BB10	VERAPAMIL	11170			L04AA18	EVEROLIMUS	141704			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.
C08DA01	VERAPAMIL	11170			A07AA12	FIDAXOMICIN	1111103			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
C08DA51	VERAPAMIL	11170			A07AA12	FIDAXOMICIN	1111103			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
C09BB10	VERAPAMIL	11170			A07AA12	FIDAXOMICIN	1111103			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
C08DA01	VERAPAMIL	11170			L01XE27	IBRUTINIB	1442981			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Strict clinicalmonitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of the two medications together.
C08DA51	VERAPAMIL	11170			L01XE27	IBRUTINIB	1442981			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Strict clinicalmonitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of the two medications together.
C09BB10	VERAPAMIL	11170			L01XE27	IBRUTINIB	1442981			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	Strict clinicalmonitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of the two medications together.
C08DA01	VERAPAMIL	11170						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires.
C08DA51	VERAPAMIL	11170						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires.
C09BB10	VERAPAMIL	11170						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	530-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires.
C08DA01	VERAPAMIL	11170			C01EB17	IVABRADINE	77417			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.	Contraindication	
C08DA51	VERAPAMIL	11170			C01EB17	IVABRADINE	77417			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.	Contraindication	
C09BB10	VERAPAMIL	11170			C01EB17	IVABRADINE	77417			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.	Contraindication	
C08DA01	VERAPAMIL	11170			N05CD08	MIDAZOLAM	6960			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation). 	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
C08DA51	VERAPAMIL	11170			N05CD08	MIDAZOLAM	6960			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation). 	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
C09BB10	VERAPAMIL	11170			N05CD08	MIDAZOLAM	6960			ANSM	530-VERAPAMIL.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation). 	Precaution for use	Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
C08DA01	VERAPAMIL	11170				ST JOHNS WORT	258326			ANSM	530-VERAPAMIL.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.	Contraindication	
C08DA51	VERAPAMIL	11170				ST JOHNS WORT	258326			ANSM	530-VERAPAMIL.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.	Contraindication	
C09BB10	VERAPAMIL	11170				ST JOHNS WORT	258326			ANSM	530-VERAPAMIL.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.	Contraindication	
C08DA01	VERAPAMIL	11170			C01BA01	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C08DA01	VERAPAMIL	11170			C01BA51	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C08DA01	VERAPAMIL	11170			C01BA71	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C08DA51	VERAPAMIL	11170			C01BA01	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C08DA51	VERAPAMIL	11170			C01BA51	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C08DA51	VERAPAMIL	11170			C01BA71	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C09BB10	VERAPAMIL	11170			C01BA01	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C09BB10	VERAPAMIL	11170			C01BA51	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C09BB10	VERAPAMIL	11170			C01BA71	QUINIDINE	9068			ANSM	530-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
C08DA01	VERAPAMIL	11170			C10AA01	SIMVASTATIN	36567			ANSM	530-VERAPAMIL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction.
C08DA51	VERAPAMIL	11170			C10AA01	SIMVASTATIN	36567			ANSM	530-VERAPAMIL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction.
C09BB10	VERAPAMIL	11170			C10AA01	SIMVASTATIN	36567			ANSM	530-VERAPAMIL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction.
C08DA01	VERAPAMIL	11170			L04AA10	SIROLIMUS	35302			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C08DA51	VERAPAMIL	11170			L04AA10	SIROLIMUS	35302			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C09BB10	VERAPAMIL	11170			L04AA10	SIROLIMUS	35302			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
C08DA01	VERAPAMIL	11170			D11AH01	TACROLIMUS	42316			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
C08DA01	VERAPAMIL	11170			L04AD02	TACROLIMUS	42316			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
C08DA51	VERAPAMIL	11170			D11AH01	TACROLIMUS	42316			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
C08DA51	VERAPAMIL	11170			L04AD02	TACROLIMUS	42316			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
C09BB10	VERAPAMIL	11170			D11AH01	TACROLIMUS	42316			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
C09BB10	VERAPAMIL	11170			L04AD02	TACROLIMUS	42316			ANSM	530-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
C08DA01	VERAPAMIL	11170			G04CA02	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C08DA01	VERAPAMIL	11170			G04CA52	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C08DA01	VERAPAMIL	11170			G04CA53	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C08DA51	VERAPAMIL	11170			G04CA02	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C08DA51	VERAPAMIL	11170			G04CA52	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C08DA51	VERAPAMIL	11170			G04CA53	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C09BB10	VERAPAMIL	11170			G04CA02	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C09BB10	VERAPAMIL	11170			G04CA52	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C09BB10	VERAPAMIL	11170			G04CA53	TAMSULOSINE	77492			ANSM	530-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosine, due to inhibition of its hepatic metabolism	Precaution for use	Clinical monitoring and adjustment of the dosage of the tamsulosine during the treatment with the enzyme inhibitor and after it is stopped, as the situation requires. 
C08DA01	VERAPAMIL	11170			B01AC24	TICAGRELOR	1116632			ANSM	530-VERAPAMIL.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
C08DA51	VERAPAMIL	11170			B01AC24	TICAGRELOR	1116632			ANSM	530-VERAPAMIL.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
C09BB10	VERAPAMIL	11170			B01AC24	TICAGRELOR	1116632			ANSM	530-VERAPAMIL.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
J05AB03	VIDARABINE	11194			M04AA01	ALLOPURINOL	519			ANSM	531-VIDARABINE.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
S01AD06	VIDARABINE	11194			M04AA01	ALLOPURINOL	519			ANSM	531-VIDARABINE.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
			VINCA ALKALOIDS	L01CA	J01FA09	CLARITHROMYCIN	21212			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic. 
			VINCA ALKALOIDS	L01CA	A02BD04	CLARITHROMYCIN	21212			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic. 
			VINCA ALKALOIDS	L01CA	A02BD05	CLARITHROMYCIN	21212			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic. 
			VINCA ALKALOIDS	L01CA	A02BD06	CLARITHROMYCIN	21212			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic. 
			VINCA ALKALOIDS	L01CA	A02BD07	CLARITHROMYCIN	21212			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic. 
			VINCA ALKALOIDS	L01CA	V03AX03	COBICISTAT	1306284			ANSM	532-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic. 
			VINCA ALKALOIDS	L01CA	D10AF02	ERYTHROMYCIN	4053			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic.
			VINCA ALKALOIDS	L01CA	D10AF52	ERYTHROMYCIN	4053			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic.
			VINCA ALKALOIDS	L01CA	J01FA01	ERYTHROMYCIN	4053			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic.
			VINCA ALKALOIDS	L01CA	S01AA17	ERYTHROMYCIN	4053			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic.
			VINCA ALKALOIDS	L01CA				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	532-VINCA-ALKALOIDS.html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor. 	Precaution for use	Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.
			VINCA ALKALOIDS	L01CA	J02AC02	ITRACONAZOLE	28031			ANSM	532-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole	Not recommended	
			VINCA ALKALOIDS	L01CA	D01AC08	KETOCONAZOLE	6135			ANSM	532-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
			VINCA ALKALOIDS	L01CA	G01AF11	KETOCONAZOLE	6135			ANSM	532-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
			VINCA ALKALOIDS	L01CA	J02AB02	KETOCONAZOLE	6135			ANSM	532-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
			VINCA ALKALOIDS	L01CA	L01DC03	MITOMYCIN C	632			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca alkaloids	Take into account	
			VINCA ALKALOIDS	L01CA	J02AC04	POSACONAZOLE	282446			ANSM	532-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole	Not recommended	
			VINCA ALKALOIDS	L01CA	J01FA15	TELITHROMYCIN	274786			ANSM	532-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism of the telithromycin	Precaution for use	Strict clinical monitoring and laboratory tests. Possibly, use another antibiotic. 
L01XX43	VISMODEGIB	1242987						ENZYMATIC INDUCERS	N03-J05-001	ANSM	533-VISMODEGIB.html	Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer	Not recommended	
L01XX43	VISMODEGIB	1242987				ST JOHNS WORT	258326			ANSM	533-VISMODEGIB.html	Risk of decrease of the plasma concentrations of vismodegib	Contraindication	
A11C	VITAMIN A	11246						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	534-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	Contraindication	
A11CA	VITAMIN A	11246						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	534-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	Contraindication	
A11CA01	VITAMIN A	11246						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	534-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	Contraindication	
A11CA02	VITAMIN A	11246						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	534-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	Contraindication	
A11CB	VITAMIN A	11246						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	534-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	Contraindication	
V04CB01	VITAMIN A	11246						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	534-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	Contraindication	
A11C	VITAMIN A	11246						RETINOIDS	D05-D10	ANSM	534-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
A11CA	VITAMIN A	11246						RETINOIDS	D05-D10	ANSM	534-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
A11CA01	VITAMIN A	11246						RETINOIDS	D05-D10	ANSM	534-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
A11CA02	VITAMIN A	11246						RETINOIDS	D05-D10	ANSM	534-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
A11CB	VITAMIN A	11246						RETINOIDS	D05-D10	ANSM	534-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
V04CB01	VITAMIN A	11246						RETINOIDS	D05-D10	ANSM	534-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	Contraindication	
			VITAMIN D	A11CC	A08AB01	ORLISTAT	37925			ANSM	535-VITAMIN-D.html	Decrease of the absorption of the vitamin D	Take into account	
J02AC03	VORICONAZOLE	121243						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	536-VORICONAZOLE.html	Risk of constriction of the coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J02AC03	VORICONAZOLE	121243			C01BD01	AMIODARONE	703			ANSM	536-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone. 	Precaution for use	Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone. 
J02AC03	VORICONAZOLE	121243						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	536-VORICONAZOLE.html	--for carbamazepine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer--for phenytoin, fosphenytoin:Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole, for another. 	Contraindication	-for carbamazepine, phenobarbital, primidone
J02AC03	VORICONAZOLE	121243						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	536-VORICONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. 
J02AC03	VORICONAZOLE	121243						OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	ANSM	536-VORICONAZOLE.html	In case of prolonged use by oral or inhaled route:increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushing's syndrome even of adrenal insufficiency	Take into account	
J02AC03	VORICONAZOLE	121243			G04BD10	DARIFENACIN	136198			ANSM	536-VORICONAZOLE.html	Increase of the concentrations of darifenacin, with risk of increase of its undesirable effects	Precaution for use	Clinical monitoring and possible adjustment of the dosage of darifenacin.
J02AC03	VORICONAZOLE	121243			A01AC02	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			C05AA09	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			D07AB19	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			D07XB05	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			D10AA03	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			H02AB02	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			R01AD03	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S01BA01	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S01CB01	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S02BA06	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S03BA01	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			D07CB04	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S01CA01	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S02CA06	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			S03CA01	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			R01AD53	DEXAMETHASONE	3264			ANSM	536-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
J02AC03	VORICONAZOLE	121243			N02CA01	DIHYDROERGOTAMINE	3418			ANSM	536-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
J02AC03	VORICONAZOLE	121243			J05AG03	EFAVIRENZ	195085			ANSM	536-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together.
J02AC03	VORICONAZOLE	121243			J05AR06	EFAVIRENZ	195085			ANSM	536-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together.
J02AC03	VORICONAZOLE	121243			N02CA02	ERGOTAMINE	4025			ANSM	536-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
J02AC03	VORICONAZOLE	121243			N02CA51	ERGOTAMINE	4025			ANSM	536-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
J02AC03	VORICONAZOLE	121243			N02CA52	ERGOTAMINE	4025			ANSM	536-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
J02AC03	VORICONAZOLE	121243			N02CA72	ERGOTAMINE	4025			ANSM	536-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	Contraindication	
J02AC03	VORICONAZOLE	121243			A10BB07	GLIPIZIDE	4821			ANSM	536-VORICONAZOLE.html	Risk of increase of the plasma concentrations of the glipizied at the origin of potentially severe hypoglycemia	Precaution for use	Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.
J02AC03	VORICONAZOLE	121243						IMMUNOSUPPRESSANTS	L04A	ANSM	536-VORICONAZOLE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole. 	Not recommended 	-with the everolimus, the sirolimus, and the temsirolimus
J02AC03	VORICONAZOLE	121243						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	536-VORICONAZOLE.html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
J02AC03	VORICONAZOLE	121243				ST JOHNS WORT	258326			ANSM	536-VORICONAZOLE.html	Significant reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect	Contraindication	
J02AC03	VORICONAZOLE	121243			J05AG01	NEVIRAPINE	53654			ANSM	536-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together. 
J02AC03	VORICONAZOLE	121243			J05AR07	NEVIRAPINE	53654			ANSM	536-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together. 
J02AC03	VORICONAZOLE	121243			J05AR05	NEVIRAPINE	53654			ANSM	536-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine	Not recommended	If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together. 
J02AC03	VORICONAZOLE	121243			C01BA01	QUINIDINE	9068			ANSM	536-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J02AC03	VORICONAZOLE	121243			C01BA51	QUINIDINE	9068			ANSM	536-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J02AC03	VORICONAZOLE	121243			C01BA71	QUINIDINE	9068			ANSM	536-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
J02AC03	VORICONAZOLE	121243			J04AB04	RIFABUTIN	55672			ANSM	536-VORICONAZOLE.html	Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another. 	Not recommended	If the administration of the substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin. 
J02AC03	VORICONAZOLE	121243			J04AB02	RIFAMPICIN	9384			ANSM	536-VORICONAZOLE.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J02AC03	VORICONAZOLE	121243			J04AM02	RIFAMPICIN	9384			ANSM	536-VORICONAZOLE.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J02AC03	VORICONAZOLE	121243			J04AM05	RIFAMPICIN	9384			ANSM	536-VORICONAZOLE.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J02AC03	VORICONAZOLE	121243			J04AM06	RIFAMPICIN	9384			ANSM	536-VORICONAZOLE.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	Contraindication	
J02AC03	VORICONAZOLE	121243			C10AA01	SIMVASTATIN	36567			ANSM	536-VORICONAZOLE.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin	Contraindication	
J02AC03	VORICONAZOLE	121243			G04BD08	SOLIFENACIN	322167			ANSM	536-VORICONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J02AC03	VORICONAZOLE	121243			G04CA53	SOLIFENACIN	322167			ANSM	536-VORICONAZOLE.html	Increase of the concentrations of solifenacin, with risk of overdose	Precaution for use	Clinical monitoring and possible adjustment of the dosage of solifenacin.
J02AC03	VORICONAZOLE	121243			N06AX16	VENLAFAXINE	39786			ANSM	536-VORICONAZOLE.html	Increase of the concentrations of venlafaxine with risk of overdose. 	Take into account	
J02AC03	VORICONAZOLE	121243			N05CF02	ZOLPIDEM	39993			ANSM	536-VORICONAZOLE.html	Slight increase of the sedative effects of the zolpidem	Take into account	
J02AC03	VORICONAZOLE	121243			N05CF01	ZOPICLONE	40001			ANSM	536-VORICONAZOLE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
G04BE04	YOHIMBINE	220982			C02AC01	CLONIDINE	2599			ANSM	537-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
G04BE04	YOHIMBINE	220982			N02CX02	CLONIDINE	2599			ANSM	537-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
G04BE04	YOHIMBINE	220982			S01EA04	CLONIDINE	2599			ANSM	537-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
G04BE04	YOHIMBINE	220982			C02LC01	CLONIDINE	2599			ANSM	537-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
G04BE04	YOHIMBINE	220982			C02LC51	CLONIDINE	2599			ANSM	537-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
J05AF03	ZALCITABINE	3363			J05AF02	DIDANOSINE	3364			ANSM	538-ZALCITABINE.html	Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. 
J05AF03	ZALCITABINE	3363			J05AB06	GANCICLOVIR	4678			ANSM	538-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together. 
J05AF03	ZALCITABINE	3363			S01AD09	GANCICLOVIR	4678			ANSM	538-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two medications together. 
J05AF03	ZALCITABINE	3363			J05AF05	LAMIVUDINE	68244			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF03	ZALCITABINE	3363			J05AR02	LAMIVUDINE	68244			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF03	ZALCITABINE	3363			J05AR07	LAMIVUDINE	68244			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF03	ZALCITABINE	3363			J05AR01	LAMIVUDINE	68244			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF03	ZALCITABINE	3363			J05AR04	LAMIVUDINE	68244			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF03	ZALCITABINE	3363			J05AR05	LAMIVUDINE	68244			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF03	ZALCITABINE	3363			P01CX01	PENTAMIDINE	7994			ANSM	538-ZALCITABINE.html	Increased risk of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together. 
J05AF03	ZALCITABINE	3363			J05AF04	STAVUDINE	59763			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites 	Not recommended	
J05AF03	ZALCITABINE	3363			J05AR07	STAVUDINE	59763			ANSM	538-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites 	Not recommended	
J05AF03	ZALCITABINE	3363			L04AX02	THALIDOMIDE	10432			ANSM	538-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the substances together. 
J05AF01	ZIDOVUDINE 	11413			A01AB04	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AF01	ZIDOVUDINE 	11413			A07AA07	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AF01	ZIDOVUDINE 	11413			G01AA03	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AF01	ZIDOVUDINE 	11413			J02AA01	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR01	ZIDOVUDINE 	11413			A01AB04	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR01	ZIDOVUDINE 	11413			A07AA07	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR01	ZIDOVUDINE 	11413			G01AA03	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR01	ZIDOVUDINE 	11413			J02AA01	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR04	ZIDOVUDINE 	11413			A01AB04	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR04	ZIDOVUDINE 	11413			A07AA07	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR04	ZIDOVUDINE 	11413			G01AA03	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR04	ZIDOVUDINE 	11413			J02AA01	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR05	ZIDOVUDINE 	11413			A01AB04	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR05	ZIDOVUDINE 	11413			A07AA07	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR05	ZIDOVUDINE 	11413			G01AA03	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AR05	ZIDOVUDINE 	11413			J02AA01	AMPHOTERICIN B 	732			ANSM	539-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC.
J05AF01	ZIDOVUDINE 	11413			D10AX05	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AF01	ZIDOVUDINE 	11413			J04BA02	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR01	ZIDOVUDINE 	11413			D10AX05	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR01	ZIDOVUDINE 	11413			J04BA02	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR04	ZIDOVUDINE 	11413			D10AX05	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR04	ZIDOVUDINE 	11413			J04BA02	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR05	ZIDOVUDINE 	11413			D10AX05	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR05	ZIDOVUDINE 	11413			J04BA02	DAPSONE	3108			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AF01	ZIDOVUDINE 	11413			D01AE21	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AF01	ZIDOVUDINE 	11413			J02AX01	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR01	ZIDOVUDINE 	11413			D01AE21	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR01	ZIDOVUDINE 	11413			J02AX01	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR04	ZIDOVUDINE 	11413			D01AE21	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR04	ZIDOVUDINE 	11413			J02AX01	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR05	ZIDOVUDINE 	11413			D01AE21	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AR05	ZIDOVUDINE 	11413			J02AX01	FLUCYTOSINE	4451			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	More frequent CBC
J05AF01	ZIDOVUDINE 	11413			J05AB06	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AF01	ZIDOVUDINE 	11413			S01AD09	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AR01	ZIDOVUDINE 	11413			J05AB06	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AR01	ZIDOVUDINE 	11413			S01AD09	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AR04	ZIDOVUDINE 	11413			J05AB06	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AR04	ZIDOVUDINE 	11413			S01AD09	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AR05	ZIDOVUDINE 	11413			J05AB06	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AR05	ZIDOVUDINE 	11413			S01AD09	GANCICLOVIR	4678			ANSM	539-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in small doses.
J05AF01	ZIDOVUDINE 	11413			J05AB04	RIBAVIRIN	9344			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together.
J05AR01	ZIDOVUDINE 	11413			J05AB04	RIBAVIRIN	9344			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together.
J05AR04	ZIDOVUDINE 	11413			J05AB04	RIBAVIRIN	9344			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together.
J05AR05	ZIDOVUDINE 	11413			J05AB04	RIBAVIRIN	9344			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the medications together.
J05AF01	ZIDOVUDINE 	11413			J05AF04	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF01	ZIDOVUDINE 	11413			J05AR07	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR01	ZIDOVUDINE 	11413			J05AF04	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR01	ZIDOVUDINE 	11413			J05AR07	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR04	ZIDOVUDINE 	11413			J05AF04	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR04	ZIDOVUDINE 	11413			J05AR07	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR05	ZIDOVUDINE 	11413			J05AF04	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AR05	ZIDOVUDINE 	11413			J05AR07	STAVUDINE	59763			ANSM	539-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
J05AF01	ZIDOVUDINE 	11413						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	539-ZIDOVUDINE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. 
J05AR01	ZIDOVUDINE 	11413						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	539-ZIDOVUDINE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. 
J05AR04	ZIDOVUDINE 	11413						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	539-ZIDOVUDINE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. 
J05AR05	ZIDOVUDINE 	11413						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	539-ZIDOVUDINE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid	Precaution for use	Regular clinical monitoring and laboratory tests. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. 
			METABOLIZED ANTICONVULSANTS	N03A-002		ST JOHNS WORT	258326			ANSM	54-METABOLIZED-ANTICONVULSANTS.html	Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant	Contraindication	
A12CB	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB01	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB02	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB03	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
B05X	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
B05XA	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
B05XA12	ZINC	1431163			A12AA	CALCIUM	1428011			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium 	Precaution for use	Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
A12CB01	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
A12CB02	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
A12CB03	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
B05X	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
B05XA	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
B05XA12	ZINC	1431163						TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	540-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
A12CB	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB01	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB02	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB03	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B05X	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B05XA	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
B05XA12	ZINC	1431163			B03A	IRON	1431589			ANSM	540-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
A12CB	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
A12CB01	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
A12CB02	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
A12CB03	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
B05X	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
B05XA	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
B05XA12	ZINC	1431163						FLUOROQUINOLONES	J01MA-001	ANSM	540-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
A12CB	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB01	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB01	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB02	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB02	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB03	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
A12CB03	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
B05X	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
B05X	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
B05XA	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
B05XA	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
B05XA12	ZINC	1431163			V10BX01	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
B05XA12	ZINC	1431163			M05BX03	STRONTIUM	81638			ANSM	540-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
N05CF02	ZOLPIDEM	39993			J01FA09	CLARITHROMYCIN	21212			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			A02BD04	CLARITHROMYCIN	21212			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			A02BD05	CLARITHROMYCIN	21212			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			A02BD06	CLARITHROMYCIN	21212			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			A02BD07	CLARITHROMYCIN	21212			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			D10AF02	ERYTHROMYCIN	4053			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			D10AF52	ERYTHROMYCIN	4053			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			J01FA01	ERYTHROMYCIN	4053			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			S01AA17	ERYTHROMYCIN	4053			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			J02AC02	ITRACONAZOLE	28031			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			D01AC08	KETOCONAZOLE	6135			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			G01AF11	KETOCONAZOLE	6135			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			J02AB02	KETOCONAZOLE	6135			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			J05AE04	NELFINAVIR	134527			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			J04AB02	RIFAMPICIN	9384			ANSM	541-ZOLPIDEM.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
N05CF02	ZOLPIDEM	39993			J04AM02	RIFAMPICIN	9384			ANSM	541-ZOLPIDEM.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
N05CF02	ZOLPIDEM	39993			J04AM05	RIFAMPICIN	9384			ANSM	541-ZOLPIDEM.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
N05CF02	ZOLPIDEM	39993			J04AM06	RIFAMPICIN	9384			ANSM	541-ZOLPIDEM.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring. Possibly use another hypnotic.
N05CF02	ZOLPIDEM	39993			J01FA15	TELITHROMYCIN	274786			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF02	ZOLPIDEM	39993			J02AC03	VORICONAZOLE	121243			ANSM	541-ZOLPIDEM.html	Slight increase of the sedative effects of the zolpidem.	Take into account	
N05CF01	ZOPICLONE	40001			J01FA09	CLARITHROMYCIN	21212			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			A02BD04	CLARITHROMYCIN	21212			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			A02BD05	CLARITHROMYCIN	21212			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			A02BD06	CLARITHROMYCIN	21212			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			A02BD07	CLARITHROMYCIN	21212			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			D10AF02	ERYTHROMYCIN	4053			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			D10AF52	ERYTHROMYCIN	4053			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			J01FA01	ERYTHROMYCIN	4053			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			S01AA17	ERYTHROMYCIN	4053			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			J02AC02	ITRACONAZOLE	28031			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			D01AC08	KETOCONAZOLE	6135			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			G01AF11	KETOCONAZOLE	6135			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			J02AB02	KETOCONAZOLE	6135			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			J05AE04	NELFINAVIR	134527			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			J04AB02	RIFAMPICIN	9384			ANSM	542-ZOPICLONE.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring.Possibly use another hypnotic.
N05CF01	ZOPICLONE	40001			J04AM02	RIFAMPICIN	9384			ANSM	542-ZOPICLONE.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring.Possibly use another hypnotic.
N05CF01	ZOPICLONE	40001			J04AM05	RIFAMPICIN	9384			ANSM	542-ZOPICLONE.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring.Possibly use another hypnotic.
N05CF01	ZOPICLONE	40001			J04AM06	RIFAMPICIN	9384			ANSM	542-ZOPICLONE.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	Clinical monitoring.Possibly use another hypnotic.
N05CF01	ZOPICLONE	40001			J01FA15	TELITHROMYCIN	274786			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
N05CF01	ZOPICLONE	40001			J02AC03	VORICONAZOLE	121243			ANSM	542-ZOPICLONE.html	Slight increase of the sedative effects of the zopiclone	Take into account	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001				ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	Limit the amount of adrenaline, for example: less than 0.1 mg of adrenalin in 10 minutes or 0.3 mg in an hour for an adult 
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	M03BX01	BACLOFEN	1292			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Risk of increase of the muscular hypotonia. 	Take into account	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	C02AC01	CLONIDINE	2599			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	N02CX02	CLONIDINE	2599			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	S01EA04	CLONIDINE	2599			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	C02LC01	CLONIDINE	2599			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	C02LC51	CLONIDINE	2599			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects	Precaution for use	Increased clinical monitoring and, if necessary, adjustment of the dosage
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	A08AB01	ORLISTAT	37925			ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Risk of therapeutic failure in cases of concomitant treatment with orlistat	Take into account	
			TRICYCLIC ANTIDEPRESSANTS	N06AA-001				ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	55-TRICYCLIC-ANTIDEPRESSANTS.html	Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
			GLITAZONE ANTIDIABETICS	A10BG0				SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	56-GLITAZONE-ANTIDIABETICS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the need for glitazone, due to decrease or increase of the secretion of endogenous glucogon.	Precaution for use	Strengthen self-monitoring of blood glucose and adjust the dosage of the glitazone if needed during the treatment with the somatostatin analog.
			GLITAZONE ANTIDIABETICS	A10BG0	C10AB04	GEMFIBROZIL	4719			ANSM	56-GLITAZONE-ANTIDIABETICS.html	Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring
			GLITAZONE ANTIDIABETICS	A10BG0	J04AB02	RIFAMPICIN	9384			ANSM	56-GLITAZONE-ANTIDIABETICS.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped
			GLITAZONE ANTIDIABETICS	A10BG0	J04AM02	RIFAMPICIN	9384			ANSM	56-GLITAZONE-ANTIDIABETICS.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped
			GLITAZONE ANTIDIABETICS	A10BG0	J04AM05	RIFAMPICIN	9384			ANSM	56-GLITAZONE-ANTIDIABETICS.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped
			GLITAZONE ANTIDIABETICS	A10BG0	J04AM06	RIFAMPICIN	9384			ANSM	56-GLITAZONE-ANTIDIABETICS.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	Clinical monitoring and laboratory tests; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped
			AZOLE ANTIFUNGALS	J02AC-001	M04AC01	COLCHICINE	2683			ANSM	57-AZOLE-ANTIFUNGALS.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	Not recommended	
			AZOLE ANTIFUNGALS	J02AC-001	P01BX01	HALOFANTRINE	50749			ANSM	57-AZOLE-ANTIFUNGALS.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	Not recommended	If it is possible, interrupt the azole antifungal. If administering the substances together cannot be avoided, testing of the QT before the beginning of the treatment and EKG monitoring
			AZOLE ANTIFUNGALS	J02AC-001	N05CD08	MIDAZOLAM	6960			ANSM	57-AZOLE-ANTIFUNGALS.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.	Precaution for use 	- with midazolam by IV route
			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001				ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	58-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Risk of severe orthostatic hypotension	Not recommended	
			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001				ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001	ANSM	58-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Greater risk of orthostatic hypotension. .	Take into account	
			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001				TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	58-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended 	-with the doxazosine
			CENTRAL ANTIHYPERTENSIVES	C02AC-001				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	59-CENTRAL-ANTIHYPERTENSIVES.html	Large increase of blood pressure in cases of sudden termination of the treatment with the central antihypertensive	Precaution for use	Avoid ending treatment with the central antihypertensive abruptly. Clinical monitoring.
			CENTRAL ANTIHYPERTENSIVES	C02AC-001				BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	59-CENTRAL-ANTIHYPERTENSIVES.html	Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in case of heart failure treated with a beta-blocking agent and vasodilator	Not recommended	
S01XA15	ASCORBIC ACID	1151			V03AC01	DEFEROXAMINE	3131			ANSM	6-ASCORBIC-ACID.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomalies, even acute heart failure (generally reversible at the end of the administration of the Vitamin C).	Precaution for use	In the case of hemochromatosis, only give Vitamin C after having started the treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001				ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	60-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Risk of greater orthostatic hypotension	Take into account	
			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001				ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	60-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Risk of greater orthostatic hypotension	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				OTHER NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	With the other non steroidal anti-inflammatory drugs: increase of the risk of causing ulcers and digestive hemorrhage 	Not recommended	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	A01AD05	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	B01AC06	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	B01AC56	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	C10BX01	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	C10BX02	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	C10BX04	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	M01BA03	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	N02BA01	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	N02BA51	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	N02BA71	ACETYLSALICYLIC ACID	1191			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the non-steroidal anti-inflammatories). These effects are generally reversible. In addition, reduction of the antihypertensive effect. 	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together.
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				ORAL ANTICOAGULANTS	B01A-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the oral anticoagulant's risk of causing hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories) 	Contraindication	-with phenylbutazone
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Reduction of the antihypertensive effect (inhibition of the vasodilating prostaglandins by the nonsteroidal anti-inflammatories and fluid retention with the phenylbutazone	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	L04AD01	CICLOSPORIN	3008			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	Monitor renal function at the beginning of the treatment with the NSAI
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	S01XA18	CICLOSPORIN	3008			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	Monitor renal function at the beginning of the treatment with the NSAI
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	V03AC03	DEFERASIROX	614373			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				DIURETICS	C0E-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with the patient at risk (older and/or dehydrated patient) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect	Precaution for use	Hydrate the patient and monitor renal function at the start of treatment 
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of ulceration and of gastrointestinal hemorrhage	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage 	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	If administering the substances together cannot be avoided, strict clinical monitoring
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those with altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.	Precaution for use	Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of the substances together.
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002				SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	D11AX04	LITHIUM	6448			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the lithemia that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	If administering the substances together cannot be avoided, monitor the lithemia strictly and adjust the dosage of the lithium during the treatment with the substances together and after the NSAI is stopped
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	L01BA01	METHOTREXATE	6851			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Contraindication 	-with the phenylbutazone, regardless of the dose of methotrexate and for all the forms of phenylbutazone, including topical. 
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	L04AX03	METHOTREXATE	6851			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Contraindication 	-with the phenylbutazone, regardless of the dose of methotrexate and for all the forms of phenylbutazone, including topical. 
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	L01BA04	PEMETREXED	68446			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)	Not recommended	With patients having weak to moderate renal function (clearance of the creatinine between 45 ml/min and 80 ml.min)
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	D11AH01	TACROLIMUS	42316			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	Monitor the renal function at the beginning of treatment with the NSAI
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	L04AD02	TACROLIMUS	42316			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	Monitor the renal function at the beginning of treatment with the NSAI
			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	J05AF07	TENOFOVIR DISOPROXIL	300195			ANSM	61-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of increase of the nephrotoxicity of the tenofovir	Precaution for use	When these are administered together, monitor renal function.
			ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES	P01B-001				MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	62-ANTIPARASITICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	--with domperidone, citalopram, escitalopram, and hydroxyzine
			ANTIPARKINSONIAN ANTICHOLINERGICS	N04AA-001				DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	63-ANTIPARKINSONIAN-ANTICHOLINERGICS.html	Risk of increase of neuropsychological disorders	Precaution for use:	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these substances together 
			ANTIPARKINSONIAN DOPAMINERGICS	N04B-001				ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	64-ANTIPARKINSONIAN-DOPAMINERGICS.html	Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).	Not recommended	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	J05AE08	ATAZANAVIR	343047			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	B03BA01	CYANOCOBALAMIN	11248			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	B03BA02	CYANOCOBALAMIN	11248			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	B03BA51	CYANOCOBALAMIN	11248			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001				METABOLIZED TYROSINE-KINASE INHIBITORS 	L01XE	ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the bioavailabilty of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption	Take into account	-except with the vandetanib
			H2 RECEPTOR ANTAGONISTS	A02BA-001	J02AC02	ITRACONAZOLE	28031			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	D01AC08	KETOCONAZOLE	6135			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	G01AF11	KETOCONAZOLE	6135			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	J02AB02	KETOCONAZOLE	6135			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	J02AC04	POSACONAZOLE	282446			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Not recommended	
			H2 RECEPTOR ANTAGONISTS	A02BA-001	G03AD02	ULIPRISTAL	1005921			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the effect of the ulipristal due to decrease of its absorption 	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	J05AE08	ATAZANAVIR	343047			ANSM	66-PROTON-PUMP-INHIBITORS.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
			PROTON PUMP INHIBITORS	A02BC-001	B03BA01	CYANOCOBALAMIN	11248			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	B03BA02	CYANOCOBALAMIN	11248			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	B03BA51	CYANOCOBALAMIN	11248			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001				METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption	Take into account	-except with the vandetanib
			PROTON PUMP INHIBITORS	A02BC-001	J02AC02	ITRACONAZOLE	28031			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	D01AC08	KETOCONAZOLE	6135			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory 	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	G01AF11	KETOCONAZOLE	6135			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory 	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	J02AB02	KETOCONAZOLE	6135			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory 	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001		LEDIPASVIR	1591922			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of ledipasvir when the proton pump inhibitor is administered before the ledipasvir	Precaution for use	It is recommended that the proton pump inhibitor and the ledipasvir be taken simultaneously.
			PROTON PUMP INHIBITORS	A02BC-001	BA01	METHOTREXATE	6851			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	-with the methotrexate in doses > 20mg /week
			PROTON PUMP INHIBITORS	A02BC-001	L04AX03	METHOTREXATE	6851			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	-with the methotrexate in doses > 20mg /week
			PROTON PUMP INHIBITORS	A02BC-001		ST JOHNS WORT	258326			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of ineffectiveness of the treatment by the antisecretory due to decrease of its metabolism by the St Johns wort	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	OLATE	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	MOFETIL	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	MYCOPHEN	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	OLIC	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	ACID	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	7145	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	L04AA06	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
			PROTON PUMP INHIBITORS	A02BC-001	J02AC04	POSACONAZOLE	282446			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal, due to increase of the intragastric pH by the antisecretory 	Not recommended	
			PROTON PUMP INHIBITORS	A02BC-001	J05AG05	RILPIVIRINE	1102270			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the plasma concentrations of the rilpivirine by the proton pump inhibitor (decreased absorption due to the increase of the gastric pH). 	Contraindication	
			PROTON PUMP INHIBITORS	A02BC-001	G03AD02	ULIPRISTAL	1005921			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
			MERCURIAL ANTISEPTICS	D08AK0	D08AG02	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
			MERCURIAL ANTISEPTICS	D08AK0	D09AA09	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
			MERCURIAL ANTISEPTICS	D08AK0	D11AC06	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
			MERCURIAL ANTISEPTICS	D08AK0	G01AX11	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
			MERCURIAL ANTISEPTICS	D08AK0	R02AA15	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
			MERCURIAL ANTISEPTICS	D08AK0	S01AX18	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
			ANTI-TNF ALPHA	LO4AB	L04AA24	ABATACEPT 	614391			ANSM	68-ANTI-TNF-ALPHA.html	Increase of the immunodepression 	Not recommended	
			ANTI-TNF ALPHA	LO4AB				ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	68-ANTI-TNF-ALPHA.html	Risk of general vaccine disease possibly fatal	Contraindication	And during the 3 months following the treatment.
			MORPHINE LIKE ANTITUSSIVES	R05DA0-001				AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	69-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
			MORPHINE LIKE ANTITUSSIVES	R05DA0-001	N02AC52	METHADONE	6813			ANSM	69-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
			MORPHINE LIKE ANTITUSSIVES	R05DA0-001	N07BC02	METHADONE	6813			ANSM	69-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
A05AA03	CHOLIC ACID	1440856			N03AA02	PHENOBARBITAL	8134			ANSM	7-CHOLIC-ACID.html	Antagonist effect of the phenobarbital	Contraindication	
			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002				AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	70-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in cases of overdose	Take into account	
			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	N02AC52	METHADONE	6813			ANSM	70-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	N07BC02	METHADONE	6813			ANSM	70-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002				AGONIST-ANTAGONIST OPIOIDS 	NO2A-001	ANSM	70-TRUE-MORPHINE-ANTITUSSIVES.html	Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
			VITAMIN K ANTAGONISTS	B01AA-001		ALCOHOL (DRINK OR INGREDIENT)				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Possible variations of the anticoagulating effect, with increase in case of acute intoxication or decrease in case of chronic alcoholism (increased metabolism)	Take into account	
			VITAMIN K ANTAGONISTS	B01AA-001	M04AA01	ALLOPURINOL	519			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	A11HA03	ALPHA-TOCOPHEROL	11256			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the vitamin E used in doses greater than or equal to 500 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	L02BG01	AMINOGLUTETHIMIDE	677			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Described for warfarin and acenocoumarol.Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	C01BD01	AMIODARONE	703			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with amiodarone and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001				ANDROGENS	A14AA0	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the androgen and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001				ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	A04AD12	APREPITANT	358255			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. 
			VITAMIN K ANTAGONISTS	B01AA-001	L04AX01	AZATHIOPRINE	1256			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment with the immunosuppressant (or the cytotoxic) and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	M04AB03	BENZBROMARONE	1385			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the benzbromarone and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	C02KX01	BOSENTAN	75207			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use 	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001	J01DC03	CEFAMANDOLE	2178			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR.
			VITAMIN K ANTAGONISTS	B01AA-001	J01DD12	CEFOPERAZONE	2184			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR.
			VITAMIN K ANTAGONISTS	B01AA-001	J01DD62	CEFOPERAZONE	2184			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR.
			VITAMIN K ANTAGONISTS	B01AA-001	J01DC05	CEFOTETAN	2184			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J01DD04	CEFTRIAXONE	2193			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01DD54	CEFTRIAXONE	2193			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	D01AE14	CICLOPIROX	21090			ANSM	71-VITAMIN-K-ANTAGONISTS.html	[no text in document]	[no text in document except "File concluding not"]	
			VITAMIN K ANTAGONISTS	B01AA-001	G01AX12	CICLOPIROX	21090			ANSM	71-VITAMIN-K-ANTAGONISTS.html	[no text in document]	[no text in document except "File concluding not"]	
			VITAMIN K ANTAGONISTS	B01AA-001	A02BA01	CIMETIDINE	2541			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	A02BA51	CIMETIDINE	2541			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	D10AF01	CLINDAMYCIN	2582			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. possible adjustment of the dosage of the vitamin Kntagonist during the treatment with clindamycin and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	G01AA10	CLINDAMYCIN	2582			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. possible adjustment of the dosage of the vitamin Kntagonist during the treatment with clindamycin and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	J01FF01	CLINDAMYCIN	2582			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. possible adjustment of the dosage of the vitamin Kntagonist during the treatment with clindamycin and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	D10AF51	CLINDAMYCIN	2582			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. possible adjustment of the dosage of the vitamin Kntagonist during the treatment with clindamycin and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	M04AC01	COLCHICINE	2683			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001				TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001				CYTOTOXICS	L01	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy	Precaution for use	More frequent testing of the INR
			VITAMIN K ANTAGONISTS	B01AA-001	G03XA01	DANAZOL	3102			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with danazol and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	V03AC03	DEFERASIROX	614373			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
			VITAMIN K ANTAGONISTS	B01AA-001	N07BB01	DISULFIRAM	3554			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	C01BD07	DRONEDARONE	233698			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	D01AC03	ECONAZOLE	3743			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Regardless of the route of administration of the econazole:increase of the effect of the vitamin K antagonist and of the risk of hemorrhage.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	G01AF05	ECONAZOLE	3743			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Regardless of the route of administration of the econazole:increase of the effect of the vitamin K antagonist and of the risk of hemorrhage.	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J05AG03	EFAVIRENZ	195085			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001	J05AR06	EFAVIRENZ	195085			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001				FIBRATES	C01AB-001	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	D01AC15	FLUCONAZOLE	4450			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J02AC01	FLUCONAZOLE	4450			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	CLASS	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	CODE	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	J01MA	FLUOROQUINOLONES				ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001				FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	If the combination is not possible to avoid, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	D01AA08	GRISEOFULVINE	5021			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the griseofulvine and a week after it is stopped 
			VITAMIN K ANTAGONISTS	B01AA-001	D01BA01	GRISEOFULVINE	5021			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the griseofulvine and a week after it is stopped 
			VITAMIN K ANTAGONISTS	B01AA-001				UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	When the heparin alternates with the vitamin K antagonist, strenghten clinical monitoring. 
			VITAMIN K ANTAGONISTS	B01AA-001				HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment
			VITAMIN K ANTAGONISTS	B01AA-001	J02AC02	ITRACONAZOLE	28031			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001				MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage the vitamin K antagonist during the treatment with the macrolide and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	L01BB02	MERCAPTOPURINE	103			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment with the immunosuppressor (or the cytotoxic) and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	D07AA01	METHYLPREDNISOLONE 	6902			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolon or in the presence of any signs of hemorrhage
			VITAMIN K ANTAGONISTS	B01AA-001	D10AA02	METHYLPREDNISOLONE 	6902			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolon or in the presence of any signs of hemorrhage
			VITAMIN K ANTAGONISTS	B01AA-001	H02AB04	METHYLPREDNISOLONE 	6902			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolon or in the presence of any signs of hemorrhage
			VITAMIN K ANTAGONISTS	B01AA-001	D07CA02	METHYLPREDNISOLONE 	6902			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolon or in the presence of any signs of hemorrhage
			VITAMIN K ANTAGONISTS	B01AA-001	S01CA08	METHYLPREDNISOLONE 	6902			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolon or in the presence of any signs of hemorrhage
			VITAMIN K ANTAGONISTS	B01AA-001	H02BX01	METHYLPREDNISOLONE 	6902			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	Testing of the INR 2 to 4 days after the bolus of mythylprednisolon or in the presence of any signs of hemorrhage
			VITAMIN K ANTAGONISTS	B01AA-001	A01AB09	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	A07AC01	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	D01AC02	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	G01AF04	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	J02AB01	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	S02AA13	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	D01AC52	MICONAZOLE 	6932			ANSM	71-VITAMIN-K-ANTAGONISTS.html	With the miconazole by general route and oral gel: unpredictable hemorrhage, possibly serious	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001		ST JOHNS WORT	258326			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)	Contraindication	In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J05AG01	NEVIRAPINE 	53654			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001	J05AR07	NEVIRAPINE 	53654			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001	J05AR05	NEVIRAPINE 	53654			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001	R05DA07	NOSCAPINE	7533			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
			VITAMIN K ANTAGONISTS	B01AA-001	A08AB01	ORLISTAT	37925			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped 
			VITAMIN K ANTAGONISTS	B01AA-001	N02BE01	PARACETAMOL	161			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	N02BE51	PARACETAMOL	161			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	N02BE71	PARACETAMOL	161			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	C04AD03	PENTOXIFYLLINE	8013			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the hemorrhagic risk	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	M01AA01	PHENYLBUTAZONE	8160			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For all forms of phenylbutazone, including topical: increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the NSAI)	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	M02AA01	PHENYLBUTAZONE	8160			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For all forms of phenylbutazone, including topical: increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the NSAI)	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	M01BA01	PHENYLBUTAZONE	8160			ANSM	71-VITAMIN-K-ANTAGONISTS.html	For all forms of phenylbutazone, including topical: increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the NSAI)	Contraindication	
			VITAMIN K ANTAGONISTS	B01AA-001	J01FG01	PRISTINAMYCIN	66958			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	P01BB01	PROGUANIL	2382			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	P01BB51	PROGUANIL	2382			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	C01BC03	PROPAFENONE	8754			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the anticoagulant and of the risk of hemorrhage. Mecanism proposed: inhibition of the metabolism of the vitamin K antagonist	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J04AB02	RIFAMPICIN	9384			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J04AM02	RIFAMPICIN	9384			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J04AM05	RIFAMPICIN	9384			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J04AM06	RIFAMPICIN	9384			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	N04BC04	ROPINIROLE	72302			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	A02BX02	SUCRALFATE	10156			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Decrease of the digestive absorption of the vitamin K antagonist	Precaution for use	Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible)
			VITAMIN K ANTAGONISTS	B01AA-001	J01EB05	SULFAFURAZOLE	10207			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	S01AB02	SULFAFURAZOLE	10207			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	B05CA04	SULFAMETHIZOLE	10179			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	D06BA04	SULFAMETHIZOLE	10179			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J01EB02	SULFAMETHIZOLE	10179			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	S01AB01	SULFAMETHIZOLE	10179			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J01EC01	SULFAMETHOXAZOLE	10180			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Not recommended	If administering the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole [of which sulfamethoxazole is an element] and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	J01EE01	SULFAMETHOXAZOLE	10180			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 	Not recommended	If administering the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole [of which sulfamethoxazole is an element] and after it is stopped. 
			VITAMIN K ANTAGONISTS	B01AA-001	L02BA01	TAMOXIFEN	10324			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist
			VITAMIN K ANTAGONISTS	B01AA-001				THROMBOLYTICS	B01AD	ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the risk of hemorrhage	Take into account	
			VITAMIN K ANTAGONISTS	B01AA-001	G03CX01	TIBOLONE	38260			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped
			VITAMIN K ANTAGONISTS	B01AA-001	N02AX02	TRAMADOL	10689			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	N02AX52	TRAMADOL	10689			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.
			VITAMIN K ANTAGONISTS	B01AA-001	J02AC03	VORICONAZOLE	121243			ANSM	71-VITAMIN-K-ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. 
B01AF02	APIXABAN	1364430						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	72-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.	Not recommended	
B01AF02	APIXABAN	1364430						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	72-APIXABAN.html	Increase of the plasma concentrations of the apixaban by the inhibitor, with increase of the risk of bleeding. 	Not recommended	
B01AF02	APIXABAN	1364430			J04AB02	RIFAMPICIN	9384			ANSM	72-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
B01AF02	APIXABAN	1364430			J04AM02	RIFAMPICIN	9384			ANSM	72-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
B01AF02	APIXABAN	1364430			J04AM05	RIFAMPICIN	9384			ANSM	72-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
B01AF02	APIXABAN	1364430			J04AM06	RIFAMPICIN	9384			ANSM	72-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. 	Not recommended	
G04BE07	APOMORPHINE	1043			A04AA01	ONDANSETRON	26225			ANSM	73-APOMORPHINE.html	Severe hypotension and loss of consciousness have been reported when ondansetron and apomorphine are taken together. 	Contraindication	
N04BC0	APOMORPHINE	1043			A04AA01	ONDANSETRON	26225			ANSM	73-APOMORPHINE.html	Severe hypotension and loss of consciousness have been reported when ondansetron and apomorphine are taken together. 	Contraindication	
A04AD12	APREPITANT	358255						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	74-APREPITANT.html	Risk of very large decrease of the concentrations of aprepitant	Not recommended	
A04AD12	APREPITANT	358255						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	74-APREPITANT.html	Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant	Precaution for use	More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. 
A04AD12	APREPITANT	358255						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	74-APREPITANT.html	Decrease of the concentrations of the estrogen-progestin contraceptive, with risk of lower contraceptive effectiveness. 	Precaution for use	Chose another contraceptive method, in particular a barrier method or IUD, during the time these medications are taken together and a cycle following. 
A04AD12	APREPITANT	358255			L01AA06	IFOSFAMIDE	5657			ANSM	74-APREPITANT.html	Risk of increase of the neurotoxicity of the ifosfamide	Take into account 	
A04AD12	APREPITANT	358255			J02AC02	ITRACONAZOLE	28031			ANSM	74-APREPITANT.html	Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the itraconazole. 	Take into account	
A04AD12	APREPITANT	358255			N05AG02	PIMOZIDE	8331			ANSM	74-APREPITANT.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
A04AD12	APREPITANT	358255						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	74-APREPITANT.html	(Except for IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness.	Precaution for use	Choose another method of contraception, in particular a barrier method or IUD during the administration of these medications together and a cycle after. 
A04AD12	APREPITANT	358255			J04AB02	RIFAMPICIN	9384			ANSM	74-APREPITANT.html	Very large decrease of the concentrations of aprepitant	Not recommended	
A04AD12	APREPITANT	358255			J04AM02	RIFAMPICIN	9384			ANSM	74-APREPITANT.html	Very large decrease of the concentrations of aprepitant	Not recommended	
A04AD12	APREPITANT	358255			J04AM05	RIFAMPICIN	9384			ANSM	74-APREPITANT.html	Very large decrease of the concentrations of aprepitant	Not recommended	
A04AD12	APREPITANT	358255			J04AM06	RIFAMPICIN	9384			ANSM	74-APREPITANT.html	Very large decrease of the concentrations of aprepitant	Not recommended	
	ATALUREN							AMINOGLYCOSIDES	J01GB-001	ANSM	75-ATALUREN.html	Risk of increase of the renal toxicity of the aminoglycoside	Contraindication	
J05AE08	ATAZANAVIR	343047						H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	76-ATAZANAVIR.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
J05AE08	ATAZANAVIR	343047						PROTON PUMP INHIBITORS	A02BC-001	ANSM	76-ATAZANAVIR.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
J05AE08	ATAZANAVIR	343047			N02AE01	BUPRENORPHINE	1819			ANSM	76-ATAZANAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
J05AE08	ATAZANAVIR	343047			N07BC01	BUPRENORPHINE	1819			ANSM	76-ATAZANAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
J05AE08	ATAZANAVIR	343047			N07BC51	BUPRENORPHINE	1819			ANSM	76-ATAZANAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
J05AE08	ATAZANAVIR	343047			J01FA09	CLARITHROMYCIN	21212			ANSM	76-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these drugs together
J05AE08	ATAZANAVIR	343047			A02BD04	CLARITHROMYCIN	21212			ANSM	76-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these drugs together
J05AE08	ATAZANAVIR	343047			A02BD05	CLARITHROMYCIN	21212			ANSM	76-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these drugs together
J05AE08	ATAZANAVIR	343047			A02BD06	CLARITHROMYCIN	21212			ANSM	76-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these drugs together
J05AE08	ATAZANAVIR	343047			A02BD07	CLARITHROMYCIN	21212			ANSM	76-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	Regular clinical monitoring and laboratory tests, especially at the beginning of the administration of these drugs together
J05AE08	ATAZANAVIR	343047			J05AG03	EFAVIRENZ	195085			ANSM	76-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AE08	ATAZANAVIR	343047			J05AR06	EFAVIRENZ	195085			ANSM	76-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AE08	ATAZANAVIR	343047			J05AG01	NEVIRAPINE 	53654			ANSM	76-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AE08	ATAZANAVIR	343047			J05AR07	NEVIRAPINE 	53654			ANSM	76-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AE08	ATAZANAVIR	343047			J05AR05	NEVIRAPINE 	53654			ANSM	76-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical monitoring and laboratory tests, especially at the beginning of the administration of the two substances together
J05AE08	ATAZANAVIR	343047			J05AF07	TENOFOVIR DISOPROXIL	300195			ANSM	76-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
J05AE08	ATAZANAVIR	343047			J05AR06	TENOFOVIR DISOPROXIL	300195			ANSM	76-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
J05AE08	ATAZANAVIR	343047			J05AR08	TENOFOVIR DISOPROXIL	300195			ANSM	76-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
J05AE08	ATAZANAVIR	343047			J05AR09	TENOFOVIR DISOPROXIL	300195			ANSM	76-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
J05AE08	ATAZANAVIR	343047			J05AR03	TENOFOVIR DISOPROXIL	300195			ANSM	76-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together	Take into account	Do not administer atazanavir with the tenofovir without ritonavir
N06BA09	ATOMOXETINE	38400			N06AB03	FLUOXETINE	4493			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism	Not recommended	If administering the two together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped. 
N06BA09	ATOMOXETINE	38400			N06CA03	FLUOXETINE	4493			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism	Not recommended	If administering the two together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped. 
N06BA09	ATOMOXETINE	38400			N06AB05	PAROXETINE 	32937			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine due to substantial decrease of its hepatic metabolism 	Not recommended	If it is not possible to avoid administering the two medications together, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped.
N06BA09	ATOMOXETINE	38400			C01BA01	QUINIDINE	9068			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism 	Not recommended	If administering the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped.
N06BA09	ATOMOXETINE	38400			C01BA51	QUINIDINE	9068			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism 	Not recommended	If administering the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped.
N06BA09	ATOMOXETINE	38400			C01BA71	QUINIDINE	9068			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to substantial decrease of its hepatic metabolism 	Not recommended	If administering the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped.
N06BA09	ATOMOXETINE	38400			D01AE15	TERBINAFINE	37801			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to large decrease of its hepatic metabolism	Not recommended	If the administration of the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped.
N06BA09	ATOMOXETINE	38400			D01BA02	TERBINAFINE	37801			ANSM	77-ATOMOXETINE.html	Risk of increase of the undesirable effects of the atomoxetine, due to large decrease of its hepatic metabolism	Not recommended	If the administration of the two substances together cannot be avoided, clinical monitoring and adjustment of the dosage of the atomoxetine during the treatment with the inhibitor and after it is stopped.
C10AA05	ATORVASTATIN	83367				GRAPEFRUIT JUICE				ANSM	78-ATORVASTATIN.html	Increase of the plasma concentrations of the cholesterol-lowering drug with risk of onset of undesirable effects, especially muscular ones	Take into account	
C10AA05	ATORVASTATIN	83367			J01FA10	AZITHROMYCIN	18631			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	Use weaker doses of the cholesterol-lowering medication or another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			J05AE12	BOCEPREVIR	1102129			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the atorvastatin	Precaution for use	Do not exceed the dosage of 20 mg/day of atorvastatin. If the therapeutic objective is not attained with this dosage, use another statin not affected by this type of interaction.
C10AA05	ATORVASTATIN	83367			L04AD01	CICLOSPORIN	3008			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	Precaution for use	Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.
C10AA05	ATORVASTATIN	83367			S01XA18	CICLOSPORIN	3008			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	Precaution for use	Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.
C10AA05	ATORVASTATIN	83367			J01FA09	CLARITHROMYCIN	21212			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			A02BD06	CLARITHROMYCIN	21212			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			A02BD07	CLARITHROMYCIN	21212			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			A02BD05	CLARITHROMYCIN	21212			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			A02BD04	CLARITHROMYCIN	21212			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			C08DB01	DILTIAZEM	3443			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			D10AF02	ERYTHROMYCIN	4053			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			D10AF52	ERYTHROMYCIN	4053			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			J01FA01	ERYTHROMYCIN	4053			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			S01AA17	ERYTHROMYCIN	4053			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached. use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			J02AC02	ITRACONAZOLE	28031			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
C10AA05	ATORVASTATIN	83367			D01AC08	KETOCONAZOLE	6135			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
C10AA05	ATORVASTATIN	83367			G01AF11	KETOCONAZOLE	6135			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
C10AA05	ATORVASTATIN	83367			J02AB02	KETOCONAZOLE	6135			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
C10AA05	ATORVASTATIN	83367						OMBITASVIR + PARITAPREVIR	OMPA	ANSM	78-ATORVASTATIN.html	Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the therapy with the two drug combination	Contraindication	
C10AA05	ATORVASTATIN	83367			J02AC04	POSACONAZOLE	282446			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	Contraindication	
C10AA05	ATORVASTATIN	83367			C01EB18	RANOLAZINE	35829			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine	Precaution for use	Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			J04AB02	RIFAMPICIN	9384			ANSM	78-ATORVASTATIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
C10AA05	ATORVASTATIN	83367			J04AM02	RIFAMPICIN	9384			ANSM	78-ATORVASTATIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
C10AA05	ATORVASTATIN	83367			J04AM05	RIFAMPICIN	9384			ANSM	78-ATORVASTATIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
C10AA05	ATORVASTATIN	83367			J04AM06	RIFAMPICIN	9384			ANSM	78-ATORVASTATIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
C10AA05	ATORVASTATIN	83367			J01FA06	ROXITHROMYCIN	9478			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type	Precaution for use	Use weaker doses of cholesterol lowering agent
C10AA05	ATORVASTATIN	83367			N03AX17	STIRIPENTOL	37119			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	Contraindication	
C10AA05	ATORVASTATIN	83367			J05AE11	TELAPREVIR	1102261			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Contraindication	
C10AA05	ATORVASTATIN	83367			J01FA15	TELITHROMYCIN	274786			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (dose-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	Contraindication	
C10AA05	ATORVASTATIN	83367			C08DA01	VERAPAMIL	11170			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			C08DA51	VERAPAMIL	11170			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
C10AA05	ATORVASTATIN	83367			C09BB10	VERAPAMIL	11170			ANSM	78-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
P01AX06	ATOVAQUONE	60212			J05AG03	EFAVIRENZ	195085			ANSM	79-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
P01AX06	ATOVAQUONE	60212			J05AR06	EFAVIRENZ	195085			ANSM	79-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
P01AX06	ATOVAQUONE	60212						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	79-ATOVAQUONE.html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
P01AX06	ATOVAQUONE	60212			J04AB04	RIFABUTIN	55672			ANSM	79-ATOVAQUONE.html	Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Take into account	
P01AX06	ATOVAQUONE	60212			J04AB02	RIFAMPICIN	9384			ANSM	79-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
P01AX06	ATOVAQUONE	60212			J04AM02	RIFAMPICIN	9384			ANSM	79-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
P01AX06	ATOVAQUONE	60212			J04AM05	RIFAMPICIN	9384			ANSM	79-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
P01AX06	ATOVAQUONE	60212			J04AM06	RIFAMPICIN	9384			ANSM	79-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
M05BA02	CLODRONIC ACID	3350			L01XX11	ESTRAMUSTINE	4089			ANSM	8-CLODRONIC-ACID.html	Risk of increase of the plasma concentrations of estrasmustine by the clodronate	Precaution for use	Clinical monitoring during the administration of these substances together. 
			OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001				RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	80-OTHER-CORTICOIDES,-NOTABLY -INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome, even adrenal insufficiency	Take into account	
			OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	J02AC02	ITRACONAZOLE	28031			ANSM	80-OTHER-CORTICOIDES,-NOTABLY -INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushing's syndrome, even adrenal insufficiency	Take into account	
			OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	D01AC08	KETOCONAZOLE	6135			ANSM	80-OTHER-CORTICOIDES,-NOTABLY -INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing's syndrome, even adrenal insufficiency	Take into account	
			OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	G01AF11	KETOCONAZOLE	6135			ANSM	80-OTHER-CORTICOIDES,-NOTABLY -INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing's syndrome, even adrenal insufficiency	Take into account	
			OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	J02AB02	KETOCONAZOLE	6135			ANSM	80-OTHER-CORTICOIDES,-NOTABLY -INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing's syndrome, even adrenal insufficiency	Take into account	
			OTHER CORTICOIDES, NOTABLY INHALED ONES	D07AC-001	J02AC03	VORICONAZOLE	121243			ANSM	80-OTHER-CORTICOIDES,-NOTABLY -INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushing's syndrome, even adrenal insufficiency	Take into account	
G04BE10	AVANAFIL	1291301				GRAPEFRUIT JUICE				ANSM	81-AVANAFIL.html	Increase of the plasma concentrations of the avanafil, with risk of hypotension	Not recommended	
L04AX01	AZATHIOPRINE	1256						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	82-AZATHIOPRINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment with the immunosuppressant (or the cytotoxic) and after it is stopped.
L04AX01	AZATHIOPRINE	1256						DERIVATIVES OF AMINOSALICYLIC ACID (ASA)	A07EC-001	ANSM	82-AZATHIOPRINE.html	Risk of increase of the myelosuppressor effect of the azathioprine due to inhibition of its hepatic metabolism by the ASA derivative, especially in patients presenting a partial deficit of thiopurine methyltransferase (TPMT)	Take into account	
L04AX01	AZATHIOPRINE	1256						XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	82-AZATHIOPRINE.html	Bone marrow suppression, possibly serious	Contraindication	
L04AX01	AZATHIOPRINE	1256			J05AB04	RIBAVIRIN	9344			ANSM	82-AZATHIOPRINE.html	Increased risk of serious undesirable hematological effects due to inhibition of the metabolism of the azothioprine by the ribavirin	Not recommended	
J01FA10	AZITHROMYCIN 	18631			C10AA05	ATORVASTATIN	83367			ANSM	83-AZITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	Use weaker doses of the cholesterol lowering medication or another statin not affected by this type of interaction.
J01FA10	AZITHROMYCIN 	18631			L04AD01	CICLOSPORIN	3008			ANSM	83-AZITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped.
J01FA10	AZITHROMYCIN 	18631			S01XA18	CICLOSPORIN	3008			ANSM	83-AZITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped.
J01FA10	AZITHROMYCIN 	18631			C01AA05	DIGOXIN 	3407			ANSM	83-AZITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the azithromycin and after it is stopped. 
J01FA10	AZITHROMYCIN 	18631						MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	83-AZITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG during the administration of the substances together. 
J01FA10	AZITHROMYCIN 	18631			C10AA01	SIMVASTATIN	36567			ANSM	83-AZITHROMYCIN.html	Increased risk of the undesirable effects (concentration-dependent) of the rhabdomyolosis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	Use weaker doses of the cholesterol lowering agent or chose another statin not affected by this type of interaction.
J01DF01	AZTREONAM	1272						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	84-AZTREONAM.html	Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid	Precaution for use	Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.
M03BX01	BACLOFEN	1292						TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	85-BACLOFEN.html	Risk of increase of hypotonia	Take into account	
M03BX01	BACLOFEN	1292			N04BA01	LEVODOPA	6375			ANSM	85-BACLOFEN.html	Risk of aggravation of the Parkinson's syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
M03BX01	BACLOFEN	1292			N04BA02	LEVODOPA	6375			ANSM	85-BACLOFEN.html	Risk of aggravation of the Parkinson's syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
M03BX01	BACLOFEN	1292			N04BA03	LEVODOPA	6375			ANSM	85-BACLOFEN.html	Risk of aggravation of the Parkinson's syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
			BARBITURATES	N05CA-001				BENZODIAZEPINES AND RELATED	N05-001	ANSM	86-BARBITURATES.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
			BARBITURATES	N05CA-001				OPIOIDS	N0-R0	ANSM	86-BARBITURATES.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
J04AK05	BEDAQUILINE	1364504						ENZYMATIC INDUCERS	N03-J05-001	ANSM	87-BEDAQUILINE.html	Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
J04AK05	BEDAQUILINE	1364504			CLASSE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504			CODE	STRONG INHIBITORS OF CYP3A4				ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.
J04AK05	BEDAQUILINE	1364504				ST JOHNS WORT	258326			ANSM	87-BEDAQUILINE.html	Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
M04AB03	BENZBROMARONE	1385						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	88-BENZBROMARONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the benzbromarone and after it is stopped. 
			BENZODIAZEPINES AND RELATED	N05-001				BARBITURATES	N05CA-001	ANSM	89-BENZODIAZEPINES-AND-RELATED.html	Increased risk of respiratory depression, which can be fatal in the case of overdose	Take into account	
			BENZODIAZEPINES AND RELATED	N05-001	N02AE01	BUPRENORPHINE	1819			ANSM	89-BENZODIAZEPINES-AND-RELATED.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression, which can be fatal. 	Take into account	Evaluate carefully the risk /benefit relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed doses. 
			BENZODIAZEPINES AND RELATED	N05-001	N07BC01	BUPRENORPHINE	1819			ANSM	89-BENZODIAZEPINES-AND-RELATED.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression, which can be fatal. 	Take into account	Evaluate carefully the risk /benefit relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed doses. 
			BENZODIAZEPINES AND RELATED	N05-001	N07BC51	BUPRENORPHINE	1819			ANSM	89-BENZODIAZEPINES-AND-RELATED.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression, which can be fatal. 	Take into account	Evaluate carefully the risk /benefit relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed doses. 
			BENZODIAZEPINES AND RELATED	N05-001	N05AH02	CLOZAPINE	2626			ANSM	89-BENZODIAZEPINES-AND-RELATED.html	Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.	Take into account	
			BENZODIAZEPINES AND RELATED	N05-001				OPIOIDS	N0-R0	ANSM	89-BENZODIAZEPINES-AND-RELATED.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
B03BB51	FOLINIC ACID	6313						FLUOROURACIL (AND BY EXTRAPOLATION, TEGAFUR AND CAPECITABINE)	L01BC-001	ANSM	9-FOLINIC-ACID.html	Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. 	Take into account	
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	N01AB01	HALOTHANE	5095			ANSM	90-BETA-2-MIMETICS.html	In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity	Not recommended	Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AC01	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AC02	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AC03	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AC04	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AD01	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AD02	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AD03	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AD04	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AD05	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AE01	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AE02	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AE03	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AE04	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AE05	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	A10AF01	INSULIN	5856			ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring
			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001				BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	90-BETA-2-MIMETICS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	Reinforce blood and urine monitoring. Possibly change to insulin if the situation requires. 
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	C01BD01	AMIODARONE	703			ANSM	91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001				CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003	ANSM	91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated during the surgical procedure by the beta-mimetics	Precaution for use	As a general rule, do not stop the treatment with the beta-blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				CENTRAL ANTIHYPERTENSIVES	C02AC-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Large increase of arterial pressure in cases of sudden discontinuation of the treatment with the central hypertensive	Precaution for use	Avoid stopping the treatment with the central antihypertensive abruptly. Clinical monitoring
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Reduction of the antihypertensive effect (inhibition of the vasodilator prostaglandins by the non steroidal anti-inflammatories and fluid retention with the phenylbutazone)	Take into account	
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				DIHYDROPYRIDINES	C08CA-002	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta-blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion 	Take into account	
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C08DB01	DILTIAZEM	3443			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	The administration of these medications together should only be done under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	B01AC07	DIPYRIDAMOLE	3521			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the dipyridamole by injection: increase of the antihypertensive effect	Take into account 	
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				GLINIDES	A10BX-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				GLIPTINS	A10B-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AC01	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AC02	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AC03	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AC04	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AD01	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AD02	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AD03	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AD04	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AD05	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AE01	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AE02	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AE03	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AE04	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AE05	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	A10AF01	INSULIN 	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C01BB01	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C05AD01	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	D04AB01	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	N01BB02	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	R02AD02	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	S01HA07	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	S02DA01	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	N01BB52	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C01BC03	PROPAFENONE	8754			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	Clinical monitoring and EKG.
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002				BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. 
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C08DA01	VERAPAMIL	11170			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	The administration of these medications together should only be undertaken under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment. 
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C08DA51	VERAPAMIL	11170			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	The administration of these medications together should only be undertaken under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment. 
			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	C09BB10	VERAPAMIL	11170			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	The administration of these medications together should only be undertaken under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment. 
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C01BD01	AMIODARONE	703			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.	Precaution for use	Regular clinical monitoring and EKG
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery 	Precaution for use	As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Contraindication	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Risk of excessive bradycardia (addition of the bradycardia inducing effects)	Precaution for use	Regular clinical monitoring, especially at the beginning of the administration of the substances together 
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				CENTRAL ANTIHYPERTENSIVES	C02AC-001	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator 	Not recommended	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				DIGITALIS GLYCOSIDES	C01AA0	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				DIHYDROPYRIDINES	C08CA-002	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C08DB01	DILTIAZEM	3443			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction	Not recommended	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				GLINIDES	A10BX-001	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the beginning of treatment, strengthen self-monitoring of blood glucose.
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AC01	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AC02	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AC03	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AC04	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AD01	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AD02	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AD03	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AD04	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AD05	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AE01	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AE02	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AE03	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AE04	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AE05	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	A10AF01	INSULIN 	5856			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C01BB01	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C05AD01	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	D04AB01	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	N01BB02	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	R02AD02	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	S01HA07	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	S02DA01	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	N01BB52	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				NEUROLEPTICS	N05AA-003	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Vasodilator effect and risks of hypotension, especially orthostatic (additive effect)	Take into account	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003				BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. 
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C08DA01	VERAPAMIL	11170			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction 	Not recommended	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C08DA51	VERAPAMIL	11170			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction 	Not recommended	
			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	C09BB10	VERAPAMIL	11170			ANSM	93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction 	Not recommended	
			BISPHOSPHONATES	M05B-001	A12AA	CALCIUM	1428011			ANSM	94-BISPHOSPHONATES.html	For calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
			BISPHOSPHONATES	M05B-001	B03A	IRON	1431589			ANSM	94-BISPHOSPHONATES.html	For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
J05AE12	BOCEPREVIR	1102129						VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	95-BOCEPREVIR.html	Risk of constriction of coronary blood vessels or of those of the extremities (ergotism), or of rapid elevation of blood pressure	Contraindication	
J05AE12	BOCEPREVIR	1102129						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	95-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these substances together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of the administration of them together.
J05AE12	BOCEPREVIR	1102129			C10AA05	ATORVASTATIN 	83367			ANSM	95-BOCEPREVIR.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the atorvastatin	Precaution for use	Do not exceed the dosage of 20mg/day of atorvastatin. If the therapeutic objective is not reached with this dosage, use another statin not affected by this type of interaction.
J05AE12	BOCEPREVIR	1102129			G03FA17	DROSPIRENONE	840781			ANSM	95-BOCEPREVIR.html	Increase by more than double of the concentrations of drosperinone when taken with the boceprevir	Nor recommended	Choose a contraceptive with another progestin, especially in cases of hyperkalemia
J05AE12	BOCEPREVIR	1102129			G03AA12	DROSPIRENONE	840781			ANSM	95-BOCEPREVIR.html	Increase by more than double of the concentrations of drosperinone when taken with the boceprevir	Nor recommended	Choose a contraceptive with another progestin, especially in cases of hyperkalemia
J05AE12	BOCEPREVIR	1102129						NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	95-BOCEPREVIR.html	Decrease of the effectiveness of the estrogen.	Precaution for use	Clinical monitoring and possible adjustment of the dosage 
J05AE12	BOCEPREVIR	1102129						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	95-BOCEPREVIR.html	Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone(1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism by the hormonal contraceptive by the boceprevir	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together. 
J05AE12	BOCEPREVIR	1102129						IMMUNOSUPPRESSANTS	L04A	ANSM	95-BOCEPREVIR.html	Increase of the blood concentrations of the immunosuppressant (substantial for the ciclosporin, extremely large for the tacrolimus)	Precaution for use	Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.
J05AE12	BOCEPREVIR	1102129						RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	95-BOCEPREVIR.html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure	Not recommended	
J05AE12	BOCEPREVIR	1102129			N02AC52	METHADONE 	6813			ANSM	95-BOCEPREVIR.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
J05AE12	BOCEPREVIR	1102129			N07BC02	METHADONE 	6813			ANSM	95-BOCEPREVIR.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	Regular clinical monitoring and possible adjustment of the dosage of methadone.
J05AE12	BOCEPREVIR	1102129						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	95-BOCEPREVIR.html	Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone(1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism by the hormonal contraceptive by the boceprevir	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together. 
J05AE12	BOCEPREVIR	1102129			J04AB02	RIFAMPICIN	9384			ANSM	95-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together.
J05AE12	BOCEPREVIR	1102129			J04AM02	RIFAMPICIN	9384			ANSM	95-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together.
J05AE12	BOCEPREVIR	1102129			J04AM05	RIFAMPICIN	9384			ANSM	95-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together.
J05AE12	BOCEPREVIR	1102129			J04AM06	RIFAMPICIN	9384			ANSM	95-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	If administering these together cannot be avoided, regular clinical monitoring and laboratory tests, especially at the beginning of treatment with the two medications together.
L01XX32	BORTEZOMIB	358258						ENZYMATIC INDUCERS	N03-J05-001	ANSM	96-BORTEZOMIB.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
L01XX32	BORTEZOMIB	358258						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	96-BORTEZOMIB.html	Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.	Precaution for use	Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzyme inhibitor.
C02KX01	BOSENTAN	75207						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	97-BOSENTAN.html	Risk of decrease of the plasma concentrations of bosentan	Not recommended	
C02KX01	BOSENTAN	75207						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	97-BOSENTAN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	More frequent testing of INR. Possible adjustment of the dosage of the vitamin K antagonist. 
C02KX01	BOSENTAN	75207			L04AD01	CICLOSPORIN	3008			ANSM	97-BOSENTAN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	Contraindication	
C02KX01	BOSENTAN	75207			S01XA18	CICLOSPORIN	3008			ANSM	97-BOSENTAN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	Contraindication	
C02KX01	BOSENTAN	75207						COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	97-BOSENTAN.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive	Precaution for use	Use a reliable contraceptive method, additional or alternative, during the length of time the two substances are administered together and for a cycle after. 
C02KX01	BOSENTAN	75207			A10BB01	GLIBENCLAMIDE	4815			ANSM	97-BOSENTAN.html	Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepotoxicity have been reported with these two substances administered together. 	Precaution for use	Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants 
C02KX01	BOSENTAN	75207						PROGESTIN CONTRACEPTIVES	G03-001	ANSM	97-BOSENTAN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism. 	Precaution for use	Use an additional or alternative reliable method of contraception during the time these substances are administered together and one cycle following 
C02KX01	BOSENTAN	75207			J04AB02	RIFAMPICIN	9384			ANSM	97-BOSENTAN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
C02KX01	BOSENTAN	75207			J04AM02	RIFAMPICIN	9384			ANSM	97-BOSENTAN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
C02KX01	BOSENTAN	75207			J04AM05	RIFAMPICIN	9384			ANSM	97-BOSENTAN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
C02KX01	BOSENTAN	75207			J04AM06	RIFAMPICIN	9384			ANSM	97-BOSENTAN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
M03AX01	BOTULINUM TOXIN	1716						AMINOGLYCOSIDES	J01GB-001	ANSM	98-BOTULINUM-TOXIN.html	Risk of increase of the effects of the botulinum toxin with the aminoglycosides (by extrapolation from the effects observed during the course of the botulism)	Not recommended	Use another antibiotic.
			BRADYCARIA INDUCING DRUGS	C0N0S0				BRADYCARIA INDUCING DRUGS	C0N0S0	ANSM	99-BRADYCARIA-INDUCING-DRUGS.html	Risk of excessive bradycardia (addition of the effects)	Take into account	
			BRADYCARIA INDUCING DRUGS	C0N0S0	L04AA27	FINGOLIMOD	1012892			ANSM	99-BRADYCARIA-INDUCING-DRUGS.html	Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms	Not recommended	Clinical monitoring and sustained EKG during the 24 hours following the first dose.
			BRADYCARIA INDUCING DRUGS	C0N0S0				MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	99-BRADYCARIA-INDUCING-DRUGS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	Clinical monitoring and EKG 
